# Table of Contents

## AMP Programs Overview
- AMP Commercial HMO Measurement and Reporting .......................................................... 1
- AMP Medicare Advantage Measurement and Reporting .................................................... 2
- AMP Commercial ACO Measurement and Reporting ........................................................ 2
- AMP Medi-Cal Managed Care Measurement and Reporting ............................................. 3
- Key Organizations Involved in Data Collection, Aggregation and Reporting ................. 4
- Participation and Use of Results ....................................................................................... 4
- Domains and Reporting Entities ..................................................................................... 6
- Joining AMP as a new Plan ............................................................................................. 8
- AMP General Program Timeline ...................................................................................... 8
- AMP Data Collection and Reporting Timeline ................................................................. 9
- Key Dates for Review and Correction of MY 2020 and 2021 Results ............................. 11
- Manual Revisions ............................................................................................................ 12
- If You Have Questions About the Specifications ............................................................. 13
- What’s in AMP MY 2020 and 2021? .............................................................................. 13
- Testing Measures ............................................................................................................. 15

## General Guidelines for Data Collection and Reporting
- Reporting Options ............................................................................................................ 18
- Encounter/Claims Submission ......................................................................................... 19
- Reporting Policies ........................................................................................................... 20
- Membership Changes ..................................................................................................... 27
- Required Enrollment Periods and Benefits ..................................................................... 28
- Data Collection ................................................................................................................ 32
- Coding Conventions ......................................................................................................... 39
- Data Submission ................................................................................................................ 43
- The Audit Review ............................................................................................................... 44

## Clinical Domain Technical Specifications
- Overview ............................................................................................................................. 48
- Guidelines for Clinical Quality Measures ........................................................................ 49

### Cardiovascular
- CBP Controlling High Blood Pressure ............................................................................. 51
- SPC Statin Therapy for Patients With Cardiovascular Disease ........................................ 55
- PDC Proportion of Days Covered by Medications ............................................................ 62

### Diabetes
- PDC Proportion of Days Covered by Medications ............................................................ 62
- CDC Comprehensive Diabetes Care ................................................................................. 70
- SPD Statin Therapy for Patients With Diabetes ................................................................. 80
- SUPD Statin Use in Persons With Diabetes ...................................................................... 89

### Musculoskeletal
- ART Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis .......... 95
- OMW Osteoporosis Management in Women Who Had a Fracture ................................. 99

### Prevention and Screening
- WCC Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents ......................................................................................................................... 105
- CIS Childhood Immunization Status ................................................................................ 107
- IMA Immunizations for Adolescents ................................................................................ 112
- CHL Chlamydia Screening in Women .............................................................................. 114
- CCS Cervical Cancer Screening ..................................................................................... 117
- CCO Cervical Cancer Overscreening .............................................................................. 119

---

September 1, 2020  
Measurement Years 2020 and 2021 AMP Manual
Table of Contents

**Access/Availability of Care**
- **PPC** Prenatal and Postpartum Care ................................................................. 130
- **WCV** Child and Adolescent Well-Care Visits .................................................. 134

**Respiratory**
- **AMR** Asthma Medication Ratio ................................................................. 136
- **CWP** Appropriate Testing for Pharyngitis .............................................. 141
- **AAB** Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis .. 145

**Behavioral Health & Substance Use**
- **HDO** Use of Opioids at High Dosage ......................................................... 150
- **COB** Concurrent Use of Opioids and Benzodiazepines ...................... 159

**Data Quality**
- **ENRST** Encounter Rate by Service Type .............................................. 166
- **ENFMT** Encounter Format .................................................................. 171
- **ENLAG** Encounter Timeliness ............................................................... 175

**Advancing Care Information Domain**
- **Overview** ............................................................................................... 179
- **Description** ............................................................................................. 179
- **Who We Measure** .................................................................................. 179
- **Data Collection** ...................................................................................... 182
- **ECBP** Controlling High Blood Pressure (e-Measure) ......................... 182
- **ESCD** Screening for Depression and Follow-Up Plan (e-Measure) .... 188

**Patient Experience Domain**
- **Overview** ............................................................................................... 198
- **Description** ............................................................................................. 198
- **Participation** ............................................................................................ 198
- **PO Requirements** .................................................................................. 199
- **Performance Areas** ............................................................................... 199
- **Specifications: Patient Population Surveyed** ...................................... 200
- **Sampling** ................................................................................................ 200
- **Fielding Surveys** .................................................................................... 201
- **Response File Preparation** ................................................................... 201
- **Analysis of Survey Data** ........................................................................ 201
- **Reports** ................................................................................................... 202
- **For More Information** ............................................................................. 202

**Appropriate Resource Use Domain**
- **Overview** ............................................................................................... 204
- **Measures** ................................................................................................ 204
- **Measure Development and Testing** ....................................................... 204
- **Calculating Measure Results** ................................................................. 204
- **Guidelines for HEDIS Utilization Measures** ....................................... 206
- **AMB** Ambulatory Care ......................................................................... 211
- **FSP** Frequency of Selected Procedures .............................................. 214
- **IPU** Inpatient Utilization—General Hospital/Acute Care ................. 220
- **GRX** Generic Prescribing .................................................................. 224
- **OSU** Outpatient Procedures Utilization—Percentage Done in Preferred Facility .. 226
- **Guidelines for HEDIS Risk Adjusted Utilization Measures** ............ 228
- **PCR** All-Cause Readmissions ............................................................... 232

---

1 Measures in this category appear in the Clinical Quality Priority Area termed “Maternity” (for the PPC measure) and “Prevention and Screening” (for the WCV measure), in the Draft AMP MY 2020 and MY 2021 Measure Sets.
October 1, 2020
Measurement Years 2020 and 2021 AMP Manual

Table of Contents

EDU Emergency Department Utilization ................................................................. 240
AHU Acute Hospital Utilization .............................................................................. 247
HALOS Hospital Average Length of Stay ............................................................. 256

Cost Domain
TCOC Total Cost of Care ...................................................................................... 260

MY 2021 Testing Measures
Overview .................................................................................................................. 265
Guidelines for Measures Reported Using Electronic Clinical Data Systems ........ 266
DSF-E Depression Screening and Follow-Up for Adolescents and Adults ........... 269
DMS-E Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults ........................................................................... 273
DRR-E Depression Remission or Response for Adolescents and Adults ............... 277

Appendix 1
Summary of Measures and Changes .................................................................... 1-1

Appendix 2
Practitioner Types .................................................................................................. 2-1
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Measure Name</th>
<th>Steward</th>
<th>Copyright</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBP</td>
<td>Controlling High Blood Pressure</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>SPC</td>
<td>Statin Therapy for Patients With Cardiovascular Disease</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>PDC</td>
<td>Proportion of Days Covered by Medications—(RAS) Antagonists</td>
<td>PQA</td>
<td>iii</td>
</tr>
<tr>
<td>PDC</td>
<td>Proportion of Days Covered by Medications—Statins</td>
<td>PQA</td>
<td>iii</td>
</tr>
<tr>
<td>PDC</td>
<td>Proportion of Days Covered by Medications—Diabetes All Class</td>
<td>PQA</td>
<td>iii</td>
</tr>
<tr>
<td>CDC</td>
<td>Comprehensive Diabetes Care—HbA1c Poor Control (&gt;9.0%)</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>CDC</td>
<td>Comprehensive Diabetes Care—HbA1c Control (&lt;8.0%)</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>CDC</td>
<td>Comprehensive Diabetes Care—Eye Exam</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>CDC</td>
<td>Comprehensive Diabetes Care—Nephropathy Monitoring</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>CDC</td>
<td>Comprehensive Diabetes Care—BP Control (&lt;140/90)</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>CDC</td>
<td>Comprehensive Diabetes Care—ODC: Optimal Diabetes Care</td>
<td>NCQA/IHA</td>
<td>i</td>
</tr>
<tr>
<td>SPD</td>
<td>Statin Therapy for Patients With Diabetes</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>SUPD</td>
<td>Statin Use in Persons with Diabetes</td>
<td>PQA</td>
<td>iii</td>
</tr>
<tr>
<td>ART</td>
<td>Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>OMW</td>
<td>Osteoporosis Management in Women Who Had a Fracture</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>CIS</td>
<td>Childhood Immunization Status</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>IMA</td>
<td>Immunizations for Adolescents</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>CHL</td>
<td>Chlamydia Screening in Women</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>CCS</td>
<td>Cervical Cancer Screening</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>CCO</td>
<td>Cervical Cancer Overscreening</td>
<td>NCQA/IHA</td>
<td>i</td>
</tr>
<tr>
<td>BCS</td>
<td>Breast Cancer Screening</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>COL</td>
<td>Colorectal Cancer Screening</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>PPC</td>
<td>Prenatal and Postpartum Care</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>WCV</td>
<td>Child and Adolescent Well-Care Visits</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>WCC</td>
<td>Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>AMR</td>
<td>Asthma Medication Ratio</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>CWP</td>
<td>Appropriate Testing for Pharyngitis</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>AAB</td>
<td>Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>HDO</td>
<td>Use of Opioids at High Dosage</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>COB</td>
<td>Concurrent Use of Opioids and Benzodiazepines</td>
<td>PQA</td>
<td>iii</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Measure Name</td>
<td>Steward</td>
<td>Copyright</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------</td>
<td>------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>ENRST</td>
<td>Encounter Rate by Service Type</td>
<td>NCQA/IHA</td>
<td>i</td>
</tr>
<tr>
<td>ENFMT</td>
<td>Encounter Format</td>
<td>IHA</td>
<td>vi</td>
</tr>
<tr>
<td>ENLAG</td>
<td>Encounter Timeliness</td>
<td>IHA</td>
<td>vi</td>
</tr>
<tr>
<td>ECBP</td>
<td>Controlling High Blood Pressure (e-Measure)</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>ECSD</td>
<td>Screening for Depression and Follow-Up Plan (e-Measure)</td>
<td>CMS</td>
<td>iv</td>
</tr>
<tr>
<td>PAS</td>
<td>Access Composite</td>
<td>AHRQ</td>
<td>v</td>
</tr>
<tr>
<td></td>
<td>Provider Communication Composite</td>
<td>AHRQ</td>
<td>v</td>
</tr>
<tr>
<td></td>
<td>Care Coordination Composite</td>
<td>AHRQ/PBGH</td>
<td>v</td>
</tr>
<tr>
<td></td>
<td>Office Staff Composite</td>
<td>AHRQ</td>
<td>v</td>
</tr>
<tr>
<td></td>
<td>Overall Ratings of Care Composite</td>
<td>AHRQ/PBGH</td>
<td>v</td>
</tr>
<tr>
<td>AMB</td>
<td>Ambulatory Care</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>FSP*</td>
<td>Frequency of Selected Procedures</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>IPU</td>
<td>Inpatient Utilization—General Hospital/Acute Care</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>GRX</td>
<td>Generic Prescribing</td>
<td>IHA</td>
<td>vi</td>
</tr>
<tr>
<td>OSU</td>
<td>Outpatient Procedures Utilization—Percentage Done in Preferred Facility</td>
<td>NCQA/IHA</td>
<td>i</td>
</tr>
<tr>
<td>PCR2</td>
<td>All-Cause Readmissions</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>EDU</td>
<td>Emergency Department Utilization</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>AHU</td>
<td>Acute Hospital Utilization</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>HALOS</td>
<td>Hospital Average Length of Stay</td>
<td>NCQA/IHA</td>
<td>i</td>
</tr>
<tr>
<td>TCOC</td>
<td>Total Cost of Care</td>
<td>HealthPartners</td>
<td>vii</td>
</tr>
<tr>
<td>DSF-E</td>
<td>Depression Screening and Follow-Up for Adolescents and Adults</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>DMS-E</td>
<td>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults</td>
<td>NCQA</td>
<td>ii</td>
</tr>
<tr>
<td>DRR-E</td>
<td>Depression Remission or Response for Adolescents and Adults</td>
<td>NCQA</td>
<td>ii</td>
</tr>
</tbody>
</table>

i. These performance measures, specifications and guidance for evaluating performance under the Align, Measure, Perform. Program (AMP Measures) were developed and are co-owned by the National Committee for Quality Assurance (NCQA) and Integrated Healthcare Association (IHA). These materials are not clinical guidelines and do not establish a standard of medical care. NCQA and IHA make no representations, warranties or endorsement about the quality of any organization or physician that uses or reports these materials and NCQA and IHA have no liability to anyone who relies on the materials.

NCQA and IHA hold a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA or IHA. Anyone desiring to use or reproduce the materials without modification for a non-commercial purpose may do so without obtaining any approval from NCQA and IHA. All commercial uses must be approved by NCQA and IHA and are subject to a license at the discretion of NCQA and IHA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA’s Measure Certification Program. © 2007–2020 National Committee for Quality Assurance and Integrated Healthcare Association, all rights reserved.

2 IHA risk adjusts the Frequency of Selected Procedures measure results (“rates”) and normalizes the All-Cause Readmissions measure results. NCQA has granted IHA permission for such adjustments from the AMP HEDIS specifications, but has not reviewed the methodology and disclaims all liability for use of the AMP Frequency of Selected Procedures and AMP All-Cause Readmissions results.
Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. NCQA and IHA disclaim all liability for use or accuracy of any coding contained in the specifications.

The American Medical Association (AMA) holds a copyright to the CPT® codes contained in the measure specifications. CPT is a trademark of the AMA. No fee schedules, basic units, relative values or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.

The American Hospital Association (AHA) holds a copyright to the Uniform Billing Codes ("UB") contained in the measure specifications. The UB Codes in the measure specifications are included with the permission of the AHA. All uses of the UB Codes may require a license from the AHA. Specifically, anyone desiring to use the UB Codes in a commercial product to generate measure results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@aha.org.

Some measure specifications contain coding from the Logical Observation Identifiers Names and Codes (LOINC®) Committee (http://loinc.org). The LOINC table, LOINC codes, LOINC panels and form file, LOINC linguistic variants file, LOINC/RSNA Radiology Playbook, and LOINC/IEEE Medical Device Code Mapping Table are copyright © 1995–2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes Committee and is available at no cost under the license at http://loinc.org/terms-of-use.

ii. These performance measures, specifications, and guidance for evaluating performance under the Align. Measure. Perform. Program (AMP HEDIS Measures) were developed and are owned by the National Committee for Quality Assurance (NCQA). The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA. These materials are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties or endorsement about the quality of any organization or physician that uses or reports these materials and NCQA has no liability to anyone who relies on the materials.

NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Anyone desiring to use or reproduce the materials without modification for a non-commercial purpose may do so without obtaining any approval from NCQA. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program. © 2007-2020 National Committee for Quality Assurance, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications.

The American Medical Association (AMA) holds a copyright to the CPT® codes contained in the measure specifications. CPT is a trademark of the AMA. No fee schedules, basic units, relative values or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.

The American Hospital Association (AHA) holds a copyright to the Uniform Billing Codes ("UB") contained in the measure specifications. The UB Codes in the AMP HEDIS specifications are included with the permission of the AHA. All uses of the UB Codes may require a license from the AHA. Specifically, anyone desiring to use the UB Codes in a commercial product to generate AMP HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@aha.org.

Some measure specifications contain coding from the Logical Observation Identifiers Names and Codes (LOINC®) Committee (http://loinc.org). The LOINC table, LOINC codes, LOINC panels and form file, LOINC linguistic variants file, LOINC/RSNA Radiology Playbook, and LOINC/IEEE Medical Device Code Mapping Table are copyright © 1995–2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes Committee and is available at no cost under the license at http://loinc.org/terms-of-use.

© 2007-2020 National Committee for Quality Assurance, all rights reserved.

iii. The PQA measures were developed by and are owned by the Pharmacy Quality Alliance (“PQA”). PQA retains the rights to these measures and can rescind or alter the measures at any time. No license is required for noncommercial use of the measures solely to report quality data for the IHA performance programs. All other uses, including reproduction, distribution, and publication must be approved by PQA and are subject to a license at the discretion of PQA. PQA reserves the right to determine the conditions under which it will approve use and/or license the measures. Users of PQA measures shall not have the right to alter, enhance, or otherwise modify the measures.

iv. This measure is included with the permission of the measure owner and steward, the Centers for Medicare & Medicaid Services (CMS). CMS contracted with Quality Insights of PA to develop this electronic measure.
v. The Patient Assessment Survey measures and methodology within this manual is copyright of the Pacific Business Group on Health (PBGH). The information contained in this document is restricted to reporting to IHA. The Patient Assessment Survey uses questions based on CAHPS®, which is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).

vi. The use of measures developed and owned by IHA is restricted to reporting to IHA. IHA retains the rights to the measure specifications.

vii. © HealthPartners. Reprints allowed for non-commercial purposes only if this copyright notice is prominently included and HealthPartners is given clear attribution as the copyright owner.
MY 2020 and 2021 Measure Set and Product Lines for Reporting

<table>
<thead>
<tr>
<th>Priority Area</th>
<th>Measures</th>
<th>Commercial HMO</th>
<th>Commercial ACO</th>
<th>Medicare Advantage*</th>
<th>Medi-Cal Managed Care</th>
<th>Non-HEDIS®</th>
<th>Differs From HEDIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>Controlling High Blood Pressure</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Statin Therapy for Patients With Cardiovascular Disease</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Proportion of Days Covered by Medications—Renin Angiotensin System (RAS) Antagonists</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Proportion of Days Covered by Medications—Statin</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Proportion of Days Covered by Medications—Diabetes All Class</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Comprehensive Diabetes Care—HbA1c Poor Control (9.0%)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Comprehensive Diabetes Care—HbA1c Control (&lt;8.0%)</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Comprehensive Diabetes Care—Eye Exam</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Comprehensive Diabetes Care—Nephropathy Monitoring</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Comprehensive Diabetes Care—BP Control (&lt;140/90)</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Comprehensive Diabetes Care—Optimal Diabetes Care Combination Rate</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Comprehensive Diabetes Care—HbA1c Testing (One Test)</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Statin Therapy for Patients With Diabetes</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Statin Use in Persons with Diabetes</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).
<table>
<thead>
<tr>
<th>Priority Area</th>
<th>Measures</th>
<th>Commercial HMO</th>
<th>Commercial ACO</th>
<th>Medicare Advantage*</th>
<th>Medi-Cal Managed Care</th>
<th>Non-HEDIS</th>
<th>Differs From HEDIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Musculoskeletal</td>
<td>Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Osteoporosis Management in Women Who Had a Fracture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Prevention and Screening</td>
<td>Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Childhood Immunization Status</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Immunizations for Adolescents</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Chlamydia Screening in Women</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Cervical Cancer Screening</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Cervical Cancer Overscreening</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Breast Cancer Screening</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Colorectal Cancer Screening</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Access/Availability of Care</td>
<td>Prenatal and Postpartum Care</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Child and Adolescent Well-Care Visits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Asthma Medication Ratio</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Appropriate Testing for Pharyngitis</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Avoidance of Antibiotic Treatment for Acute Bronchitis/ Bronchiolitis</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Behavioral Health and Substance Use</td>
<td>Use of Opioids at High Dosage</td>
<td>✓**</td>
<td>✓**</td>
<td>✓**</td>
<td>✓**</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Concurrent Use of Opioids and Benzodiazepines</td>
<td>✓</td>
<td>✓</td>
<td>✓**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Quality</td>
<td>Encounter Rate by Service Type</td>
<td>✓</td>
<td>✓**</td>
<td>✓**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Encounter Format</td>
<td>✓</td>
<td>✓</td>
<td>✓**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Encounter Timeliness</td>
<td>✓</td>
<td>✓</td>
<td>✓**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Priority Area</td>
<td>Measures</td>
<td>Commercial HMO</td>
<td>Commercial ACO</td>
<td>Medicare Advantage*</td>
<td>Medi-Cal Managed Care</td>
<td>Non-HEDIS</td>
<td>Differs From HEDIS</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------------</td>
<td>----------------</td>
<td>--------------------</td>
<td>-----------------------</td>
<td>------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Advancing Care Information</td>
<td>Controlling High Blood Pressure (e-Measure)</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Screening for Clinical Depression and Follow-Up Plan (e-Measure)</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Experience</td>
<td>Patient Experience/CG-CAHPS</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appropriate Resource Use</td>
<td>Ambulatory Care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frequency of Selected Procedures</td>
<td>✔**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inpatient Utilization—General Hospital/Acute Care</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Generic Prescribing</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Outpatient Procedure Utilization—Percent Done in Preferred Facility</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All-Cause Readmissions (risk adjusted measure)</td>
<td>✔</td>
<td>✔</td>
<td>✔**</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emergency Department Utilization (risk adjusted measure)</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute Hospital Utilization (risk adjusted measure)</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hospital Average Length of Stay</td>
<td>✔</td>
<td>✔</td>
<td>✔**</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>Total Cost of Care</td>
<td>✔</td>
<td>✔</td>
<td>✔**</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Testing Measures</td>
<td>Depression Screening and Follow-Up for Adolescents and Adults</td>
<td></td>
<td></td>
<td>✔***</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults</td>
<td></td>
<td></td>
<td>✔***</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Depression Remission or Response for Adolescents and Adults</td>
<td></td>
<td></td>
<td>✔***</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* All Medicare Advantage measures are used by CMS in their Stars Ratings program, except for Encounter Rate by Service Type, Encounter Format, Encounter Timeliness, Use of Opioids at High Dosage, Concurrent Use of Opioids and Benzodiazepines and Total Cost of Care.

**Measures collected for information only purposes; not recommended for use in incentive design or for public reporting.

***Measures added to MY 2021 for testing in respective product lines. There will be no testing measures for MY 2020.
Overview

Background

IHA’s Align. Measure. Perform. (AMP) Programs use a fair and transparent approach to measurement to generate comprehensive benchmarks and a reliable assessment of performance for medical groups, independent practice association (IPAs), and accountable care organizations (ACOs) across health plans. The AMP programs are recognized nationally for partnering with organizations across California and the nation to drive meaningful changes that reduce costs and improve healthcare quality and outcomes. Paired with the insights from IHA’s California Regional Health Care Cost & Quality Atlas, the AMP programs help reduce reporting burden for payers and providers by using a standard measure set to deliver objective data and analysis that supports performance improvement. Four programs, each focused on a specific population or product, complete the AMP suite.

In 2020, the IHA Technical Measurement and Governance Committees recommended an improved AMP Program Manual release timeline, which accelerates release of measure specifications by six months to June 1, beginning in 2021. This timeline change aligns with recent HEDIS timeline changes and allows participating POs and health plans more time to apply specifications during the measurement year. The below table describes the current AMP Program Manual release timeline, in relation to the transition year and future year timeline.

<table>
<thead>
<tr>
<th></th>
<th>Current Timeline (MY 2020)</th>
<th>Transition Year (MY 2021)</th>
<th>Future Timeline (MY 2022 and beyond)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Draft AMP Program Manual</td>
<td>September 1, 2020</td>
<td>September 1, 2020 (combined with MY 2020)</td>
<td>October 11, 2021</td>
</tr>
<tr>
<td>Final AMP Program Manual</td>
<td>December 1, 2020</td>
<td>June 1, 2021</td>
<td>June 1, 2022</td>
</tr>
</tbody>
</table>

The technical specifications and guidelines for data collection and reporting described in this Draft AMP Program Manual will cover both measurement year 2020 and measurement year 2021. Information on participating health plans and data collection and reporting timelines are specific to measurement year 2020. Updates for measurement year 2021 will be available at a later date.

AMP Commercial HMO Measurement and Reporting

Initiated in 2001, the AMP Commercial HMO program now includes participation from eleven health plans and about 200 California physician organizations caring for over 9.5 million Californians enrolled in commercial HMO and point of service products—representing 90% of commercial HMO enrollment in the state. AMP Commercial HMO has four key components: a common set of measures and benchmarks that span clinical quality, patient experience, utilization, and cost of care measures; value-based health plan incentive payments to physician organizations; public reporting of performance results for physician organizations; and public recognition awards. The AMP Commercial HMO program has demonstrated lasting and meaningful gains in quality performance, suggesting that a common performance measure set supports targeted improvement efforts.

The following plans are participating in the AMP Commercial HMO program in measurement year 2020:
• Aetna.
• Anthem Blue Cross.
• Blue Shield of California.
• Cigna Health Care of California.
• Health Net.
• Kaiser Permanente.

• LA Care Health Plan.
• Sharp Health Plan.
• Sutter Health Plus.
• UnitedHealthcare.
• Western Health Advantage.

Information on AMP Commercial HMO participation for measurement year 2021 will be available at a later date.

AMP Medicare Advantage Measurement and Reporting

AMP Medicare Advantage was prompted by the introduction of the Centers for Medicare & Medicaid Services (CMS) Star Rating incentive program for Medicare Advantage health plans. While CMS’ Star Rating program measures performance and assigns Star ratings at the plan level, AMP Medicare Advantage participants felt that measuring the same indicators and assigning Star ratings at the PO level would support quality improvement.

AMP Medicare Advantage uses the same measures (when applicable) and Star rating methodology used by CMS for their health plan Star ratings. Measure results are collected, aggregated and reported at the PO level using the same data collection and audit process used in the Commercial HMO program, and IHA calculates PO-level Star ratings for use in IHA recognition awards and public reporting through the California Office of the Patient Advocate’s Medicare Advantage Medical Group Report Card. While health plans may choose to use the results as the basis of performance incentive payments, no standard incentive design for AMP Medicare Advantage currently exists. The following plans are participating in the AMP Medicare Advantage program in measurement year 2020:

• Blue Shield of California.
• Health Net.
• Kaiser Permanente.

• SCAN Health Plan.
• Sharp Health Plan.
• UnitedHealthcare.

Information on AMP Medicare Advantage participation for measurement year 2021 will be available at a later date.

AMP Commercial ACO Measurement and Reporting

California is on the leading edge of provider payment innovation, such as accountable care organizations (ACOs), and performance measurement and benchmarking initiatives to foster better care, better health, and smarter spending. At the same time, performance measures have proliferated nationally, increasing demands on providers and potentially challenging efforts to advance high-value care.

IHA and the Pacific Business Group on Health have partnered to develop a standard measurement and benchmarking program for commercial ACOs across the nation. The AMP Commercial ACO program seeks to reduce clinician burden through standard, widespread adoption of common ACO performance measures and benchmarks by plans, purchasers, and physician organizations. The measure set is highly aligned as well as dynamic and innovative, leading the way to develop, test, and implement meaningful new measures such as patient reported outcomes.
The following plans are participating in the AMP Commercial ACO program in measurement year 2020:

- Aetna.
- Anthem Blue Cross.
- Blue Shield of California.
- Health Net.
- Oscar Health Plan.
- UnitedHealthcare.

Information on AMP Commercial ACO participation for measurement year 2021 will be available at a later date.

**AMP Medi-Cal Managed Care Measurement and Reporting**

With 11 million of 13 million Medi-Cal enrollees receiving care through managed care plans, and with increasing overlap in provider networks across insurance product types, aligned, consistent, and comparative performance measurement is critical. AMP Medi-Cal Managed Care intends to align measurement across health plans and physician organizations providing care to Medi-Cal Managed Care members. AMP Medi-Cal Managed Care implements a standard measure set across participating health plans and physician organizations. Measure results are collected, aggregated and reported at the PO level using IHA’s data collection processes. Medi-Cal Managed Care plans may use the results as the basis of performance incentive payments. The following plan is participating in AMP Medi-Cal Managed Care program in measurement year 2020:

- Blue Shield of California Promise Health Plan

Only POs contracted with Blue Shield of California Promise Health Plan may self-report for the AMP Medi-Cal Managed Care program for measurement year 2020.

Information on AMP Medi-Cal Managed Care participation for measurement year 2021 will be available at a later date.
Key Organizations Involved in Data Collection, Aggregation and Reporting

**IHA**  The Integrated Healthcare Association manages the AMP programs and convenes all relevant committees. IHA arranges for all necessary services, including measure development, data aggregation and publication of the results in a public report card.

**NCQA**  The National Committee for Quality Assurance develops and maintains the clinical measures and audit methodologies and evaluates and collects data for the Advancing Care Information domain. The majority of clinical quality measures are adapted from the NCQA Healthcare Effectiveness Data and Information Set (HEDIS) measures, the most widely used set of performance measures in the managed care industry. Non-HEDIS measures are noted in the specifications. NCQA is a nonprofit organization committed to assessing, reporting on and improving the quality of care provided by organized delivery systems.

**PBGH**  The Pacific Business Group on Health (PBGH) administers the Patient Assessment Survey (PAS), which is used to measure performance in the Patient Experience domain of AMP Commercial HMO and AMP Medi-Cal Managed Care. PBGH reports relevant PAS results to IHA for inclusion in AMP reports.

The Pacific Business Group on Health is also a partner in the launch of AMP Commercial ACO.

**TransUnion HealthCare**  TransUnion HealthCare (formerly the Diversified Data Design Corporation, a subsidiary of TransUnion LLC), helps IHA collect clinical data from POs and health plans.

**Onpoint Health Data (Onpoint)**  Onpoint Health Data (Onpoint) helps develop and maintain the non-HEDIS Appropriate Resource Use (ARU) and Total Cost of Care (TCOC) measures; collects and standardizes claims, encounter, eligibility, pharmacy, and cost data from health plans; aggregates data across health plans for each PO and calculates the ARU and TCOC measures; and creates reports for all parties. Onpoint also generates clinical results for AMP Commercial ACO and Medi-Cal Managed Care programs and for select measures in the Commercial HMO and Medicare Advantage programs.

**OPA**  The Office of the Patient Advocate (OPA) is an independent state office created to represent the interests of health plan members in getting the care they deserve and to promote transparency and quality health care. OPA uses AMP Commercial HMO and Medicare Advantage results as the basis of its annual Medical Group Quality of Care Report Cards, at http://www.opa.ca.gov.

Participation and Use of Results

All POs in California are eligible to participate in IHA’s AMP programs —regardless of specialty or geographic area. To participate, POs must contract with one or more of the health plans participating in the appropriate AMP program and sign a Consent Agreement. No data is reported for POs that have not signed a Consent Agreement.

All AMP programs include a standard measure set, which can include measures across six domains: Clinical Quality, Data Quality, Advancing Care Information, Patient Experience, Appropriate Resource Use and Cost. Domains use these data sources:
• Clinical Quality Domain results are calculated and submitted by health plans contracting with each PO, and/or by self-reporting POs, unless otherwise stated in the specifications.

• Data Quality Domain includes measures focused on improving the transmission of encounter data between POs and plans. Measures in this domain include encounter data volume, encounter format and encounter data timeliness.

• Advancing Care Information Domain data are voluntarily submitted by POs.

• Patient Experience Domain data are collected via the Patient Assessment Survey (PAS) and processed by the Center for the Study of Systems (CSS).

• Appropriate Resource Use Domain and Cost Domain results are calculated by Onpoint using data submitted by health plans contracting with each PO, unless otherwise stated in the specifications. The Appropriate Resource Use Domain includes the Appropriate Resource Use measures. The Cost domain includes the Total Cost of Care measure.

See the MY 2020 and 2021 AMP Measure Sets for more information.

Measure results for each PO are aggregated across participating health plans and can be used as the basis for individual program components such as health plan quality incentive payments, public reporting, and public recognition awards.

<table>
<thead>
<tr>
<th>AMP Program</th>
<th>Participant Reporting/Benchmarking</th>
<th>Health Plan Incentive Payments</th>
<th>Public Reporting</th>
<th>Public Recognition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial HMO</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Commercial ACO</td>
<td>✓</td>
<td>Optional</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Medicare Advantage</td>
<td>✓</td>
<td>Optional</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Medi-Cal Managed Care</td>
<td>✓</td>
<td>Optional</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

IHA seeks to ensure that the AMP measure set continues to provide stakeholders with the most relevant, meaningful, valuable and effective information on health care quality and resource use, and that it does so in the most efficient way possible.

The 2016–2021 Measure Set Strategy guides development and maintenance of the AMP measure sets. Key priorities identified in the measure set strategy include supporting alignment across commonly used measure sets, targeted development of the AMP measure set and reducing the burden of data collection and reporting. IHA also hosts an annual public comment period each September, wherein participants and industry stakeholders are encouraged to provide input on AMP measurement for consideration by the stakeholder-led committees governing the AMP programs.
Data Sharing

The AMP programs encourage data sharing between POs and health plans, however, IHA staff are not prescriptive about how this is done. POs and health plans are expected to work together early in the process to establish a data sharing process and requirements. This may include an agreement on allowable data types, file formatting, timing, confirmation of data received and of data used in health plan reports.

## Domains and Reporting Entities

<table>
<thead>
<tr>
<th>Domain</th>
<th>Health Plans Report</th>
<th>POs Voluntarily Self-Report</th>
<th>CSS/PBGH</th>
<th>Onpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓*</td>
</tr>
<tr>
<td>Data Quality</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓*</td>
</tr>
<tr>
<td>Advancing Care Information</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Experience</td>
<td>✓**</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Appropriate Resource Use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

* Onpoint will generate the HDO, COB and SUPD measures from the submitted pharmacy claims data. Onpoint will generate the Encounter Format and Encounter Timeliness measures in the Data Quality Domain.

**POs voluntarily participate in the Patient Experience Domain and must register with PAS to receive results in this domain.

PO self-reporting in the AMP programs is entirely optional. Self-reporting POs participating in more than one AMP program are not required to self-report for all programs; however, when self-reporting for any of the AMP programs, a self-reporting PO must include all data on behalf of their contracted, participating plans when submitting their results.

**Self-Reporting Example 1:** PO A is participating in AMP Commercial HMO, Commercial ACO, and Medicare Advantage. PO A chooses to self-report results in AMP Commercial HMO, but not in Commercial ACO or Medicare Advantage. When self-reporting Commercial HMO results, PO A must include data from all contracted, participating health plans in the Commercial HMO product line.

**Self-Reporting Example 2:** PO B participates in AMP Commercial HMO and AMP Medi-Cal Managed Care and wants to self-report for both programs. PO B has contracts with three Commercial plans, Plan C1, Plan C2, Plan C3 and will self-report data for all three contracted Commercial HMO plan members. PO B has contracts with two Medi-Cal plans, Blue Shield of California Promise and Plan M2. PO B will only self-report data for Blue Shield of California Promise members as they are the only Medi-Cal plan participating in AMP Medi-Cal Managed Care.
The following health plans are participating in the AMP programs in measurement year 2020:

<table>
<thead>
<tr>
<th>Health Plan</th>
<th>AMP Commercial HMO</th>
<th>AMP Commercial ACO</th>
<th>AMP Medicare Advantage</th>
<th>AMP Medi-Cal Managed Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aetna</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anthem Blue Cross</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blue Shield of California</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Blue Shield of California Promise</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Cigna Health Care of California</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Net</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Kaiser Permanente</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>LA Care Health Plan</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oscar Health Plan</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCAN Health Plan</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Sharp Health Plan</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Sutter Health Plus</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UnitedHealthcare</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Western Health Advantage</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Information on health plan AMP program participation for measurement year 2021 will be available at a later date.

Health plans and POs who choose to use a vendor to calculate their AMP program results must use an NCQA-Certified vendor.

Health plans and POs that run their own measure results (without using a vendor) have three options to report results for MY 2020:

1. Continue to program and run their own measures and undergo the required manual source code review (MSCR) by an NCQA-Certified HEDIS Compliance Auditor for their AMP program submissions. *Option ends with MY 2021.*

2. Contract directly with NCQA and use NCQA’s test-deck process to certify their measure logic using NCQA’s automated source code review (ASCR) program.

3. Contract directly with an NCQA-Certified vendor.

NCQA will discontinue MSCR as part of the HEDIS Compliance Audit (and AMP program) for MY 2021. Beginning with MY 2021 (for reporting year 2022), all health plans and POs must either transition to an NCQA-Certified vendor or contract directly with NCQA for certification through the ASCR process. If your PO is interested in contracting with an NCQA-Certified vendor, a complete list of current vendors is available [here](https://www.ncqa.org/programs/data-and-information-technology/hit-and-data-certification/hedis-compliance-audit-certification/licensed-organizations/).

Review frequently asked questions [here](https).

Joining AMP as a New Plan

New plans that want to join an AMP program should send an e-mail to amp@iha.org. IHA staff can provide plans with estimated participation costs. Plans must contract with an organization licensed by NCQA to conduct HEDIS and AMP compliance audits.

Plans can download the Health Plan Clinical and Testing Measure File Layouts from the IHA website in January and submit their audited data files to TransUnion according to the timeline specified in this section.

Plans will also need to sign a Health Plan Participation Agreement with IHA and a Business Associate Agreement with Onpoint. IHA staff will put new plans in touch with Onpoint staff.

AMP General Program Timeline

The timeline below includes information on general program activities and milestones for MY 2020 and MY 2021. The Public Comment Period (September 1-30) will apply to the MY 2020 and MY 2021 draft manual and both MY 2020 and MY 2021 proposed measure sets.

The deadline for MY 2021 Participation Confirmation will be available at a later date.

General Program Dates

<table>
<thead>
<tr>
<th>Activity or Milestone</th>
<th>PO Deadline</th>
<th>Health Plan Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calendar year <strong>2020 Public Comment Period</strong> posted to the IHA website. • Call for Public Comment document for MY 2020 and MY 2021 • Draft MY 2020 and 2021 Manual • MY 2020 and 2021 Proposed Measure Sets</td>
<td>September 1–September 30, 2020</td>
<td></td>
</tr>
<tr>
<td><strong>PAS</strong>: Registration information e-mailed to POs.</td>
<td>September 25, 2020</td>
<td></td>
</tr>
<tr>
<td><strong>MY 2020 Participation Confirmation Period</strong>: POs declare their intent to participate in the AMP programs for MY 2020 and confirm their health plan contracts.</td>
<td>November 9–November 30, 2020 November 9–December 18, 2020</td>
<td></td>
</tr>
<tr>
<td><strong>Medication List Directory (MLD)</strong>: MY 2020 MLD posted to NCQA website.</td>
<td>November 1, 2020</td>
<td></td>
</tr>
<tr>
<td><strong>Medication List Directory (MLD)</strong>: MY 2021 MLD posted to NCQA website.</td>
<td>March 31, 2021</td>
<td></td>
</tr>
<tr>
<td><strong>Auditors Guideline</strong>: MY 2020 AMP Audit Guidelines posted to NCQA and IHA website.</td>
<td>November 6, 2020</td>
<td></td>
</tr>
<tr>
<td><strong>Auditors Guideline</strong>: MY 2021 AMP Audit Guidelines posted to NCQA and IHA website.</td>
<td>November 5, 2021</td>
<td></td>
</tr>
<tr>
<td><strong>Final MY 2020 and 2021 Measure Sets</strong> posted to the IHA website.</td>
<td>December 1, 2020</td>
<td></td>
</tr>
<tr>
<td><strong>Final MY 2020 AMP Program Manual</strong> posted to the IHA website.</td>
<td>December 1, 2020</td>
<td></td>
</tr>
<tr>
<td><strong>2020 and 2021 Public Comment Responses</strong> posted to the IHA website.</td>
<td>December 1, 2020</td>
<td></td>
</tr>
<tr>
<td><strong>Final MY 2021 AMP Program Manual</strong> posted to the IHA website.</td>
<td>June 1, 2021</td>
<td></td>
</tr>
</tbody>
</table>
AMP Data Collection and Reporting Timeline

The timelines below include major milestones for measurement year 2020 in the Quality, Appropriate Resource Use and Total Cost of Care data collection and reporting processes. They ensure that data are as complete as possible, as early as possible, to maximize administrative reporting for the AMP programs.

Measurement year 2021 deadlines for Health Plan and PO Audited Clinical Data Submission (to TransUnion HealthCare), Health Plan Claims and Encounter Data Submission (to Onpoint Health Data), and AMP Report Release Dates and Review Periods will be available at a later date.

### Health Plan and PO Audited Clinical Data Submission (to TransUnion HealthCare)

<table>
<thead>
<tr>
<th>Activity or Milestone</th>
<th>PO Deadline</th>
<th>Health Plan Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data Submission File Layout:</strong> MY 2020 data submission file layout posted to IHA website. E-mail notification will also be sent out to all AMP participating health plans and self-reporting POs notifying them of the most recent postings.</td>
<td>Preliminary File: January 18, 2021</td>
<td>Final File: February 15, 2021</td>
</tr>
<tr>
<td>Q1-Q4 Encounter Data: POs that use TransUnion HealthCare as the encounter data intermediary must submit all remaining Q4 2020 encounter data to TransUnion HealthCare. POs that use a different data intermediary or supply encounters directly to health plans should confirm the final acceptance date of encounter data to be included in reporting.</td>
<td>February 12, 2021</td>
<td>NA</td>
</tr>
<tr>
<td>Supplemental Data Collection Deadline: Organization completes and stops all nonstandard supplemental data collection and entry.</td>
<td>February 12, 2021</td>
<td>March 1, 2021</td>
</tr>
</tbody>
</table>
| **Supplemental Data Validation Deadline**  
- For POs: Auditor finalizes approval of all supplemental data for POs. Primary source verification (PSV) for nonstandard supplemental data must not occur prior to February 12, unless the PO finished all supplemental data processes, collection and entry.  
- For Health Plans: Auditor finalizes approval of all supplemental data for health plans. Primary source verification (PSV) for nonstandard supplemental data must not occur prior to March 2, unless the health plan finished all supplemental data processes, collection and entry. | March 12, 2021 | March 31, 2021 |
| Supplemental Data to Health Plans: Health plans receive the audited supplemental data files and audit results from the PO. | March 31, 2021 |
| Measure Certification Deadline: Final date for vendors to earn AMP Measure Certification to demonstrate that coded measures meet current NCQA standards and produce accurate and comparable results. NCQA will post final certification reports for auditors no later than March 5. | March 1, 2021 |
| Data Layout Test Files: Self-reporting POs and health plans submit data layout test files to TransUnion HealthCare. | March 22 – May 3, 2021 |
| Self-Reporting PO review period: Self-reporting POs review all submissions before sending to auditors to ensure data validity and completeness. **Note:** IHA will not accept requests for appeal of corrections to a PO’s self-reported data during the appeals process. Please review your organization’s submission of self-reported results to ensure it is complete and correct before sending it to your auditor and to TransUnion. | April 19 – April 30, 2021 | NA |
| Submission Files to Auditors: Self-reporting POs and health plans send submission files to auditors. | April 30, 2021 |
**MY 2020 and 2021 AMP: Overview**

### Auditor-Locked Results:
Self-reporting POs and health plans submit auditor-locked clinical results to TransUnion. Non-Self-reporting POs reporting the Advancing Care Information eMeasures must also submit by this date. Health plans must submit results for all clinical measures for each contracted PO with a signed AMP Consent Agreement.

*Audit not required for AMP Commercial ACO*

<table>
<thead>
<tr>
<th>PO Deadline</th>
<th>Health Plan Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 7, 2021</td>
<td></td>
</tr>
</tbody>
</table>

### Resubmission of Auditor-Locked Results:
Self-reporting POs and health plans submit auditor-locked clinical results to TransUnion HealthCare, if needed.

| July 16, 2021 |

---

**Health Plan Claims and Encounter Data Submission (to Onpoint Health Data)**

<table>
<thead>
<tr>
<th>Activity or Milestone</th>
<th>Eligibility</th>
<th>Medical Claims</th>
<th>Pharmacy Claims</th>
<th>Member Identifier</th>
<th>Cost</th>
<th>Lab Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Q1 2020 Data Submission:</strong> Production file received by Onpoint: Monthly eligibility between January 1, 2020 and March 31, 2020 and all claims paid or changed through March 31, 2020 not previously submitted</td>
<td>April 30, 2020</td>
<td>April 30, 2020</td>
<td>April 30, 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Q2 2020 Data Submission:</strong> Monthly eligibility and all claims paid or changed between April 1, 2020 and June 30, 2020</td>
<td>July 31, 2020</td>
<td>July 31, 2020</td>
<td>July 31, 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Q3 2020 Data Submission:</strong> Monthly eligibility and all claims paid or changed between July 1, 2020 and September 30, 2020</td>
<td>October 31, 2020</td>
<td>October 31, 2020</td>
<td>October 31, 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Q4 2020 Data Submission:</strong> Monthly eligibility and all claims paid or changed between October 1, 2020 and December 31, 2020</td>
<td>January 31, 2021</td>
<td>January 31, 2021</td>
<td>January 31, 2021</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MY 2020 Plan Validation &amp; Sign-Off</strong></td>
<td>March 1, 2021</td>
<td>May 28, 2021</td>
<td>March 1, 2021</td>
<td>May 28, 2021</td>
<td>June 11, 2021</td>
<td></td>
</tr>
<tr>
<td><strong>Annual File Submission:</strong> All 2020 organizational and lab results and service dates paid through March 31, 2021</td>
<td></td>
<td></td>
<td></td>
<td>April 30, 2021</td>
<td>May 31, 2021</td>
<td>June 30, 2021</td>
</tr>
</tbody>
</table>

*Data submission to Onpoint Health Data transitioned to quarterly data submission beginning with MY 2020. IHA is working with AMP participants to help facilitate this transition.*
AMP Report Release Dates and Review Periods

<table>
<thead>
<tr>
<th>Activity or Milestone</th>
<th>Time Frame or Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AUDITED CLINICAL RESULTS REPORTING TIMELINE</strong></td>
<td></td>
</tr>
<tr>
<td>Preliminary AMP Commercial HMO and Medicare Advantage Quality Reports Release: IHA posts preliminary quality reports for POs and health plans.</td>
<td>May 28, 2021</td>
</tr>
<tr>
<td>Questions and Appeals Period: IHA staff work with POs and health plans to address any data issues or questions related to quality results. Plans and POs may submit an appeal during this time.</td>
<td>May 28–June 18, 2021</td>
</tr>
<tr>
<td>AMP Commercial HMO and Medicare Advantage Quality Appeals Hearing: The Appeals Panel reviews and decides on all appeals to change quality results, if needed.</td>
<td>June 30, 2021</td>
</tr>
<tr>
<td>Resubmission of Auditor-Locked Results: Self-reporting POs and health plans submit auditor-locked clinical results to TransUnion HealthCare, if needed.</td>
<td>July 16, 2021</td>
</tr>
<tr>
<td>Final AMP Commercial HMO and Medicare Advantage Quality Reports Released: IHA releases final quality reports to POs and health plans.</td>
<td>August 19, 2021</td>
</tr>
<tr>
<td><strong>ONPOINT GENERATED RESULTS REPORTING TIMELINE</strong></td>
<td></td>
</tr>
<tr>
<td>Preliminary AMP Results Released: IHA releases preliminary results to POs and health plans.</td>
<td>August 19, 2021</td>
</tr>
</tbody>
</table>
| • AMP Commercial HMO: ARU, TCOC, Data Quality, opioid measures
• AMP Commercial Medicare Advantage: ARU, TCOC, Data Quality, statin, opioid measures
• AMP Medi-Cal Managed Care: Quality, ARU, TCOC, Data Quality
• AMP Commercial ACO: Quality, ARU, TCOC, Data Quality | |
| Questions and Appeals Period: IHA and Onpoint work with POs and health plans to address any questions or issues related to the Onpoint generated results for AMP Commercial HMO and Medicare Advantage, as well as questions regarding all preliminary results for AMP Commercial ACO and Medi-Cal Managed Care. | August 19–September 9, 2021 |
| Appeals Hearing: The Appeals Panel reviews and decides on all appeals. | September 17, 2021 |
| Final Reports Released: IHA releases final reports to POs and health plans. | October 15, 2021 |
| • AMP Commercial HMO: ARU, TCOC, opioid measures
• AMP Commercial Medicare Advantage: ARU, TCOC, statin, opioid measures
• AMP Medi-Cal Managed Care: Quality, ARU, TCOC
• AMP Commercial ACO: Quality, ARU, TCOC | |
| **Note:** Timeline assumes resolution of appeals do not require data resubmissions. If a data resubmission is required, a revised timeline will be communicated to participants. | |

**Key Dates for Review and Correction of MY 2020 Results**

IHA is committed to providing POs and health plans an opportunity to review their AMP results and to submit questions and requests for changes if they believe any of their results are in error.

The full timeline for reviewing AMP results and requesting corrections or changes is documented in the Data Collection and Reporting Timeline. IHA staff encourage participants to seek corrections and additional information throughout the measurement cycle.

Organizations have 15 business days to review preliminary results. Corrections or changes to results may be requested from the first date when the PO Preliminary Reports become available, through the
last date of the Results Questions and Appeals Periods. Detailed instructions on how to submit a question or request an appeal will be provided before each Questions and Appeal Period.

- Quality preliminary reports are released on May 28, 2021, and the final date to submit an appeal is June 18, 2021. IHA staff work with health plans and vendors to research and respond to PO questions about results provided in the PO Quality Preliminary Reports.
- Appropriate Resource Use and Total Cost of Care Preliminary Reports are released on August 19, 2021, and the final date to submit an appeal is September 9, 2021. IHA staff work with health plans to answer PO questions about results provided in the PO Appropriate Resource Use Preliminary Report.

Based on the findings and answers in response to a results inquiry, an organization may submit an appeal at any time during the results Questions and Appeals Period if they believe an error has been made. The burden of evidence is on the organization submitting the appeal. A multi-stakeholder Appeals Review Panel will consider the evidence and make a binding determination on the appeal. POs and health plans must comply with the determination of the Appeals Review Panel, including resubmission of data, if necessary. No further reconsideration is granted.

The Appeals Panel is made up of seven members: three representatives from participating health plans, three representatives from participating physician organizations, and one at-large member. The panel receives blinded appeal requests, supporting documentation and a summary from Onpoint describing the source and reason for possible error, the scope of the change requested and a recommendation for resolution. Each appeal is voted on by the appeals panel. All results are final after the close of the Appeals Period. It will not be possible to resolve errors raised after the close of the appeals period.

The AMP programs require a firm deadline to finalize results for all participants and share them with health plans for use in program deliverables such as health plan incentive payments, PO recognition, and public reporting. Although late requests for additional data submission or reconsideration of results will be acknowledged, they will not be incorporated into the report. An exception may be made if the data aggregator (IHA or Onpoint) made an error that was discovered after the deadline.

Throughout the measurement cycle, participants can request additional information or clarification on program processes and methodology.

### Manual Revisions

NCQA and IHA update the technical specifications twice a year.


Specifications in the MY 2020 Final AMP Program Manual that are posted to the IHA website on December 1, 2020, are frozen for MY 2020, and specifications in the MY 2021 Final AMP Program Manual that are posted to the IHA website on June 1, 2021, are frozen for MY 2021.

The Medication List Directory (MLD) is available for free order on the NCQA Store page and available for download in the ‘Download Section’ of My NCQA on November 1, 2020 for MY 2020 and March 31,
For MY 2021. Health plans and POs are accountable for all changes included in the corresponding Final AMP Program Manual and the MLD lists. Auditors assess compliance based on these.

If You Have Questions About the Specifications

Policy Clarification Support

IHA partners with NCQA to maintain measure specifications used in the AMP programs. Participants who have questions regarding a measure specification should submit them through My NCQA at https://my.ncqa.org/.

Step 1 Go to the My NCQA page using the following link: https://my.ncqa.org/

Step 2 Complete the Register section.

Step 3 Log in and click My Questions.

• To ask a new question click Ask a Question.
• Click PCS Policy/Program Clarification Support.
• For Product/Program Type, click IHA — AMP Programs in the drop-down box.
• For General Content Area, select the appropriate category for your question.
• For Specific Area, scroll down and click the appropriate measure for your question, or click Not Applicable if your question type is not listed.
• For Publication Year, click 2020 for MY 2020 or 2021 for MY 2021 from the drop-down box.
• For Subject, enter a short subject for your question.
• Type your question (3,000 characters or less).

Step 4 Click Submit Your Question.

FAQs

The FAQs and Policy Updates clarify HEDIS and AMP uses and specifications, and are posted to the IHA website (www.iha.org), as needed.

What’s in AMP MY 2020 and MY 2021

Clinical Domain

The AMP clinical domain includes both HEDIS based and non-HEDIS based measures for measurement at the PO level. Health plans and self-reporting POs report data for nearly all of the measures in the Clinical Domain via the audited results submission to TransUnion. Each participating health plan submits clinical results for each of its contracted POs that serve commercial HMO, POS and Medicare Advantage members. Clinical quality results for POs and plans participating in the AMP Commercial ACO and Medi-Cal Managed Care programs are generated through the health plan claims submission to Onpoint. POs may also voluntarily self-report their own clinical results for one or more clinical measures. POs are allowed to self-report for all AMP programs, including AMP Commercial ACO and Medi-Cal Managed Care.
All clinical results submitted to TransUnion must be audited to ensure that results are an accurate reflection of PO performance (with the exception of AMP Commercial ACO results, for which an audit process does not yet exist). Audit review of the clinical measures is based on NCQA’s HEDIS Compliance Audit™ program. NCQA staff work with AMP participants to incorporate the relevant components of the HEDIS Compliance Audit, adapt policies and procedures where necessary and enhance the process based on previous years’ experience. Because this program is an adaptation, it is considered an AMP program audit review. The MY 2020 and MY 2021 AMP Audit Review Guidelines are scheduled for release in November 2020 and November 2021, respectively.

IHA aggregates data across health plans and reports the data alongside data from self-reporting POs (where applicable). IHA selects and reports the higher rate (health plan aggregate or PO self-reported) for each measure when used in health plan incentive payments, public reporting, and/or public recognition awards.

Refer to Clinical Domain Technical Specifications for a list of measures.

Advancing Care Information (ACI) Domain

This domain evaluates PO adoption and use of healthcare IT, such as electronic health records. The ACI domain measures the providers’ ability to generate clinical e-Measure results directly from their electronic health record systems. POs may voluntarily participate in the domain by submitting e-Measure results in their clinical file submission to TransUnion.

Refer to Advancing Care Information Domain Technical Specifications for a list of measures.

Patient Experience Domain

The survey used to collect data for the Patient Experience Domain is the national standard CAHPS<sup>®</sup> Clinician & Group (CG-CAHPS) Patient Experience Survey endorsed by the National Quality Forum (NQF). The CG-CAHPS was developed by the Agency for Healthcare Research and Quality (AHRQ) and its research partners in the CAHPS consortium. PBGH oversees the CG-CAHPS survey for California physician organizations, called the Patient Assessment Survey (PAS), for POs who choose to participate.

POs voluntarily participate in the Patient Experience domain through the PAS survey; health plans do not submit data for this domain.

Refer to Patient Experience Domain Technical Specifications for a list of measures.

Data Quality Domain

The Data Quality Domain includes measures focused on improving the transmission of encounter data between POs and plans. Measures in this domain include encounter data volume, which is calculated and submitted by health plans contracting with each PO, and encounter data timeliness and format which will be calculated by Onpoint.

Refer to Data Quality Domain Technical Specifications for a list of measures.

<sup>®</sup>CAHPS<sup>®</sup> is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).
**Appropriate Resource Use Domain**

This domain assesses use of key health care services to identify variation and maximize limited resources. Health plans submit claims, encounter, eligibility, pharmacy and cost data to Onpoint which calculates the measures in the Appropriate Resource Use Domain; POs and health plans do not report measures in this domain.

Beginning in MY 2013, the *All-Cause Readmissions* measure was approved for public reporting (for applicable AMP programs). All other Appropriate Resource Use results are not publicly reported but may be used by health plans as the basis for performance incentives.

Refer to *Appropriate Resource Use Domain Technical Specifications* for a list of measures.

**Cost Domain**

This domain assesses the total amount paid to care for all members of a physician organization (PO) for a year including professional, pharmacy, hospital, and ancillary services and consumer cost-sharing. Health plans submit claims, encounter, eligibility, pharmacy and cost data to Onpoint to calculate the Cost Domain; POs and health plans do not report this domain.

Beginning in MY 2014, the *Total Cost of Care* measure was approved for public reporting (for applicable AMP programs).

Refer to the *Cost Domain Technical Specifications* for more information on this measure.

**Testing Measures**

The AMP measure set includes testing measures for voluntary data collection and submission. IHA uses testing measure results to evaluate measures for future inclusion in the measure set. There is opportunity for Public Comment before testing measures are finalized by the Technical Measurement and Governance Committees. Selected measures will be tested in MY 2021 and added to the appropriate measure set in MY 2022 (barring problems identified during testing). The Governance Committee will confirm adoption of these measures in fall 2020 with input from Public Comment and recommendations from the Technical Measurement Committee.

All health plans and self-reporting POs are strongly encouraged to report testing measure results.

**Clinical**
- *Depression Screening and Follow-Up for Adolescents and Adults.*
- *Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults.*
- *Depression Remission or Response for Adolescents and Adults.*

**Data Quality**
None.

**Advancing Care Information**
None.

**Patient Experience**
None.

**Appropriate Resource Use**
None.

**Cost**
None.
Read the entire guidelines section and measure specifications before implementing MY 2020 and MY 2021 measures.
General Guidelines for Data Collection and Reporting

For MY 2020 and 2021 Health Plans and Self-Reporting POs
### General Guidelines for Data Collection and Reporting

#### Reporting Options

1. **Two Data Sources**

| Health plan reporting | Participating health plans produce administrative results for each of their contracted POs that have signed the Consent Agreement by submitting results related to all the clinical measures attributable to the PO’s eligible population. This includes data derived from all encounters, fee-for-service claims and in-network claims.

Health plans must follow the clinical specifications and submit results for all clinical measures on behalf of all contracted POs that have signed the Consent Agreement, regardless of PO eligibility for incentive payments from the health plan.

For ARU measures, health plans submit to the resource use data aggregator (Onpoint) member-level enrollment, claims and encounter files for all contracted POs that have signed the Consent Agreement, regardless of PO eligibility for incentive payments from the health plan. Onpoint applies the ARU measure specifications and produces PO results.

*For AMP Commercial ACO reporting:*

For all commercial ACO measures, participating health plans submit to Onpoint member-level enrollment, claims and encounter files for all commercial ACO contracts, including an ACO identifier along with the member eligibility file. Onpoint applies measure specifications and produces contract-level results.

| Self-reporting PO | A PO may self-report data, collecting and submitting administrative results directly to the data aggregator for any or all clinical measures.

A self-reporting PO submits clinical results based on all members belonging to a participating and contracted health plan.

IHA produces final PO rates using a combination of health plan-submitted results and PO-submitted results. For each measure, IHA determines the final rate by choosing the higher reportable rate from the aggregated health plan data or the self-reported PO data.


POs that intend to self-report in the coming year should indicate this in the annual intentions period in November. POs can download the Physician Organization Clinical and Testing Measure File Layouts from the IHA website in January and submit audited data files to TransUnion according to the timeline specified in the Overview.
For AMP Commercial ACO reporting:
A PO may self-report data for the commercial ACO population, collecting and submitting administrative results directly to the TransUnion for any or all clinical measures.

A self-reporting PO submits commercial ACO results for all commercial ACO members belonging to a participating health plan, based on the health plan member eligibility file.

There will be no audit for MY 2020 AMP Commercial ACO reporting. An audit may be required in future reporting years, and audit requirements for MY 2021 will be available at a later date.

POs can download the AMP Commercial ACO Reporting File Layout and from the IHA website in January (final files available in February), and submit unaudited data files to TransUnion according to the timeline specified in the Overview.

Electronic data only
Regardless of data source, IHA requires that only electronic data (automated claims and encounter data and auditor-approved supplemental administrative databases) be used to calculate the measures. Sampling and the HEDIS Hybrid Methodology may not be used to collect data for the AMP programs. All reported clinical measure results must be validated through an Audit Review, described in Audit Review.

For AMP Commercial ACO reporting:
Regardless of data source, IHA requires that only electronic data (automated claims and encounter data and auditor-approved supplemental administrative databases) be used to calculate the measures. Sampling and the HEDIS Hybrid Methodology may not be used to collect data for commercial ACO reporting. For MY 2020, no audit review is required for commercial ACO reporting, and audit requirements for MY 2021 will be available at a later date.

2. Reporting Level

IHA aggregates data at the PO level. For IHA to report data at a more granular “subgroup” level for a PO (e.g. by region), all the PO’s contracted health plans must be willing and able to report clinical data at the PO subgroup level. If even one health plan cannot report at the more subgroup level, all health plans must report the PO’s data at the PO parent level (i.e., the “00” level). Additionally, to report final data at the PO subgroup level, the PO must have separate PAS surveys and Advancing Care Information submissions for each PO subgroup, if the PO participates in those domains.

Note: Before enrollment in PAS, POs must decide if they can report at the PO subgroup level (most POs report at the parent level only).

3. Submitting Data

All eligible POs —self-reporting or not—must submit encounter data to their contracted health plans throughout the year. POs should follow the dates in the Data Collection and Reporting Timeline and other information communicated by contracted health plans to maximize the probability that their data are included in any health plan-generated PO results. Since complete encounter data is integral to accurately reflecting care provided to patients, and affects health plan and provider risk scores, full
encounter submission is expected. Beginning in MY 2018, the Encounter Rate by Service Type measure was expanded to include facility encounters and claims.

Additionally, ENRST will again be factored into payments from health plans to POs in MY 2020 and 2021 in order to place greater emphasis on the need for effective data sharing.

Although the AMP programs encourage data sharing between POs and health plans, IHA staff are not prescriptive about how this is done. POs and health plans are expected to work together early in the process to establish a data sharing process and requirements. This may include an agreement on allowable data types, file formatting, timing, confirmation of data received and of data use in health plan reports.

**Reporting Policies**

4. Handling Mergers and Acquisitions

There are a few PO acquisitions and mergers every year; each of these legal structural changes comes with its own set of complex circumstances. The IHA policy for handling mergers and acquisitions accommodates a variety of circumstances and ensures a consistent and fair process. Physician organizations undergoing a merger or acquisition should notify IHA by emailing amp@iha.org and/or make IHA aware of the merger/acquisition during the annual intentions period each November.

5. Consent Agreement

POs must sign the Consent Agreement to confirm their participation in the appropriate AMP program(s). No data are collected or reported for POs that have not signed a Consent Agreement. IHA only makes AMP results available to POs that sign the Consent Agreement. Signed Consent Agreements are valid until such a time that a physician organization revokes its signed Consent Agreement.

6. Attribution

IHA attributes patients to a PO in each of the following ways:

- Enrollment at the health plan level, communicated to the PO.
- Encounter data from the PO, including member identification or physician identification (so health plans can correctly attribute it), *and*
- Continuous enrollment in the PO; enrollment in the PO on the anchor date; and required benefits, as specified for each measure.

*For AMP Commercial ACO reporting:*

For the purpose of AMP Commercial ACO, IHA is defining accountable care organizations broadly, and includes any arrangement a participating health plan identifies as an ACO. IHA will document and use these definitions to inform subsequent discussions and decisions about standardizing commercial ACO measurement.

All participating plans will use their own definitions of ACO, as well as their own attribution methodologies, with the understanding that the models differ.

There are three key distinguishing features of ACOs identified that are seen as relevant to the interpretation and benchmarking of results:

- ACO participants (e.g., 2-way, 3-way or 4-way contract between health plans, POs, hospitals, pharmacy, and/or purchasers).
- Payment/incentive structure (e.g., financial risk arrangements).
• Product line (e.g., HMO, PPO, FFS).

The table below outlines the information that each participating plan will report to IHA:

<table>
<thead>
<tr>
<th>Required ACO Documentation</th>
<th>Example</th>
</tr>
</thead>
</table>
| **Product**                | • HMO  
                                • PPO  
                                • Other |
| **Party**                  | • 2-way (plan/PO)  
                                • 3-way (plan/PO/hospital)  
                                • 4-way (plan/PO/hospital/purchaser)  
                                • Other |
| **Base Provider Risk Arrangement** | • Global capitation  
                                • Dual capitation (separate institutional/facility payments)  
                                • Professional capitation  
                                • FFS  
                                • Other |
| **Performance Payment**    | • Two-sided shared savings  
                                • One-sided shared savings  
                                • P4P quality bonus  
                                • Other |
| **Member assignment**      | • Attribution algorithm  
                                • Patient selection  
                                • Plan assignment  
                                • Employer assignment |
| **Timing**                 | • Retrospective  
                                • Prospective |
| **Attribution provider definition** | • PCPs including OB-GYNs  
                                • PCPs excluding OB-GYNs  
                                • PCPs and specialists (non-surgical) |
| **Attribution coverage**   | • All members are assigned (except HMO)  
                                • Some members left unassigned |
| **Attribution provider exclusivity** | • Member assigned to only one provider |
| **Attribution methodology** | • Plurality—provider with most visits  
                                • Temporal proximity—provider with most recent visit  
                                • Hybrid—mix of both |
| **Attribution basis**      | • E&M visits  
                                • All visits |
| **Attribution period**     | • 12 months  
                                • 18 months  
                                • 24 months |
| **Attribution frequency**  | • Monthly  
                                • Quarterly |
In addition to the information above, IHA will also collect information on the target population of the ACO, in order to understand the potential impact on performance. For example, some ACOs may be formed to address specific populations or care models (e.g., high cost members, specialists managing chronic conditions). Documenting these methodologies and the rationale behind them will help inform any variation seen between ACOs for reporting. IHA will collect this information from both the plans and the ACOs.

7. Peer Groups

IHA defines peer groups as “all POs participating in a particular AMP program.” POs eligible to participate in an AMP program have a valid contract with any participating health plan during the measurement year for the appropriate product. These POs have been delegated the responsibility of managing a patient population for both the primary and specialty care provided in ambulatory and inpatient settings.

8. Risk Adjustment

<table>
<thead>
<tr>
<th>Category</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Quality</td>
<td>NCQA is the measure developer for most AMP clinical quality measures; therefore, IHA follows NCQA’s risk adjustment protocol. NCQA’s Committee on Performance Measurement (CPM) and its Board of Directors determined that risk adjustment would not be appropriate for HEDIS measures because the processes and outcomes being measured should be achieved regardless of the nature of the population. NCQA also creates or adapts the technical specifications for Clinical Quality measures that are not HEDIS based. Because those measures are also process and outcome measures, NCQA determined that risk adjustment was not appropriate.</td>
</tr>
<tr>
<td>Patient Experience</td>
<td>For Patient Experience measures, each PO’s results are adjusted for patient case-mix, to control for differences across populations. Characteristics controlled for in the case-mix adjustment model are included in the Patient Experience Specifications.</td>
</tr>
<tr>
<td>Advancing Care Information</td>
<td>Advancing Care Information measures are not risk adjusted.</td>
</tr>
<tr>
<td>Resource Use</td>
<td>Most Resource Use measures are risk adjusted. The measure specifications describe the type of risk adjustment used for each measure.</td>
</tr>
</tbody>
</table>

9. Reliability Testing/Minimum Number of Observations

IHA considers measurement error and reliability for each of the two categories of measures:

- For Clinical Quality measures, the organization uses administrative data based on the PO member population. There is no sampling. Because statistical errors can result from small numbers, IHA requires a total eligible population of 30 or more for a particular measure and excludes any measure with a bias of 5 percent or more, as determined by the auditor.
- Patient Experience data are based on surveying a sample of eligible members, and IHA does not use any results with reliability below 0.70.
10. Eligible Population

The eligible population for any measure is all members who satisfy all criteria specified in the measure, including age, continuous enrollment (including allowable gap), benefit, event or anchor-date requirement. The rate is calculated using the eligible population after exclusions.

For AMP Commercial ACO reporting:
The eligible population for any measure is all members who satisfy all criteria specified in the measure, including age, continuous enrollment (including allowable gap), benefit, event or anchor-date requirement. The rate is calculated using the eligible population after exclusions.

For MY 2020 and 2021 AMP Commercial ACO reporting, participating plans will provide an ACO identifier flag in the member eligibility file provided to the IHA data aggregator. The participating plans will also provide additional information on the effective enrollment segment for the ACO flag. See Guideline 23: AMP Commercial ACO Continuous Enrollment for more information.

11. Optional Exclusions

Some measures allow the PO or health plan to exclude members from the eligible population who are identified as having a certain procedure or comorbidity (e.g., exclude women who have had a bilateral mastectomy from the Breast Cancer Screening measure).

The technical specifications contain instructions for optional exclusions, where applicable. Look for exclusions only where administrative data indicate that the specified numerator service or procedure did not occur. The PO or plan uses the eligible population to identify members for whom administrative data show that the numerator services or procedures were rendered within the time frame specified in the measure, and then counts the members as having satisfied the measure (i.e., count these members in the numerator).

The PO or health plan verifies that the exclusions occurred by the time specified in the measure.

12. Product-Line Reporting

AMP clinical results must be collected and reported separately for four populations:

- The Commercial HMO population (including Exchange members).
- The Commercial ACO population.
- The Medicare Advantage population.
- The Medi-Cal Managed Care population.

Results should not include PPO members, except for commercial ACO reporting if the ACO contract includes the PPO product line.

Note: For AMP Commercial HMO reporting, Exchange HMO/POS members are reported with the commercial HMO/POS population. This deviates from HEDIS health plan reporting to NCQA.

For AMP Commercial ACO reporting:
For MY 2020 and 2021 AMP Commercial ACO reporting, members are reported for each individual commercial ACO contract, which may be in the HMO or PPO product line. If an ACO member is already included the AMP Commercial HMO/POS population, also include that member in the applicable ACO population and report.
13. Members with Dual Enrollment

Dual enrollment is assessed using the continuous enrollment criteria in each measure. To meet criteria for dual enrollment, members must have dual enrollment at the end of the continuous enrollment period. Per General Guideline 20: Members Who Switch Products/Product Lines, if a measure allows a gap at the end of the continuous enrollment period, members must have dual enrollment as of the last enrollment segment.

This guideline must be used consistently across all measures.

For measures without a continuous enrollment requirement, members must have dual enrollment on the date of service or the date of discharge.

<table>
<thead>
<tr>
<th>Dual commercial/Medicaid enrollment</th>
<th>Members with dual Commercial HMO and Medi-Cal Managed Care enrollment must be reported in the Commercial HMO reports. These members may be excluded from the AMP Medi-Cal Managed Care reports.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dual Medicaid enrollment</td>
<td>Members dually enrolled in two AMP Medi-Cal Managed Care plans must be reported in the primary AMP Medi-Cal Managed Care report. The secondary Medi-Cal Managed Care payer may exclude a member whose primary Medicaid enrollment was offered through a different organization.</td>
</tr>
</tbody>
</table>
| Dual commercial enrollment         | **Enrollment in different organizations**: Do not account for coordination of benefits with other insurance carriers. If members have commercial enrollment in two organizations, both organizations must include the members in their AMP Commercial HMO reports, regardless of the primary insurer. For example, dependent children who are enrolled in one organization’s commercial product line under the Parent A’s insurance and in another organization’s commercial product line under the Parent B’s insurance, are included in both AMP Commercial HMO reports. **Enrollment in the same organization**: Adhere to the following criteria for members with dual commercial enrollment (e.g., children enrolled under each parent):  
  * If members are enrolled twice in the same product and there is only one AMP commercial HMO submission, include them only once in the submission.  
  * If products are reported separately, include members with dual enrollment in both products in both AMP Commercial HMO submissions.  
  * If the different product types are reported combined, include members once in the combined submission. |
| Dual commercial/Medicare enrollment| Members with dual commercial and Medicare enrollment must be included only in the product line that provides their primary enrollment (commercial or Medicare). Self-reporting POs that are unable to identify the primary insurer should use their best judgment; the overall impact is expected to be minimal and equal across plans and POs. |
14. Reporting ASO and Self-Insured Members

**Dual Medicaid/Medicare enrollment “dual eligible”**
Include these members in *both* the AMP Medi-Cal Managed Care and AMP Medicare Advantage reports *only* if they are enrolled in the organization’s Medicare contract required to report *and* in the organization’s Medi-Cal Managed Care contract.

This decision must be applied consistently across all applicable measures.

**Medicare-Medicaid (MMP)**
These members must be included in both the AMP Medi-Cal Managed Care and AMP Medicare Advantage reports.

*Note:* The dual Medicaid/Medicare enrollment “dual eligible” and MMP sections of this guideline apply to all measures, except for PCR. For PCR, remove these members from Medicaid reporting and only include them in Medicare reporting.

**Administrative Services Only (ASO) and self-insured members**
Include ASO and self-insured members in the health plan/PO AMP Commercial HMO and ACO reports. Organizations may use different terms for these members, including, but not limited to “no-touch,” “self-funded” or “third party administrator (TPA).” Health plans/POs may exclude these members from AMP Commercial HMO and ACO reports in only either of the following situations and only with auditor approval.

- The contract prohibits the health plan/PO from contacting members for any reason.

- The *contractual agreement*, which is a contract or other written agreement between the organization (i.e., HMO, ACO) and the ASO client (e.g., employer), states that the health plan/PO may not contact these ASO and self-insured members under any circumstances or include them in reporting.

  *Note:* Exclusion from disease management, case management or quality improvement projects does not meet criteria for exclusion from reporting.

- The agreement to exclude members in the reporting year is in place (fully executed by both parties, in the case of a contract, or communicated, in the case of a written agreement) by January 1 of the measurement year.

- The health plan/PO is not responsible for administering both in-network and out-of-network claims for ASO and self-insured members (i.e., employer carve-out for both in-network and out-of-network claims).

  *Note:* If claims are administered through a third party on behalf of the plan/PO (i.e., claims delegation arrangement), the plan/PO is considered responsible for administering claims and may not exclude members.

A health plan/PO may not exclude members who cannot be reached (e.g., overseas military or Foreign Service members), unless one of the above situations applies. Non-ASO members may not be excluded under this guideline. Federal government instructions and guidance supersede the requirements in this guideline.

Exclusion of these members must be reviewed with the auditor, and contracts should be provided to the auditor to review and approve the exclusion.

If the organization excludes these ASO and self-insured members, it must also exclude them from AMP Commercial HMO reporting.
15. Members in Hospice

Exclude members who use hospice services or elect to use a hospice benefit any time during the measurement year, regardless of when the services began. These members may be identified using various methods, which may include, but are not limited to, enrollment data, claims/encounter data (Hospice Encounter Value Set; Hospice Intervention Value Set) or supplemental data for this required exclusion. If organizations use the Monthly Membership Detail Data File to identify these members, use only the run date of the file to determine if the member elected to use a hospice benefit during the measurement year.

For PQA measure reporting, use the Hospice Encounter Value Set or the Hospice Intervention Value Set to identify members in hospice for Commercial HMO, Commercial ACO and Medi-Cal Managed Care reporting. For Medicare Advantage reporting, health plans must use the Hospice flag in the Monthly Membership Detail Data File to identify members in hospice. POs reporting PQA measures for Medicare Advantage have the option of using the Monthly Membership Detail Data File or the Hospice Encounter Value Set or Hospice Intervention Value Set to identify members in hospice.

The exclusion of members in hospice is subject to auditor review.

Note

- Supplemental data may be used for the hospice exclusion for all applicable measures, including measures that say “supplemental data may not be used for the measure” (e.g., PCR).

16. Members Who Refuse Services

It is AMP program policy that patient refusal of services is not a sufficient reason for exclusion from the denominator of any measure. The AMP measure set is continually monitored and vetted by the AMP Committees to ensure that measures are evidence-based, valid, and clinically relevant to the AMP population. The stakeholder-led committees governing the AMP programs agree that measures are developed based on clinical guidelines which are intended to apply for the majority of patients but are not intended to replace clinical judgment or patient choice. Further, no guideline is expected to be followed 100 percent of the time, and the impact of patient refusal of services is expected to be minimal and impact all physician organizations equally.

17. Deceased Members

If the health plan/PO can identify members who die during the measurement year, these members must be excluded consistently from all measures and indicators. These members may be identified using various methods, that include, but are not limited to, enrollment data, claims/encounter data or supplemental data. Deceased members may NOT be excluded from the PDC, SUPD and COB measures.

The exclusion of deceased members is subject to auditor review.

Note

- IHA does not require the health plan/PO to develop databases or other methods to identify deceased members.
- Supplemental data can be used for excluding deceased members for all applicable measures, including measures that say “supplemental data may not be used for the measure” (e.g., AAB).
Membership Changes

18. Members Who Switch Health Plans or POs

Members who switch to different organizations or to a sister organization may be counted as continuously enrolled if they joined an organization that assumes ownership of or responsibility for members’ administrative data for the entire period of continuous enrollment specified in the measure.

A health plan or PO that reports these members as continuously enrolled must follow the same definition of “continuous enrollment” as in General Guideline 21: Continuous Enrollment and Allowable Gaps, and all other guidelines affecting continuous enrollment (allow switching between products [HMO, POS, PPO, EPO] or product lines [commercial HMO/POS, commercial ACO, Medicare Advantage, Exchange, and Medi-Cal Managed Care]) consistently across all measures. For example, switching from a commercial HMO/POS to an Exchange HMO/POS is not considered a gap in enrollment.

19. Members Who Switch Health Plans or POs as the Result of a Merger or Acquisition

| Measures with a continuous enrollment period | Members who switch organizations because of a merger that occurred during the measurement year may be counted as continuously enrolled. |
| Measures without a continuous enrollment period | The surviving organization may include members from the non-surviving entity in the eligible population, starting on the official date of the merger or acquisition. For example, if the merger or acquisition occurred on March 1 of the measurement year, the surviving organization excludes members acquired from the non-surviving entity from the eligible population for January and February. |

This guideline must be used consistently across all measures.

20. Members Who Switch Products/Product Lines

| Measures with a continuous enrollment requirement | Members enrolled in different products or product lines (commercial HMO/POS, commercial ACO, Medi-Cal Managed Care, Exchange, Medicare Advantage) in the time specified for continuous enrollment for a measure are continuously enrolled and are included in the product and product-line specific AMP report in which they were enrolled as of the end of the continuous enrollment period. For example, a member enrolled in the commercial product line who switches to the Medicare Advantage product line during the continuous enrollment period is reported in the AMP Medicare Advantage report. If a measure allows a gap at the end of the continuous enrollment period, report members in the product and product-line specific AMP report in which they were enrolled as of the last enrollment segment. Members who “age in” to a Medicare product line mid-year are considered continuously enrolled if they were members of the organization through another product line (e.g., commercial) during the continuous enrollment period and their enrollment did not exceed allowable gaps. The organization must use claims data from all products/product lines, even when there is a gap in enrollment. Enrollment in a Medicare Private Fee-for-Service (PFFS) plan is considered a gap in HMO/POS enrollment. |
Measures without a continuous enrollment requirement

Members who enrolled in different products or product lines are reported in the product and product line-specific AMP report in which they were enrolled on the date of service (outpatient, ED or observation visits) or date of discharge (inpatient stays).

Required Enrollment Periods and Benefits

21. Continuous Enrollment and Allowable Gaps

Continuous enrollment specifies the minimum amount of time a member must be enrolled in an organization before becoming eligible for a measure. It ensures that the organization has enough time to render services. The continuous enrollment period and allowable gaps are specified in each measure. To be considered continuously enrolled, a member must also be continuously enrolled in the benefit specified for each measure (e.g. pharmacy or mental health) accounting for any allowable gaps.

A gap is the time when a member is not covered by the organization (i.e., the time between disenrollment and re-enrollment). For example, if a member disenrolls on June 30 and re-enrolls on July 1, there is no gap because the member was covered on both June 30 and July 1. If the member disenrolls on June 30 and re-enrolls on July 2, there is a one-day gap because the member was not covered on July 1.

An allowable gap can occur at any time during continuous enrollment. For example, the Comprehensive Diabetes Care measure requires continuous enrollment from January 1–December 31 and allows one gap of up to 45 days. A member who enrolls for the first time on February 8 of the measurement year is continuously enrolled if there are no other gaps throughout the remainder of the measurement year (the member had a 38-day gap, January 1–February 7).

Enrollment in a Medicare Advantage PFFS plan is considered a gap in HMO/POS enrollment.

22. Medicaid Continuous Enrollment

If the organization applies a full-month eligibility criterion to Medicaid beneficiaries and verifies enrollment prospectively in monthly intervals (in 1-month increments), the one gap in enrollment during the continuous enrollment period may not exceed 45 days. For example, a member whose coverage lapses for 2 months (60 days) is not considered continuously enrolled.

If the organization is notified of prospective member enrollment, use the actual date of enrollment to calculate continuous enrollment, not the notification date.

Retroactive eligibility

The elapsed time between the actual date when the organization became financially responsible for the Medicaid member and the date when it received notification of the new member. For measures with a continuous enrollment requirement, members may be excluded if the retroactive eligibility period exceeds the allowable gap requirement. This guideline must be used consistently across all measures.
23. AMP Commercial ACO Continuous Enrollment

Continuous enrollment specifies the minimum amount of time a member must be enrolled in the organization before becoming eligible for a measure. The member must also be continuously enrolled in the benefit specified for each measure (e.g., pharmacy or mental health) accounting for any allowable gaps to be considered continuously enrolled. For commercial ACO reporting, the same concept applies, using the participating plans’ attribution or assignment of members. For reporting purposes, the plan attribution or assignment, as described below, will be used in the same way as continuous enrollment when applying the measure specifications.

One of several criteria used to identify the eligible population, continuous enrollment ensures that the health plan or ACO had sufficient time to render services to its members to be accountable for providing those services. The continuous enrollment period and allowable gaps are specified in each measure.

For MY 2020 and 2021 commercial ACO reporting, participating plans will provide an ACO identifier flag in the member eligibility file provided to Onpoint. The participating plans will also provide additional information on the effective member month or enrollment segment for the ACO flag. This information will be used to identify continuous enrollment to the ACO. The ACO attribution or assignment, as indicated by the member eligibility file and effective member month/enrollment segment, will be used to determine if a member met the continuous enrollment criteria for a specific measure. For example, a member that has an ACO identifier flag with effective member months dates from January through December of the measurement year will be considered continuously enrolled in the ACO from January 1–December 31, or the measurement year.

Participating plans will receive an eligibility layout file from Onpoint. Health plans will provide member eligibility and enrollment segment information to any participating, contracted physician organizations that will be self-reporting the ACO measures. The participating physician organizations must use this information to identify the eligible population for commercial ACO reporting and to determine which members meet the continuous enrollment criteria. Using this method, the plans and self-reporting ACOs will have the same denominator for all ACO measures.

A gap is the time when a member is not covered by the organization (i.e., the time between disenrollment and re-enrollment). For example, if a member disenrolls on June 30 and re-enrolls on July 1, there is no gap because the member was covered on both June 30 and July 1. If the member disenrolls on June 30 and re-enrolls on July 2, there is a one-day gap because the member was not covered on July 1.

With the member month or other enrollment segment flags described above, the gaps will be translated from the enrollment segments provided by the plan. For example, if the plan identifies member month eligibility for January and February of the measurement year, and April through December of the measurement year, the month of March, or 31 days, is considered a gap, because the member was continuously enrolled from 1/1/MY–2/28/MY and again from 4/1/MY–12/31/MY.

An allowable gap (less than 45 days) can occur at any time during continuous enrollment. For example, the Comprehensive Diabetes Care measure requires continuous enrollment from January 1–December 31 and allows one gap of up to 45 days. A member who enrolls for the first time on February 1 of the measurement year is continuously enrolled if there are no other gaps throughout the remainder of the measurement year (the member had a 31-day gap, January 1–31).

Enrollment in Medicare or Medicaid (FFS or HMO) plan is considered a gap in Commercial enrollment.
24. Continuous Enrollment Over Multiple Years

Unless otherwise specified, for measures spanning more than 1 year, members are allowed one gap in enrollment of up to 45 days during each year of continuous enrollment. A gap in enrollment that extends over multiple years of a continuous enrollment period may exceed 45 days.

For example, in the Colorectal Cancer Screening measure (which requires 2 years of continuous enrollment), a member who disenrolls on November 30 of the year prior to the measurement year and re-enrolls on February 1 of the measurement year is considered continuously enrolled as long as there are no other gaps in enrollment during either year. The member has one gap of 31 days (December 1–31) in the year prior to the measurement year and one gap of 31 days (January 1–31) in the measurement year.

25. Anchor Dates

If a measure requires a member to be enrolled and to have a benefit on a specific date, the allowable gap must not include that date; the member must also have the benefit on that date. For example, a 55-year-old with only one gap in enrollment from November 30 of the measurement year through the remainder of the year is not eligible for the Colorectal Cancer Screening measure. Although the member meets the continuous enrollment criterion, she does not meet the anchor date criterion, which requires her to be enrolled as of December 31 of the measurement year.

26. Continuous Enrollment for Health Plans

For each measure, members are assessed for continuous enrollment in the health plan and continuous enrollment in the PO (parent level).

Plans that report AMP measures determine continuous enrollment using the following steps.

Step 1 Determine if the member was continuously enrolled in the plan, including allowable gaps.

Step 2 Determine if the member was continuously enrolled in the PO (parent level), including allowable gaps.

Step 3 Determine if the member was enrolled in the plan and the PO (parent level) on the anchor date.

Step 4 For POs eligible to report at the subgroup level, determine the subgroup to which the member was assigned on the anchor date.

27. Continuous Enrollment for POs

The AMP measures require calculation of continuous enrollment at the PO parent level. POs that self-report AMP measures determine continuous enrollment using the following steps.

Step 1 Determine if the member was continuously enrolled in the PO (parent level), including allowable gaps.

Step 2 Determine if the member was enrolled in the PO (parent level) and a participating health plan on the anchor date.

Step 3 For POs eligible to report at the subgroup level, determine the subgroup to which the member was assigned on the anchor date.
For AMP Commercial ACO reporting:
For each measure, members are assessed for continuous enrollment (attribution or assignment) in the commercial ACO contract.

As described in Guideline 23, health plans will provide a membership eligibility file to Onpoint, along with an ACO flag for enrollment segments, to identify continuous enrollment in the ACO. This information will also be shared with the POs that have ACO contracts with the participating plans, for use in identifying the eligible population in each ACO measure for ACO self-reporting.

Determine continuous enrollment using the following steps.

**Step 1** Determine if the member was continuously enrolled (attributed or assigned) to the ACO contract, including allowable gaps.

**Step 2** Determine if the member was enrolled (attributed or assigned) in the ACO on the anchor date.

**Note**
- Each PO approved to self-report at the subgroup level must also ensure that all plans reporting data for it report at the subgroup level.
- Members assigned to a PO must be included, whether they sought services from the PO.
- Members who change subgroups within a PO during the continuous enrollment period are considered continuously enrolled as long as they meet the other continuous enrollment criteria.

### 28. Required Benefits

HEDIS measures evaluate performance and hold organizations accountable for services provided in their members’ benefits package. Measure specifications include benefits (medical, pharmacy, mental health, chemical dependency) required during the continuous enrollment period. HEDIS measures do not define benefits at the service level (e.g., if the organization offers a pharmacy benefit but does not cover a specific medication class, the member has a pharmacy benefit and is included in the applicable measures requiring this benefit, similarly if the member has partial coverage of mental health services (either by service or diagnosis), they are included as having a mental health benefit. Organizations must assess benefits first at the organization level and then at the individual member level using continuous enrollment data. IHA follows the HEDIS protocol for required benefits.

Some measures require benefits in addition to medical (e.g., pharmacy) as part of the eligible population criteria. Health plans and POs must determine which benefits a member has before including the member in a measure.

**...at the health plan/PO level**

Health plans and POs must report AMP measures that require a specific benefit if the plan provides the benefit, either directly or through a contractor. Health plans and POs are not required to report measures that require a benefit that the plan does not offer.

Before reporting a measure specifying a benefit, the organization must be able to determine if a member has the required benefit.

If the organization does not offer the benefit, the plan does not report the measure and receives an NB (No Benefit) audit designation. No member assessment is necessary.
Members who do not have the benefit specified in the measure should not be counted in that measure by health plans or POs. For example, the Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis measure requires a pharmacy benefit. Exclude members who do not have a pharmacy benefit. When members are dual enrolled, organizations must assess the benefit requirements based on the submission in which the member is included, refer to General Guideline 13: Members With Dual Enrollment.

Exhausted benefits (optional)

For measures with a continuous enrollment criterion, the required benefits must be active for the period of continuous enrollment, accounting for any allowable gap. Exclude a member if the period when the benefit is exhausted exceeds any allowable gap or anchor date. For example, the Asthma Medication Ratio measure requires a pharmacy benefit during the measurement year. Exclude a member whose pharmacy benefit is exhausted in September of the measurement year, because this exceeds the 45-day allowable gap period.

For measures without a continuous enrollment criterion, include only services or procedures that occurred while the member had a benefit. For a member whose benefit is lost or exhausted during the time specified in the measure, include services or procedures that occurred while the member had the benefit. For example, in the Frequency of Selected Procedures measure, for a member whose medical benefit is exhausted on November 1 of the measurement year, report only the selected procedures that occurred from January 1–October 31.

Carved-out benefits (optional)

Some health plans and POs can obtain the necessary information from a carved-out entity and may include these members in the measures. For example, if an employer contracts directly with a pharmacy benefit manager (PBM) that shares pharmacy information, the health plan and PO may include the employer’s members in the measure.

Organizations must apply the optional guidelines for exhausted and carved-out benefits consistently across all measures.

Data Collection

29. Administrative Method

The Administrative Method of data collection requires health plans and POs to use transaction or supplemental electronic clinical data from acceptable sources (e.g., administrative databases, registries, electronic health records [EHR]). The PO’s reported rate is based on all members who meet the eligible population criteria (after optional exclusions, if applicable) and who are found through administrative data to have received the service identified in the numerator.

30. What Services Count?

With the exception of the ARU measures, health plans and self-reporting POs should use all services related to each measure, including all paid, suspended, pending and denied claims. For ARU measures, health plans should submit to the Onpoint all services for which the organization actually paid or expects to pay (i.e., claims incurred but not paid). Do not include services and days denied for any reason. In cases where a member is enrolled retroactively, count all services for which the organization has paid for or expects to pay.
When applying risk adjustment in the All-Cause Readmissions (PCR) measure, include all services, whether the organization paid for them or expects to pay for them (i.e., include denied claims).

When identifying all other events (including the IHS) in the PCR measure, include only paid services and services the organization expects to pay (i.e., do not include denied services).

31. Supplemental Data

**Supplemental data uses**

To supplement claims data for calculating AMP measures, organizations may use sources other than claims and encounters to collect data about their members and about delivery of health services to their members. Validation and review of these data differ by the processes used to collect and report them.

**Supplemental data may help determine:**

- Numerators that are labeled as *numerators* in the specifications.
- Optional exclusions.
- Members in hospice and members who have died.
- Eligible-population required exclusions that are labeled as *Required Exclusions* in the specification.

**Supplemental data may not be used for:**

- Denominator events. Organizations *may not* create and use records to identify denominator events, other than for optional exclusions and required exclusions.
- Clinical conditions that change. Organizations *may not* create and use records, on an ongoing basis, for exclusions for clinical conditions that change.
- Correcting bills or identifying valid data errors. Organizations *may not* use supplemental data to adjust incorrect billing practices or to identify valid data errors. This practice results in a change in claims data and is not allowed.
- Measures where the specification specifically indicates supplemental data cannot be used, except for applying the hospice exclusion and for excluding deceased members.
Supplemental Data Definitions

The auditor determines the classification of all supplemental data, not the organization.

**Standard supplemental data**

- Electronically generated files that come from service providers (providers who rendered the service). Production of these files follows clear policies and procedures; standard file layouts remain stable from year to year.

**Audit requirements.** Standard supplemental files are not required to be accompanied by proof-of-service documents and the audit does not require primary source verification, unless requested by the auditor.

**Nonstandard supplemental data**

- Data used to capture missing service data not received through administrative sources (claims or encounters) or in the standard electronically generated files described above, whether collected by a plan, an organization, a provider or a contracted vendor. These types of data might be collected from sources on an irregular basis and could be in files or formats that are not stable over time.

Organizations must have clear policies and procedures that describe how the data are collected and by whom, how they are validated and used for AMP reporting.

Organizations may not conduct phone calls to members or providers to collect information about services already rendered.

**Audit requirements.** All nonstandard supplemental data must be substantiated by proof-of-service documentation from the legal health record. Proof-of-service documentation is required for only a sample, selected by the auditor, as part of the audit’s annual primary source verification.

Proof-of-service documentation that is allowed for primary source verification:

- A copy of information from the member’s chart from the service provider or the PCP.
- A copy of the clinical report or clinical summary from the visit for service, such as lab or radiology reports (i.e., forms from the rendering provider proving the service occurred).
- A screen shot of:
  - Online electronic health record (EHR) records.
  - State- or county-sponsored immunization registry records.

Proof-of-service documentation that is not allowed:

- *Member surveys.* Organizations and providers may not use information obtained from surveys or other documents completed by the member.
- *Phone calls.* Recorded phone calls to collect information about services rendered are not proof of service.

**Certified eCQM vendor data**

Data from a certified eCQM vendor can be considered standard supplemental data if the vendor:

- Completed the current year’s Supplemental Data Roadmap section. The Roadmap must explain how the data from the certified eCQM vendor gets to the reporting entity. If there is a hand-off between the vendor and another entity prior to reaching the health plan, this relationship must be explained and include:
  - The data flow process—how are data transferred?
What is done to the data by the intermediary entity?

- Completed NCQA’s eCQM Certification by February 15 of the reporting year and provides the auditor a certification report that indicates the measures that were certified and the date they were certified.
- Produces QRDA1 files (this result is listed in the certification report).

**Audit requirements.** The auditor confirms that the data meet all the requirements above. If all the requirements are met, data from certified eCQM vendors are not required to undergo primary source verification, unless requested by the auditor. Refer to the *MY 2020 Audit Review Guidelines* for more details.

**Continuity of Care Documents (CCD)**

CCDs are used for the electronic exchange of clinical data without loss of meaning. The files provide a summary of a patient’s care as a snapshot in time, but they are not a replacement for an EHR. These files are typically XML-based and are considered nonstandard supplemental data for at least the first year of use. The organization must demonstrate the accuracy of these (through PSV) to ensure that the data in the file match the EHR. This data source must meet both criteria:

- There is a completed, current year’s Roadmap section.
- The Roadmap must include a description of how the CCD is created and by whom (e.g., produced by the provider in the office and sent to the plan or created by a vendor), the validation process and how the data are transmitted.

**Audit requirements.** The auditor confirms that the data meet all requirements. Primary source verification is required (e.g., go back to each unique EHR) to validate the CCDs accuracy. This level of validation is required for at least the first year, or the first submission by the EHR, but may continue in subsequent years until the auditor is certain the data are accurate, reliable and have not changed.

**Required Data Elements**

**Standard supplemental data**

Organizations must have policies and procedures for using data files as standard supplemental data. Data files must have standard file layouts, standard data fields and industry standard codes, and must include all elements required by the measure specifications, including payment status when applicable, and evidence that tests or services were performed and not merely ordered.

**Nonstandard supplemental data**

Nonstandard supplemental data files must have all the data elements required to meet the criteria specified by the measure specifications, including:

- Payment status when applicable.
- Evidence that tests or services were performed, not just ordered.
- When data are abstracted from medical record sources to be used as supplemental data, codes alone (without additional documentation of the service provided) do not meet criteria for proof of service. If a provider performs a service, it is expected that there is additional documentation in the medical record or in the primary source document. Auditors must validate, through primary source verification, all elements required by the administrative measure specification.
Evidence of provider accountability from the practitioner or practitioner group (signed contracts with accountability tied to passwords, e-signatures, or NPI/TIN data). For home visits, if clinical services are rendered, there must be evidence of accountability by the practitioner, and at a minimum include the date, name and signature on each in-home form. Documentation of the practitioner’s NPI/TIN is not required; however, documentation of NPI/TIN with date, name and signature is preferred.

More than a simple yes or no attestation on provider forms. Forms must have all necessary data elements and be signed by the rendering practitioner.

All data elements for a measure must be captured for member-reported services (date and place of service, procedure, prescription, test result or finding, practitioner type). Refer to General Guideline 39: Member-Reported Services and Biometric Values for more information about member-reported data.

All supplemental data

All proof-of-service documents must show that services were rendered by the deadline established for the measure (refer to General Guideline 33: Date Specificity for date specificity requirements).

When pharmacy data are classified as supplemental data, all data elements from the NDC lists must be present: the generic name (or brand name), strength/dose, route and date when the medication was dispensed to the member. Dispensed date is required; other dates (e.g., start date, shipped date) cannot be used as a proxy. Data elements must map to a medication listed in the Medication List Directory to be eligible for use. Generic documentation in the medical record (e.g., that a patient “was prescribed” or “is taking” a medication) that does not include drug name, strength/dose and dispense date, does not meet criteria.

All supplemental data used to show eligibility for exclusion must follow the requirements for exclusion in each measure.

Supplemental data sharing between POs and health plans

Health plans that use supplemental data collected for AMP measures must include all elements required by measure specifications and meet all requirements for standard and nonstandard supplemental data. Health plans that intend to use audited supplemental data from POs must complete a Roadmap Section 4 and submit it with the Roadmap that is due by January 31.

Supplemental Data Timeline

Supplemental data may be collected during the measurement year and into the beginning of the reporting year. All supplemental data must follow the Data Collection and Reporting Timeline requirements.

Health plans that use audited PO supplemental data should receive the audited data files and PO auditor’s final audit results from the PO by the deadline listed in the Data Collection and Reporting timeline. The health plan should receive all supporting documents for each supplemental data source (e.g., PO Roadmap Section 4, data file layouts, training materials) at the time the Roadmap is submitted to the auditor. The PO is responsible for sending the health plan all necessary documentation to support the use of supplemental data.

Refer to the Data Collection and Reporting Timeline for all deadline requirements.
Identifying and Validating Supplemental Data

All supplemental data (standard and nonstandard) must be identifiable. Because supplemental data can affect reporting and incentives, POs, plans or vendors that include supplemental data files for AMP reporting must mark the supplemental data files, regardless of the source. Auditors must be able to assess the contribution of each supplemental data source to the applicable components of the measure (numerator events or appropriate exclusions).

The auditor must review all supplemental data annually—there are no exceptions. At a minimum, the annual review includes the following for each supplemental data source:

- A completed current year’s Supplemental Data section of the PO Roadmap Section 4, including all attachments.
- Impact of supplemental data source, by measure (e.g., lists of numerator-positive hits from the supplemental data, by measure; year-to-year comparisons of percentage increases associated with supplemental data; proportion of numerator compliance from supplemental data).
- Primary source verification, where required or requested by the auditor.

Supplemental data that do not pass all audit validation steps by the deadline may not be used to calculate AMP rates by either the PO or the health plan. Organizations may wait to load supplemental data until primary source verification is complete and the source is approved.

For additional details about audit requirements for supplemental data, refer to the MY 2020 Audit Review Guidelines, released in November.

Note: Only health plans that participate in the AMP programs may use audited PO supplemental data for their NCQA HEDIS submission. The PO must provide the health plan with a completed Roadmap section for each supplemental data source, all applicable attachments, the auditor’s review findings. Health plans are not required to also collect the proof-of-service documents for these audited and approved PO data. Refer to the MY 2020 Audit Review Guidelines, released each November.

32. Date of Service for Laboratory Tests

Laboratory tests can have multiple dates of service; an order date (the date the provider ordered the test), a collection date (the date when the specimen was drawn), a result/reported date (the date when results were calculated and reported), a claim date (the date of service on the claim) and a documented date (the date the provider documented the result in the medical record).

Order date and documented date are not eligible for use in AMP reporting.

For laboratory tests identified using claims data (numerator events by administrative data) use the claim date of service.

For supplemental data and when abstracting laboratory tests from the medical record the documentation must include the test date and the result. The result/reported date can be used as the test date.

In addition, a health plan/PO may consider all events with dates no more than seven days apart to be the same test and may use the collected date for reporting. For example:

- If a test had a collection date of December 1 and a reported date of December 8, these dates are not more than seven days apart and can be considered the same test.
- If a test had a collection date of December 1 and a reported date of December 9, these dates are more than seven days apart and cannot be considered the same test.
33. Date Specificity

HEDIS requires that a date be specific enough to determine that an event occurred during the time established in the measure. For example, in the Childhood Immunization Status measure, members should receive three hepatitis B vaccines. For MY 2020 assume a member was born on February 5, 2018. Documentation that the first hepatitis B vaccine was given “at birth” is specific enough to determine that it was given prior to the deadline for this measure (the child’s second birthday), but if the documentation states that the third hepatitis B vaccine was given in February 2020, the organization cannot count the immunization, because the date is not specific enough to confirm that it occurred prior to the member’s second birthday.

There are instances when documentation of the year alone is adequate; these include most optional exclusions and measures that look for events in the “measurement year or year prior to the measurement year.” Terms such as “recent,” “most recent” or “at a prior visit” are not acceptable.

For documented history of an event (e.g., documented history of a disease), undated documentation may be used if it is specific enough to determine that the event occurred during the time frame specified in the measure. For example, for the Breast Cancer Screening measure, undated documentation on a problem list stating “bilateral mastectomy in 1999” is specific enough to determine that this exclusion occurred on or before December 31 of the measurement year.

34. Collecting Data for Measures With Multiple Numerator Events

The following measures require more than one event to satisfy the numerator:

- Childhood Immunization Status.
- Immunizations for Adolescents.
- Cervical Cancer Overscreening.

For only the measures listed above, the organization may use a single data source or a combination of administrative data, which may include audited supplemental data to determine numerator compliance for members in the denominator. To avoid double-counting, all events must be at least 14 days apart.

For example, the organization may count two influenza vaccines identified through administrative data if the dates of service are at least 14 days apart; if the service date for the first vaccine was February 1, then the service date for the second vaccine must be on or after February 15.

35. Measures That Use Medication Lists

Some measures require the use of available clinical pharmacy data or pharmacy claims data to identify dispensed medications.

The specifications reference medication lists that must be used for AMP reporting for each pharmacy-dependent measure. In the specifications, medication list references are underlined (e.g., ACE Inhibitor/ARB Medications List). Medication lists used for AMP reporting are included in the Medication List Directory. A medication list includes the National Drug Codes (NDC) and RxNorm codes that may be used for reporting along with the generic name, the brand name (if applicable), the strength/dose and the route for each code.

If an organization uses both pharmacy data (NDC codes) and clinical data (RxNorm codes) for reporting, to avoid double counting, if there are both NDC codes and RxNorm codes on the same date of service, use only one data source for that date of service (use only NDC codes or only RxNorm codes) for reporting.
36. Identifying Events/Diagnoses Using Laboratory or Pharmacy Data

Many organizations find a high rate of false positives when they use laboratory data to identify members with a disease or condition. Diagnosis codes are frequently reported on laboratory tests in cases where the condition is being ruled out. Use laboratory claims and data only for the Pregnancy Tests Value Set and the Sexual Activity Value Set (which do not contain LOINC codes) and value sets that contain LOINC codes.

Claims data indicating a member had a laboratory test during a visit with a provider are not considered laboratory data. Laboratory data are claims or lab result data for the sole purpose of a laboratory test performed outside of a visit with a provider. Claims with a code from the Independent Laboratory Value Set are considered laboratory claims. Organizations may need to use other methods to differentiate between laboratory claims data and clinical/provider claims that may include a laboratory test.

Note: This guideline does not apply to the ENRST measure. POSs and plans should include all encounters that meet the measure criteria based on the current ENRST measure specifications, even those that include POS code 81 on the claim.

Diagnosis codes on pharmacy claims may not be used.

37. Facility Data

With the exception of ARU and certain maternity measures, AMP measures do not require facility data (e.g., inpatient, ED) for reporting rates, but facility data may be used as specified. Professional codes associated with facility-based events may help capture some services, such as ED care for asthmatics.

38. Member-Collected Samples

Test results from member-collected samples may be used for FOBT, urinalysis testing and blood spots for HbA1c, LDL-C, glucose and total cholesterol. Member-collected samples must be sent to the laboratory or provider’s office for analysis.

39. Member-Reported Services and Biometric Values

Member-reported services and biometric values (height, weight, BMI percentile) are acceptable only if the information is collected by a primary care practitioner (refer to Appendix 2 for the definition of “PCP”), or by a specialist who is providing a primary care service related to the condition being assessed, while taking a patient’s history. The information must be recorded, dated and maintained in the member’s legal health record.

Coding Conventions

40. Coding Systems Included in AMP Reporting

AMP measures include codes from the following coding systems:

- CMS Place of Service (POS).
- CVX—Vaccines Administered.
- Healthcare Common Procedure Coding System (HCPCS) Level II.

LOINC® is a registered trademark of the Regenstrief Institute.

CPT® is trademarked and copyright 2020 by the American Medical Association. All rights reserved.
• International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM).
• International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM).
• International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS).
• Logical Observation Identifiers Names and Codes (LOINC).
• Systematized Nomenclature of Medicine—Clinical Terms (SNOMED CT).
• Uniform Bill (UB) Revenue and Type of Bill (TOB).
• Prescription Drugs Hierarchical Condition Categories (RXHCC).

41. Presentation of Codes in AMP Value Sets

A value set is the complete set of codes used to identify the service or condition. Measure specifications reference value sets that must be used for AMP reporting. In the specifications, value set references are capitalized and underlined (e.g., Essential Hypertension Value Set). Only use the codes included in the value sets for AMP reporting.

Value sets used for AMP reporting are included in the Value Set Directory (VSD) which can be downloaded at http://store.ncqa.org/index.php/my-2020-my-2021-align-measure-perform-amp-manual-and-value-set-directories.html

42. Telehealth

Synchronous telehealth visits, telephone visits and asynchronous telehealth (e-visits, virtual check-ins) are considered separate modalities for reporting.

Synchronous telehealth requires real-time interactive audio and video telecommunications. A measure specification that is silent about telehealth includes synchronous telehealth. This is because telehealth is billed using standard CPT and HCPCS codes for professional services in conjunction with a telehealth modifier and/or a telehealth POS code. Therefore, the CPT or HCPCS code in the value set will meet criteria (regardless of whether a telehealth modifier or POS code is present). A measure specification will indicate when synchronous telehealth is not eligible for use and should be excluded.

A measure will indicate when telephone visits are eligible for use by referencing the Telephone Visits Value Set.

Asynchronous telehealth, sometimes referred to as an e-visit or virtual check-in, is not “real-time” but still requires two-way interaction between the member and provider. For example, asynchronous telehealth can occur using a patient portal, secure text messaging or email. A measure will indicate when asynchronous telehealth visits are eligible for use by referencing the Online Assessments Value Set.

43. Using Claims to Identify Events in Conjunction With Diagnoses or other Events

Many measures require that a visit code or procedure code be used in conjunction with a diagnosis code. Some measures (e.g., Osteoporosis Management in Women Who Had a Fracture) require that a visit code be used in conjunction with another procedure code (e.g., fracture fixation).

Except for inpatient stays (as described below) and unless otherwise stated in a measure specification, when a measure requires a code be in conjunction with another code the codes must be from the same visit. The organization (health plan or PO) develops a method for identifying claims from the same visit (e.g., the same outpatient visit, the same inpatient stay). The method is subject to review by the auditor.
Identifying acute or nonacute inpatient stays is a two-step process. The first step uses the Inpatient Stay Value Set to identify all acute and nonacute inpatient stays. The second step uses the Nonacute Inpatient Stay Value Set to identify stays that were nonacute. When identifying nonacute codes in step 2, the nonacute code must be on the same claim that was identified in step 1. In addition, any required diagnosis or procedure must be on the same claim.

**Note:** If sharing supplemental data between a PO and plan, the plan and PO should work together to ensure clear data submission processes between the PO and plan.

### 44. Visits that Result in an Inpatient Stay

Some measures require exclusion of online assessments, telephone, outpatient, ED or observation visits that result in an inpatient stay or observation stay.

When the visit and the stay are billed on separate claims, the visit results in a stay when the visit date of service occurs on the day prior to the admission date or any time during the admission (admission date through discharge date). A visit billed on the same claim as a stay is considered a visit that resulted in a stay.

### 45. Principal vs. Secondary Diagnosis

Principal and secondary diagnoses are mentioned throughout the specifications. Generally, a principal diagnosis or a primary diagnosis is the diagnosis given at discharge and is listed in the first position on a claim/encounter form. A secondary diagnosis is any diagnosis listed on a claim or encounter form that is not classified as the principal diagnosis. A claim or encounter can contain several secondary diagnoses. Organizations should follow the measure specifications to determine if a diagnosis must be the principal diagnosis or if it can be secondary. If the specification does not state that the principal or primary diagnosis must be used, any applicable diagnosis must be used.

Some measures require a specific principal diagnosis for a member to be in the eligible population; other measures allow any diagnosis (principal or secondary) for a member to be eligible. For example, the Comprehensive Diabetes Care measure specifies a member with any diagnosis of diabetes as eligible. If a member’s claim lists the principal diagnosis as severe head injury trauma, but diabetes is listed as a second, third, fourth or fifth diagnosis on the same claim, the member should be included in the Comprehensive Diabetes Care measure. If the measure specifies that a principal diagnosis is required, health plans and POs should search for only the principal diagnosis (e.g., identifying the eligible population for the Asthma Medication Ratio measure).

The concept of “principal,” “primary,” and “secondary” diagnoses is unique to claims data. Supplemental data (such as EHR data) may not include this concept. Therefore, when using supplemental data to identify a “principal” or “primary” diagnosis, use any diagnosis.

### 46. Code Modifiers

Modifiers are two-digit extensions that, when added to CPT codes or HCPCS, provide additional information about a service or procedure.

Exclude any CPT Category II code in conjunction with a 1P, 2P, 3P or 8P modifier code (CPT CAT II Modifier Value Set) from AMP reporting. These modifiers indicate the service did not occur. In the Value Set Directory, CPT Category II codes are identified in the Code System column as “CPT-CAT-II.”

Unless otherwise specified, if a CPT or HCPCS code specified in HEDIS appears in the organization’s database with any modifier other than those specified above, the code may be counted in the AMP measure.
47. SNOMED Codes

When using SNOMED codes to identify “history of” procedures, the date of the procedure must be available (do not use the date the provider documented the procedure as the date of the procedure).

48. Uniform Bill Codes Specificity

Uniform Bill (UB) codes, primarily type of bill and revenue codes, are used to identify services.

The AMP Value Set Directory specifies UB Type of Bill codes using four digits. The organization may also use the equivalent three-digit version of the code (which consists of the four-digit code without the leading zero); for example, to identify skilled nursing facility (SNF) encounters, use either 21x or 021x.

Note: Three-digit versions of the codes are not included in the Value Set Directory.

49. Mapping Proprietary or Other Codes

Organizations may only map the following codes for use in AMP reporting:

- **State-specific codes.** The organization must provide the auditor with evidence that the codes are required by the state.

- **NDC codes.** An NDC code that is not in the HEDIS Medication List Directory (MLD) can only be mapped if its generic name (or brand name), strength/dose and route match those of a code in the MLD. NDC codes that identify immunizations can be mapped to codes in value sets that identify immunizations.

- **RxNorm codes.** An RxNorm code that is not in the HEDIS Medication List Directory (MLD) can only be mapped if its generic name (or brand name), strength/dose and route match those of a code in the MLD.

For audit purposes, health plans and POs should document the method used to map codes. At a minimum, documentation should include a crosswalk containing the relevant codes, descriptions and clinical information.

Health plans and POs document the process for implementing codes. Auditors may request additional information.

50. Retiring Codes

NCQA annually tracks billing, diagnostic, procedure and NDC codes that are designated obsolete. NCQA does not remove codes in the year in which they receive the designation of obsolete because of the look-back period in many HEDIS measures. Obsolete codes are deleted from the AMP specifications one year after the look-back period is exhausted. For example, since the *Asthma Medication Ratio* measure counts a principal diagnosis of asthma in the measurement year or the year prior to the measurement year, asthma codes, for this measure, have a two-year look-back period.

A code that is designated obsolete effective January 1, 2018, is deleted from the specifications in MY 2020 after the two-year look-back period (2019, 2020) plus one additional year (2018) is exhausted.

---

CPT® is trademarked and copyright 2020 by the American Medical Association. All rights reserved.
51. Table Names

Measure specifications contain tables to present specification requirements. A standardized naming system is used to refer to the tables.

**Medication tables**

Medication tables are labeled with the corresponding medication list name found in the Medication List Directory.

Data Submission

52. Reporting Small Numbers

Health plans and POs must report all available denominators, numerators and rates to the data aggregator even if the denominators are small. Only measures with aggregated denominators (the total for all health plans) of 30 or more are recommended for payment and public reporting. Measures with denominators less than 30 will be publicly reported as “Too Few Patients in Sample to Report.”

53. Reporting Date

The previous calendar year is the standard measurement year for AMP clinical data. IHA supplies the data submission file format to POs and health plans, and the Certified Auditor validates and locks the submission file before it is sent to TransUnion HealthCare. All health plan and PO-reported audited clinical data should be submitted to TransUnion HealthCare on or before the date specified in the **Data Collection and Reporting Timeline**.

For AMP Commercial ACO reporting:
The previous calendar year is the standard measurement year for the ACO clinical data. All ACO-reported clinical data should be submitted to TransUnion HealthCare on or before the date specified in the **Data Collection and Reporting Timeline**.

Note

- POs that use TransUnion HealthCare as the encounter data intermediary must submit all Q1–Q4 2020 encounter data to TransUnion HealthCare by February 12, 2021. No new data will be accepted after this deadline. POs that use a different data intermediary or supply encounters directly to health plans should confirm the final acceptance date of encounter data to be included in AMP reporting.
- Self-reporting POs and health plans must submit auditor-locked AMP clinical results by May 7, 2021. Health plans must submit results for all clinical measures for each contracted PO with a signed Consent Agreement.

54. Required Data Elements

Health plans and POs should report data based on all services delivered through December 31 of the measurement year, not encounters submitted or claims paid through that date. Data elements that must be submitted for each measure are listed below.

- Record type (Header—HDR, Detail—DTL, Trailer—TRL).
- PO ID (parent level, or subgroup level, for eligible POs).
- Enrollment (HMO and POS separately) with the PO as of December 31 of the measurement year.
- Measure ID.
- Numerator.
- Denominator.
• Rate.
• Audit result.
• Vendor ID (for NCQA-Certified vendors).

The Certified Auditor approves and locks the submission file before it is sent to TransUnion HealthCare.

For AMP Commercial ACO reporting:
ACOs should report data based on all services delivered through December 31 of the measurement year, not encounters submitted or claims paid through that date. Data elements that must be submitted for each measure are listed below.

• Record type (Header—HDR, Detail—DTL, Trailer—TRL).
• ACO ID (IHA will assign)
• ACO enrollment as of December 31 of the measurement year (must match plan-provided enrollment).
• Measure ID.
• Numerator.
• Denominator.
• Rate.

The Audit Review

55. Audit Review Principles

IHA requires health plans and self-reporting POs to undergo an audit review of clinical results conducted by an NCQA Certified Auditor. This review ensures that results are an accurate report of PO performance. The Audit Review incorporates relevant components of the HEDIS Compliance Audit described in the current volume, HEDIS Compliance Audit™: Standards, Policies and Procedures. A separate manual with Audit Specifications will be posted to the IHA website in November 2020. In MY 2020, audit is only required for AMP Commercial HMO/POS, Medicare Advantage and Medi-Cal Managed Care reporting. Audit requirements do not apply to AMP Commercial ACO for MY 2020.

The underlying principles of the Audit Review are:

• Ensure accurate, reliable, publicly reportable data that can be used to compare POs.
• Verify that measure calculation processes conform to technical specifications, including, but not limited to, use of administrative only data, correct calculation of encounter rates and appropriate application of continuous enrollment requirement.
• Assess information system capabilities and evaluate an organization’s ability to process medical, member and practitioner information to report clinical measures accurately.
• Ensure consistency across audit reviews by having the audit review conducted by an NCQA Licensed Organization and a Certified HEDIS Compliance Auditor using NCQA’s standard audit methodology.

The audit review is conducted during the data collection process, allowing the auditor to detect errors while there is time to correct them and minimize the possibility of a Biased Rate (BR). The audit review process includes various tasks and requirements to ensure accurate data reporting. A PO that does not self-report clinical measures does not need an audit.
56. Audit Components

Audit review components depend on the reporting option.

**Health plan reporting**

A health plan that undergoes a HEDIS Compliance Audit and also reports AMP data on behalf of contracted POs must have a Certified Auditor review the PO results. The auditor reviews and confirms any additional activities required for calculating results at the PO level, including the following:

- The health plan’s ability to attribute members to POs, including enrollment spans, and report the data at the PO level.
- The health plan’s ability to produce AMP measures according to specifications.
- The algorithms and source code used to report rates by PO.

**PO self-reporting**

A PO that collects and reports clinical measures must undergo an audit review adapted from NCQA’s HEDIS Compliance Audit. The review includes all PO-relevant HEDIS Compliance Audit standards and policies and procedures described in the *Audit Review Guidelines*.

*Note: Health plans that use supplemental data audited at the PO are not required to collect the proof-of-service documents also. Refer to the Audit Review Guidelines, released in November 2020.*

57. Audit Results

In MY 2020, audit is only required for Commercial HMO, Medicare Advantage and Medi-Cal Managed Care reporting. This section does not apply to Commercial ACO.

Audit Reviews result in audited rates at the measure level and indicate if a measure can be publicly reported. All clinical and encounter rate measures where applicable, must have a final, audited rate/result.

**Health plan results**

Audit reviews for health plans provide assessments for each of their contracted POs, indicating each measure’s suitability for data aggregation. The auditor gives a designation for the rate of each measure included in the audit, as shown in the table below.

<table>
<thead>
<tr>
<th>Rate/Result</th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–XXX</td>
<td>Reportable</td>
<td>A reportable rate was submitted for the measure. The rate of 0 includes instances when the health plan calculated the rate but found that no members met the criteria specified in the denominator.</td>
</tr>
<tr>
<td>BR</td>
<td>Biased Rate</td>
<td>The calculated rate was materially biased. The auditor determines a result is not reportable due to material bias.</td>
</tr>
<tr>
<td>NR</td>
<td>Not Reported</td>
<td>The health plan chose not to report the measure (may only be used for testing measures).</td>
</tr>
<tr>
<td>NB*</td>
<td>No Benefit</td>
<td>The health plan did not offer the health benefit required by the measure (e.g., pharmacy).</td>
</tr>
</tbody>
</table>

*Benefits are assessed at the global level, not the service level (refer to General Guideline 28: Required Benefits).*

*Note: Small Denominator (“SD”) is not a valid Rate/Result for health plan clinical data because IHA aggregates all health plan/PO data together for final PO clinical results. If a health plan reports a measure...*
with a denominator of less than 30, the health plan should also report the numerical rate for that measure (i.e., do not report “SD” as the rate).

PO results

For self-reporting POs, audit results indicate the suitability of each measure for public reporting. The auditor approves the rate or result of each measure included in the audit, as shown in the table below.

If the denominator for any measure is 0, the result should be 0, BR, NB or NR. The rate of 0 indicates that the PO calculated the measure, but no members met the criteria specified for the denominator.

<table>
<thead>
<tr>
<th>Rate/Result</th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–XXX</td>
<td>Reportable</td>
<td>A reportable rate was submitted for the measure. The rate of 0 includes instances when the PO calculated the rate but found that no members met the criteria specified in the denominator.</td>
</tr>
<tr>
<td>BR</td>
<td>Biased Rate</td>
<td>The calculated rate was materially biased. The auditor determines a result is not reportable due to material bias.</td>
</tr>
<tr>
<td>SD</td>
<td>Small Denominator</td>
<td>The PO followed the specifications, but the denominator was too small to report a valid rate.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>a. For clinical measures, when the denominator is &lt;30.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b. For Total Cost of Care (TCOC) when the denominator is &lt;200-member years.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Small denominator criteria are used for public reporting only.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>c. For All Cause Readmissions (PCR) when the denominator (index hospital stays) is &lt;30. Small denominator criteria are used for public reporting only. For all risk-adjusted utilization measures, except PCR, when the denominator is &lt;150.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>d. For utilization measures that count member months, when the denominator is fewer than 360 member months.</td>
</tr>
<tr>
<td>NB*</td>
<td>No Benefit</td>
<td>The health plan did not offer the health benefit required by the measure (e.g., pharmacy).</td>
</tr>
<tr>
<td>NR</td>
<td>Not Reported</td>
<td>The PO chose not to report the measure.</td>
</tr>
</tbody>
</table>

*Benefits are assessed at the global level, not the service level (refer to General Guideline 28: Required Benefits).

58. Multiple Audit Designations

Measures with multiple rates may have multiple audit results. For example, it is possible for the Childhood Immunization measure to be assigned a reportable rate for the MMR rate but a BR for VZV.

59. Material Bias

Any error that causes a (+/-) 5 percentage point or greater difference in the reported rate is considered materially biased and receives a BR for the affected measures.

60. Marketing

Release of Audit results must be in accordance with NCQA’s Guidelines for Advertising and Marketing, posted on the NCQA website at https://my.ncqa.org/. Organizations may release the entire Final Audit Report without prior authorization from NCQA but must obtain written authorization from NCQA before releasing abridged, summarized or quoted information from the Final Audit Report.

Organizations that refer to the audit or to data audited by a Certified HEDIS Compliance Auditor must adhere to the guidelines.
Clinical Domain Technical Specifications

For AMP MY 2020 and MY 2021
Health Plans and Self-Reporting POs
Overview

This section includes the AMP program technical specifications for use in collecting California PO clinical performance data in 2021 and 2022 for MY 2020 and MY 2021. The AMP program specifications are based on HEDIS measures and non-HEDIS measures. NCQA adapts measures for assessing performance at the PO level. All measures are collected using administrative data systems, including EHRs, registries and other clinical databases. The Hybrid Methodology or medical chart review is not permitted and hybrid specifications have been removed from respective HEDIS measures.

The following Clinical Domain Technical Specifications apply to health plans and self-reporting POs. Differences between the HEDIS Technical Specifications for Health Plans and the Clinical Domain Technical Specifications are clearly noted under each measure’s Modifications From HEDIS section. It is the policy of the AMP program to change HEDIS specifications only if the specifications are not possible for the program (i.e., they include manual chart review), or there is a very compelling reason to differ from HEDIS.
Guidelines for Clinical Quality Measures

GUIDANCE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021

• None.

Guidelines

Which services count? Unless otherwise specified in a measure, report all services for the Clinical measures, whether the organization paid for them. For example, report services paid for by a third party, such as a community center; or services for which payment was denied because they were not properly authorized.

The organization must include all paid, suspended, pending and denied claims, and is ultimately responsible for the quality of care it provides to members.

Organizations may choose whether to include reversed claims when reporting services. If an organization includes reversals, it must include these claims in all measures and avoid double counting services (e.g., if a subsequent claim is filed, use only the corrected or adjudicated claim).

Note: Denied claims are not included when identifying numerator events, but must be used to determine the eligible population for the following measures in the Clinical domain:

• Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis.

Denied claims are not included when identifying the eligible population (except for required exclusions) or numerator events for the following measures in the Behavioral Health & Substance Use subdomain:

• Use of Opioids at High Dosage.

Organizations must include all claims (paid, suspended, pending and denied) for required exclusions in all measures in the Behavioral Health & Substance Use subdomain.

Optional exclusions

Some measures in the Clinical domain allow members to be excluded from the denominator if they are identified as having a certain procedure or comorbidity (e.g., exclude women who have had a bilateral mastectomy from the Breast Cancer Screening measure).

The technical specifications contain instructions for optional exclusions, where applicable. Look for exclusions only where administrative data indicate that the specified numerator service or procedure did not occur. The organization uses the eligible population to identify members for whom administrative data show the numerator services or procedures were rendered within the time frame specified in the measure, and then counts the members as having satisfied the measure (i.e., count these members in the numerator).

The organization verifies that the exclusion occurred by the time specified in the measure.
Measure format

There are 8 possible sections in each measure specification in this domain:

1. Summary of Changes
2. Description
3. Calculation
4. Definitions
5. Eligible Population
6. Administrative Specification
7. Exclusion
8. Notes

Eligible population criteria

The eligible population includes all members who meet the following seven criteria:

1. **Product line** (Commercial HMO/POS, Commercial ACO, Medi-Cal Managed Care, Medicare Advantage) applicable to the measure.
2. **Age** group and gender requirements.
3. **Continuous enrollment** criteria for the measure.
4. **Allowable gap** in benefits during the continuous enrollment period. There are different allowable gap criteria for the Medi-Cal Managed Care product line.
5. **Anchor date** specifies the required enrollment date for the eligible population (e.g., children must be enrolled in the organization on their second birthday for inclusion in the *Childhood Immunization Status* measure).
6. **Benefit** a member must have during the continuous enrollment period to be included in the eligible population (e.g., members must have both medical and pharmacy benefits for inclusion in the *Asthma Medication Ratio* measure).
7. **Event/diagnosis** specifies the medical event or diagnosis requirements for the eligible population.

Administrative Specification

The **Administrative Specification** outlines the collection and calculation of a measure using only administrative data, and describes the eligible population, the numerator requirements and any optional exclusion allowed for the measure.
Controlling High Blood Pressure (CBP)

Measure Updates September 2020 for AMP MY 2020 and 2021

- Revised the time frame in the event/diagnosis criteria to look for two outpatient visits with a diagnosis of hypertension in the first six months of the measurement year and the year prior to the measurement year.
- Removed the restriction that only one of the two visits with a hypertension diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Added palliative care as a required exclusion.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.
- In the Administrative Specification, added telephone visits, e-visits and virtual check-ins as appropriate settings for BP readings.

Modifications From HEDIS

- The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

Description

The percentage of members 18–85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled (<140/90 mm Hg) during the measurement year.

Definitions

Adequate control

Both a representative systolic BP <140 mm Hg and a representative diastolic BP of <90 mm Hg.

Representative BP

The most recent BP reading during the measurement year on or after the second diagnosis of hypertension. If multiple BP measurements occur on the same date, or are noted in the chart on the same date, use the lowest systolic and lowest diastolic BP reading. If no BP is recorded during the measurement year, assume that the member is “not controlled.”

Eligible Population

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Product lines

Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care, (report each product line separately).

Ages

18–85 years as of December 31 of the measurement year.

Continuous enrollment

The measurement year.
...for self-reporting POs

The measurement year in the PO (parent level).

...for health plans

The measurement year in the health plan and the PO (parent level).

Allowable gap

No more than one gap in continuous enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

Anchor date

December 31 of the measurement year.

...for self-reporting POs

Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in an AMP plan on December 31 of the measurement year.

...for health plans

Enrolled in the health plan and the PO (parent level, or, for eligible POs, subgroup level) on December 31 of the measurement year.

Benefit

Medical.

Event/diagnosis

Members who had at least two visits on different dates of service with a diagnosis of hypertension on or between January 1 of the year prior to the measurement year and June 30 of the measurement year. Visit type need not be the same for the two visits. Any of the following code combinations meet criteria:

- Outpatient visit (Outpatient Without UBREV Value Set) with any diagnosis of hypertension (Essential Hypertension Value Set).
- A telephone visit (Telephone Visits Value Set) with any diagnosis of hypertension (Essential Hypertension Value Set).
- An e-visit or virtual check-in (Online Assessments Value Set) with any diagnosis of hypertension (Essential Hypertension Value Set).

Required exclusion

Members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the measurement year.

Exclusions

Exclude members who meet any of the following criteria:

Note: Supplemental data may not be used for these exclusions.

- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
  - *Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.

- Members 66–80 years of age as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must
meet **both** of the following frailty and advanced illness criteria to be excluded:

1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.

2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
   - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
     1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
     2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
     3. Identify the discharge date for the stay.
   - At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
   - At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
     1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
     2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
     3. Identify the discharge date for the stay.
   - A dispensed dementia medication (Dementia Medications List).

- Members 81 years of age and older as of December 31 of the measurement year (all product lines) with frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.

*The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.*

**Dementia Medications**

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinesterase inhibitors</td>
<td>• Donepezil</td>
</tr>
<tr>
<td></td>
<td>• Galantamine</td>
</tr>
<tr>
<td></td>
<td>• Rivastigmine</td>
</tr>
<tr>
<td>Miscellaneous central nervous system agents</td>
<td>• Memantine</td>
</tr>
<tr>
<td>Dementia combinations</td>
<td>• Donepezil-memantine</td>
</tr>
</tbody>
</table>
**Administrative Specification**

**Denominator**
The eligible population.

**Numerator**
Identify the most recent BP reading (Systolic Blood Pressure Value Set; Diastolic Blood Pressure Value Set) taken during an outpatient visit (Outpatient Without UBREV Value Set), telephone visit (Telephone Visits Value Set), e-visit or virtual check-in (Online Assessments Value Set), a nonacute inpatient encounter (Nonacute Inpatient Value Set), or remote monitoring event (Remote Blood Pressure Monitoring Value Set) during the measurement year.

The BP reading must occur on or after the date of the second diagnosis of hypertension (identified using the event/diagnosis criteria).

The member is numerator compliant if the BP is <140/90 mm Hg. The member is not compliant if the BP is ≥140/90 mm Hg, if there is no BP reading during the measurement year or if the reading is incomplete (e.g., the systolic or diastolic level is missing). If there are multiple BPs on the same date of service, use the lowest systolic and lowest diastolic BP on that date as the representative BP.

Organizations that use CPT Category II codes to identify numerator compliance for this indicator must search for all codes in the following value sets and use the most recent codes during the measurement year to determine numerator compliance for both systolic and diastolic levels.

<table>
<thead>
<tr>
<th>Value Set</th>
<th>Numerator Compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic Less Than 140 Value Set</td>
<td>Systolic compliant</td>
</tr>
<tr>
<td>Systolic Greater Than or Equal To 140 Value Set</td>
<td>Systolic not compliant</td>
</tr>
<tr>
<td>Diastolic Less Than 80 Value Set</td>
<td>Diastolic compliant</td>
</tr>
<tr>
<td>Diastolic 80–89 Value Set</td>
<td>Diastolic compliant</td>
</tr>
<tr>
<td>Diastolic Greater Than or Equal To 90 Value Set</td>
<td>Diastolic not compliant</td>
</tr>
</tbody>
</table>

**Exclusions (optional)**

- Exclude from the eligible population all members with evidence of end-stage renal disease (ESRD) (ESRD Diagnosis Value Set), dialysis (Dialysis Procedure Value Set), nephrectomy (Nephrectomy Value Set) or kidney transplant (Kidney Transplant Value Set; History of Kidney Transplant Value Set) on or prior to December 31 of the measurement year.

- Exclude from the eligible population female members with a diagnosis of pregnancy (Pregnancy Value Set) during the measurement year.

- Exclude from the eligible population all members who had a nonacute inpatient admission during the measurement year. To identify nonacute inpatient admissions:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
  3. Identify the admission date for the stay.
Statin Therapy for Patients With Cardiovascular Disease (SPC)

**Measure Updates September 2020 for AMP MY 2020 and 2021**

- Updated rules for allowable gap for the Medi-Cal Managed Care product line.
- Removed the restriction that only one of the two visits with an IVD diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added palliative care as a required exclusion.
- Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.

** Modifications from HEDIS**

- The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

**Description**

The percentage of males 21–75 years of age and females 40–75 years of age during the measurement year, who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria. The following rates are reported:

1. *Received Statin Therapy.* Members who were dispensed at least one high-intensity or moderate-intensity statin medication during the measurement year.

2. *Statin Adherence 80%.* Members who remained on a high-intensity or moderate-intensity statin medication for at least 80% of the treatment period.

**Definitions**

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPSD</td>
<td>Index prescription start date. The earliest prescription dispensing date for any statin medication of at least moderate intensity during the measurement year.</td>
</tr>
<tr>
<td>Treatment period</td>
<td>The period of time beginning on the IPSD through the last day of the measurement year.</td>
</tr>
<tr>
<td>PDC</td>
<td>Proportion of days covered. The number of days the member is covered by at least one statin medication prescription of appropriate intensity, divided by the number of days in the treatment period.</td>
</tr>
</tbody>
</table>
Calculating number of days covered for multiple prescriptions

If multiple prescriptions for different medications are dispensed on the same day, calculate the number of days covered by a statin medication (for the numerator) using the prescriptions with the longest days supply. For multiple different prescriptions dispensed on different days with overlapping days supply, count each day in the treatment period only once toward the numerator.

If multiple prescriptions for the same medication are dispensed on the same day or on different days, sum the days supply and use the total to calculate the number of days covered by a statin medication (for the numerator). For example, three prescriptions for the same medication are dispensed on the same day, each with a 30-day supply. Sum the days supply for a total of 90 days covered by a statin. Subtract any days supply that extends beyond December 31 of the measurement year.

Use the medication lists to determine if drugs are the same or different. Drugs in different medication lists are considered different drugs. For example, a dispensing event from the Amlodipine Atorvastatin High Intensity Medications List and a dispensing event from the Amlodipine Atorvastatin Moderate Intensity Medications List are dispensing events for different medications.

Eligible Population: Rate 1—Received Statin Therapy

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Product line
Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).

Age
Report two age/gender stratifications and a total rate.
- Males 21–75 years as of December 31 of the measurement year.
- Females 40–75 years as of December 31 of the measurement year.
- Total.

Continuous enrollment

...for self-reporting POs
The measurement year and the year prior to the measurement year in the PO (parent level).

...for health plans
The measurement year and the year prior to the measurement year in the health plan and PO (parent level).

Allowable gap
No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

Anchor date

...for self-reporting POs
Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in an AMP plan on December 31 of the measurement year.
Enrolled in the health plan and the PO (parent level, or, for eligible POs, subgroup level) on December 31 of the measurement year.

**Benefit**
Medical. Pharmacy during the measurement year.

**Event/diagnosis**
Follow the steps below to identify the eligible population.

**Step 1**
Members are identified for the eligible population in two ways: by event or by diagnosis. The organization must use both methods to identify the eligible population, but a member only needs to be identified by one method to be included in the measure.

*Event.* Any of the following during the year prior to the measurement year meet criteria:

- **MI.** Discharged from an inpatient setting with an MI (MI Value Set) on the discharge claim. To identify discharges:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Identify the discharge date for the stay.
- **CABG.** Members who had CABG (CABG Value Set) in any setting.
- **PCI.** Members who had PCI (PCI Value Set) in any setting.
- **Other revascularization.** Members who had any other revascularization procedures (Other Revascularization Value Set) in any setting.

*Diagnosis.* Identify members as having ischemic vascular disease (IVD) who met at least one of the following criteria during both the measurement year and the year prior to the measurement year. Criteria need not be the same across both years.

- At least one outpatient visit (Outpatient Value Set) with an IVD diagnosis (IVD Value Set),
- A telephone visit (Telephone Visits Value Set) with an IVD diagnosis (IVD Value Set),
- An e-visit or virtual check-in (Online Assessments Value Set) with an IVD diagnosis (IVD Value Set),
- At least one acute inpatient encounter (Acute Inpatient Value Set) with an IVD diagnosis (IVD Value Set) without telehealth (Telehealth Modifier Value Set; Telehealth POS Value Set),
- At least one acute inpatient discharge with an IVD diagnosis (IVD Value Set) on the discharge claim. To identify an acute inpatient discharge:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
  3. Identify the discharge date for the stay.
Step 2: Required exclusions

Exclude members who meet any of the following criteria:

- Female members with a diagnosis of pregnancy (Pregnancy Value Set) during the measurement year or the year prior to the measurement year.
- In vitro fertilization (IVF Value Set) in the measurement year or year prior to the measurement year.
- Dispensed at least one prescription for clomiphene (Estrogen Agonists Medications List) during the measurement year or the year prior to the measurement year.
- ESRD (ESRD Diagnosis Value Set) or dialysis (Dialysis Procedure Value Set) during the measurement year or the year prior to the measurement year.
- Cirrhosis (Cirrhosis Value Set) during the measurement year or the year prior to the measurement year.
- Myalgia, myositis, myopathy, or rhabdomyolysis (Muscular Pain and Disease Value Set) during the measurement year.
- Members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the measurement year.

### Estrogen Agonists Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrogen agonists</td>
<td>Clomiphene</td>
</tr>
</tbody>
</table>

Step 3: Exclusions

Exclude members who meet any of the following criteria:

**Note: Supplemental data may not be used for these exclusions.**

- Members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
  - "Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.
- Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet both of the following frailty and advanced illness criteria to be excluded:
  1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.
  2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
    - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim)
on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
3. Identify the discharge date for the stay.
   – At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
   – At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
      1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
      2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
      3. Identify the discharge date for the stay.
      – A dispensed dementia medication (Dementia Medications List).

*The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

### Dementia Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinesterase inhibitors</td>
<td>• Donepezil</td>
</tr>
<tr>
<td></td>
<td>• Galantamine</td>
</tr>
<tr>
<td></td>
<td>• Rivastigmine</td>
</tr>
<tr>
<td>Miscellaneous central nervous system agents</td>
<td>• Memantine</td>
</tr>
<tr>
<td>Dementia combinations</td>
<td>• Donepezil-memantine</td>
</tr>
</tbody>
</table>

### Administrative Specification: Rate 1—Received Statin Therapy

**Denominator**
The Rate 1 eligible population.

**Numerator**
The number of members who had at least one dispensing event for a high-intensity or moderate-intensity statin medication during the measurement year. Use all the medication lists below to identify statin medication dispensing events.

### High and Moderate-Intensity Statin Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
<th>Medication Lists</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-intensity statin therapy</td>
<td>• Atorvastatin 40-80 mg</td>
<td>Atorvastatin High Intensity Medications List</td>
</tr>
<tr>
<td>High-intensity statin therapy</td>
<td>• Amlodipine-atorvastatin 40-80 mg</td>
<td>Amlodipine Atorvastatin High Intensity Medications List</td>
</tr>
<tr>
<td>High-intensity statin therapy</td>
<td>• Rosuvastatin 20-40 mg</td>
<td>Rosuvastatin High Intensity Medications List</td>
</tr>
<tr>
<td>High-intensity statin therapy</td>
<td>• Simvastatin 80 mg</td>
<td>Simvastatin High Intensity Medications List</td>
</tr>
<tr>
<td>High-intensity statin therapy</td>
<td>• Ezetimibe-simvastatin 80 mg</td>
<td>Ezetimibe Simvastatin High Intensity Medications List</td>
</tr>
<tr>
<td>Description</td>
<td>Prescriptions</td>
<td>Medication Lists</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>------------------------------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Atorvastatin 10-20 mg</td>
<td>Atorvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Amlodipine-atorvastatin 10-20 mg</td>
<td>Amlodipine Atorvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Rosuvastatin 5-10 mg</td>
<td>Rosuvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Simvastatin 20-40 mg</td>
<td>Simvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Ezetimibe-simvastatin 20-40 mg</td>
<td>Ezetimibe Simvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Pravastatin 40-80 mg</td>
<td>Pravastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Lovastatin 40 mg</td>
<td>Lovastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Fluvastatin 40-80 mg</td>
<td>Fluvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Pitavastatin 2–4 mg</td>
<td>Pitavastatin Moderate Intensity Medications List</td>
</tr>
</tbody>
</table>

### Eligible Population: Rate 2—Statin Adherence 80%

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

- **Product line**
  - Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).

- **Age**
  - Report two age/gender stratifications and a total rate.
  - Males 21–75 years as of December 31 of the measurement year.
  - Females 40–75 years as of December 31 of the measurement year.
  - Total.

- **Continuous enrollment**
  - **...for self-reporting POs**
    - The measurement year and the year prior to the measurement year in the PO (parent level).
  - **...for health plans**
    - The measurement year and the year prior to the measurement year in the health plan and PO (parent level).

- **Allowable gap**
  - No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

- **Anchor date**
  - December 31 of the measurement year.

- **Benefit**
  - Medical. Pharmacy during the measurement year.

- **Event/diagnosis**
  - All members who meet the numerator criteria for Rate 1.
Administrative Specification: *Rate 2—Statin Adherence 80%*

<table>
<thead>
<tr>
<th>Denominator</th>
<th>The Rate 2 eligible population.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numerator</td>
<td>The number of members who achieved a PDC of at least 80% during the treatment period.</td>
</tr>
</tbody>
</table>

Follow the steps below to identify numerator compliance.

**Step 1** Identify the IPSD. The IPSD is the earliest dispensing event for any high-intensity or moderate-intensity statin medication during the measurement year. Use all the medications lists above to identify statin medication dispensing events.

**Step 2** To determine the treatment period, calculate the number of days beginning on the IPSD through the end of the measurement year.

**Step 3** Count the days covered by at least one prescription for any high-intensity or moderate-intensity statin medication during the treatment period. To ensure that days supply that extends beyond the measurement year is not counted, subtract any days supply that extends beyond December 31 of the measurement year.

**Step 4** Calculate the member's PDC using the following equation. Multiply the equation by 100 and round (using the .5 rule) to the nearest whole number. For example, if a member has 291 total days covered by a medication during a 365-day treatment period, this calculates to 0.7972. Multiply this number by 100, convert it to 79.72% and round it to 80%, the nearest whole number.

\[
\text{PDC} = \left( \frac{\text{Total Days Covered by a Statin Medication in the Treatment Period (step 3)}}{\text{Total Days in Treatment Period (step 2)}} \right) \times 100
\]

**Step 5** Sum the number of members whose PDC is ≥80% for the treatment period.

**Note**
- *All members who are numerator compliant for Rate 1 must be used as the eligible population for Rate 2 (regardless of the data source used to capture the Rate 1 numerator). For example, if supplemental data were used to identify compliance for the Rate 1 numerator, then supplemental data will be included in identifying the Rate 2 eligible population.*
Proportion of Days Covered by Medications (PDC)

MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021

- Updated language in Treatment period.
- Updated language in Continuous Enrollment criteria to include a 1-day allowable gap.
- Added definition for Prescription Claims.
- Added clarification to Step 3 of numerator calculation.
- Changed Medication Table names.
- Added niacinamide to insulin medications.

MODIFICATIONS FROM HEDIS

- This is a non-HEDIS measure developed by the Pharmacy Quality Alliance (PQA).

Description

- Proportion of Days Covered by Medications—Renin Angiotensin System (RAS) Antagonists is the same as the CMS Stars measure Medication Adherence for Hypertension (RAS Antagonists).
- Proportion of Days Covered by Medications—Statins is the same as the CMS Stars measure Medication Adherence for Cholesterol (Statins).
- Proportion of Days Covered by Medications—Diabetes All-Class Medications is the same as the CMS Stars measure Medication Adherence for Diabetes All-Class Medications.

The percentage of members 18 years of age and older who met the proportion of days covered (PDC) threshold of 80 percent for select medications during the measurement year. Members must have filled at least two prescriptions in a given medication category on different dates of service during the treatment period to be included in the measure.

Report a performance rate for each of the following:

**Cardiovascular**
- Proportion of Days Covered by Medications: RAS antagonists (PDC-RASA) (i.e., ACEI, ARB, direct renin inhibitors).
- Proportion of Days Covered by Medications: Statins (PDC-STA).

**Diabetes**
- Proportion of Days Covered by Medications: Diabetes (PDC-DR) (i.e., biguanides, sulfonylureas, thiazolidinediones or DPP-IV inhibitors, incretin mimetic agents, meglitinides and sodium glucose co-transporter 2 [SGLT2] inhibitors).

**Note:** Refer to the AMP Value Set Directory download for a comprehensive list of PQA medications and associated codes (PQA NDC Code List and PQA ICD Code List). Do not distribute NDC lists outside your organization.
**Definitions**

**IPSD**

Index prescription start date. The date of the first fill of the target medication that meets the following criteria:

- The fill date is between January 1 and October 2 of the measurement year.
- The member’s treatment period begins on this date. Only paid, non-reversed claims for target medications count for this measure.

**Treatment period**

The period of time beginning on a member’s IPSD through the last day of enrollment during the measurement year, death, or the end of the measurement year. The last day of enrollment in the pharmacy benefit counts as the last day of enrollment. The treatment period must be at least 91 days long.

**Prescription claims**

Only paid, non-reversed prescription claims are included in the data set to calculate the measure.

**PDC**

The proportion of days in the treatment period “covered” by prescription claims for the same medication or another in its therapeutic category.

**PDC threshold**

The level of PDC above which the medication has a reasonable likelihood of achieving most of the potential clinical benefit (i.e., 80 percent).

**Hospice exclusion**

For Commercial HMO and Medi-Cal Managed Care reporting, refer to General Guideline 15: Members in Hospice.

Health plans reporting for Medicare Advantage, identify any member with a hospice indicator from the Monthly Membership Detail File.

POs reporting for Medicare Advantage have the option of using the Monthly Membership Detail File or the HEDIS Hospice Encounter Value Set and Hospice Intervention Value Set to identify members in Hospice, refer to General Guideline 15: Members in Hospice.

**End-Stage Renal Disease diagnosis exclusion**

Applies to PDC-DR, PDC-RASA and PDC-STA.

Any members with an ESRD diagnosis at any time during the measurement year. Refer to PQA Value Set, ESRD.

An ESRD diagnosis is defined as having at least one claim with any of the listed ESRD diagnoses, including primary diagnosis or any other diagnosis fields during the measurement year.

Medicare Data (if ICD codes not available): RxHCC 261—Dialysis Status for Payment Year 2019. Available at: [https://www.cms.gov/Medicare/Health-Plans/MedicareAdvGTgSpecRateStats/Risk-Adjustors.html](https://www.cms.gov/Medicare/Health-Plans/MedicareAdvGTgSpecRateStats/Risk-Adjustors.html)

**Note:** Use the most current information for the ESRD exclusion; using diagnosis codes is the preferred method. The RxHCC code can be found in the CMS Medicare Advantage and Prescription Drug System (MARx), which provides a monthly report of members’ RxHCCs to plan sponsors. If the MARx System output is used, then the most recent version applies. Although the time frames are not consistent between diagnosis codes and the MARx System, using the most recent version provides the most current information to identify members with ESRD.
**Insulin exclusion**
Applies to PDC-DR.

Any members who have one or more prescriptions for insulin in the treatment period. Refer to Medication Table INSULINS: Insulin Exclusion.

**Sacubitril/Valsartan exclusion**
Applies to PDC-RASA.

Any members with one or more prescription claims for the medication sacubitril/valsartan during the treatment period. Refer to Medication Table SAC-VAL: Sacubitril/Valsartan Exclusion.

---

**Eligible Population**

**Product lines**
Commercial HMO/POS, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).

**Age**
18 years and older as of the first day of the measurement year.

**Continuous enrollment**

---

**...for self-reporting POs**
*Treatment period:* The IPSD through the end of the measurement year or until death or disenrollment from the PO (parent level).

*Exclude members with >1-day gap in enrollment during the treatment period.* **Note:**
This allows for a one-day gap to compensate for discrepancies in the enrollment data. For example, if a member was eligible from 1/1-4/1 and 4/3-12/31, they would still be continuously enrolled despite the one-day gap in eligibility on 4/2.

---

**...for health plans**
*Treatment period:* The IPSD through the end of the measurement year or until death or disenrollment from in the health plan and from the PO (parent level).

*Exclude members with >1-day gap in enrollment during the treatment period.* **Note:**
This allows for a one-day gap to compensate for discrepancies in the enrollment data. For example, if a member was eligible from 1/1-4/1 and 4/3-12/31, they would still be continuously enrolled despite the one-day gap in eligibility on 4/2.

---

**Anchor date**

---

**...for self-reporting POs**
None.

**...for health plans**
None.

**Benefit**
Medical, pharmacy.

**Event/diagnosis**
Refer to Additional Eligible Population Criteria for each rate.

---

**Note**

- *If a PO receives pharmacy claim information for a member, the PO can assume the member has a pharmacy benefit, and that the pharmacy benefit dates align with the medical benefit dates.*
- *Do not include members who disenroll and reenroll more than one day later at any time during the measurement year, after the treatment period.*
Administrative Specification

Report each rate separately. Members may be counted in the denominator for multiple rates if they have been dispensed the relevant medications, though for each rate, the proportion of days covered should only be counted once per member.

PDC for Renin Angiotensin System (RAS) Antagonists

**Additional eligible population criteria**

Members who filled at least two prescriptions for a RAS antagonist: ACEI/ARB/direct renin inhibitor or ACEI/ARB/direct renin inhibitor combination (Medication Table RASA: Renin Angiotensin System [RAS]) Antagonist Medications) on different dates of service during the treatment period. Use only paid, non-reversed claims for target medications to determine if members are eligible. The prescriptions may be for the same or different medications.

**Denominator**
The eligible population.

**Denominator exclusion (required)**
Any members with one or more of the following:

- **Hospice**: A hospice indicator at any time during the measurement year.
- **ESRD**: An ESRD diagnosis at any time during the measurement year.
- **Sacubitril/valsartan**: A prescription claim for sacubitril/valsartan during the treatment period. Refer to Table SAC-VAL.

### Table RASA: Renin Angiotensin System (RAS) Antagonists

#### Direct Renin Inhibitor Medications and Combinations

- Aliskiren (+/- hydrochlorothiazide)

#### ARB Medications and Combinations

- Azilsartan (+/- chlorthalidone)
- Candesartan (+/- hydrochlorothiazide)
- Eprosartan (+/- hydrochlorothiazide)
- Irbesartan (+/- hydrochlorothiazide)
- Losartan (+/- hydrochlorothiazide)
- Olmesartan (+/- amlodipine, hydrochlorothiazide)
- Telmisartan (+/- amlodipine, hydrochlorothiazide)
- Valsartan (+/- amlodipine, hydrochlorothiazide, nebivolol)

#### ACE Inhibitor Medications and Combination Products

- Benazepril (+/- amlodipine, hydrochlorothiazide)
- Captopril (+/- hydrochlorothiazide)
- Enalapril (+/- hydrochlorothiazide)
- Lisinopril (+/- hydrochlorothiazide)
- Moexipril (+/- hydrochlorothiazide)
- Perindopril (+/- amlodipine)
- Quinapril (+/- hydrochlorothiazide)
- Ramipril
- Trandolapril (+/- verapamil)

**Note:** Active ingredients are limited to oral formulations only. Excludes nutritional supplement/dietary management combination products.
Table SAC-VAL: Sacubitril/Valsartan

<table>
<thead>
<tr>
<th>ARB/Neprilysin Inhibitor Combination Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Sacubitril/valsartan</td>
</tr>
</tbody>
</table>

**Numerator**
The number of members who met the PDC threshold during the measurement year. Follow the steps below for each member to determine whether the member meets the PDC threshold.

**Step 1**
Determine the treatment period, defined as the index prescription date (IPSD) to the end of the measurement year, disenrollment, or death.

**Step 2**
Within the treatment period, count the days the member was covered by at least one drug in the class based on the prescription fill date and days of supply. If prescriptions for the same target drug (generic ingredient) overlap, adjust the prescription start date to be the day after the previous fill has ended. *

*Adjustment of overlap should also occur when there is overlap of a single drug product to a combination product containing the single target drug or when there is an overlap of a combination product to another combination product where at least one of the drugs is common.

**Step 3**
Divide the number of covered days found in Step 2 by the number of days found in Step 1. Multiply this number by 100 to obtain the PDC (as a percentage) for each member. Then, round the PDC to the nearest hundredth (e.g. 79.996% is rounded to 80.00%, 79.992% is rounded to 79.99%).

**Step 4**
Count the number of members who had a PDC of 80.00 percent or greater.

Calculate performance rate
Divide the number of members from step 4 by the total number of eligible members.

An example of SAS code for steps 1–3 is available from PQA upon request and at http://www2.sas.com/proceedings/forum2007/043-2007.pdf

**PDC for Statin Medications**

**Additional eligible population criteria**
Members who filled at least two prescriptions for a statin or statin combination (Medication Table STATINS) on different dates of service during the treatment period. Use only paid, non-reversed claims for target medications to determine if members are eligible. The prescriptions may be for the same or different medications.

**Denominator**
The eligible population.

**Denominator exclusion (required)**
Any members with the following:

- **Hospice**: A hospice indicator at any time during the measurement year.
- **ESRD**: An ESRD diagnosis at any time during the measurement year.
### Table STATINS: Statins

<table>
<thead>
<tr>
<th>Statin Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Atorvastatin (+/- amlodipine)</td>
</tr>
<tr>
<td>• Fluvastatin</td>
</tr>
<tr>
<td>• Lovastatin (+/- niacin)</td>
</tr>
<tr>
<td>• Pitavastatin</td>
</tr>
<tr>
<td>• Pravastatin</td>
</tr>
<tr>
<td>• Rosuvastatin</td>
</tr>
<tr>
<td>• Simvastatin (+/-ezetimibe, niacin)</td>
</tr>
</tbody>
</table>

**Note:** Active ingredients are limited to oral formulations only.

### Numerator

The number of members who met the PDC threshold during the measurement year. Follow the steps below for each member to determine whether the member meets the PDC threshold.

#### Step 1

Determine the treatment period, defined as the IPSD to the end of the measurement year, disenrollment or death.

#### Step 2

Within the treatment period, count the days the member was covered by at least one drug in the class based on the prescription fill date and days of supply. If prescriptions for the same target drug (generic ingredient) overlap, adjust the prescription start date to be the day after the previous fill has ended. *

*Adjustment of overlap should also occur when there is overlap of a single drug product to a combination product containing the single target drug or when there is an overlap of a combination product to another combination product where at least one of the drugs is common.*

#### Step 3

Divide the number of covered days found in Step 2 by the number of days found in Step 1. Multiply this number by 100 to obtain the PDC (as a percentage) for each individual. Then, round the PDC to the nearest hundredth (e.g. 79.996% is rounded to 80.00%, 79.992% is rounded to 79.99%).

#### Step 4

Count the number of members who had a PDC of 80.00 percent or greater.

**Calculate performance rate**

Divide the number of members from step 4 by the total number of eligible members.


### PDC Diabetes All-Class Medications

**Additional eligible population criteria**

Members who filled at least two prescriptions for any Diabetes All-Class medication (Medication Tables BG, SFU, TZD, DPP4, GLP1, MEG, or SGLT2) on different dates of service during the treatment period. Use only paid, non-reversed claims for target medications to determine if members are eligible. The prescriptions may be for the same or different medications, and from any of the seven diabetic categories.

**Denominator**

The eligible population.

**Denominator exclusion (required)**

Any members with one or more of the following:

- *Hospice:* A hospice indicator at any time during the measurement year.
- *ESRD:* An ESRD diagnosis at any time during the measurement year.
- *Insulin:* A prescription claim for insulin during the treatment period (Refer to Medication Table INSULINS).
**Table BG: Biguanides**

<table>
<thead>
<tr>
<th>Biguanide Medications and Combinations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Metformin (+/- alogliptin, canagliflozin, dapagliflozin, empagliflozin, eruditoflozin, glipizide, glyburide, linagliptin, pioglitazone, repaglinide, rosiglitazone, saxagliptin, sitagliptin)</td>
</tr>
</tbody>
</table>

**Note:** Active ingredients are limited to oral formulations only. Excludes nutritional supplement/dietary management combination products.

**Table SFU: Sulfonylureas**

<table>
<thead>
<tr>
<th>Sulfonylurea Medications and Combinations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Chlorpropamide</td>
</tr>
<tr>
<td>• Glimepiride (+/- pioglitazone)</td>
</tr>
<tr>
<td>• Glipizide (+/- metformin)</td>
</tr>
<tr>
<td>• Glyburide (+/- metformin)</td>
</tr>
<tr>
<td>• Tolazamide</td>
</tr>
<tr>
<td>• Tolbutamide</td>
</tr>
</tbody>
</table>

**Note:** Active ingredients are limited to oral formulations only. Includes all salts and dosage forms.

**Table TZD: Thiazolidinediones**

<table>
<thead>
<tr>
<th>Thiazolidinedione Medications and Combinations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Pioglitazone (+/- alogliptin, glimepiride, metformin)</td>
</tr>
<tr>
<td>• Rosiglitazone (+/- metformin)</td>
</tr>
</tbody>
</table>

**Note:** Active ingredients are limited to oral formulations only.

**Table DPP4: DPP-4 Inhibitors**

<table>
<thead>
<tr>
<th>DPP-4 Medications and Combinations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Alogliptin (+/- metformin, pioglitazone)</td>
</tr>
<tr>
<td>• Linagliptin (+/- empagliflozin, metformin)</td>
</tr>
<tr>
<td>• Saxagliptin (+/- metformin, dapagliflozin)</td>
</tr>
<tr>
<td>• Sitagliptin (+/- metformin, eruditoflozin)</td>
</tr>
</tbody>
</table>

**Note:** Active ingredients are limited to oral formulations only.

**Table GLP1: GLP-1 Receptor Agonists**

<table>
<thead>
<tr>
<th>GLP-1 Receptor Agonist Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Albiglutide</td>
</tr>
<tr>
<td>• Dulaglutide</td>
</tr>
<tr>
<td>• Exenatide</td>
</tr>
<tr>
<td>• Liraglutide</td>
</tr>
<tr>
<td>• Lixisenatide</td>
</tr>
<tr>
<td>• Semaglutide</td>
</tr>
</tbody>
</table>

**Table MEG: Meglitinides**

<table>
<thead>
<tr>
<th>Meglitinides and Combinations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Nateglinide</td>
</tr>
<tr>
<td>• Repaglinide (+/- metformin)</td>
</tr>
</tbody>
</table>

**Note:** Active ingredients are limited to oral formulations only.

**Table SGLT2: Sodium Glucose Co-Transporter2 (SGLT2) Inhibitors**

<table>
<thead>
<tr>
<th>SGLT2 Inhibitors and Combinations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Canagliflozin (+/- metformin)</td>
</tr>
<tr>
<td>• Dapagliflozin (+/- metformin, saxagliptin)</td>
</tr>
<tr>
<td>• Empagliflozin (+/- metformin, linagliptin)</td>
</tr>
<tr>
<td>• Ertugliflozin (+/- sitagliptin, metformin)</td>
</tr>
</tbody>
</table>

**Note:** Active ingredients are limited to oral formulations only.
Table INSULINS: Insulin Exclusion
Refer to the Insulins tab in the PQA NDC Code list.

<table>
<thead>
<tr>
<th>Insulins</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Insulin aspart (+/-insulin aspart protamine, niacinamide)</td>
</tr>
<tr>
<td>• Insulin degludec (+/- liraglutide)</td>
</tr>
<tr>
<td>• Insulin detemir</td>
</tr>
<tr>
<td>• Insulin glargine (+/- lixisenatide)</td>
</tr>
<tr>
<td>• Insulin glulisine</td>
</tr>
<tr>
<td>• Insulin isophane (+/- regular insulin)</td>
</tr>
<tr>
<td>• Insulin lispro (+/- insulin lispro protamine)</td>
</tr>
<tr>
<td>• Insulin regular (including inhalation powder)</td>
</tr>
</tbody>
</table>

Note: The active ingredients are limited to inhaled and injectable formulations only.

Numerator The number of members who met the PDC threshold during the measurement year. Follow the steps below for each member to determine whether the member meets the PDC threshold.

Step 1 Determine the treatment period, defined as the index prescription date (IPSD) to the end of the enrollment year, disenrollment or death.

Step 2 Within the treatment period, count the days the member was covered by at least one drug from any of the diabetes drugs (listed in Medication Tables BG, SFU, TZD, DPP4, GLP1, MEG, or SGLT2) based on the prescription fill date and days of supply. If prescriptions for the same target drug (generic ingredient) overlap, adjust the prescription start date to be the day after the previous fill has ended. *

* Adjustment of overlap should also occur when there is overlap of a single drug product to a combination product containing the target single drug or when there is an overlap of a combination product to another combination product where at least one of the drugs is common.

Step 3 Divide the number of covered days found in Step 2 by the number of days found in Step 1. Multiply this number by 100 to obtain the PDC (as a percentage) for each individual. Then, round the PDC to the nearest hundredth (e.g. 79.996% is rounded to 80.00%, 79.992% is rounded to 79.99%).

Step 4 Count the number of members who had a PDC 80.00 percent or greater.

Calculate performance rate Divide the number of members from step 4 by the total number of eligible members.

## Comprehensive Diabetes Care (CDC)

*HbA1c Testing (One Test), HbA1c Poor Control (>9.0%), HbA1c Control (<8.0%), Eye Exam, Medical Attention for Nephropathy, Blood Pressure Control (<140/90), Optimal Diabetes Care*

### MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021

- Updated rules for allowable gap for the Medi-Cal Managed Care product line.
- Removed the restriction that only one of the two visits with a diabetes diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added palliative care as a required exclusion.
- Deleted the HbA1c Level 7.0-9.0 Value Set.
- Updated the Administrative Specification logic and value sets for the Eye Exam indicator.
- Added telephone visits, e-visits and virtual check-ins to the Administrative Specification as appropriate settings for BP readings.
- Added Nebivolol-valsartan to the “Antihypertensive combinations” description in the ACE inhibitor and ARB Medications List.
- Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.
- Added polycystic ovarian syndrome to the optional exclusions.

### MODIFICATIONS FROM HEDIS

- Optimal Diabetes Care Combination Rate is a non-HEDIS measure that is an “all or none” combination rate composed of four indicators.
- AMP does not include Medicare SES Stratifications for the Eye Exam indicator.
- The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

### Description

- *Comprehensive Diabetes Care—Medical Attention for Nephropathy* is the same measure as the CMS Stars measure Diabetes Care—Kidney Disease Monitoring.
- *Comprehensive Diabetes Care—HbA1c Poor Control (>9.0%)* is the same measure as the CMS Stars measure Diabetes Care—Blood Sugar Controlled.
- *Comprehensive Diabetes Care—Eye Exam* is the same measure as the CMS Stars measure Diabetes Care—Eye Exam.

The percentage of members 18–75 years of age with diabetes (type 1 and type 2) who had each of the following:

- Hemoglobin A1c (HbA1c) Testing (One Test)
- HbA1c poor control (>9.0%).
- HbA1c control (<8.0%).
- Eye exam (retinal) performed.
- Medical attention for nephropathy.
- BP control (<140/90 mm Hg).
Also report the following measure: Optimal Diabetes Care Combination Rate. *

- HbA1c Control (<8.0%).
- BP Control (<140/90 mm Hg)
- Medical Attention for Nephropathy.
- Eye Exam (Retinal) Performed.

*The Optimal Diabetes Care Combination Rate measure comprises four process and outcome indicators; “all or none” criterion is used to qualify for each combination rate.

### Eligible Population

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

**Product line** Report each product line separately.

<table>
<thead>
<tr>
<th>Clinical Measures</th>
<th>Commercial HMO</th>
<th>Commercial ACO</th>
<th>Medicare Advantage</th>
<th>Medi-Cal Managed Care</th>
<th>Non-HEDIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comprehensive Diabetes Care—HbA1c Testing (One Test)</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Comprehensive Diabetes Care—HbA1c Poor Control (&gt;9.0%)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Comprehensive Diabetes Care—HbA1c Control (&lt;8.0%)</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive Diabetes Care—Eye Exam (Retinal) Performed</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Comprehensive Diabetes Care—Medical Attention for Nephropathy</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Comprehensive Diabetes Care—Blood Pressure Control (&lt;140/90 mm Hg)</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Comprehensive Diabetes Care—Optimal Diabetes Care</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

**Ages** 18–75 years as of December 31 of the measurement year.

**Continuous enrollment**

...for self-reporting POs

The measurement year in the PO (parent level).

...for health plans

The measurement year in the health plan and the PO (parent level).

**Allowable gap**

No more than one gap in enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g. a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
Anchor date

...for self-reporting POs
Enrolled in the PO (parent level, or, for eligible POs, subgroup level) and in an AMP plan on December 31 of the measurement year.

...for health plans
Enrolled in the health plan and the PO (parent level, or, for eligible POs, subgroup level) on December 31 of the measurement year.

Benefit
Medical.

Event/diagnosis
There are two ways to identify members with diabetes: by claim/encounter data and by pharmacy data. The organization must use both methods to identify the eligible population, but a member only needs to be identified by one method to be included in the measure. Members may be identified as having diabetes during the measurement year or the year prior to the measurement year.

Claim/encounter data. Members who met any of the following criteria during the measurement year or the year prior to the measurement year (count services that occur over both years):

- At least one acute inpatient encounter (Acute Inpatient Value Set) with a diagnosis of diabetes (Diabetes Value Set) without telehealth (Telehealth Modifier Value Set; Telehealth POS Value Set).
- At least one acute inpatient discharge with a diagnosis of diabetes (Diabetes Value Set) on the discharge claim. To identify an acute inpatient discharge:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
  3. Identify the discharge date for the stay.
- At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), ED visits (ED Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim), on different dates of service, with a diagnosis of diabetes (Diabetes Value Set). Visit type need not be the same for the two encounters. To identify a nonacute inpatient discharge:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
  3. Identify the discharge date for the stay.
Only include nonacute inpatient encounters (Nonacute Inpatient Value Set) without telehealth (Telehealth Modifier Value Set; Telehealth POS Value Set).

Pharmacy data. Members who were dispensed insulin or hypoglycemics/antihyperglycemics on an ambulatory basis during the measurement year or the year prior to the measurement year (Diabetes Medications List).
## Diabetes Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-glucosidase inhibitors</td>
<td>• Acarbose</td>
</tr>
<tr>
<td></td>
<td>• Miglitol</td>
</tr>
<tr>
<td>Amylin analogs</td>
<td>• Pramlinitide</td>
</tr>
<tr>
<td>Antidiabetic combinations</td>
<td>• Alogliptin-metformin</td>
</tr>
<tr>
<td></td>
<td>• Alogliptin-pioglitazone</td>
</tr>
<tr>
<td></td>
<td>• Canagliflozin-metformin</td>
</tr>
<tr>
<td></td>
<td>• Dapagliflozin-metformin</td>
</tr>
<tr>
<td></td>
<td>• Empagliflozin-linagliptin</td>
</tr>
<tr>
<td></td>
<td>• Empagliflozin-metformin</td>
</tr>
<tr>
<td></td>
<td>• Glimepiride-pioglitazone</td>
</tr>
<tr>
<td></td>
<td>• Glipizide-metformin</td>
</tr>
<tr>
<td></td>
<td>• Glyburide-metformin</td>
</tr>
<tr>
<td></td>
<td>• Linagliptin-metformin</td>
</tr>
<tr>
<td></td>
<td>• Metformin-pioglitazone</td>
</tr>
<tr>
<td></td>
<td>• Metformin-rosiglitazone</td>
</tr>
<tr>
<td></td>
<td>• Metformin-saxagliptin</td>
</tr>
<tr>
<td></td>
<td>• Metformin-sitagliptin</td>
</tr>
<tr>
<td>Insulin</td>
<td>• Insulin aspart</td>
</tr>
<tr>
<td></td>
<td>• Insulin aspart-insulin aspart protamine</td>
</tr>
<tr>
<td></td>
<td>• Insulin degludec</td>
</tr>
<tr>
<td></td>
<td>• Insulin detemir</td>
</tr>
<tr>
<td></td>
<td>• Insulin glargine</td>
</tr>
<tr>
<td></td>
<td>• Insulin glulisine</td>
</tr>
<tr>
<td></td>
<td>• Insulin isophane human</td>
</tr>
<tr>
<td></td>
<td>• Insulin isophane-insulin regular</td>
</tr>
<tr>
<td></td>
<td>• Insulin lispro</td>
</tr>
<tr>
<td></td>
<td>• Insulin lispro-insulin lispro protamine</td>
</tr>
<tr>
<td></td>
<td>• Insulin regular human</td>
</tr>
<tr>
<td></td>
<td>• Insulin human inhaled</td>
</tr>
<tr>
<td>Meglitinides</td>
<td>• Nateglinide</td>
</tr>
<tr>
<td></td>
<td>• Repaglinide</td>
</tr>
<tr>
<td>Glucagon-like peptide-1 (GLP1) agonists</td>
<td>• Dulaglutide</td>
</tr>
<tr>
<td></td>
<td>• Exenatide</td>
</tr>
<tr>
<td></td>
<td>• Albiglutide (excluding Saxenda®)</td>
</tr>
<tr>
<td>Sodium glucose cotransporter 2 (SGLT2)</td>
<td>• Canagliflozin</td>
</tr>
<tr>
<td>inhibitor</td>
<td>• Dapagliflozin</td>
</tr>
<tr>
<td></td>
<td>• Empagliflozin</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>• Chlorpropamide</td>
</tr>
<tr>
<td></td>
<td>• Glimepiride</td>
</tr>
<tr>
<td></td>
<td>• Glipizide</td>
</tr>
<tr>
<td></td>
<td>• Glyburide</td>
</tr>
<tr>
<td></td>
<td>• Tolazamide</td>
</tr>
<tr>
<td></td>
<td>• Tolbutamide</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>• Pioglitazone</td>
</tr>
<tr>
<td></td>
<td>• Rosiglitazone</td>
</tr>
<tr>
<td>Dipeptidyl peptidase-4 (DDP-4) inhibitors</td>
<td>• Alogliptin</td>
</tr>
<tr>
<td></td>
<td>• Linagliptin</td>
</tr>
<tr>
<td></td>
<td>• Saxagliptin</td>
</tr>
<tr>
<td></td>
<td>• Sitagliptin</td>
</tr>
</tbody>
</table>

**Note:** Glucophage/metformin as a solo agent is not included because it is used to treat conditions other than diabetes; members with diabetes on these medications are identified through diagnosis codes only.

**Required exclusion**

Exclude members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the measurement year.

**Exclusions**

Exclude members who meet any of the following criteria:

**Note:** Supplemental data may not be used for these exclusions.

- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
• Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.

• Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet BOTH of the following frailty and advanced illness criteria to be excluded:
  1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.
  2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
     - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
       1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
       2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
       3. Identify the discharge date for the stay.
     - At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
     - At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
       1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
       2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
       3. Identify the discharge date for the stay.
     - A dispensed dementia medication (Dementia Medications List).

*The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

Dementia Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinesterase inhibitors</td>
<td>• Donepezil</td>
</tr>
<tr>
<td></td>
<td>• Galantamine</td>
</tr>
<tr>
<td></td>
<td>• Rivastigmine</td>
</tr>
<tr>
<td>Miscellaneous central nervous system agents</td>
<td>• Memantine</td>
</tr>
<tr>
<td>Dementia combinations</td>
<td>• Donepezil-memantine</td>
</tr>
</tbody>
</table>
### Administrative Specification

**Denominator**
The eligible population.

**Numerators**

**HbA1c Testing**
One HbA1c test (HbA1c Lab Test Value Set; HbA1c Test Result or Finding Value Set) performed during the measurement year.

**HbA1c Poor Control >9%**
Use codes in the (HbA1c Lab Test Value Set; HbA1c Test Result or Finding Value Set) to identify the most recent HbA1c test during the measurement year. The member is numerator compliant if the most recent HbA1c level is >9.0% or is missing a result, or if an HbA1c test was not done during the measurement year. The member is not numerator compliant if the result for the most recent HbA1c test during the measurement year is ≤9.0%.

Organizations that use CPT Category II codes to identify numerator compliance for this indicator must search for all codes in the following value sets and use the most recent code during the measurement year to evaluate whether the member is numerator compliant.

<table>
<thead>
<tr>
<th>Value Set</th>
<th>Numerator Compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c Level Less Than 7.0 Value Set</td>
<td>Not compliant</td>
</tr>
<tr>
<td>HbA1c Level Greater than or Equal To 7.0 and Less Than 8.0 Value Set</td>
<td>Not compliant</td>
</tr>
<tr>
<td>HbA1c Level Greater than or Equal To 8.0 and Less than or Equal To 9.0 Value Set</td>
<td>Not compliant</td>
</tr>
<tr>
<td>HbA1c Level Greater Than 9.0 Value Set</td>
<td>Compliant</td>
</tr>
</tbody>
</table>

**Note:** A lower rate indicates better performance for this indicator (i.e., low rates of poor control indicate better care).

**HbA1c Control <8%**
Use codes in the (HbA1c Lab Test Value Set; HbA1c Test Result or Finding Value Set) to identify the most recent HbA1c test during the measurement year. The member is numerator compliant if the most recent HbA1c level is <8.0%. The member is not numerator compliant if the result for the most recent HbA1c test is ≥8.0% or is missing a result, or if an HbA1c test was not done during the measurement year.

Organizations that use CPT Category II codes to identify numerator compliance for this indicator must search for all codes in the following value sets and use the most recent code during the measurement year to evaluate whether the member is numerator compliant.

<table>
<thead>
<tr>
<th>Value Set</th>
<th>Numerator Compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c Level Less Than 7.0 Value Set</td>
<td>Compliant</td>
</tr>
<tr>
<td>HbA1c Level Greater than or Equal To 7.0 and Less Than 8.0 Value Set</td>
<td>Compliant</td>
</tr>
<tr>
<td>HbA1c Level Greater than or Equal To 8.0 and Less than or Equal To 9.0 Value Set</td>
<td>Not compliant</td>
</tr>
<tr>
<td>HbA1c Level Greater Than 9.0 Value Set</td>
<td>Not compliant</td>
</tr>
</tbody>
</table>
Eye Exam  Screening or monitoring for diabetic retinal disease as identified by administrative data. This includes diabetics who had one of the following:

- A retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist) in the measurement year.
- A negative retinal or dilated eye exam (negative for retinopathy) by an eye care professional in the year prior to the measurement year.
- Bilateral eye enucleation anytime during the member’s history through December 31 of the measurement year.

Any of the following meet criteria:

- Any code in the Diabetic Retinal Screening Value Set billed by an eye care professional (optometrist or ophthalmologist) during the measurement year.
- Any code in the Diabetic Retinal Screening Value Set billed by an eye care professional (optometrist or ophthalmologist) during the year prior to the measurement year, with a negative result (negative for retinopathy).
- Any code in the Diabetic Retinal Screening Value Set billed by an eye care professional (optometrist or ophthalmologist) during the year prior to the measurement year, with a diagnosis of diabetes without complications (Diabetes Mellitus Without Complications Value Set).
- Any code in the Eye Exam With Evidence of Retinopathy Value Set or Eye Exam Without Evidence of Retinopathy Value Set billed by any provider type during the measurement year.
- Any code in the Eye Exam Without Evidence of Retinopathy Value Set billed by any provider type during the year prior to the measurement year.
- Any code in the Diabetic Retinal Screening Negative In Prior Year Value Set billed by any provider type during the measurement year.
- Unilateral eye enucleation (Unilateral Eye Enucleation Value Set) with a bilateral modifier (Bilateral Modifier Value Set).
- Two unilateral eye enucleations (Unilateral Eye Enucleation Value Set) with service dates 14 days or more apart. For example, if the service date for the first unilateral eye enucleation was February 1 of the measurement year, the service date for the second unilateral eye enucleation must be on or after February 15.
- Left unilateral eye enucleation (Unilateral Eye Enucleation Left Value Set) and right unilateral eye enucleation (Unilateral Eye Enucleation Right Value Set) on the same or different dates of service.
- A unilateral eye enucleation (Unilateral Eye Enucleation Value Set) and a left unilateral eye enucleation (Unilateral Eye Enucleation Left Value Set) with service dates 14 days or more apart.
- A unilateral eye enucleation (Unilateral Eye Enucleation Value Set) and a right unilateral eye enucleation (Unilateral Eye Enucleation Right Value Set) with service dates 14 days or more apart.
A nephropathy screening or monitoring test or evidence of nephropathy, as documented through administrative data. This includes diabetics who had one of the following during the measurement year:

- A nephropathy screening or monitoring test (Urine Protein Tests Value Set).
- Evidence of treatment for nephropathy or ACE/ARB therapy (Nephropathy Treatment Value Set).
- Evidence of stage 4 chronic kidney disease (CKD Stage 4 Value Set).
- Evidence of ESRD (ESRD Diagnosis Value Set) or dialysis (Dialysis Procedure Value Set).
- Evidence of nephrectomy (Nephrectomy Value Set) or kidney transplant (Kidney Transplant Value Set).
- A visit with a nephrologist, as identified by the organization’s specialty provider codes (no restriction on the diagnosis or procedure code submitted).
- At least one ACE inhibitor or ARB dispensing event (ACE Inhibitor/ARB Medications List).

### ACE Inhibitor and ARB Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiotensin converting enzyme inhibitors</td>
<td>Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril</td>
</tr>
<tr>
<td>Angiotensin II inhibitors</td>
<td>Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</td>
</tr>
</tbody>
</table>
**BP Control <140/90 mm Hg**

Identify the most recent BP reading (Systolic Blood Pressure Value Set; Diastolic Blood Pressure Value Set) taken during an outpatient visit (Outpatient Value Set), telephone visit (Telephone Visits Value Set), e-visit or virtual check-in (Online Assessments Value Set), or a nonacute inpatient encounter (Nonacute Inpatient Value Set), or remote monitoring event (Remote Blood Pressure Monitoring Value Set) during the measurement year.

The member is numerator compliant if the BP is <140/90 mm Hg. The member is not compliant if the BP is ≥140/90 mm Hg, if there is no BP reading during the measurement year or if the reading is incomplete (e.g., the systolic or diastolic level is missing). If there are multiple BPs on the same date of service, use the lowest systolic and lowest diastolic BP on that date as the representative BP.

Organizations that use CPT Category II codes to identify numerator compliance for this indicator must search for all codes in the following value sets and use the most recent codes during the measurement year to determine numerator compliance for both systolic and diastolic levels.

<table>
<thead>
<tr>
<th>Value Set</th>
<th>Numerator Compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic Less Than 140 Value Set</td>
<td>Systolic compliant</td>
</tr>
<tr>
<td>Systolic Greater Than or Equal To 140 Value Set</td>
<td>Systolic not compliant</td>
</tr>
<tr>
<td>Diastolic Less Than 80 Value Set</td>
<td>Diastolic compliant</td>
</tr>
<tr>
<td>Diastolic 80–89 Value Set</td>
<td>Diastolic compliant</td>
</tr>
<tr>
<td>Diastolic Greater Than or Equal To 90 Value Set</td>
<td>Diastolic not compliant</td>
</tr>
</tbody>
</table>

**Optimal Diabetes Care Combination rate**

Calculate the following combination rate:

- HbA1c Control (<8.0%).
- BP Control (<140/90 mm Hg).
- Medical Attention for Nephropathy.
- Eye exam (retinal) performed.

---

CPT® is trademarked and copyright 2020 by the American Medical Association. All rights reserved.
Exclusions (optional)

- Members who do not have a diagnosis of diabetes (Diabetes Value Set), in any setting, during the measurement year or the year prior to the measurement year **and** who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes (Diabetes Exclusions Value Set), in any setting, during the measurement year or the year prior to the measurement year.

- Organizations that apply optional exclusions must exclude members from the denominator for all indicators. The denominator for all rates must be the same.

- If the member was included in the measure based on claim or encounter data, as described in the event/diagnosis criteria, the optional exclusions do not apply because the member had a diagnosis of diabetes.

**Note**

- **Blindness is not an exclusion for a diabetic eye exam, because it is difficult to distinguish between individuals who are legally blind but require a retinal exam and those who are completely blind and therefore do not require an exam.**

- **To facilitate AMP reporting the denominator for all rates must be the same. While an eye exam is not possible, services measured in the other indicators are important for members with bilateral eye enucleation. For these reasons bilateral eye enucleation is considered a numerator hit (rather than an optional exclusion).**

- **Hypertensive retinopathy is not handled differently from diabetic retinopathy when reporting the Eye Exam indicator; for example, an eye exam documented as positive for hypertensive retinopathy is counted as positive for diabetic retinopathy and an eye exam documented as negative for hypertensive retinopathy is counted as negative for diabetic retinopathy. The intent of the Eye Exam indicator is to ensure that members with evidence of any type of retinopathy have an eye exam annually, while members who remain free of retinopathy (i.e., the retinal exam was negative for retinopathy) are screened every other year.**

- **If a combination of administrative and supplemental data is used, the most recent result must be used, regardless of data source, for the indicators that require use of the most recent result.**

- **If an organization chooses to apply the optional exclusions, members must be numerator negative for at least one indicator, with the exception of HbA1c Poor Control (>9%). Remove members from the eligible population who are numerator negative for any indicator (other than for HbA1c Poor Control [>9%]). Do not exclude members who are numerator compliant for all indicators except HbA1c Poor Control (>9%), because a lower rate indicates better performance for this indicator.**
**Statin Therapy for Patients With Diabetes (SPD)**

**Measure Updates September 2020 for AMP MY 2020 and 2021**

- Updated rules for allowable gap for the Medi-Cal Managed Care product line.
- Added polycystic ovarian syndrome to the optional exclusions.
- Removed the restriction that only one of the two visits with a diabetes diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Removed the restriction that only one of the two visits with an IVD diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis, step 2 required exclusions.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added palliative care as a required exclusion.
- Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.
- Added Pitavastatin 1 mg to the Pitavastatin Moderate Intensity Medications List and deleted the Pitavastatin Low Intensity Medications List.

**Modifications from HEDIS**

- The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

**Description**

The percentage of members 40–75 years of age during the measurement year with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) who met the following criteria. Two rates are reported:

1. *Received Statin Therapy.* Members who were dispensed at least one statin medication of any intensity during the measurement year.
2. *Statin Adherence 80%.* Members who remained on a statin medication of any intensity for at least 80% of the treatment period.

**Definitions**

- **IPSD** Index prescription start date. The earliest prescription dispensing date for any statin medication of any intensity during the measurement year.
- **Treatment period** The period of time beginning on the IPSD through the last day of the measurement year.
- **PDC** Proportion of days covered. The number of days the member is covered by at least one statin medication prescription of appropriate intensity, divided by the number of days in the treatment period.
Calculating number of days covered for multiple prescriptions

If multiple prescriptions for different medications are dispensed on the same day, calculate number of days covered by a statin medication (for the numerator) using the prescriptions with the longest days supply. For multiple different prescriptions dispensed on different days with overlapping days supply, count each day within the treatment period only once toward the numerator.

If multiple prescriptions for the same medication are dispensed on the same or different day, sum the days supply and use the total to calculate the number of days covered by a statin medication (for the numerator). For example, three prescriptions for the same medication are dispensed on the same day, each with a 30-day supply, sum the days supply for a total of 90 days covered by a statin. Subtract any day's supply that extends beyond December 31 of the measurement year.

Use the medication lists to determine if drugs are the same or different. Drugs in different lists are considered different drugs. For example, a dispensing event from the Amlodipine Atorvastatin High Intensity Medications List and a dispensing event from the Amlodipine Atorvastatin Moderate Intensity Medications List are dispensing events for different medications.

---

**Eligible Population: Rate 1—Received Statin Therapy**

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

**Product lines**
Commercial HMO/POS, Commercial ACO, Medi-Cal Managed Care (report each product line separately).

**Ages**
40–75 years as of December 31 of the measurement year.

**Continuous enrollment**

...for self-reporting POs
The measurement year and the year prior to the measurement year in the PO (parent level).

...for health plans
The measurement year and the year prior to the measurement year in the health plan and in the PO (parent level).

**Allowable gap**
No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

**Anchor date**

...for self-reporting POs
Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in an AMP plan on December 31 of the measurement year.

...for health plans
Enrolled in the health plan and the PO (parent level, or, for eligible POs, subgroup level) on December 31 of the measurement year.

**Benefit**
Medical. Pharmacy during the measurement year.

**Event/diagnosis**
Follow the steps below to identify the eligible population.
Step 1  There are two ways to identify members with diabetes: by claim/encounter data and by pharmacy data. The organization must use both methods to identify the eligible population, but a member only needs to be identified by one method to be included in the measure. Members may be identified as having diabetes during the measurement year or the year prior to the measurement year.

Claim/encounter data. Members who met any of the following criteria during the measurement year or the year prior to the measurement year (count services that occur over both years):

- At least one acute inpatient encounter (Acute Inpatient Value Set) with a diagnosis of diabetes (Diabetes Value Set) without (Telehealth Modifier Value Set; Telehealth POS Value Set).

- At least one acute inpatient discharge with a diagnosis of diabetes (Diabetes Value Set) on the discharge claim. To identify an acute inpatient discharge:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
  3. Identify the discharge date for the stay.

- At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), ED visits (ED Value Set), non-acute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim), on different dates of service, with a diagnosis of diabetes (Diabetes Value Set). Visit type need not be the same for the two encounters. To identify a nonacute inpatient discharge:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
  3. Identify the discharge date for the stay.

Only include nonacute inpatient encounters (Nonacute Inpatient Value Set) without telehealth (Telehealth Modifier Value Set; Telehealth POS Value Set).

Pharmacy data. Members who were dispensed insulin or hypoglycemics/antihyperglycemics on an ambulatory basis during the measurement year or the year prior to the measurement year (Diabetes Medications List).
## Diabetes Medications

<table>
<thead>
<tr>
<th></th>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-glucosidase inhibitors</td>
<td>• Acarbose</td>
<td>• Miglitol</td>
</tr>
<tr>
<td>Amylin analogs</td>
<td>• Pramlintide</td>
<td></td>
</tr>
<tr>
<td>Antidiabetic combinations</td>
<td>• Alogliptin-metformin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Alogliptin-pioglitazone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Canagliflozin-metformin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dapagliflozin-metformin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Empagliflozin-linagliptin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Empagliflozin-metformin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Glimepiride-pioglitazone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Glipizide-metformin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Glyburide-metformin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Linagliptin-metformin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Metformin-pioglitazone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Metformin-repaglinide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Metformin-rosiglitazone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Metformin-saxagliptin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Metformin-sitagliptin</td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td>• Insulin aspart</td>
<td>• Insulin glulisine</td>
</tr>
<tr>
<td></td>
<td>• Insulin aspart-insulin aspart protamine</td>
<td>• Insulin isophane human</td>
</tr>
<tr>
<td></td>
<td>• Insulin degludec</td>
<td>• Insulin isophane-insulin regular</td>
</tr>
<tr>
<td></td>
<td>• Insulin detemir</td>
<td>• Insulin lispro</td>
</tr>
<tr>
<td></td>
<td>• Insulin glargine</td>
<td>• Insulin lispro-insulin lispro protamine</td>
</tr>
<tr>
<td></td>
<td>• Insulin human inhaled</td>
<td>• Insulin regular human</td>
</tr>
<tr>
<td>Meglitinides</td>
<td>• Nateglinide</td>
<td>• Repaglinide</td>
</tr>
<tr>
<td>Glucagon-like peptide-1 (GLP1) agonists</td>
<td>• Albilglutide</td>
<td>• Liraglutide (excluding Saxenda®)</td>
</tr>
<tr>
<td></td>
<td>• Dulaglutide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Exenatide</td>
<td></td>
</tr>
<tr>
<td>Sodium glucose cotransporter 2 (SGLT2) inhibitor</td>
<td>• Canagliflozin</td>
<td>• Empagliflozin</td>
</tr>
<tr>
<td></td>
<td>• Dapagliflozin</td>
<td></td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>• Chlorpropamide</td>
<td>• Glyburide</td>
</tr>
<tr>
<td></td>
<td>• Glimepiride</td>
<td>• Tolazamide</td>
</tr>
<tr>
<td></td>
<td>• Glipizide</td>
<td>• Tolbutamide</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>• Pioglitazone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Rosiglitazone</td>
<td></td>
</tr>
<tr>
<td>Dipeptidyl peptidase-4 (DDP-4) inhibitors</td>
<td>• Alogliptin</td>
<td>• Saxagliptin</td>
</tr>
<tr>
<td></td>
<td>• Linagliptin</td>
<td>• Sitagliptin</td>
</tr>
</tbody>
</table>

*Note: Glucophage/metformin as a solo agent is not included because it is used to treat conditions other than diabetes; members with diabetes on these medications are identified through diagnosis codes only.*
Step 2: Required exclusions

Excluded members who meet any of the following criteria:

- Members with cardiovascular disease are identified in two ways: by event or by diagnosis. The organization must use both methods to identify this population, but a member only needs to be identified by one method to be excluded from the measure.
  - Event. Any of the following during the year prior to the measurement year meet criteria:
    - **MI.** Discharged from an inpatient setting with an MI (MI Value Set) on the discharge claim. To identify discharges:
      1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
      2. Identify the discharge date for the stay.
    - **CABG.** Members who had CABG (CABG Value Set) in any setting.
    - **PCI.** Members who had PCI (PCI Value Set) in any setting.
    - **Other revascularization.** Members who had any other revascularization procedure (Other Revascularization Value Set) in any setting.
  - Diagnosis. Identify members as having ischemic vascular disease (IVD) who met at least one of the following criteria during both the measurement year and the year prior to the measurement year. Criteria need not be the same across both years.
    - At least one outpatient visit (Outpatient Value Set) with an IVD diagnosis (IVD Value Set).
    - A telephone visit (Telephone Visits Value Set) with an IVD diagnosis (IVD Value Set).
    - An e-visit or virtual check-in (Online Assessments Value Set) with an IVD diagnosis (IVD Value Set).
    - At least one acute inpatient encounter (Acute Inpatient Value Set) with an IVD diagnosis (IVD Value Set) without telehealth (Telehealth Modifier Value Set; Telehealth POS Value Set).
    - At least one acute inpatient discharge with an IVD diagnosis (IVD Value Set) on the discharge claim. To identify an acute inpatient discharge:
      1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
      2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
      3. Identify the discharge date for the stay.
    - Female members with a diagnosis of pregnancy (Pregnancy Value Set) during the measurement year or year prior to the measurement year.
    - In vitro fertilization (IVF Value Set) in the measurement year or year prior to the measurement year.
    - Dispensed at least one prescription for clomiphene (Estrogen Agonists Medications List) during the measurement year or the year prior to the measurement year.
    - ESRD (ESRD Diagnosis Value Set) or dialysis (Dialysis Procedure Value Set) during the measurement year or the year prior to the measurement year.
    - Cirrhosis (Cirrhosis Value Set) during the measurement year or the year prior to the measurement year.
Myalgia, myositis, myopathy or rhabdomyolysis (Muscular Pain and Disease Value Set) during the measurement year.

Members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the measurement year.

### Estrogen Agonists Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrogen agonists</td>
<td>Clomiphene</td>
</tr>
</tbody>
</table>

### Step 3: Exclusions

Exclude members who meet any of the following criteria:

**Note:** Supplemental data may not be used for these exclusions.

- Members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
  - *Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.

- Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet BOTH of the following frailty and advanced illness criteria to be excluded:
  1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.
  2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
     - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
       1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
       2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
       3. Identify the discharge date for the stay.
     - At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
     - At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
3. Identify the discharge date for the stay.
   - A dispensed dementia medication (Dementia Medications List).

*The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

### Dementia Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinesterase inhibitors</td>
<td>• Donepezil, • Galantamine, • Rivastigmine</td>
</tr>
<tr>
<td>Miscellaneous central nervous system agents</td>
<td>• Memantine</td>
</tr>
<tr>
<td>Dementia combinations</td>
<td>• Donepezil-memantine</td>
</tr>
</tbody>
</table>

### Administrative Specification: Rate 1—Received Statin Therapy

**Denominator**

The Rate 1 eligible population.

**Numerator**

The number of members who had at least one dispensing event for a high-intensity, moderate-intensity, or low-intensity statin medication during the measurement year. Use all the medication lists below to identify statin medication dispensing events.

### High, Moderate and Low-Intensity Statin Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
<th>Medication Lists</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-intensity statin therapy</td>
<td>• Atorvastatin 40-80 mg</td>
<td>Atorvastatin High Intensity Medications List</td>
</tr>
<tr>
<td>High-intensity statin therapy</td>
<td>• Amlodipine-atorvastatin 40-80 mg</td>
<td>Amlodipine Atorvastatin High Intensity Medications List</td>
</tr>
<tr>
<td>High-intensity statin therapy</td>
<td>• Rosuvastatin 20-40 mg</td>
<td>Rosuvastatin High Intensity Medications List</td>
</tr>
<tr>
<td>High-intensity statin therapy</td>
<td>• Simvastatin 80 mg</td>
<td>Simvastatin High Intensity Medications List</td>
</tr>
<tr>
<td>High-intensity statin therapy</td>
<td>• Ezetimibe-simvastatin 80 mg</td>
<td>Ezetimibe Simvastatin High Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Atorvastatin 10-20 mg</td>
<td>Atorvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Amlodipine-atorvastatin 10-20 mg</td>
<td>Amlodipine Atorvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Rosuvastatin 5-10 mg</td>
<td>Rosuvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Simvastatin 20-40 mg</td>
<td>Simvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Ezetimibe-simvastatin 20-40 mg</td>
<td>Ezetimibe Simvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Pravastatin 40-80 mg</td>
<td>Pravastatin Moderate Intensity Medications List</td>
</tr>
</tbody>
</table>

*Measurement Years 2020 and 2021 AMP Manual*
<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
<th>Medication Lists</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Lovastatin 40 mg</td>
<td>Lovastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Fluvastatin 40-80 mg</td>
<td>Fluvastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Moderate-intensity statin therapy</td>
<td>• Pitavastatin 1–4 mg</td>
<td>Pitavastatin Moderate Intensity Medications List</td>
</tr>
<tr>
<td>Low-intensity statin therapy</td>
<td>• Ezetimibe-simvastatin 10 mg</td>
<td>Ezetimibe Simvastatin Low Intensity Medications List</td>
</tr>
<tr>
<td>Low-intensity statin therapy</td>
<td>• Fluvastatin 20 mg</td>
<td>Fluvastatin Low Intensity Medications List</td>
</tr>
<tr>
<td>Low-intensity statin therapy</td>
<td>• Lovastatin 10-20 mg</td>
<td>Lovastatin Low Intensity Medications List</td>
</tr>
<tr>
<td>Low-intensity statin therapy</td>
<td>• Pravastatin 10–20 mg</td>
<td>Pravastatin Low Intensity Medications List</td>
</tr>
<tr>
<td>Low-intensity statin therapy</td>
<td>• Simvastatin 5-10 mg</td>
<td>Simvastatin Low Intensity Medications List</td>
</tr>
</tbody>
</table>

**Eligible Population: Rate 2—Statin Adherence 80%**

*Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.*

**Product lines**
- Commercial HMO/POS, Commercial ACO, Medi-Cal Managed Care (report each product line separately).

**Age**
- 40–75 years as of December 31 of the measurement year.

**Continuous enrollment**
- **...for self-reporting POs**
  - The measurement year and the year prior to the measurement year in the PO (parent level).
- **...for health plans**
  - The measurement year and the year prior to the measurement year in the health plan and in the PO (parent level).

**Allowable gap**
- No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

**Anchor date**
- **...for self-reporting POs**
  - Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in an AMP plan on December 31 of the measurement year.
- **...for health plans**
  - Enrolled in the health plan and the PO (parent level, or, for eligible POs, subgroup level) on December 31 of the measurement year.

**Benefit**
- Medical. Pharmacy during the measurement year.

**Event/diagnosis**
- All members who meet the numerator criteria for Rate 1.
Administrative Specification: Rate 2—Statin Adherence 80%

Denominator
The Rate 2 eligible population.

Numerator
The number of members who achieved a PDC of at least 80% during the treatment period.

Follow the steps below to identify numerator compliance.

Step 1 Identify the IPSD. The IPSD is the earliest dispensing event for any high-intensity, moderate-intensity or low-intensity statin medication during the measurement year. Use all the medication lists above to identify statin medication dispensing events.

Step 2 To determine the treatment period, calculate the number of days on the IPSD to the end of the measurement year.

Step 3 Count the days covered by at least one prescription for any high-intensity, moderate-intensity or low-intensity statin medication during the treatment period. To ensure the measure does not give credit for supply that extends beyond the measurement year, subtract any days supply that extends beyond December 31 of the measurement year.

Step 4 Calculate the member’s PDC using the following equation. Multiply the equation by 100 and round (using the .5 rule) to the nearest whole number. For example, if a member has 291 total days covered by a medication during a 365-day treatment period, this calculates to 0.7972. Multiply this number by 100, convert it to 79.72% and round it to 80%, the nearest whole number.

\[
\frac{\text{Total Days Covered by a Statin Medication in the Treatment Period (step 3)}}{\text{Total Days in Treatment Period (step 2)}} \times 100\% \]

Step 5 Sum the number of members whose PDC is ≥80% for the treatment period.

Exclusion (optional)

Members who do not have a diagnosis of diabetes (Diabetes Value Set), in any setting, during the measurement year or the year prior to the measurement year and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes (Diabetes Exclusions Value Set), in any setting, during the measurement year or the year prior to the measurement year.

Organizations that apply optional exclusions must exclude members from the denominator for both rates.

If the member was included in the measure based on claim or encounter data, as described in the event/diagnosis criteria, the optional exclusions do not apply because the member had a diagnosis of diabetes.

Note

- All members who are numerator compliant for Rate 1 must be used as the eligible population for Rate 2 (regardless of the data source used to capture the Rate 1 numerator). For example, if supplemental data were used to identify compliance for the Rate 1 numerator, then supplemental data will be included in identifying the Rate 2 eligible population.
Statin Use in Persons with Diabetes (SUPD)

Measure Updates September 2020 for AMP MY 2020 and 2021

- Added FERTILITY: Fertility Medications to the Medication Table.
- Changed Medication Table to Table SUPD-A: Diabetes Medications to DIABETES: Diabetes Medications and Table SUPD-B: Statin Medications to STATINS: Statin Medications.
- Added insulin aspart and niacinamide (DIABETES) to statins medications.
- Added requirement that IPSD occurs ≥ 90 days prior to the end of the measurement year.
- Added exclusions for Rhabdomyolysis or Myopathy, Pregnancy, Lactation, or Fertility, Liver Disease, Pre-Diabetes, and Polycystic Ovary Syndrome (PCOS).

Modifications from HEDIS

- This is a non-HEDIS measure developed by the Pharmacy Quality Alliance (PQA).

Description

The percentage of members ages 40–75 years who were dispensed a medication for diabetes that receive a statin medication.

Note: Refer to the AMP Value Set Directory download for a comprehensive list of PQA medications and associated codes (PQA NDC Code List and PQA ICD Code List). Do not distribute NDC lists outside your organization.

Onpoint will run this measure for health plans in MY 2020 and 2021. Health plans are not expected to report the measure. POs may self-report this measure.

Definitions

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes medications</td>
<td>Refer to Medication Table DIABETES: Diabetes Medications.</td>
</tr>
<tr>
<td>Statin medications</td>
<td>Refer to Medication Table STATINS: Statin Medications.</td>
</tr>
<tr>
<td>Measurement year</td>
<td>The calendar year (January 1 through December 31) when the measure is assessed.</td>
</tr>
<tr>
<td>Prescription claims</td>
<td>Only paid, non-reversed prescription claims are included in the data set to calculate the measure.</td>
</tr>
<tr>
<td>Hospice exclusion</td>
<td>Health plans reporting for Medicare Advantage, identify any member with a hospice indicator from the Monthly Membership Detail File. POs reporting for Medicare Advantage have the option of using the Monthly Membership Detail File or the HEDIS Hospice Encounter Value Set and Hospice Intervention Value Set to identify members in Hospice, refer to General Guideline 15: Members in Hospice.</td>
</tr>
</tbody>
</table>
### ESRD diagnosis exclusion

Any members with an ESRD diagnosis at any time during the measurement year.

Refer to PQA Value Set, ESRD.

An ESRD diagnosis is defined as having at least one claim with any of the listed ESRD diagnoses, including primary diagnosis or any other diagnosis fields during the measurement year. Medicare Data (if ICD codes not available): RxHCC 261 - Dialysis Status for Payment Year 2019. Available at: https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Risk-Adjustors.html.

**Note:** Use the most current information for the ESRD exclusion; using diagnosis codes is the preferred method. The RxHCC code can be found in the CMS Medicare Advantage and Prescription Drug System (MARx), which provides a monthly report of members’ RxHCCs to plan sponsors. If the MARx System output is used, then the most recent version applies. Although the time frames are not consistent between diagnosis codes and the MARx System, using the most recent version provides the most current information to identify members with ESRD.

### Rhabdomyolysis and Myopathy Exclusions

Members with a diagnosis of rhabdomyolysis or myopathy at any time during the measurement year.

Refer to PQA Value Set, RHABDO-MYOPATHY.

A rhabdomyolysis or myopathy diagnosis is defined as having at least one claim with rhabdomyolysis or myopathy in the primary diagnosis or any other diagnosis fields during the measurement year.

### Pregnancy, Lactation, and Fertility Exclusions

Members with a diagnosis of pregnancy or lactation at any time during the measurement year or with fertility treatment during the measurement year.

- A pregnancy diagnosis is defined as having at least one claim with pregnancy in the primary diagnosis or any other diagnosis fields during the measurement year. Refer to PQA ICD Value Set, PREGNANCY;
- A lactation diagnosis is defined as having at least one claim with lactation in the primary diagnosis or any other diagnosis fields during the measurement year. Refer to PQA ICD Value Set, LACTATION;
- Fertility treatment is defined as having at least one claim for a medication indicated for fertility during the measurement year. Refer to Medication Table FERTILITY: Fertility Medications.

### Liver Disease Exclusion

Members with a diagnosis of liver disease at any time during the measurement year.

Refer to PQA Value Set, LIVER DISEASE.

A liver disease diagnosis is defined as having at least one claim with liver disease in the primary diagnosis or any other diagnosis fields during the measurement year.

### Pre-Diabetes Exclusion

Members with a diagnosis of pre-diabetes at any time during the measurement year.

Refer to PQA Value Set, PRE-DIABETES.
A pre-diabetes diagnosis is defined as having at least one claim with pre-diabetes in the primary diagnosis or any other diagnosis fields during the measurement year.

**Polycystic Ovary Syndrome (PCOS) Exclusion**

Members with a diagnosis of polycystic ovary syndrome (PCOS) at any time during the measurement year.

Refer to PQA Value Set, PCOS.

A PCOS diagnosis is defined as having at least one claim with polycystic ovary syndrome (PCOS) in the primary diagnosis or any other diagnosis fields during the measurement year. See Value Set, PCOS.

### Eligible Population

<table>
<thead>
<tr>
<th>Product line</th>
<th>Medicare Advantage.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ages</td>
<td>40–75 years as of January 1 of the measurement year.</td>
</tr>
<tr>
<td>Continuous enrollment</td>
<td></td>
</tr>
<tr>
<td>...for self-reporting POs</td>
<td>The measurement year in the PO (parent level).</td>
</tr>
<tr>
<td>...for health plans</td>
<td>The measurement year in the health plan and the PO (parent level).</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No more than one gap in enrollment of up to 31 days during the measurement year. When enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).</td>
</tr>
<tr>
<td>Anchor date</td>
<td>None.</td>
</tr>
<tr>
<td>...for self-reporting POs</td>
<td>None.</td>
</tr>
<tr>
<td>...for health plans</td>
<td>None.</td>
</tr>
<tr>
<td>Benefit</td>
<td>Medical, pharmacy.</td>
</tr>
<tr>
<td>Event/diagnosis</td>
<td>Members with 2 or more prescription claims for a diabetes medication during the measurement year. Use the steps below to determine the eligible population.</td>
</tr>
</tbody>
</table>

**Step 1** Identify members aged 40–75 years as of the first day of the measurement year.

**Step 2** Identify members meeting the continuous enrollment criteria.

**Step 3** Identify members with 2 or more prescription claims on different dates of service for a diabetes medication during the measurement year.
Step 4: Required Exclusions

Exclude members who met any of the following:

- **Hospice**: A hospice indicator at any time during the measurement year.
- **ESRD**: An ESRD diagnosis at any time during the measurement year.
- **Rhabdomyolysis or Myopathy**: A rhabdomyolysis or myopathy diagnosis at any time during the measurement year.
- **Pregnancy, Lactation, or Fertility**: A pregnancy or lactation diagnosis or fertility treatment at any time during the measurement year.
- **Liver Disease**: A liver disease diagnosis at any time during the measurement year.
- **Pre-Diabetes**: A pre-diabetes diagnosis at any time during the measurement year.
- **Polycystic Ovary Syndrome (PCOS)**: A polycystic ovary syndrome (PCOS) diagnosis at any time during the measurement year.

**Note**

- If a PO receives pharmacy claim information for a member, the PO can assume the member has a pharmacy benefit, and that the pharmacy benefit dates align with the medical benefit dates.

**Administrative Specification**

<table>
<thead>
<tr>
<th>Denominator</th>
<th>The eligible population.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numerator</td>
<td>Members who had at least one dispensing event for a statin or statin combination (Table SUPD-B: Statin Medications) during the measurement year. Use only paid, non-reversed claims for target medications to determine if members meet the numerator.</td>
</tr>
</tbody>
</table>
### Table DIABETES: Diabetes Medications

<table>
<thead>
<tr>
<th>Class</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biguanides</strong></td>
<td>• Metformin (+/- alogliptin, canagliflozin, dapagliflozin, empagliflozin,</td>
</tr>
<tr>
<td></td>
<td>ertugliflozin, glipizide, glyburide, linagliptin, linagliptazone,</td>
</tr>
<tr>
<td></td>
<td>repaglinide, rosiglitazone, saxagliptin, sitagliptin)</td>
</tr>
<tr>
<td><strong>Sulfonylureas</strong></td>
<td>• Chlorpropamide</td>
</tr>
<tr>
<td></td>
<td>• Glipizide (+/- metformin)</td>
</tr>
<tr>
<td></td>
<td>• Glyburide (+/- metformin)</td>
</tr>
<tr>
<td></td>
<td>• Tolazamide</td>
</tr>
<tr>
<td></td>
<td>• Tolbutamide</td>
</tr>
<tr>
<td><strong>Meglitinides</strong></td>
<td>• Nateglinide</td>
</tr>
<tr>
<td></td>
<td>• Repaglinide (+/- metformin)</td>
</tr>
<tr>
<td><strong>Alpha-Glucosidase Inhibitors</strong></td>
<td>• Acarbose</td>
</tr>
<tr>
<td></td>
<td>• Miglitol</td>
</tr>
<tr>
<td><strong>Thiazolidinediones</strong></td>
<td>• Pioglitazone (+/- alogliptin, glimepiride, metformin)</td>
</tr>
<tr>
<td></td>
<td>• Rosiglitazone (+/- metformin)</td>
</tr>
<tr>
<td><strong>GLP-1 Receptor Agonists</strong></td>
<td>• Albiglutide</td>
</tr>
<tr>
<td></td>
<td>• Dulaglutide</td>
</tr>
<tr>
<td></td>
<td>• Exenatide</td>
</tr>
<tr>
<td></td>
<td>• Liraglutide (+/- insulin degludec)</td>
</tr>
<tr>
<td><strong>Amylin Analogs</strong></td>
<td>• Pramlintide</td>
</tr>
<tr>
<td><strong>DPP-4 Inhibitors</strong></td>
<td>• Alogliptin (+/- metformin, pioglitazone)</td>
</tr>
<tr>
<td></td>
<td>• Linagliptin (+/- empagliflozin, metformin)</td>
</tr>
<tr>
<td></td>
<td>• Saxagliptin (+/- dapagliflozin, metformin)</td>
</tr>
<tr>
<td></td>
<td>• Sitagliptin (+/- metformin, ertugliflozin)</td>
</tr>
<tr>
<td><strong>Insulins</strong></td>
<td>• Insulin aspart (+/- insulin aspart protamine, niacinamide)</td>
</tr>
<tr>
<td></td>
<td>• Insulin degludec (+/- liraglutide)</td>
</tr>
<tr>
<td></td>
<td>• Insulin detemir</td>
</tr>
<tr>
<td></td>
<td>• Insulin glargine (+/- lixisenatide)</td>
</tr>
<tr>
<td></td>
<td>• Insulin glulisine</td>
</tr>
<tr>
<td></td>
<td>• Insulin isophane (+/- regular insulin)</td>
</tr>
<tr>
<td></td>
<td>• Insulin lispro (+/- insulin lispro protamine)</td>
</tr>
<tr>
<td></td>
<td>• Insulin regular (including inhalation powder)</td>
</tr>
<tr>
<td><strong>Sodium Glucose Co-transporter2 (SGLT2) Inhibitors</strong></td>
<td>• Canagliflozin (+/- metformin)</td>
</tr>
<tr>
<td></td>
<td>• Dapagliflozin (+/- metformin, saxagliptin)</td>
</tr>
<tr>
<td></td>
<td>• Empagliflozin (+/- linagliptin, metformin)</td>
</tr>
<tr>
<td></td>
<td>• Ertugliflozin (+/- sitagliptin, metformin)</td>
</tr>
</tbody>
</table>

**Note:** The active ingredients are limited to oral, inhalation and injectable formulations only (includes all dosage forms; excludes nutritional supplement/dietary management combination products).

### Table STATINS: Statin Medications

<table>
<thead>
<tr>
<th>Statin Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Atorvastatin (+/- amlodipine)</td>
</tr>
<tr>
<td>• Fluvastatin</td>
</tr>
<tr>
<td>• Lovastatin (+/- niacin)</td>
</tr>
<tr>
<td>• Pitavastatin</td>
</tr>
<tr>
<td>• Pravastatin</td>
</tr>
<tr>
<td>• Rosuvastatin</td>
</tr>
<tr>
<td>• Simvastatin (+/-ezetimibe, niacin)</td>
</tr>
</tbody>
</table>
Note: The active ingredients are limited to oral formulations only.

Table FERTILITY: Fertility Medications

<table>
<thead>
<tr>
<th>Fertility Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clomiphene</td>
</tr>
</tbody>
</table>

Note: The active ingredients are limited to oral formulations only.
**Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)**

**MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021**

- Removed the restriction that only one of the two visits with a rheumatoid arthritis diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added Upadacitinib to the “Janus kinase (JAK)” description in the DMARD Medications List.
- Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.
- Added Mycophenolic acid to the “Immunosuppressive agents” description in the DMARD Medications List.

**MODIFICATIONS FROM HEDIS**

- The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

**Description**

- *Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis* is the same measure as the CMS Stars measure Rheumatoid Arthritis Management.

The percentage of Medicare Advantage members 18 years of age and older who were diagnosed with rheumatoid arthritis and who were dispensed at least one ambulatory prescription for a disease modifying anti-rheumatic drug (DMARD).

**Eligible Population**

*Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.*

<table>
<thead>
<tr>
<th>Product line</th>
<th>Medicare Advantage.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ages</td>
<td>18 years and older as of December 31 of the measurement year.</td>
</tr>
<tr>
<td>Continuous enrollment</td>
<td>...for self-reporting POs The measurement year in the PO (parent level).</td>
</tr>
<tr>
<td></td>
<td>...for health plans The measurement year in the health plan and PO (parent level).</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No more than one gap in enrollment of up to 45 days during the measurement year.</td>
</tr>
</tbody>
</table>
Anchor date

...for self-reporting POs
Enrolled in the PO (parent level, or, for eligible POs, subgroup level) and in an AMP plan on December 31 of the measurement year.

...for health plans
Enrolled in the health plan and PO (parent level, or, for eligible POs, subgroup level) and in an AMP plan on December 31 of the measurement year.

Benefit
Medical and pharmacy.

Event/diagnosis
Two of the following with different dates of service on or between January 1 and November 30 of the measurement year. Visit type need not be the same for the two visits.

- An outpatient visit (Outpatient Value Set), with any diagnosis of rheumatoid arthritis (Rheumatoid Arthritis Value Set).
- A telephone visit (Telephone Visits Value Set) with any diagnosis of rheumatoid arthritis (Rheumatoid Arthritis Value Set).
- An e-visit or virtual check-in (Online Assessments Value Set) with any diagnosis of rheumatoid arthritis (Rheumatoid Arthritis Value Set).
- A nonacute inpatient discharge, with any diagnosis of rheumatoid arthritis (Rheumatoid Arthritis Value Set) on the discharge claim. To identify nonacute inpatient discharges:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
  3. Identify the discharge date for the stay.

Count a nonacute-to-nonacute direct transfer as two discharges only if both discharges have a diagnosis of rheumatoid arthritis and different discharge dates.

Exclusions
Exclude members who meet any of the following criteria:

*Note: Supplemental data may not be used for these exclusions.*

- Members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
  - *Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.

- Members 66–80 years of age as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet BOTH of the following frailty and advanced illness criteria to be excluded:
1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.

2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
   - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
     1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
     2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
     3. Identify the discharge date for the stay.
   - At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
   - At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
     1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
     2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
     3. Identify the discharge date for the stay.
   - A dispensed dementia medication (Dementia Medications List).

• Members 81 years of age and older as of December 31 of the measurement year (all product lines) with frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.

*The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

### Dementia Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinesterase inhibitors</td>
<td>• Donepezil</td>
</tr>
<tr>
<td></td>
<td>• Galantamine</td>
</tr>
<tr>
<td></td>
<td>• Rivastigmine</td>
</tr>
<tr>
<td>Miscellaneous central nervous system agents</td>
<td>• Memantine</td>
</tr>
<tr>
<td>Dementia combinations</td>
<td>• Donepezil-memantine</td>
</tr>
</tbody>
</table>
Administrative Specification

**Denominator**
The eligible population.

**Numerator**
Members who had at least one ambulatory prescription dispensed for a DMARD during the measurement year. There are two ways to identify members who received a DMARD: by claim/encounter data and by pharmacy data. The organization may use both methods to identify the numerator, but a member need only be identified by one method to be included in the numerator.

*Claim/encounter data.* A DMARD prescription ([DMARD Value Set](#)) during the measurement year.

*Pharmacy data.* Members who were dispensed a DMARD during the measurement year on an ambulatory basis ([DMARD Medications List](#)).

### DMARD Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-Aminosalicylates</td>
<td>Sulfasalazine</td>
</tr>
<tr>
<td>Alkylating agents</td>
<td>Cyclophosphamide</td>
</tr>
<tr>
<td>Aminoquinolines</td>
<td>Hydroxychloroquine</td>
</tr>
<tr>
<td>Anti-rheumatics</td>
<td>Auranofin</td>
</tr>
<tr>
<td></td>
<td>Leflunomide</td>
</tr>
<tr>
<td></td>
<td>Methotrexate</td>
</tr>
<tr>
<td></td>
<td>Penicillamine</td>
</tr>
<tr>
<td>Immunomodulators</td>
<td>Abatacept</td>
</tr>
<tr>
<td></td>
<td>Etanercept</td>
</tr>
<tr>
<td></td>
<td>Infliximab</td>
</tr>
<tr>
<td></td>
<td>Rituximab</td>
</tr>
<tr>
<td></td>
<td>Sarilumab</td>
</tr>
<tr>
<td></td>
<td>Tocilizumab</td>
</tr>
<tr>
<td>Immunosuppressive agents</td>
<td>Azathioprine</td>
</tr>
<tr>
<td></td>
<td>Cyclosporine</td>
</tr>
<tr>
<td></td>
<td>Mycophenolate mofetil</td>
</tr>
<tr>
<td></td>
<td>Mycophenolic acid</td>
</tr>
<tr>
<td>Janus kinase (JAK) inhibitor</td>
<td>Baricitinib</td>
</tr>
<tr>
<td></td>
<td>Tofacitinib</td>
</tr>
<tr>
<td></td>
<td>Upadacitinib</td>
</tr>
<tr>
<td>Tetracyclines</td>
<td>Minocycline</td>
</tr>
</tbody>
</table>

### Exclusions (optional)

- A diagnosis of HIV ([HIV Value Set](#); [HIV Type 2 Value Set](#)) any time during the member’s history through December 31 of the measurement year.

- Female members with a diagnosis of pregnancy ([Pregnancy Value Set](#)) any time during the measurement year.

### Note

- *This measure is administrative only; therefore, the use of valid data errors is not permitted, nor may supplemental data be used as a substitute for claims data for the event/diagnosis criteria (to correct billing errors) or to identify valid data errors.*
**Osteoporosis Management in Women Who Had a Fracture (OMW)**

### Measure Updates September 2020 for AMP MY 2020/2021

- Updated the instructions for excluding visits that result in an inpatient stay (steps 1 and 2).
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added palliative care as a required exclusion.
- Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.
- Added Romosozumab to the “Other agents” description in the Osteoporosis Medications List.

### Modifications From HEDIS

- The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

### Description

- **Osteoporosis Management in Women Who Had a Fracture** is the same measure as the CMS Stars measure Osteoporosis Management in Women Who Had a Fracture.

The percentage of women 67–85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

### Definitions

- **Intake Period**
  
  A 12-month (1 year) window that begins on July 1 of the year prior to the measurement year and ends on June 30 of the measurement year. The Intake Period is used to capture the first fracture.

- **Episode Date**
  
  The date of service for an eligible encounter during the Intake Period with a diagnosis of fracture.

  *For an outpatient, observation or ED visit,* the Episode Date is the date of service.

  *For an inpatient stay,* the Episode Date is the date of discharge.

  *For direct transfers,* the Episode Date is the discharge date from the last admission.

- **IESD**
  
  Index Episode Start Date. The earliest Episode Date during the Intake Period that meets all eligible population criteria.
Direct transfer  

A direct transfer is when the discharge date from the first inpatient setting precedes the admission date to a second inpatient setting by one calendar day or less. For example:

- An inpatient discharge on June 1, followed by an admission to another inpatient setting on June 1, is a direct transfer.
- An inpatient discharge on June 1, followed by an admission to an inpatient setting on June 2, is a direct transfer.
- An inpatient discharge on June 1, followed by an admission to another inpatient setting on June 3, is not a direct transfer; these are two distinct inpatient stays.

Use the following method to identify admissions to and discharges from inpatient settings.

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Identify the admission and discharge dates for the stay.

**Note:** The direct transfer does not require a fracture diagnosis.

Active prescription  

A prescription is considered active if the “days supply” indicated on the date the member filled the prescription is the number of days or more between that date and the relevant service date.

Eligible Population

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

**Product line**  
Medicare Advantage.

**Ages**  
Women 67–85 years as of December 31 of the measurement year.

**Continuous enrollment**

...for self-reporting POs  
12 months (1 year) before the Episode Date through 180 days (6 months) after the Episode Date in the PO (parent level).

...for health plans  
12 months (1 year) before the Episode Date through 180 days (6 months) after the Episode Date in the health plan and PO (parent level).

**Allowable gap**  
No more than one gap in enrollment of up to 45 days during the continuous enrollment period.

**Anchor date**

...for self-reporting POs  
Episode Date in the PO (parent level, or, for eligible POs, subgroup level) and in an AMP plan.

...for health plans  
Episode Date in the health plan and the PO (parent level, or, for eligible POs, subgroup level).

**Benefit**  
Medical and pharmacy.

**Event/diagnosis**  
Follow the steps below to identify the eligible population.
Step 1  Identify all members who had either of the following during the Intake Period.

- An outpatient visit (Outpatient Value Set), an observation visit (Observation Value Set) or an ED visit (ED Value Set), for a fracture (Fractures Value Set) without (Telehealth Modifier Value Set; Telehealth POS Value Set).
  - Do not include visits that result in an inpatient stay (Inpatient Stay Value Set).

- An acute or nonacute inpatient discharge with a fracture (Fractures Value Set) on the discharge claim. To identify acute and nonacute inpatient discharges:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Identify the discharge date for the stay.

If the member had more than one fracture, identify all fractures and assess eligibility in steps 2-4 below.

Step 2  Test for Negative Diagnosis History. Exclude fractures where either of the following occurred during the 60-day (2 months) period prior to the Episode Date.

- An outpatient visit (Outpatient Value Set), a telephone visit (Telephone Visits Value Set), an e-visit or virtual check-in (Online Assessments Value Set), an observation visit (Observation Value Set) or an ED visit (ED Value Set) for a fracture (Fractures Value Set).
  - Do not include visits that result in an inpatient stay (Inpatient Stay Value Set).

- An acute or nonacute inpatient discharge with a fracture (Fractures Value Set) on the discharge claim. To identify acute and nonacute inpatient discharges:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Identify the discharge date for the stay.

*For an acute or nonacute inpatient episode*, use the date of admission to determine the 60-day period.

*For episodes that were direct transfers*, use the first admission to determine the Negative Diagnosis History.

*For inpatient stay episodes* that were a result of an outpatient, ED or observation visit, use the date of the outpatient, ED or observation visit to determine negative diagnosis history.

Step 3  Calculate continuous enrollment. Members must be continuously enrolled during the 12 months prior to the Episode Date through 180 days (6 months) post-Episode Date.

Step 4: Required exclusions  Exclude Episode Dates where any of the following are met:

- Members who had a BMD test (Bone Mineral Density Tests Value Set) during the 730 days (24 months) prior to the Episode Date.
• Members who had a claim/encounter for osteoporosis therapy (Osteoporosis Medication Therapy Value Set) during the 365 days (12 months) prior to the Episode Date.

• Members who received a dispensed prescription or had an active prescription to treat osteoporosis (Osteoporosis Medications List) during the 365 days (12 months) prior to the Episode Date.

• Members who received palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the intake period through the end of the measurement year.

For an acute or nonacute inpatient event, use the date of admission to identify the number of days prior to the Episode Date.

For direct transfers, use the first admission date to identify the number of days prior to the Episode Date.

For outpatient, ED and observation visits that result in an inpatient stay, use the date of the outpatient, ED or observation visit to identify the days prior to the Episode Date.

Step 5: Select the Episode Date. The measure examines the earliest eligible episode per member that meets the criteria above.

Step 6: Exclusions

Note: Supplemental data may not be used for these exclusions.

• Members 67 years of age and older as of December 31 of the measurement year who meet either of the following:
  – Enrolled in an Institutional SNP (I-SNP) any time during the intake period through the end of the measurement year.
  – *Living long-term in an institution any time during the intake period through the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the intake period through the end of the measurement year.

• Members 67–80 years of age as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet BOTH of the following frailty and advanced illness criteria to be excluded:
  1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the intake period through the end of the measurement year.
  2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
    – At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges.
(instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
3. Identify the discharge date for the stay.
   - At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
   - At least acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
     1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
     2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
     3. Identify the discharge date for the stay.
     - A dispensed dementia medication (Dementia Medications List).

• Members 81 years of age and older as of December 31 of the measurement year (all product lines) with frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the intake period through the end of the measurement year.

*The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

**Dementia Medications**

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinesterase inhibitors</td>
<td>• Donepezil</td>
</tr>
<tr>
<td></td>
<td>• Galantamine</td>
</tr>
<tr>
<td></td>
<td>• Rivastigmine</td>
</tr>
<tr>
<td>Miscellaneous central nervous system agents</td>
<td>• Memantine</td>
</tr>
<tr>
<td>Dementia combinations</td>
<td>• Donepezil-memantine</td>
</tr>
</tbody>
</table>

**Administrative Specification**

**Denominator**

The eligible population.

**Numerator**

Appropriate testing or treatment for osteoporosis after the fracture defined by any of the following criteria:

- A BMD test (Bone Mineral Density Tests Value Set), in any setting, on the IESD or in the 180-day (6-month) period after the IESD.
- If the IESD was an inpatient stay, a BMD test (Bone Mineral Density Tests Value Set) during the inpatient stay.
- Osteoporosis therapy (Osteoporosis Medication Therapy Value Set) on the IESD or in the 180-day (6-month) period after the IESD.
• If the IESD was an inpatient stay, long-acting osteoporosis therapy (Long-Acting Osteoporosis Medications Value Set) during the inpatient stay.

• A dispensed prescription to treat osteoporosis (Osteoporosis Medications List) on the IESD or in the 180-day (6-month) period after the IESD.

### Osteoporosis Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bisphosphonates</td>
<td>• Alendronate</td>
</tr>
<tr>
<td></td>
<td>• Alendronate-cholecalciferol</td>
</tr>
<tr>
<td></td>
<td>• Ibandronate</td>
</tr>
<tr>
<td></td>
<td>• Risedronate</td>
</tr>
<tr>
<td></td>
<td>• Zoledronic acid</td>
</tr>
<tr>
<td>Other agents</td>
<td>• Abaloparatide</td>
</tr>
<tr>
<td></td>
<td>• Denosumab</td>
</tr>
<tr>
<td></td>
<td>• Raloxifene</td>
</tr>
<tr>
<td></td>
<td>• Romosozumab</td>
</tr>
<tr>
<td></td>
<td>• Teriparatide</td>
</tr>
</tbody>
</table>

### Note

• Fractures of finger, toe, face and skull are not included in this measure.
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)

Measure Updates September 2020 for AMP MY 2020 and 2021

- None.

Modifications from HEDIS

- The AMP WCC measure only includes the BMI percentile indicator.

Description

The percentage of members 3–17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of the following during the measurement year:

- BMI percentile documentation*.

*Because BMI norms for youth vary with age and gender, this measure evaluates whether BMI percentile is assessed rather than an absolute BMI value.

Definitions

BMI percentile

The percentile ranking based on the CDC’s BMI-for-age growth charts, which indicates the relative position of the patient’s BMI number among others of the same gender and age.

Eligible Population

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Product line

Medi-Cal Managed Care.

Ages

3–17 years as of December 31 of the measurement year. Report two age stratifications and a total for each of the three indicators:

- 3–11 years.
- 12–17 years.
- Total.

The total is the sum of the age stratifications.

Continuous enrollment

...for self-reporting POs

The measurement year in the PO (parent level).

.... for health plans

The measurement year in the health plan and the PO (parent level).
Allowable gap

No more than one gap in continuous enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

Anchor date

...for self-reporting POs

Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in a AMP plan on December 31 of the measurement year.

.... for health plans

Enrolled in the health plan and the PO (parent level, or, for eligible POs, subgroup level) on December 31 of the measurement year.

Benefit

Medical.

Event/diagnosis

An outpatient visit (Outpatient Value Set) with a PCP or an OB/GYN during the measurement year.

Administrative Specification

Denominator

The eligible population.

Numerator

BMI Percentile

BMI percentile (BMI Percentile Value Set) during the measurement year.

Exclusions (optional)

Female members who have a diagnosis of pregnancy (Pregnancy Value Set) during the measurement year. The denominator for all rates must be the same. An organization that excludes these members must do so for all rates.

Note

- Refer to Appendix 2 for the definition of PCP and OB/GYN practitioner.
Childhood Immunization Status (CIS)

Measure Updates September 2020 for AMP MY 2020 and 2021

- Updated rules for allowable gap for the Medi-Cal Managed Care product line.
- Added a requirement that LAIV (influenza) vaccination must occur on the child’s second birthday.

Modifications from HEDIS

- The AMP CIS measure only includes one combination rate (Combination 10).

Description

The percentage of enrolled children two years of age who were identified as having completed the following antigen series by their second birthday. The measure calculates a rate for each vaccine and one separate combination rate.

- Four diphtheria, tetanus and acellular pertussis (DTaP).
- Three polio (IPV).
- One measles, mumps, rubella (MMR).
- Three haemophilus influenza type B (HiB).
- Three hepatitis B (HepB).
- One chicken pox (VZV).
- Four pneumococcal conjugate (PCV).
- One hepatitis A (HepA).
- Two or three rotavirus (RV).
- Two influenza (flu) vaccinations.
- Combination 10.

Eligible Population

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Product line
Commercial HMO/POS, Commercial ACO, Medi-Cal Managed Care (report each product line separately).

Age
Children who turn 2 years of age during the measurement year.

Continuous enrollment

...for self-reporting POs
12 months prior to the child’s second birthday in the PO (parent level).

...for health plans
12 months prior to the child’s second birthday in the health plan and in the PO (parent level).

Allowable gap
No more than one gap in enrollment of up to 45 days during the 12 months prior to the child’s second birthday. To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
### Anchor date

**…for self-reporting POs** Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in an AMP plan on the child’s second birthday.

**…for health plans** Enrolled in the health plan and the PO (parent level, or subgroup level, for eligible POs) on the child’s second birthday.

### Benefit
Medical.

### Event/diagnosis
None.

### Administrative Specification

<table>
<thead>
<tr>
<th>Denominator</th>
<th>The eligible population.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Numerators</th>
<th>For MMR, hepatitis B, VZV and hepatitis A, count any of the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Evidence of the antigen or combination vaccine, or</td>
</tr>
<tr>
<td></td>
<td>• Documented history of the illness, or</td>
</tr>
<tr>
<td></td>
<td>• A seropositive test result for each antigen.</td>
</tr>
</tbody>
</table>

For DTaP, IPV, HiB, pneumococcal conjugate, rotavirus and influenza, count only:

- Evidence of the antigen or combination vaccine.

For combination vaccinations that require more than one antigen (DTaP and MMR), the organization must find evidence of all the antigens.

**DTaP** At least four DTaP vaccinations (DTaP Immunization Value Set; DTaP Vaccine Procedure Value Set) with different dates of service on or before the child’s second birthday. Do not count a vaccination administered prior to 42 days after birth.

**IPV** At least three IPV vaccinations (Inactivated Polio Vaccine (IPV) Immunization Value Set; Inactivated Polio Vaccine (IPV) Procedure Value Set), with different dates of service on or before the child’s second birthday. Do not count a vaccination administered prior to 42 days after birth.

**MMR** Any of the following meet criteria:

- At least one MMR vaccination (Measles, Mumps and Rubella (MMR) Immunization Value Set; Measles, Mumps and Rubella (MMR) Vaccine Procedure Value Set) on or between the child’s first and second birthdays.

- At least one measles and rubella vaccination (Measles Rubella Immunization Value Set; Measles Rubella Vaccine Procedure Value Set) on or between the child’s first and second birthdays and one of the following:
  - At least one mumps vaccination (Mumps Immunization Value Set; Mumps Vaccine Procedure Value Set) on or between the child’s first and second birthdays.
  - History of mumps illness (Mumps Value Set) any time on or before the child’s second birthday.
• Any combination of codes from the table below that indicates evidence of all three antigens (on the same or different date of service).

<table>
<thead>
<tr>
<th>Measles (any of the following)</th>
<th>Mumps (any of the following)</th>
<th>Rubella (any of the following)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• At least one measles vaccination (Measles Immunization Value Set; Measles Vaccine Procedure Value Set) administered on or between the child’s first and second birthdays.</td>
<td>• At least one mumps vaccination (Mumps Immunization Value Set; Mumps Vaccine Procedure Value Set) administered on or between the child’s first and second birthdays.</td>
<td>• At least one rubella vaccination (Rubella Immunization Value Set; Rubella Vaccine Procedure Value Set) administered on or between the child’s first and second birthdays.</td>
</tr>
<tr>
<td>• History of measles (Measles Value Set) illness anytime on or before the child’s second birthday.</td>
<td>• History of mumps (Mumps Value Set) illness anytime on or before the child’s second birthday.</td>
<td>• History of rubella (Rubella Value Set) illness anytime on or before the child’s second birthday.</td>
</tr>
</tbody>
</table>

**Note:** General Guideline 34: Collecting Data for Measures With Multiple Numerator Events (i.e., the 14-day rule) does not apply to MMR.

**HiB** At least three HiB vaccinations (Haemophilus Influenzae Type B (HiB) Immunization Value Set; Haemophilus Influenzae Type B (HiB) Vaccine Procedure Value Set), with different dates of service on or before the child’s second birthday. Do not count a vaccination administered prior to 42 days after birth.

**Hepatitis B** Any of the following on or before the child’s second birthday meet criteria:

• At least three hepatitis B vaccinations (Hepatitis B Immunization Value Set; Hepatitis B Vaccine Procedure Value Set), with different dates of service.
  – One of the three vaccinations can be a newborn hepatitis B vaccination (Newborn Hepatitis B Vaccine Administered Value Set) during the eight-day period that begins on the date of birth and ends seven days after the date of birth. For example, if the member’s date of birth is December 1, the newborn hepatitis B vaccination must be on or between December 1 and December 8.

• History of hepatitis B (Hepatitis B Value Set).

**VZV** Either of the following meet criteria:

• At least one VZV vaccination (Varicella Zoster (VZV) Immunization Value Set; Varicella Zoster (VZV) Vaccine Procedure Value Set), with a date of service on or between the child’s first and second birthdays.

• History of varicella zoster (e.g., chicken pox) illness (Varicella Zoster Value Set) on or before the child’s second birthday.

**Pneumococcal conjugate** At least four pneumococcal conjugate vaccinations (Pneumococcal Conjugate Immunization Value Set; Pneumococcal Conjugate Vaccine Procedure Value Set), with different dates of service on or before the child’s second birthday. Do not count a vaccination administered prior to 42 days after birth.
**Hepatitis A** Either of the following meet criteria:

- At least one hepatitis A vaccination (Hepatitis A Immunization Value Set; Hepatitis A Vaccine Procedure Value Set), with a date of service on or between the child’s first and second birthdays.
- History of hepatitis A illness (Hepatitis A Value Set) on or before the child’s second birthday.

**Rotavirus** Any of the following on or before the child’s second birthday meet criteria. Do not count a vaccination administered prior to 42 days after birth.

- At least two doses of the two-dose rotavirus vaccine (Rotavirus (2 Dose Schedule) Immunization Value Set; Rotavirus Vaccine (2 Dose Schedule) Procedure Value Set) on different dates of service.
- At least three doses of the three-dose rotavirus vaccine (Rotavirus (3 Dose Schedule) Immunization Value Set; Rotavirus Vaccine (3 Dose Schedule) Procedure Value Set) on different dates of service.
- At least one dose of the two-dose rotavirus vaccine (Rotavirus (2 Dose Schedule) Immunization Value Set; Rotavirus Vaccine (2 Dose Schedule) Procedure Value Set) and at least two doses of the three-dose rotavirus vaccine (Rotavirus (3 Dose Schedule) Immunization Value Set; Rotavirus Vaccine (3 Dose Schedule) Procedure Value Set), all on different dates of service.

**Influenza** At least two influenza vaccinations (Influenza Immunization Value Set; Influenza Vaccine Procedure Value Set), with different dates of service on or before the child’s second birthday. Do not count a vaccination administered prior to 6 months (180 days) after birth.

- One of the two vaccinations can be an LAIV vaccination (Influenza Virus LAIV Immunization Value Set; Influenza Virus LAIV Vaccine Procedure Value Set) administered on the child’s second birthday. Do not count an LAIV vaccination administered before the child’s second birthday.

---

**Combination rates** Calculate the following rates for Combinations 10.

**Combination Vaccination for Childhood Immunization Status**

<table>
<thead>
<tr>
<th>Combination</th>
<th>DTaP</th>
<th>IPV</th>
<th>MMR</th>
<th>HiB</th>
<th>HepB</th>
<th>VZV</th>
<th>PCV</th>
<th>HepA</th>
<th>RV</th>
<th>Influenza</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combination 10</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
</tbody>
</table>

**Exclusions (optional)**

- Exclude children who had a contraindication for a specific vaccine from the denominator for all antigen rates and the combination rate. The denominator for all rates must be the same.
- Exclude contraindicated children only if administrative data do not indicate that the contraindicated immunization was rendered in its entirety.

Any of the following on or before the member’s second birthday meet optional exclusion criteria:

- **Any particular vaccine** Anaphylactic reaction to the vaccine or its components (Anaphylactic Reaction Due To Vaccination Value Set).
**DTaP**
- Encephalopathy *(Encephalopathy Due To Vaccination Value Set)* with a vaccine adverse-effect code *(Vaccine Causing Adverse Effect Value Set)*.

**MMR and VZV and influenza**
- Immunodeficiency *(Disorders of the Immune System Value Set)*.
- HIV *(HIV Value Set; HIV Type 2 Value Set)*.
- Lymphoreticular cancer, multiple myeloma or leukemia *(Malignant Neoplasm of Lymphatic Tissue Value Set)*.
- Anaphylactic reaction to neomycin.

**Rotavirus**
- Severe combined immunodeficiency *(Severe Combined Immunodeficiency Value Set)*.
- History of intussusception *(Intussusception Value Set)*.

**IPV**
- Anaphylactic reaction to streptomycin, polymyxin B or neomycin.

**Hepatitis B**
- Anaphylactic reaction to common baker’s yeast.
IMMUNIZATIONS FOR ADOLESCENTS (IMA)

MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021

• Updated rules for allowable gap for the Medi-Cal Managed Care product line.

MODIFICATIONS FROM HEDIS

• None.

DESCRIPTION

The percentage of adolescents 13 years of age who had one dose of meningococcal vaccine, one tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday. The measure calculates a rate for each vaccine and two combination rates.

ELIGIBLE POPULATION

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Product lines: Commercial HMO/POS, Commercial ACO, Medi-Cal Managed Care (report each product line separately).

Age: Adolescents who turn 13 years of age during the measurement year.

Continuous enrollment:

...for self-reporting POs: 12 months prior to the member’s 13th birthday in the PO (parent level).

...for health plans: 12 months prior to the member’s 13th birthday in the health plan and in the PO (parent level).

Allowable gap: No more than one gap in enrollment of up to 45 days during the 12 months prior to the 13th birthday. To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

Anchor date:

...for self-reporting POs: Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in a AMP plan on the member’s 13th birthday.

...for health plans: Enrolled in the health plan and the PO (parent level, or subgroup level, for eligible POs) on the member’s 13th birthday.

Benefit: Medical.

Event/diagnosis: None.
## Administrative Specification

**Denominator**  
The eligible population.

**Numerators**  
For meningococcal, Tdap and HPV count only evidence of the antigen or combination vaccine.

- **Meningococcal serogroups A, C, W, Y**  
  At least one meningococcal serogroups A, C, W, Y vaccine (Meningococcal Immunization Value Set; Meningococcal Vaccine Procedure Value Set), with a date of service on or between the member’s 11th and 13th birthdays.

- **Tdap**  
  At least one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine (Tdap Immunization Value Set; Tdap Vaccine Procedure Value Set), with a date of service on or between the member’s 10th and 13th birthdays.

- **HPV**  
  - At least two HPV vaccines (HPV Immunization Value Set; HPV Vaccine Procedure Value Set), with dates of service at least 146 days apart on or between the member’s 9th and 13th birthdays. For example, if the service date for the first vaccine was March 1, then the service date for the second vaccine must be after July 25.
  
  **OR**
  
  - At least three HPV vaccines (HPV Immunization Value Set; HPV Vaccine Procedure Value Set), with different dates of service on or between the member’s 9th and 13th birthdays.

**Combination 1**  
Adolescents who are numerator compliant for both the meningococcal conjugate and Tdap indicators.

**Combination 2**  
Adolescents who are numerator compliant for all three indicators (meningococcal, Tdap, HPV).

## Exclusion (optional)

Exclude adolescents who had a contraindication for a specific vaccine from the denominator for all antigen rates and the combination rates. The denominator for all rates must be the same. Contraindicated adolescents may be excluded only if administrative data do not indicate that the contraindicated immunization was rendered.

Any of the following meet optional exclusion criteria:

- **Any particular vaccine**  
  - Anaphylactic reaction to the vaccine or its components (Anaphylactic Reaction Due To Vaccination Value Set) any time on or before the member’s 13th birthday.
  - Anaphylactic reaction to the vaccine or its components (Anaphylactic Reaction Due To Serum Value Set), with a date of service prior to October 1, 2011.

- **Tdap**  
  - Encephalopathy (Encephalopathy Due To Vaccination Value Set) with a vaccine adverse-effect code (Vaccine Causing Adverse Effect Value Set) anytime on or before the member’s 13th birthday.
**Chlamydia Screening in Women (CHL)**

**MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020/2021**

- Added Dienogest-estradiol (multiphasic) and removed Estradiol-medroxyprogesterone and Ethinyl estradiol-folic acid-levonorgestrel from the “Contraceptives” description in the Contraceptive Medications List.

**MODIFICATIONS FROM HEDIS**

- None.

**Description**

The percentage of women 16–24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.

**Eligible Population**

*Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.*

- **Product line**: Commercial HMO/POS, Commercial ACO, Medi-Cal Managed Care (report each product line separately).

- **Ages**: Women 16–24 years as of December 31 of the measurement year. Report two age stratifications and a total rate:
  - 16–20 years.
  - 21–24 years.
  - Total.

  The total is the sum of the age stratifications.

- **Continuous enrollment**
  
  **...for self-reporting POs**: The measurement year in the PO (parent level).

  **...for health plans**: The measurement year in the health plan and in the PO (parent level).

- **Allowable gap**: No more than one gap in enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

- **Anchor date**
  
  **...for self-reporting POs**: Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in a AMP plan on December 31 of the measurement year.
...for health plans

Enrolled in the health plan and the PO (parent level, or subgroup level, for eligible POs) on December 31 of the measurement year.

Benefit

Medical.

Event/diagnosis

Sexually active. Two methods identify sexually active women: pharmacy data and claim/encounter data. The organization must use both methods to identify the eligible population; however, a member only needs to be identified in one method to be eligible for the measure.

Claim/encounter data. Members who had a claim or encounter indicating sexual activity during the measurement year. A code from any of the following meets criteria:

- Pregnancy Value Set.
- Sexual Activity Value Set.
- Pregnancy Tests Value Set.

Pharmacy data. Members who were dispensed prescription contraceptives during the measurement year (Contraceptive Medications List).

Contraceptive Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contraceptives</td>
<td>• Desogestrel-ethinyl estradiol</td>
</tr>
<tr>
<td></td>
<td>• Dienogest-estradiol (multiphasic)</td>
</tr>
<tr>
<td></td>
<td>• Drospirenone-ethinyl estradiol</td>
</tr>
<tr>
<td></td>
<td>• Drospirenone-ethinyl estradiol-levomefolate</td>
</tr>
<tr>
<td></td>
<td>(biphasic)</td>
</tr>
<tr>
<td></td>
<td>• Ethinyl estradiol-ethynodiol</td>
</tr>
<tr>
<td></td>
<td>• Ethinyl estradiol-etonogestrel</td>
</tr>
<tr>
<td></td>
<td>• Ethinyl estradiol-levonorgestrel</td>
</tr>
<tr>
<td></td>
<td>• Ethinyl estradiol-norelgestromin</td>
</tr>
<tr>
<td></td>
<td>• Ethinyl estradiol-norethindrone</td>
</tr>
<tr>
<td></td>
<td>• Ethinyl estradiol-norgestimate</td>
</tr>
<tr>
<td></td>
<td>• Ethinyl estradiol-norgestrel</td>
</tr>
<tr>
<td></td>
<td>• Ethinyl estradiol-norgestrel</td>
</tr>
<tr>
<td></td>
<td>• Etonogestrel</td>
</tr>
<tr>
<td></td>
<td>• Levonorgestrel</td>
</tr>
<tr>
<td></td>
<td>• Medroxyprogesterone</td>
</tr>
<tr>
<td></td>
<td>• Mestranol-norethindrone</td>
</tr>
<tr>
<td></td>
<td>• Norethindrone</td>
</tr>
<tr>
<td>Diaphragm</td>
<td>• Diaphragm</td>
</tr>
<tr>
<td>Spermicide</td>
<td>• Nonoxynol 9</td>
</tr>
</tbody>
</table>

Administrative Specification

Denominator

The eligible population.

Numerator

At least one chlamydia test (Chlamydia Tests Value Set) during the measurement year.
Exclusion (optional)

Exclude members who qualified for the denominator based on a pregnancy test (Pregnancy Tests Value Set) alone and who meet either of the following criteria:

- A pregnancy test (Pregnancy Test Exclusion Value Set) during the measurement year and a prescription for isotretinoin (Retinoid Medications List) on the date of the pregnancy test or during the six days after the pregnancy test.

- A pregnancy test (Pregnancy Test Exclusion Value Set) during the measurement year and an x-ray (Diagnostic Radiology Value Set) on the date of the pregnancy test or during the six days after the pregnancy test.

Retinoid Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retinoid</td>
<td>Isotretinoin</td>
</tr>
</tbody>
</table>
Cervical Cancer Screening (CCS)

MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021

- Added palliative care as a required exclusion.

MODIFICATIONS FROM HEDIS

- The measure exclusion is required.

Description

The percentage of women 21–64 years of age who were screened for cervical cancer using either of the following criteria:

- Women 21–64 years of age who had cervical cytology performed within the last 3 years.
- Women 30–64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years.
- Women 30–64 years of age who had cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the last 5 years.

Eligible Population

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Product lines: Commercial HMO/POS, Commercial ACO, Medi-Cal Managed Care (report each product line separately).

Ages: Women 24–64 years as of December 31 of the measurement year.

Continuous enrollment

...for self-reporting POs: The measurement year and the two years prior to the measurement year in the PO (parent level).

For Medi-Cal Managed Care reporting: The measurement year in the PO (parent level).

...for health plans: The measurement year and the two years prior to the measurement year in the health plan and in the PO (parent level).

For Medi-Cal Managed Care reporting: The measurement year in the health plan PO (parent level).
Allowable gap

No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

Anchor date

...for self-reporting POs

Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in a AMP plan on December 31 of the measurement year.

...for health plans

Enrolled in the health plan and the PO (parent level, or, for eligible POs, subgroup level) on December 31 of the measurement year.

Benefit

Medical.

Event/diagnosis

None.

Administrative Specification

Denominator

The eligible population.

Numerator

The number of women who were screened for cervical cancer. Either of the following meets criteria:

- Women 24–64 years of age as of December 31 of the measurement year who had cervical cytology (Cervical Cytology Lab Test Value Set; Cervical Cytology Result or Finding Value Set) during the measurement year or the two years prior to the measurement year.

- Women 30–64 years of age as of December 31 of the measurement year who had cervical high-risk human papillomavirus (hrHPV) testing (High Risk HPV Lab Test Value Set, High Risk HPV Test Result or Finding Value Set) during the measurement year or the four years prior to the measurement year and who were 30 years or older on the date of the test.

Note: Evidence of hrHPV testing within the last 5 years also captures patients who had cotesting; therefore, additional methods to identify cotesting are not necessary.

Exclusion (required)

- Members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the measurement year.

- Hysterectomy with no residual cervix, cervical agenesis or acquired absence of cervix (Absence of Cervix Diagnosis Value Set; Hysterectomy With No Residual Cervix Value Set) any time during the member’s history through December 31 of the measurement year.
MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021

- Added palliative care as a required exclusion.

MODIFICATIONS FROM HEDIS

- This is a non-HEDIS measure.

Description

The percentage of women 21–64 years of age who received more cervical cancer screenings than necessary according to evidence-based guidelines, using either of the following criteria:

- Women 21–64 who had more than one cervical cytology performed within the last three years.
- Women 30–64 who had more than one cervical high-risk human papillomavirus (hrHPV) testing performed within the last five years.
- Women 30–64 who had more than one cervical cytology/high-risk human papillomavirus (hrHPV) co-testing within the last five years.

Report one total rate.

Because this measure assesses overscreening, a lower rate indicates better performance.

Eligible Population

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Product lines

Commercial HMO/POS, Commercial ACO, Medi-Cal Managed Care (report each product line separately).

Ages

Women 24–64 years as of December 31 of the measurement year.

Continuous enrollment

...for self-reporting POs

The measurement year and the two years prior to the measurement year in the PO (parent level).

For Medi-Cal Managed Care reporting: The measurement year in the PO (parent level).
...for health-plans

The measurement year and the two years prior to the measurement year in the health plan and in the PO (parent level).

For Medi-Cal Managed Care reporting: The measurement year in the health plan PO (parent level).

Allowable gap

No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

Anchor date

...for self-reporting POs

Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in an AMP plan on December 31 of the measurement year.

...for health plans

Enrolled in the health plan and the PO (parent level, or, for eligible POs, subgroup level) on December 31 of the measurement year.

Benefit

Medical.

Event/diagnosis

None.

Administrative Specification

<table>
<thead>
<tr>
<th>Denominator</th>
<th>The eligible population.</th>
</tr>
</thead>
</table>
| Numerator   | The number of women who were screened too frequently for cervical cancer. Either of the following meet criteria:

  - Women 24–64 years of age as of December 31 of the measurement year who had more than one cervical cytology (Cervical Cytology Lab Test Value Set; Cervical Cytology Result or Finding Value Set) during the measurement year or the two years prior to the measurement year.

  - Women 30–64 years of age as of December 31 of the measurement year who had more than one cervical high-risk human papillomavirus (hrHPV) testing (High Risk HPV Lab Test Value Set, High Risk HPV Test Result or Finding Value Set) during the measurement year or the four years prior to the measurement year and who were 30 years or older on the date of both tests.

Note: Evidence of more than one hrHPV testing within the last 5 years also captures patients who had cotesting; therefore, additional methods to identify cotesting are not necessary.

If two or more claims/encounters with qualifying numerator codes for cervical cytology occur within 14 days of each other, count only the first one. Refer to General Guideline 34.
Exclusions *(required)*

- Members receiving palliative care *(Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set)* during the measurement year.

- Hysterectomy with no residual cervix, cervical agenesis or acquired absence of cervix *(Absence of Cervix Diagnosis Value Set; Hysterectomy With No Residual Cervix Value Set)* any time during the member’s history through December 31 of the measurement year.

- A diagnosis of dysplasia, HPV codes or an abnormal cervical cytology screening *(CCO Exclusions Group 1 Value Set)* during the measurement year or four years prior to the measurement year.

- A history of cervical cancer, DES exposure, HIV or immunodeficiency, including genetic (congenital) immunodeficiency syndromes *(CCO Exclusions Group 2 Value Set)* any time during the member’s history through December 31 of the measurement year.

*Note:* Current cervical cancer screening guidelines for average-risk women do not state that women 30–64 years of age with a “cervical cytology” in 3 years and a “cervical cytology and HPV co-test” in 5 years are considered overscreened. For AMP reporting, we look only at cases of overscreening as explicitly outlined by the guidelines. AMP staff and committees will continue to review clinical practices and cervical cancer screening guidelines.
Breast Cancer Screening (BCS)

Measure Updates September 2020 for AMP MY 2020 and 2021

- Added palliative care as a required exclusion.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.

Modifications from HEDIS

- AMP does not include the Medicare SES Stratifications.
- The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

Description

Breast Cancer Screening is the same measure as the CMS Stars Measure Breast Cancer Screening. The percentage of women 50–74 years of age who had a mammogram to screen for breast cancer. The eligible population starts at 52 years of age to account for the look-back period.

Eligible Population

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

- Product lines: Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).
- Ages: Women 52–74 years as of December 31 of the measurement year.
- Continuous enrollment:
  - ...for self-reporting POs: October 1 two years prior to the measurement year through December 31 of the measurement year in the PO (parent level).
  - ...for health plans: October 1 two years prior to the measurement year through December 31 of the measurement year in the health plan and in the PO (parent level).
- Allowable gap: No more than one gap in enrollment of up to 45 days for each full calendar year of continuous enrollment (the measurement year and the year prior to the measurement year). To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled) during each year of continuous enrollment.
- Anchor date: No gaps in enrollment are allowed from October 1 two years prior to the measurement year through December 31 two years prior to the measurement year.
...for self-reporting POs

Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in an AMP plan on December 31 of the measurement year.

...for health plans

Enrolled in the health plan and the PO (parent level, or subgroup level, for eligible POs) on December 31 of the measurement year.

Benefit

Medical.

Event/diagnosis

None.

Required exclusion

Members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the measurement year.

Exclusions

Exclude members who meet any of the following criteria:

Note: Supplemental data may not be used for these exclusions.

- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
  - "Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.

- Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness.
  Members must meet BOTH of the following frailty and advanced illness criteria to be excluded:
  1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.
  2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
    - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
      1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
      2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
      3. Identify the discharge date for the stay.
    - At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set). To identify an acute inpatient discharge:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
3. Identify the discharge date for the stay.

A dispensed dementia medication (Dementia Medications List).

*The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

<table>
<thead>
<tr>
<th>Dementia Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
</tr>
<tr>
<td>Prescriptions</td>
</tr>
<tr>
<td>Cholinesterase inhibitors</td>
</tr>
<tr>
<td>• Donepezil</td>
</tr>
<tr>
<td>• Galantamine</td>
</tr>
<tr>
<td>• Rivastigmine</td>
</tr>
<tr>
<td>Miscellaneous central nervous system agents</td>
</tr>
<tr>
<td>• Memantine</td>
</tr>
<tr>
<td>Dementia combinations</td>
</tr>
<tr>
<td>• Donepezil-memantine</td>
</tr>
</tbody>
</table>

**Administrative Specification**

- **Denominator**: The eligible population.
- **Numerator**: One or more mammograms (Mammography Value Set) any time on or between October 1 two years prior to the measurement year and December 31 of the measurement year.

**Exclusion (optional)**

Bilateral mastectomy any time during the member’s history through December 31 of the measurement year. Any of the following meet criteria for bilateral mastectomy:

- Bilateral mastectomy (Bilateral Mastectomy Value Set).
- Unilateral mastectomy (Unilateral Mastectomy Value Set) with a bilateral modifier (Bilateral Modifier Value Set). Codes must be on the same claim.
- Unilateral mastectomy found in clinical data (Clinical Unilateral Mastectomy Value Set) with a bilateral modifier (Clinical Bilateral Modifier Value Set).

**Note**: The “clinical” mastectomy value sets identify mastectomy; the word “clinical” refers to the data source, not to the type of mastectomy.

- History of bilateral mastectomy (History of Bilateral Mastectomy Value Set).
- Any combination of codes from the table below that indicate a mastectomy on both the left and right side on the same or different dates of service.

<table>
<thead>
<tr>
<th>Left Mastectomy (any of the following)</th>
<th>Right Mastectomy (any of the following)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Unilateral mastectomy (Unilateral Mastectomy Value Set) with a left-side modifier (Left Modifier Value Set) (same procedure)</td>
<td>• Unilateral mastectomy (Unilateral Mastectomy Value Set) with a right-side modifier (Right Modifier Value Set) (same procedure)</td>
</tr>
<tr>
<td>• Unilateral mastectomy found in clinical data (Clinical Unilateral Mastectomy Value Set) with a left-side</td>
<td>• Unilateral mastectomy found in clinical data (Clinical Unilateral Mastectomy Value Set) with a</td>
</tr>
<tr>
<td>Modifier (Clinical Left Modifier Value Set) (same procedure)</td>
<td>Right-side Modifier (Clinical Right Modifier Value Set) (same procedure)</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td>• Absence of the left breast (Absence of Left Breast Value Set)</td>
<td>• Absence of the right breast (Absence of Right Breast Value Set)</td>
</tr>
<tr>
<td>• Left unilateral mastectomy (Unilateral Mastectomy Left Value Set)</td>
<td>• Right unilateral mastectomy (Unilateral Mastectomy Right Value Set)</td>
</tr>
</tbody>
</table>

**Note**

- This measure assesses the use of imaging to detect early breast cancer in women. Because the measure denominator does not remove women at higher risk of breast cancer, all types and methods of mammograms (screening, diagnostic, film, digital or digital breast tomosynthesis) qualify for numerator compliance. Do not count MRIs, ultrasounds or biopsies towards the numerator. Although these procedures may be indicated for evaluating women at higher risk for breast cancer or for diagnostic purposes, they are performed as an adjunct to mammography and do not alone count toward the numerator.
Colorectal Cancer Screening (COL)

**Measure Updates September 2020 for AMP MY 2020 and 2021**

- Added palliative care as a required exclusion.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.

**Modifications from HEDIS**

- AMP does not include the Medicare SES Stratifications.
- The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

**Description**

- *Colorectal Cancer Screening* is the same measure as the CMS Stars measure Colorectal Cancer Screening.

The percentage of adults 50–75 years of age who had appropriate screening for colorectal cancer.

**Eligible Population**

*Note:* Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

- **Product lines**
  - Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).

- **Ages**
  - 51–75 years as of December 31 of the measurement year.

- **Continuous enrollment**
  - **...for self-reporting POs**
    - The measurement year and the year prior to the measurement year in the PO (parent level).
    - *For Medi-Cal Managed Care reporting:* The measurement year in the PO (parent level).
  
  - **...for health plans**
    - The measurement year and the year prior to the measurement year in the health plan and in the PO (parent level).
    - *For Medi-Cal Managed Care reporting:* The measurement year in the health plan and PO (parent level).

- **Allowable gap**
  - No more than one gap in enrollment of up to 45 days during each year of continuous enrollment.

To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
Anchor date

...for self-reporting POs
Enrolled in the PO (parent level, or subgroup level, for eligible POs) and in an AMP plan on December 31 of the measurement year.

...for health plans
Enrolled in the health plan and the PO (parent level, or subgroup level, for eligible POs) on December 31 of the measurement year.

Benefit
Medical.

Event/diagnosis
None.

Required exclusion
Members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the measurement year.

Exclusions
Exclude members who meet any of the following criteria:

Note: Supplemental data may not be used for these exclusions.

- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
  - *Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.

- Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet BOTH of the following frailty and advanced illness criteria to be excluded:
  1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.
  2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
     - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
       1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
       2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
       3. Identify the discharge date for the stay.
At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).

At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
3. Identify the discharge date for the stay.

A dispensed dementia medication (Dementia Medications List).

*The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.

### Dementia Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinesterase inhibitors</td>
<td>• Donepezil</td>
</tr>
<tr>
<td></td>
<td>• Galantamine</td>
</tr>
<tr>
<td></td>
<td>• Rivastigmine</td>
</tr>
<tr>
<td>Miscellaneous central nervous system agents</td>
<td>• Memantine</td>
</tr>
<tr>
<td>Dementia combinations</td>
<td>• Donepezil-memantine</td>
</tr>
</tbody>
</table>

### Administrative Specification

**Denominator**
The eligible population.

**Numerator**
One or more screenings for colorectal cancer. Any of the following meet criteria:

- Fecal occult blood test (FOBT Lab Test Value Set; FOBT Test Result or Finding Value Set) during the measurement year. For administrative data, assume the required number of samples were returned, regardless of FOBT type.

- Flexible sigmoidoscopy (Flexible Sigmoidoscopy Value Set; History of Flexible Sigmoidoscopy Value Set) during the measurement year or the four years prior to the measurement year.

- Colonoscopy (Colonoscopy Value Set; History of Colonoscopy Value Set) during the measurement year or the nine years prior to the measurement year.

- CT colonography (CT Colonography Value Set) during the measurement year or the four years prior to the measurement year.

- FIT-DNA test (FIT DNA Lab Test Value Set; FIT DNA Test Result or Finding Value Set) during the measurement year or the two years prior to the measurement year.
Exclusion (optional)

Either of the following any time during the member’s history through December 31 of the measurement year:

- Colorectal cancer (Colorectal Cancer Value Set).
- Total colectomy (Total Colectomy Value Set; History of Total Colectomy Value Set)
Prenatal and Postpartum Care (PPC)

**MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021**

- Revised the definition of last enrollment segment.
- Clarified that visits that occur prior to the enrollment start date (during the pregnancy) meet criteria.
- Added telephone visits (Telephone Visits Value Set) e-visits and virtual check-ins (Online Assessments Value Set) to the Timeliness of Prenatal Care rate (administrative specification) and clarified in the *Notes* that services provided via telephone, e-visit or virtual check-in are eligible for use in reporting both rates.

**MODIFICATIONS FROM HEDIS**

- None.

**Description**

The percentage of deliveries of live births on or between October 8 of the year prior to the measurement year and October 7 of the measurement year. For these women, the measure assesses the following facets of prenatal and postpartum care.

- *Timeliness of Prenatal Care.* The percentage of deliveries that received a prenatal care visit in the first trimester, on or before the enrollment start date or within 42 days of enrollment in the organization.
- *Postpartum Care.* The percentage of deliveries that had a postpartum visit on or between 7 and 84 days after delivery.

**Definitions**

<table>
<thead>
<tr>
<th><strong>First trimester</strong></th>
<th>280–176 days prior to delivery (or EDD).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Last enrollment segment</strong></td>
<td>The period of continuous enrollment (with no gaps in enrollment) during the pregnancy with the start date that is closest to the delivery date. Refer to General Guideline 20: Members Who Switch Products/Product Lines to determine continuous enrollment.</td>
</tr>
</tbody>
</table>

**Eligible Population**

*Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.*

<table>
<thead>
<tr>
<th><strong>Product line</strong></th>
<th>Medi-Cal Managed Care.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>None specified.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Continuous enrollment</strong></th>
<th>43 days prior to delivery through 60 days after delivery in the PO (parent level).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>...for self-reporting POs</strong></td>
<td>43 days prior to delivery through 60 days after delivery in the health plan and the PO (parent level).</td>
</tr>
</tbody>
</table>

September 1, 2020
Allowable gap
No allowable gap during the continuous enrollment period.

Anchor date
Date of delivery.

Benefit
Medical.

Event/diagnosis
Delivered a live birth on or between October 8 of the year prior to the measurement year and October 7 of the measurement year. Include women who delivered in any setting.

*Multiple births.* Women who had two separate deliveries (different dates of service) between October 8 of the year prior to the measurement year and October 7 of the measurement year count twice. Women who had multiple live births during one pregnancy count once.

Follow the steps below to identify the eligible population, which is the denominator for both rates.

**Step 1** Identify deliveries. Identify all women with a delivery (Deliveries Value Set) on or between October 8 of the year prior to the measurement year and October 7 of the measurement year.

*Note:* The intent is to identify the date of delivery (the date of the “procedure”). If the date of delivery cannot be interpreted on the claim, use the date of service or, for inpatient claims, the date of discharge.

**Step 2** Exclude non-live births (Non-live Births Value Set).

**Step 3** Identify continuous enrollment. Determine if enrollment was continuous 43 days prior to delivery through 60 days after delivery, with no gaps.

*Note:* If a member has multiple enrollment segments with no gaps in enrollment leading up to delivery, use the beginning of the first segment as the start of the last segment (i.e. treat multiple enrollment segments with no gap in enrollment as one segment).

**Administrative Specification**

<table>
<thead>
<tr>
<th>Denominator</th>
<th>The eligible population.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numerator</td>
<td>A prenatal visit during the required timeframe. Follow the steps below to identify numerator compliance.</td>
</tr>
<tr>
<td><em>Timeliness of Prenatal Care</em></td>
<td></td>
</tr>
<tr>
<td><strong>Step 1</strong></td>
<td>Identify women whose last enrollment segment started before, on or between 280 and 219 days before delivery (or EDD). These women must have a prenatal visit during the first trimester.</td>
</tr>
<tr>
<td><strong>Step 2</strong></td>
<td>Identify women whose last enrollment segment started less than 219 days before delivery (or EDD). These women must have a prenatal visit any time during the period that begins 280 days prior to delivery and ends 42 days after enrollment start date. Do not count visits that occur on or after the date of delivery.</td>
</tr>
</tbody>
</table>
Visits that occur prior to the woman’s enrollment start date during the pregnancy meet criteria.

**Step 3** Identify prenatal visits that occurred during the required timeframe (the time frame identified in step 1 or 2). Any of the following, where the practitioner type is an OB/GYN or other prenatal care practitioner or PCP, meet criteria for a prenatal visit:

- A bundled service (Prenatal Bundled Services Value Set) where the organization can identify the date when prenatal care was initiated (because bundled service codes are used on the date of delivery, these codes may be used only if the claim form indicates when prenatal care was initiated).

- A visit for prenatal care (Stand Alone Prenatal Visits Value Set).

- A prenatal visit (Prenatal Visits Value Set; Telephone Visits Value Set; Online Assessments Value Set) with a pregnancy-related diagnosis code (Pregnancy Diagnosis Value Set).

**Postpartum Care** A postpartum visit on or between 7 and 84 days after delivery. Any of the following meet criteria:

- A postpartum visit (Postpartum Visits Value Set).

- Cervical cytology (Cervical Cytology Lab Test Value Set; Cervical Cytology Result or Finding Value Set).

- A bundled service (Postpartum Bundled Services Value Set) where the organization can identify the date when postpartum care was rendered (because bundled service codes are used on the date of delivery, not on the date of the postpartum visit, these codes may be used only if the claim form indicates when postpartum care was rendered).

Exclude services provided in an acute inpatient setting (Acute Inpatient Value Set; Acute Inpatient POS Value Set).

**Note:** The organization is not required to identify practitioner type in administrative data.

**Note**

- Criteria for identifying prenatal care for women who were not continuously enrolled during the first trimester allow more flexibility than criteria for women who were continuously enrolled.
  - For women whose last enrollment segment started before, on or between 280 and 219 days before delivery, the organization has sufficient opportunity to provide prenatal care by the end of the first trimester.
  - For women whose last enrollment segment started less than 219 days before delivery, the organization has sufficient opportunity to provide prenatal care within 42 days after enrollment.

- Services that occur over multiple visits count toward this measure if all services are within the time frame established in the measure. Ultrasound and lab results alone are not considered a visit; they must be combined with an office visit with an appropriate practitioner in order to count for this measure.

- For each member, the organization must use one date (date of delivery or EDD) to define the start and end of the first trimester. If multiple EDDs are documented, the organization must define a method to determine which EDD to use, and use that date consistently. If the organization elects to
use EDD, and the EDD is not on or between October 8 of the year prior to the measurement year and October 7 of the measurement year, the member is excluded as a valid data error and replaced by the next member of the oversample. The LMP may not be used to determine the first trimester.

- The organization may use EDD to identify the first trimester for the Timeliness of Prenatal Care rate and use the date of delivery for the Postpartum Care rate.

- A Pap test does not count as a prenatal care visit for the administrative specification of the Timeliness of Prenatal Care rate, but is acceptable for the Postpartum Care rate as evidence of a pelvic exam. A colposcopy alone is not numerator compliant for either rate.

- The intent is that a prenatal visit is with a PCP or OB/GYN or other prenatal care practitioner. Ancillary services (lab, ultrasound) may be delivered by an ancillary provider. Nonancillary services (e.g., fetal heart tone, prenatal risk assessment) must be delivered by the required provider type.

- The intent is to assess whether prenatal and preventive care was rendered on a routine, outpatient basis rather than assessing treatment for emergent events.

- Refer to Appendix 2 for the definition of PCP and OB/GYN and other prenatal care practitioner.

- For both rates, services provided during a telephone visit, e-visit or virtual check-in are eligible for use in reporting.
**Child and Adolescent Well-Care Visits (WCV)**

**Measure Updates September 2020 for AMP MY 2020 and 2021**

- This measure is a combination measure that replaces the former “Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life” and “Adolescent Well-Care Visits” HEDIS measures.
- Added members age 7-11 years.
- Added age stratifications.
- Removed the telehealth exclusion.

**Modifications from HEDIS**

- None.

**Description**

The percentage of members 3–21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year.

**Note**

- This measure has the same structure as measures in the Clinical Measures domain. The organization must follow the Guidelines for Clinical Quality measures when calculating this measure.

**Eligible Population**

*Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.*

- **Product line**: Medi-Cal Managed Care.
- **Ages**: 3–21 years as of December 31 of the measurement year. Report three age stratifications and total rate:
  - 3-11 years.
  - 12-17 years.
  - 18-21 years.
  - Total

The total is the sum of the age stratifications for each product line.

**Continuous enrollment**

*...for self-reporting POs*

The measurement year in the PO (parent level).

*...for health plans*

The measurement year in the health plan and the PO (parent level).
**Allowable gap**  
No more than one gap in enrollment of up to 45 days during the continuous enrollment period. To determine continuous enrollment for a Medi-Cal Managed Care member for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

**Anchor date**  
December 31 of the measurement year.

**Benefit**  
Medical.

**Event/diagnosis**  
None.

### Administrative Specification

<table>
<thead>
<tr>
<th>Denominator</th>
<th>The eligible population.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numerator</td>
<td>One or more well-care visits (Well-Care Value Set) during the measurement year. The well-care visit must occur with a PCP or an OB/GYN practitioner, but the practitioner does not have to be the practitioner assigned to the member.</td>
</tr>
</tbody>
</table>

**Note**

- Refer to Appendix 2 for the definition of PCP and OB/GYN and other prenatal care practitioners.
- This measure is based on the American Academy of Pediatrics Bright Futures: Guidelines for Health Supervision of Infants, Children and Adolescents (published by the National Center for Education in Maternal and Child Health). Visit the Bright Futures website for more information about well-child visits (https://brightfutures.aap.org/materials-and-tools/guidelines-and-pocket-guide/).
Asthma Medication Ratio (AMR)

**MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021**

- Removed the restriction that only three of the four visits with an asthma diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Clarified in step 1 when the diagnosis must be on the discharge claim.
- Added Dupilumab to the “Anti-interleukin-4” description in the Dupilumab Medications List.
- Clarified NDC code mapping requirements in the Notes.

**MODIFICATIONS FROM HEDIS**
- None.

**Description**

The percentage of members 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.

**Definitions**

- **Oral medication dispensing event**: An oral medication dispensing event is one prescription of an amount lasting 30 days or less. To calculate dispensing events for prescriptions longer than 30 days, divide the days supply by 30 and round down to convert. For example, a 100-day prescription is equal to three dispensing events \((100/30 = 3.33, \text{rounded down to } 3)\). The organization should allocate the dispensing events to the appropriate year based on the date when the prescription is filled.

  Multiple prescriptions for different medications dispensed on the same day should be assessed separately. If multiple prescriptions for the same medication are dispensed on the same day, sum the days supply and divide by 30.

  Use the medication lists to determine if drugs are the same or different. Drugs in different medication lists are considered different drugs.

- **Inhaler dispensing event**: When identifying the eligible population, use the definition below to count inhaler dispensing events.

  All inhalers (i.e., canisters) of the same medication dispensed on the same day count as one dispensing event. Different inhaler medications dispensed on the same day are counted as different dispensing events. For example, if a member received three canisters of Medication A and two canisters of Medication B on the same date, it would count as two dispensing events.

  Allocate the dispensing events to the appropriate year based on the date when the prescription was filled.

  Use the medication lists to determine if drugs are the same or different. Drugs in different medication lists are considered different drugs.
Injection dispensing event

Each injection counts as one dispensing event. Multiple dispensed injections of the same or different medications count as separate dispensing events. For example, if a member received two injections of Medication A and one injection of Medication B on the same date, it would count as three dispensing events.

Use the medication lists to determine if drugs are the same or different. Drugs in different medication lists are considered different drugs.

Allocate the dispensing events to the appropriate year based on the date when the prescription was filled.

Units of medications

When identifying medication units for the numerator, count each individual medication, defined as an amount lasting 30 days or less, as one medication unit. One medication unit equals one inhaler canister, one injection, one infusion or a 30-day or less supply of an oral medication. For example, two inhaler canisters of the same medication dispensed on the same day count as two medication units and only one dispensing event.

Use the package size and units columns in the medication list to determine the number of canisters or injections. Divide the dispensed amount by the package size to determine the number of canisters or injections dispensed. For example, if the package size for an inhaled medication is 10 g and pharmacy data indicates the dispensed amount is 30 g, three inhaler canisters were dispensed.

Eligible Population for Persistent Asthmatics

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Product lines

Commercial HMO/POS, Commercial ACO, Medi-Cal Managed Care (report each product line separately).

Ages

5–64 years by December 31 of the measurement year. Report the following age stratifications and one total rate.

- 5–11 years.
- 12–18 years.
- 19–50 years.
- 51–64 years.
- Total.

The total is the sum of the age stratifications for each product line.

Continuous enrollment

...for self-reporting POs

The measurement year and the year prior to the measurement year in the PO (parent level)

...for health plans

The measurement year and the year prior to the measurement year in the health plan and in the PO (parent level).

Allowable gap

No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medi-Cal Managed Care beneficiary for whom enrollment is verified monthly, the member
may not have more than a 1-month gap in coverage during each year of continuous enrollment.

Anchor date

...for self-reporting POs
Enrolled in the PO (parent level, or, for eligible POs, subgroup level) and in an AMP plan on December 31 of the measurement year.

...for health plans
Enrolled in the health plan and the PO (parent level, or, for eligible POs, subgroup level) on December 31 of the measurement year.

Benefits
Medical. Pharmacy during the measurement year.

Event/diagnosis
Follow the steps below to identify the eligible population.

Step 1
Identify members as having persistent asthma who met at least one of the following criteria during both the measurement year and the year prior to the measurement year. Criteria need not be the same across both years.

- At least one ED visit (ED Value Set), with a principal diagnosis of asthma (Asthma Value Set).
- At least one acute inpatient encounter (Acute Inpatient Value Set), with a principal diagnosis of asthma (Asthma Value Set) without telehealth (Telehealth Modifier Value Set; Telehealth POS Value Set).
- At least one acute inpatient discharge with a principal diagnosis of asthma (Asthma Value Set) on the discharge claim. To identify an acute inpatient discharge:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
  3. Identify the discharge date for the stay.
- At least four outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), telephone visits (Telephone Visits Value Set) or e-visits or virtual check-ins (Online Assessments Value Set), on different dates of service, with any diagnosis of asthma (Asthma Value Set) and at least two asthma medication dispensing events for any controller or reliever medication. Visit type need not be the same for the four visits. Use all the medication lists in the tables below to identify asthma controller and reliever medications.
- At least four asthma medication dispensing events for any controller or reliever medications. Use all the medication lists in the tables below to identify asthma controller and reliever medications.
Step 2
A member identified as having persistent asthma because of at least four asthma medication dispensing events, where leukotriene modifiers or antibody inhibitors were the sole asthma medication dispensed in that year, must also have at least one diagnosis of asthma (Asthma Value Set), in any setting, in the same year as the leukotriene modifier or antibody inhibitor (i.e., the measurement year or the year prior to the measurement year).

Step 3: Required exclusions
Exclude members who met any of the following criteria:

- Members who had any diagnosis from any of the following value sets, any time during the member's history through December 31 of the measurement year:
  - Emphysema Value Set.
  - Other Emphysema Value Set.
  - COPD Value Set.
  - Obstructive Chronic Bronchitis Value Set.
  - Chronic Respiratory Conditions Due to Fumes or Vapors Value Set.
  - Cystic Fibrosis Value Set.
  - Acute Respiratory Failure Value Set.

- Members who had no asthma controller or reliever medications dispensed during the measurement year. Use all the medication lists in the tables below to identify asthma controller and reliever medications.

Administrative Specification

Denominator
The eligible population.

Numerator
The number of members who have a medication ratio of 0.50 or greater during the measurement year. Follow the steps below to calculate the ratio.

Use all the medication lists in the Asthma Controller Medications table below to identify asthma controller medications. Use all the medication lists in the Asthma Reliever Medications table below to identify asthma reliever medications.

Step 1
For each member, count the units of asthma controller medications dispensed during the measurement year. Refer to the definition of Units of medications.

Step 2
For each member, count the units of asthma reliever medications dispensed during the measurement year. Refer to the definition of Units of medications.

Step 3
For each member, sum the units calculated in step 1 and step 2 to determine units of total asthma medications.

Step 4
For each member, calculate the ratio of controller medications to total asthma medications using the following formula. Round (using the .5 rule) to the nearest whole number.

\[
\frac{\text{Units of Controller Medications (step 1)}}{\text{Units of Total Asthma Medications (step 3)}}
\]

Step 5
Sum the total number of members who have a ratio of 0.50 or greater in step 4.
### Asthma Controller Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescriptions</th>
<th>Medication Lists</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiasthmatic combinations</td>
<td>• Dyphylline-guaifenesin</td>
<td>Dyphylline Guaifenesin Medications List</td>
<td>Oral</td>
</tr>
<tr>
<td>Antibody inhibitors</td>
<td>• Omalizumab</td>
<td>Omalizumab Medications List</td>
<td>Injection</td>
</tr>
<tr>
<td>Anti-interleukin-4</td>
<td>• Dupilumab</td>
<td>Dupilumab Medications List</td>
<td>Injection</td>
</tr>
<tr>
<td>Anti-interleukin-5</td>
<td>• Benralizumab</td>
<td>Benralizumab Medications List</td>
<td>Injection</td>
</tr>
<tr>
<td>Anti-interleukin-5</td>
<td>• Mepolizumab</td>
<td>Mepolizumab Medications List</td>
<td>Injection</td>
</tr>
<tr>
<td>Anti-interleukin-5</td>
<td>• Reslizumab</td>
<td>Reslizumab Medications List</td>
<td>Injection</td>
</tr>
<tr>
<td>Inhaled steroid combinations</td>
<td>• Budesonide-formoterol</td>
<td>Budesonide Formoterol Medications List</td>
<td>Inhalation</td>
</tr>
<tr>
<td>Inhaled steroid combinations</td>
<td>• Fluticasone-salmeterol</td>
<td>Fluticasone Salmeterol Medications List</td>
<td>Inhalation</td>
</tr>
<tr>
<td>Inhaled steroid combinations</td>
<td>• Fluticasone-vilanterol</td>
<td>Fluticasone Vilanterol Medications List</td>
<td>Inhalation</td>
</tr>
<tr>
<td>Inhaled steroid combinations</td>
<td>• Formoterol-mometasone</td>
<td>Formoterol Mometasone Medications List</td>
<td>Inhalation</td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td>• Beclomethasone</td>
<td>Beclomethasone Medications List</td>
<td>Inhalation</td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td>• Budesonide</td>
<td>Budesonide Medications List</td>
<td>Inhalation</td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td>• Ciclesonide</td>
<td>Ciclesonide Medications List</td>
<td>Inhalation</td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td>• Flunisolide</td>
<td>Flunisolide Medications List</td>
<td>Inhalation</td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td>• Fluticasone</td>
<td>Fluticasone Medications List</td>
<td>Inhalation</td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td>• Mometasone</td>
<td>Mometasone Medications List</td>
<td>Inhalation</td>
</tr>
<tr>
<td>Leukotriene modifiers</td>
<td>• Montelukast</td>
<td>Montelukast Medications List</td>
<td>Oral</td>
</tr>
<tr>
<td>Leukotriene modifiers</td>
<td>• Zafirlukast</td>
<td>Zafirlukast Medications List</td>
<td>Oral</td>
</tr>
<tr>
<td>Leukotriene modifiers</td>
<td>• Zileuton</td>
<td>Zileuton Medications List</td>
<td>Oral</td>
</tr>
<tr>
<td>Methylxanthines</td>
<td>• Theophylline</td>
<td>Theophylline Medications List</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Asthma Reliever Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescriptions</th>
<th>Medication Lists</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-acting, inhaled beta-2 agonists</td>
<td>Albuterol</td>
<td>Albuterol Medications List</td>
<td>Inhalation</td>
</tr>
<tr>
<td>Short-acting, inhaled beta-2 agonists</td>
<td>Levalbuterol</td>
<td>Levalbuterol Medications List</td>
<td>Inhalation</td>
</tr>
</tbody>
</table>

**Note**

- Do not use RxNorm codes when assessing the numerator.
- When mapping NDC codes, medications described as “injection,” “prefilled syringe,” “subcutaneous,” “intramuscular” or “auto-injector” are considered “injections” (route).
- When mapping NDC codes, medications described as “metered dose inhaler,” “dry powder inhaler” or “inhalation powder” are considered “inhalation” (route) medications.
- Do not map medications described as “nasal spray” to “inhalation” medications.
**Appropriate Testing for Pharyngitis (CWP)**

**Measure Updates September 2020 for AMP MY 2020 and 2021**
- Updated the instructions for excluding visits that result in an inpatient stay.
- Removed Sulfisoxazole from the “Sulfonamides” description in the CWP Antibiotic Medications List.
- Deleted step 8; this step is unnecessary because these members are removed in step 5.

**Modifications from HEDIS**
- None.

**Description**
The percentage of episodes for members 3 years and older where the member was diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode.

**Definitions**

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intake Period</td>
<td>A 12-month window that begins on July 1 of the year prior to the measurement year and ends on June 30 of the measurement year. The Intake Period captures eligible episodes of treatment.</td>
</tr>
<tr>
<td>Episode Date</td>
<td>The date of service for any outpatient, telephone, observation or ED visit, e-visit or virtual check-in during the Intake Period with a diagnosis of pharyngitis.</td>
</tr>
<tr>
<td>Negative Medication History</td>
<td>To qualify for Negative Medication History, the following criteria must be met:</td>
</tr>
<tr>
<td></td>
<td>• A period of 30 days prior to the Episode Date, when the member had no pharmacy claims for either new or refill prescriptions for a listed antibiotic drug.</td>
</tr>
<tr>
<td></td>
<td>• No prescriptions filled more than 30 days prior to the Episode Date that are active on the Episode Date.</td>
</tr>
<tr>
<td></td>
<td>A prescription is considered active if the “days supply” indicated on the date when the member filled the prescription is the number of days or more between that date and the relevant service date. The 30-day look-back period for pharmacy data includes the 30 days prior to the Intake Period.</td>
</tr>
<tr>
<td>Negative Comorbid Condition History</td>
<td>A period of 12 months prior to and including the Episode Date, when the member had no claims/encounters with any diagnosis for a comorbid condition.</td>
</tr>
<tr>
<td>Negative Competing Diagnosis</td>
<td>The Episode Date and three days following the Episode Date when the member had no claims/encounters with a competing diagnosis.</td>
</tr>
</tbody>
</table>

**Eligible Population**

*Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.*
Product lines
Commercial HMO/POS, Commercial ACO, Medi-Cal Managed Care (report each product line separately).

Ages
Members who were 3 years or older as of the Episode Date.

Report three age stratifications and total rate:
- 3–17 years.
- 18–64 years.
- 65 years and older.
- Total.

The total is the sum of the age stratifications.

Continuous enrollment:
- **for self-reporting POs** 30 days prior to the Episode Date through 3 days after the Episode Date (34 total days) in the PO (parent level).
- **for health plans** 30 days prior to the Episode Date through 3 days after the Episode Date (34 total days) in the health plan and in the PO (parent level).

Allowable gap
No gaps in enrollment during the continuous enrollment period.

Anchor date:
- **for self-reporting POs** None.
- **for health plans** None.

Benefits
Medical and pharmacy.

Event/diagnosis
Follow the steps below to identify the eligible population.

**Step 1** Identify all members who had an outpatient visit (Outpatient Value Set), a telephone visit (Telephone Visits Value Set), an e-visit or virtual check-in (Online Assessments Value Set), an observation visit (Observation Value Set) or an ED visit (ED Value Set) during the intake period, with a diagnosis of pharyngitis (Pharyngitis Value Set).

**Step 2** Determine all pharyngitis Episode Dates. For each member identified in step 1, determine all outpatient telephone, observation or ED visits, e-visits and virtual check-ins with a diagnosis of pharyngitis.

Do not include visits that result in an inpatient stay (Inpatient Stay Value Set).

**Step 3** Determine if antibiotics (CWP Antibiotic Medications List) were dispensed for any of the Episode Dates. For each Episode Date with a qualifying diagnosis, determine if antibiotics were dispensed on or up to three days after.

Exclude Episode Dates if the member did not receive antibiotics on or up to three days after the Episode Date.
### CWP Antibiotic Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aminopenicillins</strong></td>
<td></td>
</tr>
<tr>
<td>• Amoxicillin</td>
<td>• Ampicillin</td>
</tr>
<tr>
<td><strong>Beta-lactamase inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>• Amoxicillin-clavulanate</td>
<td></td>
</tr>
<tr>
<td><strong>First generation cephalosporins</strong></td>
<td></td>
</tr>
<tr>
<td>• Cefadroxil</td>
<td>• Cephalexin</td>
</tr>
<tr>
<td>• Cefazolin</td>
<td></td>
</tr>
<tr>
<td><strong>Folate antagonist</strong></td>
<td>• Trimethoprim</td>
</tr>
<tr>
<td><strong>Lincomycin derivatives</strong></td>
<td>• Clindamycin</td>
</tr>
<tr>
<td><strong>Macrolides</strong></td>
<td></td>
</tr>
<tr>
<td>• Azithromycin</td>
<td>• Erythromycin ethylsuccinate</td>
</tr>
<tr>
<td>• Clarithromycin</td>
<td>• Erythromycin lactobionate</td>
</tr>
<tr>
<td>• Erythromycin</td>
<td>• Erythromycin stearate</td>
</tr>
<tr>
<td><strong>Natural penicillins</strong></td>
<td></td>
</tr>
<tr>
<td>• Penicillin G benzathine</td>
<td>• Penicillin V potassium</td>
</tr>
<tr>
<td>• Penicillin G potassium</td>
<td></td>
</tr>
<tr>
<td>• Penicillin G sodium</td>
<td></td>
</tr>
<tr>
<td><strong>Penicillinase-resistant penicillins</strong></td>
<td></td>
</tr>
<tr>
<td>• Dicloxacillin</td>
<td></td>
</tr>
<tr>
<td><strong>Quinolones</strong></td>
<td></td>
</tr>
<tr>
<td>• Ciprofloxacin</td>
<td>• Moxifloxacin</td>
</tr>
<tr>
<td>• Levofloxacin</td>
<td>• Ofloxacin</td>
</tr>
<tr>
<td><strong>Second generation cephalosporins</strong></td>
<td></td>
</tr>
<tr>
<td>• Cefaclor</td>
<td>• Cefuroxime</td>
</tr>
<tr>
<td>• Cefprozil</td>
<td></td>
</tr>
<tr>
<td><strong>Sulfonamides</strong></td>
<td></td>
</tr>
<tr>
<td>• Sulfamethoxazole-trimethoprim</td>
<td></td>
</tr>
<tr>
<td><strong>Tetracyclines</strong></td>
<td></td>
</tr>
<tr>
<td>• Doxycycline</td>
<td>• Tetracycline</td>
</tr>
<tr>
<td>• Minocycline</td>
<td></td>
</tr>
<tr>
<td><strong>Third generation cephalosporins</strong></td>
<td></td>
</tr>
<tr>
<td>• Cefdinir</td>
<td>• Ceftibuten</td>
</tr>
<tr>
<td>• Cefixime</td>
<td>• Cefditoren</td>
</tr>
<tr>
<td>• Cefpodoxime</td>
<td>• Ceftriaxone</td>
</tr>
</tbody>
</table>

**Step 4** Test for Negative Comorbid Condition History. Exclude Episode Dates when the member had a claim/encounter with any diagnosis for a comorbid condition during the 12 months prior to or on the Episode Date. A code from any of the following meets criteria for a comorbid condition:

- HIV Value Set.
- HIV Type 2 Value Set.
- Malignant Neoplasms Value Set.
- Other Malignant Neoplasms of Skin Value Set.
- Emphysema Value Set.
- COPD Value Set.
- Comorbid Conditions Value Set.
- Disorders of the Immune System Value Set.
Step 5  Test for Negative Medication History. Exclude Episode Dates where a new or refill prescription for an antibiotic medication (CWP Antibiotic Medications List) was filled 30 days prior to the Episode Date or was active on the Episode Date.

Step 6  Test for Negative Competing Diagnosis. Exclude Episode Dates where the member had a claim/encounter with a competing diagnosis (Competing Diagnosis Value Set) on or 3 days after the Episode Date.

Step 7  Calculate continuous enrollment. The member must be continuously enrolled without a gap in coverage from 30 days prior to the Episode Date through 3 days after the Episode Date (34 total days).

Administrative Specification

<table>
<thead>
<tr>
<th>Denominator</th>
<th>The eligible population.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numerator</td>
<td>A group A streptococcus test (Group A Strep Tests Value Set) in the seven-day period from three days prior to the Episode Date through three days after the Episode Date.</td>
</tr>
</tbody>
</table>
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)

Measure Updates September 2020 for AMP MY 2020 and 2021

- Updated the instructions for excluding visits that result in an inpatient stay.
- Removed Ticarcillin-clavulanate from the “Beta-lactamase inhibitors” description, Erythromycin-sulfisoxazole from the “Miscellaneous antibiotics” description and Norfloxacin from the “Quinolones” description in the AAB Antibiotic Medications List.

Modifications from HEDIS

- None.

Description

The percentage of episodes for members ages 3 months and older with a diagnosis of acute bronchitis/bronchiolitis that did not result in an antibiotic dispensing event.

Submit the data for the measure as the direct rates not as the inverted calculation of numerator and denominator.

Calculation

After submission, the measure is reported as an inverted rate \[1 - \left(\frac{\text{numerator}}{\text{eligible population}}\right)\]. A higher rate indicates appropriate acute bronchitis/bronchiolitis treatment (i.e., the proportion of episodes that did not result in an antibiotic dispensing event).

Definitions

Intake Period

A 12-month window that begins on July 1 of the year prior to the measurement year and ends on June 30 of the measurement year. The Intake Period captures eligible episodes of treatment.

Episode Date

The date of service for any outpatient, telephone, observation or ED visit, e-visit or virtual check-in during the Intake Period with a diagnosis of acute bronchitis/bronchiolitis.

Negative Medication History

To qualify for Negative Medication History, the following criteria must be met:

- A period of 30 days prior to the Episode Date, when the member had no pharmacy claims for either new or refill prescriptions for a listed antibiotic drug.
- No prescriptions that were filled more than 30 days prior to the Episode Date and are active on the Episode Date.

A prescription is considered active if the “days supply” indicated on the date when the member filled the prescription is the number of days or more between that date and the relevant service date. The 30-day look-back period for pharmacy data includes the 30 days prior to the Intake Period.
### Negative Comorbid Condition History
A period of 12 months prior to and including the Episode Date, when the member had no claims/encounters with any diagnosis for a comorbid condition.

### Negative Competing Diagnosis
The Episode Date and 3 days following the Episode Date when the member had no claims/encounters with any competing diagnosis.

### Eligible Population

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

**Product lines**
Commercial HMO/POS, Commercial ACO, Medi-Cal Managed Care (report each product line separately).

**Ages**
Members who were 3 months or older as of the Episode Date.

Report three age stratifications and a total rate:
- 3 months–17 years.
- 18–64 years.
- 65 years and older.
- Total.

The total is the sum of the age stratifications.

**Continuous enrollment**

| .... for self-reporting POs | 30 days prior to the Episode Date through three days after the Episode Date (34 total days) in the PO (parent level). |
| .... for health plans | 30 days prior to the Episode Date through three days after the Episode Date (34 total days) in the health plan and the PO (parent level). |

**Allowable gap**
No gaps in enrollment during the continuous enrollment period.

- .... for self-reporting POs
  - Episode Date in the PO (parent level, or, for eligible POs, subgroup level) and in an AMP plan.
- .... for health plans
  - Episode Date in the health plan and the PO (parent level, or, for eligible POs, subgroup level).

**Benefits**
Medical and pharmacy.

**Event/diagnosis**
Follow the steps below to identify the eligible population:

**Step 1**
Identify all members who had an outpatient visit (Outpatient Value Set), a telephone visit (Telephone Visits Value Set), an e-visit or virtual check-in (Online Assessments Value Set), an observation visit (Observation Value Set) or an ED visit (ED Value Set) during the Intake Period, with a diagnosis of acute bronchitis/bronchiolitis (Acute Bronchitis Value Set).

**Step 2**
Determine all acute bronchitis/bronchiolitis Episode Dates. For each member identified in step 1, determine all outpatient, telephone, online assessment, observation or ED visits with a diagnosis of acute bronchitis/bronchiolitis.
Do not include visits that result in an inpatient stay (Inpatient Stay Value Set).

Step 3 Test for Negative Comorbid Condition History. Exclude Episode Dates when the member had a claim/encounter with a diagnosis for a comorbid condition during the 12 months prior to or on the Episode Date. A code from any of the following meets criteria for a comorbid condition:

- HIV Value Set.
- HIV Type 2 Value Set.
- Malignant Neoplasms Value Set.
- Other Malignant Neoplasm of Skin Value Set.
- Emphysema Value Set.
- COPD Value Set.
- Comorbid Conditions Value Set.
- Disorders of the Immune System Value Set.

Step 4 Test for Negative Medication History. Exclude Episode Dates where a new or refill prescription for an antibiotic medication (AAB Antibiotic Medications List) was filled 30 days prior to the Episode Date or was active on the Episode Date.

Step 5 Test for Negative Competing Diagnosis. Exclude Episode Dates where the member had a claim/encounter with a competing diagnosis on or 3 days after the Episode Date. A code from either of the following meets criteria for a competing diagnosis:

- Pharyngitis Value Set.
- Competing Diagnosis Value Set.

Step 6 Calculate continuous enrollment. The member must be continuously enrolled without a gap in coverage from 30 days prior to the Episode Date through 3 days after the Episode Date (34 total days).

Step 7 Deduplicate eligible episodes. If a member has more than one eligible episode in a 31-day period, include only the first eligible episode. For example, if a member has an eligible episode on January 1, include the January 1 visit and do not include eligible episodes that occur on or between January 2 and January 31; then, if applicable, include the next eligible episode that occurs on or after February 1. Identify visits chronologically, including only one per 31-day period.

Note: The denominator for this measure is based on episodes, not on members. All eligible episodes that were not excluded or deduplicated remain in the denominator.

### Administrative Specification

<table>
<thead>
<tr>
<th>Denominator</th>
<th>The eligible population.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numerator</td>
<td>Dispensed prescription for an antibiotic medication (AAB Antibiotic Medications List) on or three days after the Episode Date.</td>
</tr>
</tbody>
</table>
## AAB Antibiotic Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminoglycosides</td>
<td>• Amikacin</td>
</tr>
<tr>
<td></td>
<td>• Gentamicin</td>
</tr>
<tr>
<td></td>
<td>• Streptomycin</td>
</tr>
<tr>
<td></td>
<td>• Tobramycin</td>
</tr>
<tr>
<td>Aminopenicillins</td>
<td>• Amoxicillin</td>
</tr>
<tr>
<td></td>
<td>• Ampicillin</td>
</tr>
<tr>
<td>Beta-lactamase inhibitors</td>
<td>• Amoxicillin-clavulanate</td>
</tr>
<tr>
<td></td>
<td>• Ampicillin-sulbactam</td>
</tr>
<tr>
<td></td>
<td>• Piperacillin-tazobactam</td>
</tr>
<tr>
<td>First-generation cephalosporins</td>
<td>• Cefadroxil</td>
</tr>
<tr>
<td></td>
<td>• Cefazolin</td>
</tr>
<tr>
<td></td>
<td>• Cephalexin</td>
</tr>
<tr>
<td>Fourth-generation cephalosporins</td>
<td>• Cefepime</td>
</tr>
<tr>
<td>Ketolides</td>
<td>• Telithromycin</td>
</tr>
<tr>
<td>Lincomycin derivatives</td>
<td>• Clindamycin</td>
</tr>
<tr>
<td></td>
<td>• Lincomycin</td>
</tr>
<tr>
<td>Macrolides</td>
<td>• Azithromycin</td>
</tr>
<tr>
<td></td>
<td>• Clarithromycin</td>
</tr>
<tr>
<td></td>
<td>• Erythromycin</td>
</tr>
<tr>
<td></td>
<td>• Erythromycin ethylsuccinate</td>
</tr>
<tr>
<td></td>
<td>• Erythromycin lactobionate</td>
</tr>
<tr>
<td></td>
<td>• Erythromycin stearate</td>
</tr>
<tr>
<td>Miscellaneous antibiotics</td>
<td>• Aztreonam</td>
</tr>
<tr>
<td></td>
<td>• Chloramphenicol</td>
</tr>
<tr>
<td></td>
<td>• Dalfopristin-quinupristin</td>
</tr>
<tr>
<td></td>
<td>• Daptomycin</td>
</tr>
<tr>
<td></td>
<td>• Linezolid</td>
</tr>
<tr>
<td></td>
<td>• Metronidazole</td>
</tr>
<tr>
<td></td>
<td>• Vancomycin</td>
</tr>
<tr>
<td>Natural penicillins</td>
<td>• Penicillin G benzathine-procaine</td>
</tr>
<tr>
<td></td>
<td>• Penicillin G potassium</td>
</tr>
<tr>
<td></td>
<td>• Penicillin G procaine</td>
</tr>
<tr>
<td></td>
<td>• Penicillin G sodium</td>
</tr>
<tr>
<td></td>
<td>• Penicillin V potassium</td>
</tr>
<tr>
<td></td>
<td>• Penicillin G benzathine</td>
</tr>
<tr>
<td>Penicillinase resistant penicillins</td>
<td>• Dicloxacillin</td>
</tr>
<tr>
<td></td>
<td>• Nafcillin</td>
</tr>
<tr>
<td></td>
<td>• Oxacillin</td>
</tr>
<tr>
<td>Quinolones</td>
<td>• Ciprofloxacin</td>
</tr>
<tr>
<td></td>
<td>• Gemifloxacin</td>
</tr>
<tr>
<td></td>
<td>• Levofoxacin</td>
</tr>
<tr>
<td></td>
<td>• Moxifloxacin</td>
</tr>
<tr>
<td></td>
<td>• Ofloxacin</td>
</tr>
<tr>
<td>Rifamycin derivatives</td>
<td>• Rifampin</td>
</tr>
<tr>
<td>Second generation cephalosporin</td>
<td>• Cefaclor</td>
</tr>
<tr>
<td></td>
<td>• Cefotetan</td>
</tr>
<tr>
<td></td>
<td>• Cefoxitin</td>
</tr>
<tr>
<td></td>
<td>• Cefprozil</td>
</tr>
<tr>
<td></td>
<td>• Cefuroxime</td>
</tr>
<tr>
<td>Sulfonamides</td>
<td>• Sulfadiazine</td>
</tr>
<tr>
<td></td>
<td>• Sulfamethoxazole-trimethoprim</td>
</tr>
<tr>
<td>Tetracyclines</td>
<td>• Doxycycline</td>
</tr>
<tr>
<td></td>
<td>• Minocycline</td>
</tr>
<tr>
<td></td>
<td>• Tetracycline</td>
</tr>
</tbody>
</table>
### Description

<table>
<thead>
<tr>
<th>Third generation cephalosporins</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefdinir</td>
<td>Cefotaxime</td>
</tr>
<tr>
<td>Cefditoren</td>
<td>Cefpodoxime</td>
</tr>
<tr>
<td>Cefixime</td>
<td>Ceftazidime</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Urinary anti-infectives</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fosfomycin</td>
<td>Nitrofurantoin macrocrystals-monohydrate</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>Trimethoprim</td>
</tr>
<tr>
<td>Nitrofurantoin macrocrystals</td>
<td></td>
</tr>
</tbody>
</table>

### Note

- Although denied claims are not included when assessing the numerator, all claims (paid, suspended, pending and denied) must be included when identifying the eligible population.
- Supplemental data may not be used for this measure.
Use of Opioids at High Dosage (HDO)*

*Adapted with financial support from CMS and with permission from the measure developer, Pharmacy Quality Alliance (PQA).

MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021

- Clarified the instructions for calculating covered days for the denominator.
- Clarified the instructions for treatment period.
- Added palliative care as a required exclusion.
- Added medication lists for acetaminophen benzhydrocodone, aspirin codeine and codeine phosphate.
- Removed Acetaminophen Hydrocodone 7.5 mg Medications List from the Hydrocodone description in Table HDO-A: Opioid Medications.

MODIFICATIONS FROM HEDIS

- None.

Description

The proportion of members 18 years and older who received prescription opioids at a high dosage (average morphine milligram equivalent dose [MME] ≥90) for ≥15 days during the measurement year.

Note: A lower rate indicates better performance. Onpoint will run this measure using Health Plans claims submission for MY 2020 and 2021. Health plans and POs are not expected to report it.

Definitions

Calculating number of days covered for the denominator

Use the following steps to identify and calculate covered days for the denominator.

Step 1

Identify dispensing events where multiple prescriptions for the same medication are dispensed with overlapping days supply (i.e. dispensed on the same day or dispensed on different days with overlapping days supply. Sum the days supply for these dispensing events.

Identify the start and end dates: The start date is the date of service of the earliest dispensing event and the end date is the start date plus the summed days supply minus one. The start date through the end date are considered covered days. For example:

- If there are three 7-day supply dispensing events for the same medication on January 1, the start date is January 1 and the end date is January 21. Covered days include January 1-21.
- If there are two 7-day supply dispensing events for the same medication on January 1 and January 5, the start date is January 1 and the end date is January 14. Covered days include January 1-14.
• If there are three 7-day supply dispensing events for the same medication on January 1, a 7-day supply dispensing event on January 20, and a 7-day supply dispensing event on January 28, the start date is January 1 and the end date is February 4. Covered days include January 1-February 4.

**Step 2** For all other dispensing events (i.e. multiple prescriptions for the same medication on different days without overlap, and multiple prescriptions for different medications on the same or different days, with or without overlap), identify the start and end dates for each dispensing event individually. The start date through the end date are considered covered days.

**Step 3** Count the covered days. Consider each calendar day covered by one or more medications to be one covered day.

**Identifying same or different drugs**

To identify “same” or “different” drugs, use Table HDO-A, which identifies the medications lists for the measure. Dispensing events from any of the Fentanyl Medications Lists, even if they are on different rows, are all considered the “same” drug.

For all other types of opioids, the table includes a “Medication Lists” column that identifies the “same” high-risk medications by grouping them on the same row.

For example, a dispensing event from the Codeine Sulfate 15 mg Medications List is considered the same drug as a dispensing event from the Codeine Sulfate 30 mg Medications List. Conversely, a dispensing event from the Codeine Sulfate 15 mg Medications List is considered a different drug than a dispensing event from the Acetaminophen Codeine 15 mg Medications List because they are in different table rows.

**Treatment period**

To identify the treatment period: For all dispensing events, identify the start and end dates for each dispensing event individually. The treatment period start date is the start date of the earliest dispensing event during the measurement year. The treatment period end date is the last end date during the measurement year.

**MME**

Morphine milligram equivalent. The dose of oral morphine that is the analgesic equivalent of a given dose of another opioid analgesic (Table HDO-A).

**Opioid Dosage Unit**

For each dispensing event, use the following calculate to determine the Opioid Dosage Unit.

\[
\text{# of Opioid Dosage Units per day} = \frac{\text{opioid quantity dispensed}}{\text{opioid days supply}}
\]

**MME Daily Dose**

For each dispensing event, use the following calculation to determine the MME Daily Dose. Convert each medication into the MME using the appropriate MME conversion factor and strength associated with the opioid product of the dispensing event (refer to Table HDO-A for MME conversion factor and strength).

\[
\text{MME Daily Dose} = \left(\text{# of opioid dosage units per day}\right) \times \left(\text{strength (e.g., mg, mcg)}\right) \times \left(\text{MME conversion factor [Table HDO-A]}\right).
\]
Example 1: 10 mg oxycodone tablets X (120 tablets / 30 days) X 1.5 = 60 MME/day.

Example 2: 25 mcg/hr fentanyl patch X (10 patches / 30 days) X 7.2 = 60 MME/day.

**Total Daily MME**
The total sum of the MME Daily Doses for all opioid dispensing events on one day.

**Average MME**
The average MME for all opioids dispensed during the treatment period.

---

### Eligible Population

*Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.*

**Product lines**
Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).

**Age**
18 years and older as of January 1 of the measurement year.

**Continuous enrollment**

- For self-reporting POs: The measurement year in the PO (parent level).
- For health plans: The measurement year in the health plan and the PO (parent level).

**Allowable gap**
No gaps in enrollment.

**Anchor date**
None.

**Benefit**
Medical and pharmacy.

**Event/diagnosis**
Use the steps below to determine the eligible population.

**Step 1**
Identify members who met both of the following criteria during the measurement year:
- Two or more opioid dispensing events on different dates of service. Use all the medication lists in Table HDO-A to identify opioid medication dispensing events.
- ≥15 total days covered by opioids.

**Step 2: Required exclusions**
Exclude members who met at least one of the following during the measurement year:
- Cancer (Malignant Neoplasms Value Set).
- Sickle cell disease (Sickle Cell Anemia and HB-S Disease Value Set).
- Members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set).
Administrative Specification

**Denominator**
The eligible population.

**Numerator**
The number of members whose average MME was ≥90 MME during the treatment period. Follow the steps below to identify numerator compliance.

**Step 1** Use all the medication lists in Table HDO-A to identify all opioid medication dispensing events during the measurement year.

**Step 2** For each member, calculate the MME Daily Dose for each medication dispensing event.

**Step 3** For a single dispensing event, multiply the MME Daily Dose by the dispensing event’s days supply. For example, a dispensing event with a MME Daily Dose of 90 mg and a days supply of 5 would have a total MME of 450 mg for that dispensing event. As multiple dispensing events can overlap on one calendar day, for each day, sum the MME Daily Doses for all dispensing events to determine the Total Daily MME for that day.

**Step 4** Determine the treatment period.

**Step 5** Determine the Average MME. Sum the Total Daily MME for the treatment period and divide by the number of days in the treatment period. Members whose Average MME was ≥90 meet the numerator criteria.

Table HDO-A: Opioid Medications

<table>
<thead>
<tr>
<th>Type of Opioid</th>
<th>Medications List</th>
<th>Strength</th>
<th>MME Conversion Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzhydrocodone</td>
<td>Acetaminophen Benzhydrocodone 4.08 mg Medications</td>
<td>4.08 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>List</td>
<td></td>
<td>1.2</td>
</tr>
<tr>
<td></td>
<td>Acetaminophen Benzhydrocodone 6.12 mg Medications</td>
<td>6.12 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>List</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acetaminophen Benzhydrocodone 8.16 mg Medications</td>
<td>8.16 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>List</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Butorphanol</td>
<td>Butorphanol 10 MGPML Medications List</td>
<td>10 mg per mL</td>
<td>7</td>
</tr>
<tr>
<td>Codeine</td>
<td>Codeine Sulfate 15 mg Medications List</td>
<td>15 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Codeine Sulfate 30 mg Medications List</td>
<td>30 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Codeine Sulfate 60 mg Medications List</td>
<td>60 mg</td>
<td></td>
</tr>
<tr>
<td>Codeine</td>
<td>Codeine Phosphate 15 mg Medications List</td>
<td>15 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Codeine Phosphate 2 MGPML Medications List</td>
<td>2 mg per mL</td>
<td>0.15</td>
</tr>
<tr>
<td>Codeine</td>
<td>Acetaminophen Codeine 2.4 MGPML Medications List</td>
<td>2.4 mg per mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acetaminophen Codeine 15 mg Medications List</td>
<td>15 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acetaminophen Codeine 30 mg Medications List</td>
<td>30 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acetaminophen Codeine 60 mg Medications List</td>
<td>60 mg</td>
<td></td>
</tr>
<tr>
<td>Codeine</td>
<td>Acetaminophen Butalbital Caffeine Codeine 30 mg</td>
<td>30 mg</td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>Medications List</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Codeine</td>
<td>Aspirin Butalbital Caffeine Codeine 30 mg Medications List</td>
<td>30 mg</td>
<td>0.15</td>
</tr>
<tr>
<td>Codeine</td>
<td>Aspirin Carisoprodol Codeine 16 mg Medications List</td>
<td>16 mg</td>
<td>0.15</td>
</tr>
<tr>
<td>Type of Opioid</td>
<td>Medications List</td>
<td>Strength</td>
<td>MME Conversion Factor</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>----------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Codeine</td>
<td>Aspirin Codeine 8 mg Medications List</td>
<td>8 mg</td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>Aspirin Codeine 30 mg Medications List</td>
<td>30 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aspirin Codeine 60 mg Medications List</td>
<td>60 mg</td>
<td></td>
</tr>
<tr>
<td>Dihydrocodeine</td>
<td>Acetaminophen Caffeine Dihydrocodeine 16 mg Medications List</td>
<td>16 mg</td>
<td>0.25</td>
</tr>
<tr>
<td>Dihydrocodeine</td>
<td>Aspirin Caffeine Dihydrocodeine 16 mg Medications List</td>
<td>16 mg</td>
<td>0.25</td>
</tr>
<tr>
<td>Fentanyl buccal or sublingual tablet, transmucosal lozenge (mcg)²</td>
<td>Fentanyl 100 mcg Medications List</td>
<td>100 mcg</td>
<td>0.13</td>
</tr>
<tr>
<td></td>
<td>Fentanyl 200 mcg Medications List</td>
<td>200 mcg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 300 mcg Medications List</td>
<td>300 mcg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 400 mcg Medications List</td>
<td>400 mcg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 600 mcg Medications List</td>
<td>600 mcg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 800 mcg Medications List</td>
<td>800 mcg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 1200 mcg Medications List</td>
<td>1200 mcg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 1600 mcg Medications List</td>
<td>1600 mcg</td>
<td></td>
</tr>
<tr>
<td>Fentanyl oral spray (mcg)³</td>
<td>Fentanyl 100 MCGPS Oral Medications List</td>
<td>100 mcg per spray</td>
<td>0.18</td>
</tr>
<tr>
<td></td>
<td>Fentanyl 200 MCGPS Oral Medications List</td>
<td>200 mcg per spray</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 400 MCGPS Oral Medications List</td>
<td>400 mcg per spray</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 600 MCGPS Oral Medications List</td>
<td>600 mcg per spray</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 800 MCGPS Oral Medications List</td>
<td>800 mcg per spray</td>
<td></td>
</tr>
<tr>
<td>Fentanyl nasal spray (mcg)⁴</td>
<td>Fentanyl 100 MCGPS Nasal Medications List</td>
<td>100 mcg per spray</td>
<td>0.16</td>
</tr>
<tr>
<td></td>
<td>Fentanyl 300 MCGPS Nasal Medications List</td>
<td>300 mcg per spray</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 400 MCGPS Nasal Medications List</td>
<td>400 mcg per spray</td>
<td></td>
</tr>
<tr>
<td>Fentanyl transdermal film/patch (mcg/hr)⁵</td>
<td>Fentanyl 12 MCGPH Medications List</td>
<td>12 mcg per hour</td>
<td>7.2</td>
</tr>
<tr>
<td></td>
<td>Fentanyl 25 MCGPH Medications List</td>
<td>25 mcg per hour</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 37.5 MCGPH Medications List</td>
<td>37.5 mcg per hour</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 50 MCGPH Medications List</td>
<td>50 mcg per hour</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 62.5 MCGPH Medications List</td>
<td>62.5 mcg per hour</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 75 MCGPH Medications List</td>
<td>75 mcg per hour</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 87.5 MCGPH Medications List</td>
<td>87.5 mcg per hour</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fentanyl 100 MCGPH Medications List</td>
<td>100 mcg per hour</td>
<td></td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>Hydrocodone 10 mg Medications List</td>
<td>10 mg</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Hydrocodone 15 mg Medications List</td>
<td>15 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hydrocodone 20 mg Medications List</td>
<td>20 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hydrocodone 30 mg Medications List</td>
<td>30 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hydrocodone 40 mg Medications List</td>
<td>40 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hydrocodone 50 mg Medications List</td>
<td>50 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hydrocodone 60 mg Medications List</td>
<td>60 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hydrocodone 80 mg Medications List</td>
<td>80 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hydrocodone 100 mg Medications List</td>
<td>100 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hydrocodone 120 mg Medications List</td>
<td>120 mg</td>
<td></td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>Acetaminophen Hydrocodone .5 MGPML Medications List</td>
<td>.5 mg per mL</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Acetaminophen Hydrocodone .67 MGPML Medications List</td>
<td>.67 mg per mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acetaminophen Hydrocodone 2.5 mg Medications List</td>
<td>2.5 mg</td>
<td></td>
</tr>
<tr>
<td>Type of Opioid</td>
<td>Medications List</td>
<td>Strength</td>
<td>MME Conversion Factor</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Acetaminophen Hydrocodone 5 mg Medications List</td>
<td>5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetaminophen Hydrocodone 10 mg Medications List</td>
<td>10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocodone 2.5 mg Medications List</td>
<td>2.5 mg</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Hydrocodone 5 mg Medications List</td>
<td>5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocodone 7.5 mg Medications List</td>
<td>7.5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocodone 10 mg Medications List</td>
<td>10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone 1 mg per mL Medications List</td>
<td>1 mg per mL</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Hydromorphone 2 mg Medications List</td>
<td>2 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone 3 mg Medications List</td>
<td>3 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone 4 mg Medications List</td>
<td>4 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone 8 mg Medications List</td>
<td>8 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone 12 mg Medications List</td>
<td>12 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone 16 mg Medications List</td>
<td>16 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone 32 mg Medications List</td>
<td>32 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levorphanol 1 mg Medications List</td>
<td>1 mg</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Levorphanol 2 mg Medications List</td>
<td>2 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levorphanol 3 mg Medications List</td>
<td>3 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meperidine 10 mg per mL Medications List</td>
<td>10 mg per mL</td>
<td>0.1</td>
<td></td>
</tr>
<tr>
<td>Meperidine 50 mg Medications List</td>
<td>50 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meperidine 100 mg Medications List</td>
<td>100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methadone 1 mg per mL  Medications List</td>
<td>1 mg per mL</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Methadone 2 mg per mL Medications List</td>
<td>2 mg per mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methadone 5 mg Medications List</td>
<td>5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methadone 10 mg Medications List</td>
<td>10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methadone 10 mg per mL Medications List</td>
<td>10 mg per mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methadone 40 mg Medications List</td>
<td>40 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine .4 mg per mL  Medications List</td>
<td>.4 mg per mL</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Morphine 2 mg per mL Medications List</td>
<td>2 mg per mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 4 mg per mL Medications List</td>
<td>4 mg per mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 5 mg Medications List</td>
<td>5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 10 mg Medications List</td>
<td>10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 15 mg Medications List</td>
<td>15 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 20 mg per mL Medications List</td>
<td>20 mg per mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 20 mg Medications List</td>
<td>20 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 30 mg Medications List</td>
<td>30 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 40 mg Medications List</td>
<td>40 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 45 mg Medications List</td>
<td>45 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 50 mg Medications List</td>
<td>50 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 60 mg Medications List</td>
<td>60 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 70 mg Medications List</td>
<td>70 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine 75 mg Medications List</td>
<td>75 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of Opioid</td>
<td>Medications List</td>
<td>Strength</td>
<td>MME Conversion Factor</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Morphine</td>
<td>Morphine 80 mg Medications List</td>
<td>80 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine 90 mg Medications List</td>
<td>90 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine 100 mg Medications List</td>
<td>100 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine 120 mg Medications List</td>
<td>120 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine 130 mg Medications List</td>
<td>130 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine 150 mg Medications List</td>
<td>150 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine 200 mg Medications List</td>
<td>200 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine Naltrexone 20 mg Medications List</td>
<td>20 mg</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Morphine Naltrexone 30 mg Medications List</td>
<td>30 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine Naltrexone 50 mg Medications List</td>
<td>50 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine Naltrexone 60 mg Medications List</td>
<td>60 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine Naltrexone 80 mg Medications List</td>
<td>80 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphine Naltrexone 100 mg Medications List</td>
<td>100 mg</td>
<td></td>
</tr>
<tr>
<td>Opium</td>
<td>Belladonna Opium 30 mg Medications List</td>
<td>30 mg</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Belladonna Opium 60 mg Medications List</td>
<td>60 mg</td>
<td></td>
</tr>
<tr>
<td>Oxycodone</td>
<td>Oxycodone 1 MGPML Medications List</td>
<td>1 mg per mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 5 mg Medications List</td>
<td>5 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 7.5 mg Medications List</td>
<td>7.5 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 9 mg Medications List</td>
<td>9 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 10 mg Medications List</td>
<td>10 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 13.5 mg Medications List</td>
<td>13.5 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 15 mg Medications List</td>
<td>15 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 18 mg Medications List</td>
<td>18 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 20 mg Medications List</td>
<td>20 mg</td>
<td>1.5</td>
</tr>
<tr>
<td></td>
<td>Oxycodone 20 MGPML Medications List</td>
<td>20 mg per mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 27 mg Medications List</td>
<td>27 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 30 mg Medications List</td>
<td>30 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 36 mg Medications List</td>
<td>36 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 40 mg Medications List</td>
<td>40 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 60 mg Medications List</td>
<td>60 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxycodone 80 mg Medications List</td>
<td>80 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acetaminophen Oxycodone 2.5 mg Medications List</td>
<td>2.5 mg</td>
<td>1.5</td>
</tr>
<tr>
<td></td>
<td>Acetaminophen Oxycodone 5 mg Medications List</td>
<td>5 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acetaminophen Oxycodone 7.5 mg Medications List</td>
<td>7.5 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acetaminophen Oxycodone 10 mg Medications List</td>
<td>10 mg</td>
<td></td>
</tr>
<tr>
<td>Oxycodone</td>
<td>Aspirin Oxycodone 4.8355 mg Medications List</td>
<td>4.8355 mg</td>
<td>1.5</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>Ibuprofen Oxycodone 5 mg Medications List</td>
<td>5 mg</td>
<td>1.5</td>
</tr>
<tr>
<td>Oxymorphone</td>
<td>Oxymorphone 5 mg Medications List</td>
<td>5 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxymorphone 7.5 mg Medications List</td>
<td>7.5 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxymorphone 10 mg Medications List</td>
<td>10 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxymorphone 15 mg Medications List</td>
<td>15 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxymorphone 20 mg Medications List</td>
<td>20 mg</td>
<td>3</td>
</tr>
<tr>
<td>Type of Opioid</td>
<td>Medications List</td>
<td>Strength</td>
<td>MME Conversion Factor</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------------------------------------------</td>
<td>----------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Oxymorphone</td>
<td>Oxymorphone 30 mg Medications List</td>
<td>30 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxymorphone 40 mg Medications List</td>
<td>40 mg</td>
<td></td>
</tr>
<tr>
<td>Pentazocine</td>
<td>Naloxone Pentazocine 50 mg Medications List</td>
<td>50 mg</td>
<td>0.37</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>Tapentadol 50 mg Medications List</td>
<td>50 mg</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>Tapentadol 75 mg Medications List</td>
<td>75 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tapentadol 100 mg Medications List</td>
<td>100 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tapentadol 150 mg Medications List</td>
<td>150 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tapentadol 200 mg Medications List</td>
<td>200 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tapentadol 250 mg Medications List</td>
<td>250 mg</td>
<td></td>
</tr>
<tr>
<td>Tramadol</td>
<td>Tramadol 50 mg Medications List</td>
<td>50 mg</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>Tramadol 100 mg Medications List</td>
<td>100 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tramadol 150 mg Medications List</td>
<td>150 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tramadol 200 mg Medications List</td>
<td>200 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tramadol 300 mg Medications List</td>
<td>300 mg</td>
<td></td>
</tr>
<tr>
<td>Tramadol</td>
<td>Acetaminophen Tramadol 37.5 mg Medications List</td>
<td>37.5 mg</td>
<td>0.1</td>
</tr>
</tbody>
</table>

MME conversion factor for fentanyl buccal tablets, sublingual tablets, and lozenges/troche is 0.13. This conversion factor should be multiplied by the number of micrograms in a given tablet or lozenge/troche.

MME conversion factor for fentanyl films and oral sprays is 0.18. This reflects a 40% greater bioavailability for films compared to lozenges/tablets and 38% greater bioavailability for oral sprays compared to lozenges/tablets.

MME conversion factor for fentanyl nasal spray is 0.16, which reflects a 20% greater bioavailability for sprays compared to lozenges/tablets.

MME conversion factor for fentanyl patches is 7.2 based on the assumption that one milligram of parenteral fentanyl is equivalent to 100 milligrams of oral morphine and that one patch delivers the dispensed micrograms per hour over a 24-hour day and remains in place for 3 days. Using the formula, Strength per Unit * (Number of Units/ Days Supply) * MME conversion factor = MME/Day: 25 µg/hr. fentanyl patch * (10 patches/30 days) * 7.2 = 60 MME/day.


Note

- Do not include denied claims when identifying the eligible population (except for required exclusions) or assessing the numerator.
- Do not include supplemental data when identifying the eligible population or assessing the numerator. Supplemental data can be used for only required exclusions for this measure.
- This measure does not include the following opioid medications:
  - Injectables.
  - Opioid cough and cold products.
  - Ionsys® (fentanyl transdermal patch), because:
    - This is for inpatient use only and is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)
  - Methadone for the treatment of opioid use disorder.
Concurrent Use of Opioids and Benzodiazepines (COB)

Measure Updates September 2020 for AMP MY 2020 and 2021

- None.

Modifications From HEDIS

- This is a non-HEDIS measure developed by the Pharmacy Quality Alliance (PQA).

Measure Description

The percentage of members 18 years of age and older with concurrent use of prescription opioids and benzodiazepines during the measurement year.

A lower rate indicates better performance for this measure.

Note: Refer to the AMP Value Set Directory download for a comprehensive list of PQA medications and associated codes (PQA NDC Code List and PQA ICD Code List). Do not distribute NDC lists outside your organization. Onpoint will run this measure for MY 2020 and 2021. Health plans and POs are not expected to report it.

Definitions

Opioids: Refer to Medication Table COB-A: Opioids.

Benzodiazepines: Refer to Medication Table COB-B: Benzodiazepines.

Measurement year: The calendar year (January 1–December 31) when the measure is assessed.

Prescription claims: Only paid, non-reversed prescription claims are included in the data set to calculate the measure.

IPSD: Index prescription start date. The earliest prescription dispensing date for any opioid during the measurement year.
### Concurrent use

Overlapping supply for an opioid and a benzodiazepine for 30 or more cumulative days.

Concurrent use is identified using the dates of service and days supply of an individual’s prescription claims. The days of concurrent use is the count of the number of days with overlapping days supply for an opioid and a benzodiazepine.

### Hospice exclusion

For Commercial HMO, Commercial ACO and Medi-Cal Managed Care reporting, refer to General Guideline 15: Members in Hospice.

Health plans reporting for Medicare Advantage, identify any member with a hospice indicator from the Monthly Membership Detail File.

POs reporting for Medicare Advantage have the option of using the Monthly Membership Detail File or the HEDIS Hospice Encounter Value Set and Hospice Intervention Value Set to identify members in Hospice, refer to General Guideline 15: Members in Hospice.

### Cancer diagnosis exclusion

Any member with a cancer diagnosis during the measurement year.

Refer to PQA Value Set Cancer.

A cancer diagnosis is defined as having at least one claim with any of the listed cancer diagnoses, including primary diagnosis or any other diagnosis fields during the measurement year.

Medicare Data (if ICD codes not available): RxHCCs 15, 16, 17, 18, 19 for Payment Year 2019. Available at: [https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Risk-Adjustors.html](https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Risk-Adjustors.html).

### Sickle cell disease diagnosis exclusion

Any member with a sickle cell disease diagnosis during the measurement year.

Refer to the PQA Value Set Sickle Cell Disease.

A sickle cell disease diagnosis is defined as having at least one claim with any of the list sickle cell disease diagnoses, including primary diagnosis or any other diagnosis fields during the measurement year.

---

### Eligible Population

**Product Lines**

Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).

**Ages**

18 years and older as of the first day of the measurement year.

**Benefit**

Medical, Pharmacy.

**Continuous Enrollment**

*...for health plans* The measurement year, with one allowable gap.

*...for POs* The measurement year, with one allowable gap.
Allowable gap

No more than one gap in enrollment of up to 31 days during the measurement year. When enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

Anchor date

...for self-reporting POs

December 31 of the measurement year.

...for health plans

December 31 of the measurement year.

Event/diagnosis

Members who filled at least two prescriptions for any opioid (Table COB-A: Opioids) on different dates of service during the measurement year where the sum of the days supply is 15 days or more.

Step 1

Identify individuals aged 18 years and older as of the first day of the measurement year.

Step 2

Identify individuals meeting the continuous enrollment criteria.

Step 3

Identify individuals with an IPSD that is 30 or more days from the last day of the measurement year (January 1 through December 2).

Step 4

Identify individuals with 2 or more prescription claims for opioids on different dates of service and with 15 or more cumulative days’ supply during the measurement year. Exclude any days supply that occur after the end of the measurement year.

Note:

- The prescription can be for the same or different opioids.
- If multiple prescriptions for opioids are dispensed on the same day, calculate the number of days covered by an opioid using the prescriptions with the longest days supply.
- If multiple prescriptions for opioids are dispensed on different days, sum the days supply for all the prescription claims, regardless of overlapping days supply.

Step 5

Exclude individuals who met at least one of the following:

- Hospice: A hospice indicator at any time during the measurement year.
- Cancer: A cancer diagnosis at any time during the measurement year.
- Sickle cell disease: A sickle cell disease diagnosis at any time during the measurement year.

Note

- If a PO receives pharmacy claim information for a member, the PO can assume the member has a pharmacy benefit, and that the pharmacy benefit dates align with the medical benefit dates.
Administrative Specification

Denominator The eligible population.
Numerator Members with:
• Two or more prescription claims for any benzodiazepines on different dates of service, AND
• Concurrent use of opioids and benzodiazepines for 30 or more cumulative days.

Step 1 Identify members who filled two or more prescriptions for any benzodiazepine (Table COB-B) on different dates of service during the measurement year.

Step 2 For each member identified in step 1, determine the total days of overlap (concurrent use) between opioids and benzodiazepines during the measurement year.

Concurrent use is identified using the dates of service and days supply of an individual’s opioid and benzodiazepine prescription drug claims. The days of concurrent use is the count of days during the measurement year with overlapping days supply for an opioid and a benzodiazepine. Exclude days supply and overlap that occur after the end of the measurement year.

Note:
• If multiple prescriptions for opioids (or benzodiazepines) are dispensed on the same day, calculate the number of days covered by an opioid (or benzodiazepine) using the prescriptions with the longest days supply.
• If multiple prescription claims of opioids (or benzodiazepines) are dispensed on different days with overlapping days supply, count each day in the measurement year only once toward the numerator. There is no adjustment for early fills or overlapping days supply for opioids (or benzodiazepines).

Step 3 Count the number of individuals with concurrent use for 30 or more cumulative days.

Table COB-A: Opioids

<table>
<thead>
<tr>
<th>Opioid Medications</th>
<th>Opioid Medications</th>
<th>Opioid Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzhydrocodone</td>
<td>Hydromorphone</td>
<td>Oxycodone</td>
</tr>
<tr>
<td>Buprenorphine b</td>
<td>Levorphanol</td>
<td>Oxydone</td>
</tr>
<tr>
<td>Butorphanol</td>
<td>Meperidine</td>
<td>Oxymorphone</td>
</tr>
<tr>
<td>Codeine</td>
<td>Methadone</td>
<td>Pentazocine</td>
</tr>
<tr>
<td>Dihydrocodeine</td>
<td>Morphine</td>
<td>Tapentadol</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>Opium</td>
<td>Tramadol</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a Includes combination products and prescription opioid cough medications.
b Excludes the following: injectable formulations; sufentanil (used in a supervised setting); and single-agent and combination buprenorphine products used to treat opioid use disorder (i.e., buprenorphine sublingual tablets, Probuphine® Implant kit subcutaneous implant, and all buprenorphine/naloxone combination products).
Table COB-B: Benzodiazepines\textsuperscript{a,\textit{b}}

<table>
<thead>
<tr>
<th>Benzodiazepines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alprazolam</td>
</tr>
<tr>
<td>Chlordiazepoxide</td>
</tr>
<tr>
<td>Clobazam</td>
</tr>
<tr>
<td>Clonazepam</td>
</tr>
<tr>
<td>Clorazepate</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Includes combination products.
\textsuperscript{b} Excludes injectable formulations.

Note

- \textbf{This measure is not intended for clinical decision making.} This measure is intended for retrospective evaluation of populations of patients and should not be used to guide clinical decisions for individual patients. For clinical guidance on opioid prescribing, see the Center for Disease Control and Prevention CDC Guideline for Prescribing Opioids for Chronic Pain and Guideline Resources.
Data Quality
For AMP MY 2020 and MY 2021
**Encounter Rate by Service Type (ENRST)**

**MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021**

- Added clarification that health plans should submit the denominator as total member months.
- Added a calculation for 'overall rate'.

**MODIFICATIONS FROM HEDIS**

- This is a non-HEDIS measure.

**Description**

The encounter rate is the number of encounters and claims by service type for each PO. Each health plan calculates the rate for each PO with which it contracts and uses it to measure data completeness. The method for identifying encounters by service type is based on the HEDIS Use of Service measures and the General Guidelines. Each service type is calculated as a separate rate.

*Health plans submit the denominator data for the measure as the total member months.*

**Calculation**

After submission, the denominator data will be recalculated and reported as member years per the calculation below. The encounter rate is total encounters and claims/total member years. Plans should report the total number of unduplicated encounters or claims for each service type and the member months only (see Steps 1 and 2 in the Member years Definition section below for instructions on calculating member months).

POs are not expected to report this measure.

**Definitions**

*Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.*

**Member years**

Calculate the member years of enrollment for the measurement year for all members. Include all members (adults and children) in the commercial HMO and POS lines of business, regardless of the type of reimbursement contract. This will be the denominator for rates 1–8.

**Step 1** Determine the PO’s total member months for a health plan using a specified day of each month (e.g., the 15th or the last day of the month), to be determined according to the health plan’s administrative processes. The day selected must be consistent from member to member, month to month and year to year. For example, if the health plan or PO computes membership on the 15th of the month and Ms. X is enrolled in the PO on January 15, Ms. X contributes one member month in January.

**Step 2** Use the member’s product line and PO affiliation on the specified day of each month to determine the product line and PO to which the member months will be contributed.
Step 3  
For each PO, calculate member years by dividing total member months by 12.

X member months/12 months = Y member years

Encounter  
An encounter differs from a claim in that it represents a service for which there is no claim for payment sent to the health plan (i.e., all member encounters are covered in the health plan’s capitation payment), or a service where the PO may pay the provider a fee for service for the encounter but does not bill the health plan for the service. Follow these guidelines for determining encounters. Include all encounters and claims for services rendered, whether or not they were approved or paid by the PO.

Determining encounters/claims  
Count any code that represents a unique date of service, a unique provider identifier and a unique patient.

Count multiple lab tests in one day by the same lab provider as one unique encounter. An encounter for the same date of service, provider and patient that contains multiple types of services should be counted in each category, as appropriate (e.g., an office visit with lab procedures should be included in both categories).

Allow at least a two-month lag in submission and count all commercial HMO and POS member encounters or transactions (including out of network POS claims) with a date of service in 2020.

Report services without regard to practitioner type, training or licensing. Include after-hours, nonemergency urgent care, nursing home visits and outpatient surgical procedures.

IHA encourages detailed service reporting to facilitate comparability and complete reporting, even when the financial reimbursement arrangement does not require it.

Overall professional encounter rate  
Sum of the numerators for rates 1, 2, 3, 4a and 5a divided by member years for the PO.

Overall facility encounter rate  
Sum of the numerators for rates 6, 7 and 8 divided by member years for the PO.

Overall rate  
Sum of the numerators for rates 1, 2, 3, 4a, 5a and 6 divided by member years for the PO.

Eligible Population

Product lines  
Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).

Encounter Rate 1: Office and Other Outpatient Services

Denominator  
Member years.
Numerator Count the total number of unduplicated office and other outpatient services encounters/claims using the (Outpatient Services Value Set) and the (Observation Value Set).

Note

- Count office-based surgeries/procedures in this category.

**Encounter Rate 2: Preventive Medicine**

Denominator Member years.

Numerator Count the total number of preventive medicine encounters/claims using the (Preventive Medicine Services Value Set).

**Encounter Rate 3: Ophthalmology and Optometry**

Denominator Member years.

Numerator Count the total number of ophthalmology or optometry encounters/claims (Ophthalmological Services Value Set). Report services without regard to practitioner type, training or licensing.

**Encounter Rate 4: Laboratory/Pathology Services**

Denominator Member years.

Numerator

- **Rate 4a** Count the total number of encounters/claims (Laboratory and Pathology Services Value Set).
  
  **Note:** Identify one encounter/claim as the same person receiving at least one test on the same day from the same (lab) provider. Do not count multiple tests (i.e., codes) separately that occurred on the same day with the same provider (either within the same encounter/claim record or on a different encounter/claim record).

- **Rate 4b** Calculate the total number of tests (Laboratory and Pathology Services Value Set).
  
  Count all laboratory/pathology procedure codes separately. For example, if an encounter record contains three different codes (i.e., for three different lab tests), record three “tests.” Sum all the tests to calculate the total numerator.

**Encounter Rate 5: Radiology and Imaging**

Denominator Member years.

Numerator
**Rate 5a** Count the total number of radiology and imaging encounters/claims using the (Radiology and Imaging Services Value Set).

*Note:* Identify one encounter/claim as the same person receiving at least one test on the same day from the same provider. Do not count multiple tests (e.g., CPT codes) separately that occurred on the same day with the same provider (either within the same encounter/claim record or on a different encounter record).

**Rate 5b** Calculate the total number of tests using the (Radiology and Imaging Services Value Set). Count all radiology procedure codes separately for this metric. For example, if an encounter record contains three different CPT codes (i.e., for three different imaging tests), record three “tests.” Sum all the tests to calculate the total numerator.

### Encounter Rate 6: Ambulatory Surgery/Procedures

<table>
<thead>
<tr>
<th>Denominator</th>
<th>Member years.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numerator</td>
<td>Count the total number of ambulatory surgery/procedure encounters/claims. A claim with a code from any of the following value set combinations meet the criteria:</td>
</tr>
</tbody>
</table>

- **Ambulatory Surgery Option A Value Set with Ambulatory Surgery POS Value Set.**
- **Ambulatory Surgery Option A Value Set with Ambulatory Surgery UBTOB Value Set.**

Report services without regard to practitioner type, training or licensing.

The health plan/PO must avoid double counting and report only ambulatory surgery/procedures performed at a hospital outpatient facility or at a free-standing surgery center. Count every ambulatory surgery/procedure encounter/claim, which is one discrete service date for a specific member at a specific site (regardless of the number of services provided at that site on that day for that member).

*Note*

- Do not report office-based surgeries/procedures in this category; report them under Office and Other Outpatient Services.
**Encounter Rate 7: ED Visits**

<table>
<thead>
<tr>
<th>Denominator</th>
<th>Member years.</th>
</tr>
</thead>
</table>
| Numerator         | Count each visit to an ED once, regardless of the intensity or duration of the visit. Count multiple ED visits on the same date of service as one visit. Identify ED visits using either of the following:  
  - An ED visit (ED Value Set).  
  - A procedure code (ED Procedure Code Value Set) with an ED place of service code (ED POS Value Set).  
  Do not include ED visits that result in an inpatient stay (Inpatient Stay Value Set). |

**Encounter Rate 8: Inpatient Stays**

<table>
<thead>
<tr>
<th>Denominator</th>
<th>Member years.</th>
</tr>
</thead>
</table>
| Numerator         | Identify all acute inpatient discharges on or between January 1 and December 31 of the measurement year. To identify acute inpatient discharges:  
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).  
  2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).  
  3. Identify the discharge date for the stay. |

**Exclusions (required)**

- Duplicate encounters/claims within a service type. Do not count multiple encounters/claims within this service type where the member, provider and date of service are the same, regardless of whether the procedure (CPT) codes are the same or different; if this occurs, only record one encounter/claim.

- Rates 4b and 5b should count the actual number of tests performed and are not subject to de-duplication by:  
  - Member.  
  - Provider.  
  - Date of service.

---

CPT® is trademarked and copyright 2020 by the American Medical Association. All rights reserved.
Measure Updates September 2020 for AMP MY 2020 and 2021

- Added clarifying information to Visits definition.
- Added clarifying information to Step 3 of Encounter Format Calculation: Procedure Modifier and Rendering Provider Identifier Per Service Line.

Modifications From HEDIS

- This a non-HEDIS measure.

Description

Correct coding and formatting of the content included in an encounter submission affects both its acceptance by a health plan and its usability for a variety of purposes – everything from care gap reporting and performance measurement to risk adjustment and rate setting.

The following measures assess whether key encounter data elements meet expectations on use of standard codes, consistency, and completeness.

- Review of Codes:
  - Procedure Codes, including use of procedure modifiers.
  - Revenue Codes.
  - Diagnosis Codes.
- Review of Identifiers:
  - Billing Provider Identifier.
  - Rendering Provider Identifier.
  - Prescribing Provider Identifier.

Rates for each measure are reported by service type (i.e., institutional and professional) and transaction type (i.e., claims and encounters).

For additional information on timeliness measures, refer to the California Department of Health Care Services Quality Measures for Encounter Data.

Note: Health plans and POs are not expected to report this measure. Onpoint will run this measure using health plans claim and encounter submissions for MY 2020 and 2021.

Definitions

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Service Line

All individual service records within a claim or encounter submitted to the health plan. This is identified by each record that health plans submit to Onpoint.

Claims

A claim reflects a set of service lines reflected in a unique claim for health plan payment.
**Encounter**

An **encounter** differs from a **claim** in that it represents a service for which there is no claim for payment sent to the health plan (i.e., all member encounters are covered in the health plan’s capitation payment), or a service where the PO may pay the provider a fee for service for the encounter but does not bill the health plan for the service. Include all encounters and claims for services rendered, whether or not they were approved or paid by the PO.

**Visits**

Records with a unique combination of date of service, a unique billing provider identifier, and a unique patient identifier.

If one record is capitated within a claim/encounter, then the event should be treated as an encounter. An example of this would be a regular office visit (capitated) that had various lab tests (fee-for-service).

Allow at least a three-month lag in submission (i.e. January 1 – March 31 of the year following the measurement year) and count all commercial HMO and POS member encounters or transactions (including out of network POS claims) with a date of service in the measurement year.

Report services without regard to practitioner type, training or licensing. Include after-hours, nonemergency urgent care, nursing home visits and outpatient surgical procedures.

IHA encourages detailed service reporting to facilitate comparability and complete reporting, even when the financial reimbursement arrangement does not require it.

**Institutional Claims**

Services submitted with a unique claim ID using an 837I format for health plan payment.

**Institutional Encounters**

Services submitted with a unique claim ID using an 837I format for reasons other than reimbursement.

**Professional Claims**

Services submitted with a unique claim ID using an 837P format for health plan payment.

**Professional Encounters**

Services submitted with a unique claim ID using an 837P format for reasons other than reimbursement.

**Pharmacy Claims/Encounters**

Prescription records submitted to health plans using NCDPDP format. There is currently not a way to distinguish between pharmacy claims from encounters. Prescription records will be considered as pharmacy claims.

**Eligible Population**

**Product lines**

Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).

**Encounter Format Calculation: Valid Standard Codes**

**Step 1**

Identify all Institutional (837I) and Professional (837P) claims and/or encounters.
Step 2  Calculate the percentage of all claims/encounters with a valid national standard field. Divide the number of claims/encounters populated with a valid national standard field by the total count of claims/encounters submitted. Please refer to the list of valid national standard fields below.

Step 3  Calculate the average number of valid national standard fields per claim and/or encounter. Divide the total number of valid national standard fields by the number of all claims/encounters submitted. Please refer to the list of valid national standard fields below.

List of Valid National Standard Fields

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Include claims and/or encounters populated with a valid national standard procedure code (CPT, HCPCS) for professional and outpatient service.</td>
</tr>
<tr>
<td>Revenue Code</td>
<td>Include encounters and claims populated with a valid national standard revenue code (From (National Uniform Billing Committee) for institutional records. Institutional records are those that would be reported with a populated type of bill code on a UB04 under a fee-for-service arrangement.</td>
</tr>
<tr>
<td>Diagnosis Code</td>
<td>Include claims and/or encounters populated with a valid national standard diagnosis code (ICD-10-CM). To make information comparable across POs and consistent across AMP programs, diagnosis codes will be limited to 13 professional/13 facility.</td>
</tr>
</tbody>
</table>

Encounter Format Calculation: Standard Provider Identifiers

Step 1  Identify all Institutional (837I) and Professional (837P) claims and/or encounters.

Step 2  Calculate the percentage of all claims/encounters with a valid NPI. Divide the total count of claims/encounters by the number of claims/encounters populated with a valid NPI for each of the following provider categories:
   - Billing Provider.
   - Referring Provider.
   - Prescribing Provider.

Encounter Format Calculation: Procedure Codes Per Visit

Step 1  Identify all visits based on institutional (837I) and professional (837P) claims and/or encounters. “Visits” are defined as the unique combination of billing provider, beneficiary, and DOS.

Step 2  Calculate the percentage of visits with more than one procedure code. Divide the number of visits with more than one procedure code by the total number of visits.

Step 3  Calculate the average number of procedure codes per visit. Count the number of procedure codes and divide by the number of visits with a procedure code.

Encounter Format Calculation: Procedure Modifier and Rendering Provider Identifier Per Service Line

Step 1  Identify all service lines from institutional (837I) and professional (837P) claims and/or encounters that include a procedure code.
Step 2  *Calculate the percentage of service lines with a valid Rendering Provider Identifier NPI.* Count the number of service lines with Rendering Provider Identifier populated with a valid NPI and divide by the count of all service lines.

Step 3  *Calculate the average number of modifiers per service line with a procedure code.* Count the number of procedure modifiers and divide by the total count of service lines with a procedure code for professional and facility outpatient service lines.
Encounter Timeliness (ENLAG)

**Measure Updates September 2020 for AMP MY 2020 and 2021**

- Added additional reported Categories of Lagtime for Zero to 180 days and Zero to 364 days.
- Added clarifying information in Average Lagtime by Service Date and Average Lagtime by Paid/Remittance Date.
- Clarified time frame for included service dates in Step 4 of Encounter Timeliness Lagtime Categories Calculation.
- Clarified time frame for included service dates in Steps 1 and 2 of Encounter Timeliness Average Lagtime Calculation.

**Modifications From HEDIS**

- This a non-HEDIS measure.

**Description**

Encounter data timeliness assesses the elapsed time in days between the date a patient receives care (date of service [DOS]) and the date when the claim or encounter is accepted by the health plan (submission date). The number of calendar days between those dates is the “lag time.” Shortening the lag time between the DOS and the submission date ensures that the information provided on the encounter is available for health plan quality improvement initiatives, performance measurement reporting and risk-score calculations.

The following three measures are reported by service type (Facility, Professional, Pharmacy) and by transaction type (claim and encounter).

- **Categories of Lagtime**: The percentage of claims/encounters where the lag time falls within the category duration. Reported categories are:
  - Zero to 30 days (higher is better).
  - Zero to 60 days (higher is better).
  - Zero to 90 days (higher is better).
  - Zero to 180 days (higher is better).
  - Zero to 364 days (higher is better).
  - Greater than or equal to 365 days (lower is better).

- **Average Lagtime by Service Date**: The average lagtime for claims/encounters with dates of service during the measurement period and including the date of payment during the measurement year plus a 3-month runout (i.e. January 1 – March 31 of the year following the measurement year).

- **Average Lagtime by Paid/Remittance Date**: The average lagtime for claims/encounters with paid/remittance dates during the measurement period where the service date is during the year prior to the measurement year and during the measurement year.

For additional information on timeliness measures under consideration, refer to the California Department of Health Care Services Quality Measures for Encounter Data.
Note: Health plans and POs are not expected to report this measure. Onpoint will run this measure using health plans claim and encounter submissions for MY 2020 and 2021.

**Definitions**

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

- **Service Line**: All individual service records within a claim or encounter submitted to the health plan. This is identified by each record that health plans submit to Onpoint.
- **Claims**: A claim reflects a set of service lines reflected in a unique claim for health plan payment.
- **Encounter**: An encounter differs from a claim in that it represents a service for which there is no claim for payment sent to the health plan (i.e., all member encounters are covered in the health plan’s capitation payment), or a service where the PO may pay the provider a fee for service for the encounter but does not bill the health plan for the service. Include all claims and/or encounters for services rendered, whether or not they were approved or paid by the health plan.
- **Lagtime**: The elapsed time in days between the date a patient receives care (DOS) and the date when claim/encounter is accepted by the health plan (submission date).
- **Institutional Claims**: Services submitted with a unique claim ID using an 837I format for health plan payment.
- **Institutional Encounters**: Services submitted with a unique claim ID using an 837I format for reasons other than reimbursement.
- **Professional Claims**: Services submitted with a unique claim ID using an 837P format for health plan payment.
- **Professional Encounters**: Services submitted with a unique claim ID using an 837P format for reasons other than reimbursement.
- **Pharmacy Claims/Encounters**: Prescription records submitted to health plans using NCDPDP format. There is currently not a way to distinguish between pharmacy claims from encounters. Prescription records will be considered as pharmacy claims.

**Eligible Population**

- **Product lines**: Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).

**Encounter Timeliness Lagtime Categories Calculation**

1. **Step 1**: Distinguish encounters from claims.
2. **Step 2**: Determine the lagtime for each claim/encounter. Health plans submit all claims/encounters through their medical claims file submission to Onpoint. Onpoint will identify the lagtime for each member claim/encounter by identifying the elapsed time in days between the DOS and the submission date.
**Step 3** Categorize all claims/encounters by service type (Professional, Facility, Pharmacy) using the following determination is used:

- Institutional: Records for services that would be submitted using the UB04 format with a Type of Bill code populated under a fee-for-service arrangement.
- Professional: Records for services that would be submitted via CMS 1500 with a Place of Service Code populated under a fee-for-service arrangement.
- Pharmacy: Records for services for prescription drug coverage normally provided at a pharmacy that have a National Drug Code populated. Pharmaceuticals provided as part of medical procedures or hospital stays would not be included in here, but instead would be grouped with the corresponding professional and institutional service.

**Step 4** Assign claims/encounters into the appropriate category based on lagtime. For the total number of Professional, Facility and Pharmacy claims/encounters with a service date during the measurement year and a submission date on or before March 31 of the year following the measurement year, calculate the percentage of claims/encounters whose lagtime meets the following categories:

- Zero to 30 days.
- Zero to 60 days.
- Zero to 90 days.
- Zero to 180 days.
- Zero to 364 days.
- Greater than or equal to 365 days.

**Step 5** Calculate the percentage of claims/encounters that fall into each category. For each claim/encounter type, count claims/encounters within a lagtime category and divide by the count of all claims/encounters of that type.

**Encounter Timeliness Average Lagtime Calculation**

**Step 1** Calculate the average lagtime by service date. For all claims/encounters with a DOS occurring January 1–December 31 of the measurement year (and with a submission date on or before March 31 of the year following the measurement year), identify the average lagtime of all claims/encounters in days. For each claim/encounter type, sum the lagtimes across all claims/encounters and divide by the count of all claims/encounters.

**Step 2** Calculate the average lagtime by submission date. For all encounters/claims with a submission date occurring January 1–December 31 of the measurement year, identify the average lagtime of all claims/encounters in days for claims/encounters with a service date prior to the measurement year and during the measurement year. For each claim/encounter type, sum the lagtimes across all claims/encounters and divide by the count of all claims/encounters.
Advancing Care Information
For AMP MY 2020 and MY 2021
Overview

Description

To support the continued implementation of technology and eliminate redundancy, the IHA committees recommended aligning with the CMS EHR Incentive Program starting in MY 2011. Promoting health IT adoption and use will also allow the future addition of measures that require clinically enriched data from EHRs.

Starting in MY 2014, IHA began collecting two e-Measures as part of the Advancing Care Information domain.

- Controlling High Blood Pressure.
- Screening for Depression and Follow-Up Plan.

Both measures are included for reporting under the Merit-Based Incentive Payment System (MIPS) Quality Measure reporting program; eCQMs are included as one of the one of the 5 collection types for Quality measures.

For AMP, credit is based on the PO's ability to report these two measures. While the data for these measures will be collected through the Physician Organization Clinical Measure File Layout, points will be assigned to the Advancing Care Information Domain.

A list of all the CMS eCQMs and measure specifications can be found on the CMS website at: https://ecqi.healthit.gov/ep-ec-ecqms

IHA staff will hold training Webinars for e-Measure reporting in early 2021.

Who We Measure

For the Advancing Care Information domain, IHA will score POs based on all primary care physicians (MDs and DOs), including internists, family practitioners, GPs and pediatricians who can report both e-Measure rates to the PO.

Data Collection

Electronic Clinical Quality Measures (eCQMs) are measures that have specifications for calculation from EHR data. Measures are already programmed into the ONC-ATCB certified EHR systems of providers who can report the measures.

For each measure, report two metrics:

- **Rate 1: Percentage reportable.** The percentage of providers who can report the e-Measure (i.e., report a numerator and denominator to the PO).
  - Providers in your denominator should include all employed and contracted PCPs (MD or DO) in the following specialties: family/general practice, internal medicine and pediatric/adolescent medicine.

- **Rate 2: PO-level aggregated performance.** The aggregated patient numerator and denominator, for those providers who can report the e-Measure.
  - To calculate, pull the numerators and denominators from the EHR systems of all providers who can report the measures. Certified EHR systems should be able to create a report with the patient numerator and denominators for the e-Measures.
IHA staff are not prescriptive about how POs collect e-Measure data, and assume that POs use different methods to collect data. POs using one integrated EHR system may be able to create a global report to generate numerators and denominators for providers across the PO. Organizations not using one centralized EHR system may need to collect numerators and denominators from individual providers and aggregate across the PO. Methods for collecting these data may include, but are not limited to, surveys or direct correspondence with the practice or provider.

### Submitting Results

These e-Measures are included in the Advancing Care Information domain, but the numerators and denominators will be collected as part of the Physician Organization Clinical Measure File Layout and submitted to TransUnion. All participating POs, whether or not they self-report, may participate in e-Measure reporting. Non-self-reporting POs complete a separate file layout provided for non-self-reporting PO submission of e-Measures.

#### Note

- To receive credit, POs must submit valid rates (i.e., greater than zero) for each e-Measure. If the PO cannot report a valid numerator and denominator for Rate 2, this is considered not reportable.
- The PO-level aggregated patient numerator and denominator for Rate 2 are only for those PCPs that can report the e-Measure in Rate 1; the patient denominator in Rate 2 are the patients of PCPs counted in the numerator for Rate 1.
- POs may include all patients for the provider, even if they are not PO members. If the provider has the ability to include only PO members, that is also accepted.
- The AMP program intends to measure all commercial HMO/POS members, but we understand that not all POs can limit their numerators and denominators to specific product lines. For this reason, and because IHA is not currently scoring the PO-level aggregated performance, POs may include all payer types. If the PO has the ability to limit the patient population to only commercial HMO/POS, that is also accepted.

#### Example

- The PO has 50 PCPs that meet the measure criteria.
- 40 of the PCPs have an EHR and have the Controlling High Blood Pressure e-Measure activated in their EHRs, and the PO can collect the e-Measure (including numerator, denominator and rate) from those PCPs.
  - These 40 PCPs can report an individual performance rate to the PO, with patient numerators and denominators, for this measure. This is Rate 1: Percent Reportable (40 of the 50 PCPs, or 80%).
- The total number of patients in the rates reported by these 40 PCPs (aggregated, across-PO denominator) is 1,000. Of those 1,000 patients, 450 have a controlled blood pressure. This is Rate 2: PO-Level Aggregated Performance (450 of 1,000 patients, or 45%).

<table>
<thead>
<tr>
<th>e-Measure Name</th>
<th>Measure ID</th>
<th>Measure Rate</th>
<th>Denominator</th>
<th>Numerator</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controlling High Blood Pressure</td>
<td>MU_CBPH_RPT</td>
<td>Rate 1: Percent Reportable</td>
<td>50</td>
<td>40</td>
<td>80%</td>
</tr>
<tr>
<td></td>
<td>MU_CBPH</td>
<td>Rate 2: PO-Level Aggregated Performance</td>
<td>1,000</td>
<td>450</td>
<td>45%</td>
</tr>
</tbody>
</table>
Optional Exclusions for Rate 1 of Each e-Measure

- Pediatricians may be excluded from the Controlling High Blood Pressure e-Measure denominator.
- Providers who were employed or contracted with a PO for less than six months of the measurement year.
- Providers who meet the criterion but are employed in an administrative-only role (e.g., medical director).
Controlling High Blood Pressure (e-Measure)

MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021

- Updated eCQM Version Number.
- Updated copyright.
- Updated the clinical recommendations statement to remove outdated references and update with the most recent clinical recommendations.
- Updated references.
- Added text to identify the Quality Data Model (QDM) version used in the measure specification.
- Added text to indicate whether the measure is patient-based or episode-based.
- Updated denominator exclusions to add the word 'consecutive' to clarify that the Long-Term Illness (LTI) exclusion should be for 90 consecutive days.

Note: This Advancing Care Information measure is collected with the clinical measures. The measure specification is provided for reference. POs are not expected to program this measure. If a provider’s EHR system already has this measure programmed, the provider should be able to report this measure. The PO should report the percentage of its providers who can report the measure, and the aggregated numerator and denominator for those providers across the PO.

Specifications

<table>
<thead>
<tr>
<th>e-Measure identifier</th>
<th>165</th>
<th>e-Measure version number¹</th>
<th>9.2.000</th>
</tr>
</thead>
<tbody>
<tr>
<td>NQF number</td>
<td>Not Applicable</td>
<td>GUID</td>
<td>abdc37cc-bac6-4156-9b91-d1be2c8b7268</td>
</tr>
<tr>
<td>Measure steward</td>
<td>National Committee for Quality Assurance.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure developer</td>
<td>National Committee for Quality Assurance.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endorsed by</td>
<td>None.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Description</td>
<td>Percentage of patients 18–85 years of age who had a diagnosis of hypertension overlapping the measurement period and whose recent blood pressure was adequately controlled (&lt;140/90mmHg) during the measurement period.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹This measure specification is based on the most recent version of the eCQM Specifications for Eligible Professionals Update, published by CMS in May 2020. These specifications are available on the eCQM Library page of the CMS website (https://ecqi.healthit.gov/ep-ec-ecqms) AMP does not specify which version of the measure specification POs comply with.

The full measure specifications are located at https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS165v8.html
**Copyright**

This Physician Performance Measure (Measure) and related data specifications are owned and were developed by the National Committee for Quality Assurance (NCQA). NCQA is not responsible for any use of the Measure. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. NCQA holds a copyright in the Measure. The Measure can be reproduced and distributed, without modification, for noncommercial purposes (e.g., use by healthcare providers in connection with their practices) without obtaining approval from NCQA. Commercial use is defined as the sale, licensing, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain. All commercial uses or requests for modification must be approved by NCQA and are subject to a license at the discretion of NCQA. (C) 2012-2020 National Committee for Quality Assurance. All Rights Reserved. Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any third party codes contained in the specifications. CPT(R) contained in the Measure specifications is copyright 2004-2020 American Medical Association. LOINC(R) copyright 2004-2020 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2020 International Health Terminology Standards Development Organization. ICD-10 copyright 2018 World Health Organization. All Rights Reserved.

**Disclaimer**

These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS,” WITHOUT WARRANTY OF ANY KIND.

Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].

**Measure scoring**

Proportion.

**Measure type**

Intermediate Clinical Outcome.

**Stratification**

None.

**Risk adjustment**

None.

**Rate aggregation**

None.

**Rationale**

High blood pressure (HBP), also known as hypertension, is when the pressure in blood vessels is higher than normal (Centers for Disease Control and Prevention [CDC], 2016). The causes of hypertension are multiple and multifaceted and can be based on genetic predisposition, environmental risk factors, being overweight and obese, sodium intake, potassium intake, physical activity, and alcohol use. High Blood Pressure is common, according to the National Health and Nutrition Examination Survey (NHANES), approximately 85.7 million adults >= 20 years of age had HBP (140/90 mm Hg) between 2011 to 2014 (Crim, 2012). Between 2011-2014 the prevalence of hypertension
(>=140/90 mm Hg) among US adults 60 and older was approximately 67.2 percent (Benjamin et al., 2017).

HBP, known as the “silent killer,” increases risks of heart disease and stroke which are two of the leading causes of death in the U.S. (Yoon, Fryar, & Carroll, 2015). A person who has HBP is four times more likely to die from a stroke and three times more likely to die from heart disease (CDC, 2012). The National Vital Statistics Systems Center for Disease Control and Prevention reported that in 2014 there were approximately 73,300 deaths directly due to HBP and 410,624 deaths with any mention of HBP (CDC, 2015). Between 2004 and 2014 the number of deaths due to HBP rose by 34.1 percent (Benjamin et al., 2017). Managing and treating HBP would reduce cardiovascular disease mortality for males and females by 30.4 percent and 38.0 percent, respectively (Patel et al., 2015).

The estimated annual average direct and indirect cost of HBP from 2012 to 2013 was $51.2 billion (Benjamin et al., 2017). Total direct costs of HBP is projected to increase to $200 billion by 2030 (Benjamin et al., 2017). A study on cost-effectiveness on treating hypertension found that controlling HBP in patients with cardiovascular disease and systolic blood pressures of >=160 mm Hg could be effective and cost-saving (Moran et al., 2015).

Many studies have shown that controlling high blood pressure reduces cardiovascular events and mortality. The Systolic Blood Pressure Intervention Trial (SPRINT) investigated the impact of obtaining a SBP goal of <120 mm Hg compared to a SBP goal of <140 mm Hg among patients 50 and older with established cardiovascular disease and found that the patients with the former goal had reduced cardiovascular events and mortality (SPRINT Research Group et al., 2015).

Controlling HBP will significantly reduce the risks of cardiovascular disease mortality and lead to better health outcomes like reduction of heart attacks, stroke, and kidney disease (James et al., 2014). Thus, the relationship between the measure (control of hypertension) and the long-term clinical outcomes listed is well established.

Clinical recommendation statement

The U.S. Preventive Services Task Force (2015) recommends screening for high blood pressure in adults age 18 years and older. This is a grade A recommendation.

American College of Cardiology/American Heart Association (2017)

- For adults with confirmed hypertension and known CVD or 10-year ASCVD event risk of 10% or higher, a blood pressure target of less than 130/80 mmHg is recommended (Level of evidence: B-R (for systolic blood pressures), Level of evidence: C-EO (for diastolic blood pressure))

- For adults with confirmed hypertension, without additional markers of increased CVD risk, a blood pressure target of less than 130/80 mmHg may be reasonable (Note: clinical trial evidence is strongest for a target blood pressure of 140/90 mmHg in this population. However observational studies suggest that these individuals often have a high lifetime risk and would benefit from blood pressure control earlier in life) (Level of evidence: B-NR (for systolic blood pressure), Level of evidence: C-EO (for diastolic blood pressure))
American College of Physicians and the American Academy of Family Physicians (2017):

- Initiate intensifying pharmacologic treatment in adults aged 60 and older at high cardiovascular risk, based on individualized assessment, to achieve a target systolic blood pressure of less than 140 mmHg (Grade: weak recommendation, quality of evidence: low)

- Initiate intensifying pharmacologic treatment in adults aged 60 and older with a history of stroke or transient ischemic attack to achieve a target systolic blood pressure of less than 140 mmHg to reduce the risk of recurrent stroke (Grade: weak recommendation, quality of evidence: moderate)

American Diabetes Association (2019):

For individuals with diabetes and hypertension at higher cardiovascular risk (existing atherosclerotic cardiovascular disease or 10-year atherosclerotic cardiovascular disease risk >15%), a blood pressure target of <130/80 mmHg may be appropriate, if it can be safely attained (Level of evidence: C)-For individuals with diabetes and hypertension at lower risk for cardiovascular disease (10-year atherosclerotic cardiovascular disease risk <15%), treat to a blood pressure target of <140/90 mmHg (Level of evidence: A)

<table>
<thead>
<tr>
<th>Improvement notation</th>
<th>Higher score indicates better quality.</th>
</tr>
</thead>
</table>


Definition None.

Guidance In reference to the numerator element, only blood pressure readings performed by a clinician in the provider office are acceptable for numerator compliance with this measure.

Do not include BP readings:

- Taken during an acute inpatient stay or an ED visit.
- Taken on the same day as a diagnostic test or diagnostic or therapeutic procedure that requires a change in diet or change in medication on or one day before the day of the test or procedure, with the exception of fasting blood tests.
- Reported by or taken by the member.

If no blood pressure is recorded during the measurement period, the patient's blood pressure is assumed “not controlled.”

If there are multiple blood pressure readings on the same day, use the lowest systolic and the lowest diastolic reading as the most recent blood pressure reading.

This eCQM is a patient-based measure.

This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center (https://ecqi.healthit.gov/qdm) for more information on the QDM.

Transmission format

TBD.

Initial patient population

Patients 18–85 years of age who had a diagnosis of essential hypertension overlapping the measurement period

Denominator

Equals initial population.

Denominator exclusions

Patients with evidence of end stage renal disease (ESRD), dialysis or renal transplant before or during the measurement period. Also exclude patients with a diagnosis of pregnancy during the measurement period.

Exclude patients whose hospice care overlaps the measurement period.

Exclude patients 66 and older who are living long term in an institution for more than 90 consecutive days during the measurement period.

Exclude patients 66 and older with advanced illness and frailty because it is unlikely that patients will benefit from the services being measured.

Numerator

Patients whose blood pressure at the most recent visit is adequately controlled (systolic blood pressure <140 mmHg; diastolic blood pressure <90 mmHg) during the measurement period.

Numerator exclusions

NA

Denominator exceptions

None.

Supplemental data elements

For every patient evaluated by this measure, also identify payer, race, ethnicity and sex.
Screening for Depression and Follow-Up Plan (e-Measure)

MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021

- Updated eCQM Version Number.
- Updated the measure developer field.
- Revised description to improve alignment with measure intent and initial population language.
- Updated copyright.
- Updated disclaimer.
- Revised rationale to align with updated guidelines and evidence.
- Removed clinical recommendation statement from an outdated guideline.
- Removed reference to outdated guideline.
- Updated references to align with American Psychological Association (APA) formatting.
- Removed guidance related to additional evaluation or assessment for depression and suicide risk assessment as appropriate follow-up. Added guidance about the importance of escalating patient care or certain circumstances which are not captured in the measure.
- Added guidance about the intent of the denominator exclusions.
- Added guidance to clarify the measure's use of the most recent depression screening.
- Added text to identify the Quality Data Model (QDM) version used in the measure specification.
- Added text to indicate whether the measure is patient-based or episode-based.
- Removed guidance inconsistent with measure intent.
- Revised existing guidance pertaining to using an age-appropriate depression screening tool.
- Revised guidance related to examples of appropriate follow-up plans.
- Revised guidance to consolidate and more accurately reflect the intent of using a standardized age-appropriate depression screening tool.
- Revised denominator exclusions language based upon subject matter experts' feedback to reflect that any patient with a current or historical diagnosis of bipolar disorder or depression should be excluded from the measure.
- Revised denominator exception language to follow a similar format as other eCQMs.

Note: This Advancing Care Information measure is collected with the Clinical measures. The measure specification is provided for reference. POS are not expected to program this measure. If a provider's EHR system already has this measure programmed, the provider should be able to report this measure. The PO should report the percentage of its providers who can report the measure, and the aggregated numerator and denominator for those providers across the PO.
## Specifications

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Value</th>
<th>Version Number</th>
<th>NQF Number</th>
<th>GUID</th>
</tr>
</thead>
<tbody>
<tr>
<td>e-Measure identifier</td>
<td>2</td>
<td>10.2.000</td>
<td>0418e</td>
<td>9a031e24-3d9b-11e1-8634-00237d5bf174</td>
</tr>
<tr>
<td>Measure period</td>
<td>January 1–December 31, 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure steward</td>
<td>Centers for Medicare &amp; Medicaid Services (CMS)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure developer</td>
<td>PCPI(R) Foundation (PCPI(R))</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endorsed by</td>
<td>National Quality Forum.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Description</td>
<td>Percentage of patients aged 12 years and older screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool, and if positive, a follow-up plan is documented on the date of the eligible encounter.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copyright</td>
<td>Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Quality Insights, Inc. disclaims all liability for use or accuracy of any Current Procedural Terminology (CPT(R)) or other coding contained in the specifications. CPT(R) contained in the Measure specifications is copyright 2007-2020 American Medical Association. LOINC(R) copyright 2004-2020 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT(R)) copyright 2004-2020 International Health Terminology Standards Development Organisation. ICD-10 is copyright 2019 World Health Organization. All Rights Reserved.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disclaimer</td>
<td>These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND. Due to technical limitations, registered trademarks are indicated by (R) or [R].</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure scoring</td>
<td>Proportion.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure type</td>
<td>Process.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stratification</td>
<td>None.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

²This measure specification is based on the most recent version of the eCQM Specifications for Eligible Professionals Update, published by CMS in May 2018. These specifications are available on the eCQM Library page of the CMS website (https://ecqi.healthit.gov/ep-ec-ecqms). IHA does not specify which version of the measure specification POs comply with. Full measure specifications are located at https://ecqi.healthit.gov/ecqm/ep/2020/cms002v9
Risk adjustment  None.
Rate aggregation  None.

Rationale  Depression is a serious medical illness associated with higher rates of chronic disease, increased health care utilization, and impaired functioning (Katon, 2003; Wells et al., 1989). 2016 U.S. survey data indicate that 12.8 percent of adolescents (3.1 million adolescents) had a major depressive episode (MDE) in the past year, with nine percent of adolescents (2.2 million adolescents) having one MDE with severe impairment. The same data indicate that 6.7 percent of adults aged 18 or older (16.2 million adults) had at least one MDE with 4.3 percent of adults (10.3 million adults) having one MDE with severe impairment in the past year (Substance Abuse and Mental Health Services Administration, 2017). Data indicate that severity of depressive symptoms factor into having difficulty with work, home, or social activities. For example, as the severity of depressive symptoms increased, rates of having difficulty with work, home, or social activities related to depressive symptoms increased. For those twelve and older with mild depressive symptoms, 45.7% reported difficulty with activities and those with severe depressive symptoms, 88.0% reported difficulty (Pratt & Brody, 2014). Children and teens with major depressive disorder (MDD) have been found to have difficulty carrying out their daily activities, relating to others, growing up healthy, and also are at an increased risk of suicide (Siu on behalf of the U.S. Preventive Services Task Force [USPSTF], 2016). Additionally, perinatal depression (considered here as depression arising in the period from conception to the end of the first postnatal year) affects up to 12% of women (Woody, Ferrari, Siskind, Whiteford, & Harris, 2017). Depression and other mood disorders, such as bipolar disorder and anxiety disorders, especially during the perinatal period, can have devastating effects on women, infants, and families (American College of Obstetricians and Gynecologists, 2018). Maternal suicide rates rise over hemorrhage and hypertensive disorders as a cause of maternal mortality (Palladino, Singh, Campbell, Flynn, & Gold, 2011).

Negative outcomes associated with depression make it crucial to screen in order to identify and treat depression in its early stages. While Primary Care Providers (PCPs) serve as the first line of defense in the detection of depression, studies show that PCPs fail to recognize up to 50% of depressed patients (Bomer, Braunstein, St. Victor, & Pollack, 2010). "In nationally representative U.S. surveys, about eight percent of adolescents reported having major depression in the past year. Only 36% to 44% of children and adolescents with depression receive treatment, suggesting that the majority of depressed youth are undiagnosed and untreated" (Siu on behalf of USPSTF, 2016, p. 360 & p. 364). Evidence supports that screening for depression in pregnant and postpartum women is of moderate net benefit and treatment options for positive depression screening should be available for patients twelve and older including pregnant and postpartum women. If preventing negative patient outcomes is not enough, the substantial economic burden of depression for individuals and society alike makes a case for screening for depression on a regular basis. Depression imposes economic burden through direct and indirect costs: "In the United States, an estimated $22.8 billion was spent on depression treatment in 2009, and lost productivity cost an additional estimated $23 billion in 2011" (Siu & USPSTF, 2016, p. 383-384).
This measure seeks to align with clinical guideline recommendations as well as the Healthy People 2020 recommendation for routine screening for mental health problems as a part of primary care for both children and adults (U.S. Department of Health and Human Services, 2014) and makes an important contribution to the quality domain of community and population health.

### Clinical recommendation statement

**Adolescent Recommendation (12–18 years):**

“The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation)” (Siu on behalf of USPSTF, 2016, p. 360).

**Adult Recommendation (18 years and older):**

“The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation)” (Siu & USPSTF, 2016, p. 380).

The Institute for Clinical Systems Improvement (ICSI) health care guideline, Adult Depression in Primary Care, provides the following recommendations:

1. “Clinicians should routinely screen all adults for depression using a standardized instrument.”
2. “Clinicians should establish and maintain follow-up with patients.”
3. “Clinicians should screen and monitor depression in pregnant and post-partum women.” (Trangle, 2016 p.p. 8–10)

### Improvement notation

Higher score indicates better quality.

**Reference**


Definitions

**Screening**
Completion of a clinical or diagnostic tool used to identify people at risk of developing or having a certain disease or condition, even in the absence of symptoms.

**Standardized depression screening tool**
A normalized and validated depression screening tool developed for the patient population in which it is being utilized.

Examples of depression screening tools include, but are not limited to:

- Adolescent screening tools (12–17 years):
– Patient Health Questionnaire for Adolescents (PHQ-A).
– Beck Depression Inventory-Primary Care Version (BDI-PC).
– Mood Feeling Questionnaire (MFQ).
– Center for Epidemiologic Studies Depression Scale (CES-D).
– Patient Health Questionnaire (PHQ-9).
– Pediatric Symptom Checklist (PSC-17).
– PRIME MD-PHQ2.

- Adult screening tools (18 years and older):
  – Patient Health Questionnaire (PHQ-9).
  – Beck Depression Inventory (BDI or BDI-II).
  – Center for Epidemiologic Studies Depression Scale (CES-D).
  – Depression Scale (DEPS).
  – Duke Anxiety-Depression Scale (DADS).
  – Geriatric Depression Scale (GDS).
  – Cornell Scale Screening for Depression in Dementia (CSDD).
  – PRIME MD-PHQ2.
  – Hamilton Rating Scale for Depression (HAM-D).
  – Quick Inventory of Depressive Symptomatology Self-Report (QID-SR).
  – Computerized Adaptive Testing Depression Inventory (CAT-DI).
  – Computerized Adaptive Diagnostic Screener (CAD-MDD).

- Perinatal Screening Tools
  – Edinburgh Postnatal Depression Scale.
  – Postpartum Depression Screening Scale.
  – Patient Health Questionnaire 9 (PHQ-9).
  – Beck Depression Inventory.
  – Beck Depression Inventory-II.
  – Center for Epidemiologic Studies Depression Scale.
  – Zung Self-rating Depression Scale.

**Follow-up plan**

Documented follow-up for a positive depression screening must include one or more of the following:

- Additional evaluation or assessment for depression.
- Suicide risk assessment.
- Referral to a practitioner who is qualified to diagnose and treat depression.
- Pharmacological interventions.
- Other interventions or follow-up for the diagnosis or treatment of depression.
Guidance

A depression screen is completed on the date of the encounter or up to 14 days prior to the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan must be documented on the date of the encounter, such as referral to a practitioner who is qualified to treat depression, pharmacological interventions, or other interventions for the treatment of depression.

This eCQM is a patient-based measure. Depression screening is required once per measurement period, not all encounters.

The intent of the measure is to screen for depression in patients who have never had a diagnosis of depression or bipolar disorder prior to the eligible encounter used to evaluate the numerator. Patients who have ever been diagnosed with depression or bipolar disorder will be excluded from the measure.

Screening Tools:

- An age-appropriate, standardized, and validated depression screening tool must be used for numerator compliance.
- The name of the age appropriate standardized depression screening tool utilized must be documented in the medical record.
- The depression screening must be reviewed and addressed in the office of the provider, filing the code, on the date of the encounter. Positive pre-screening results indicating a patient is at high risk for self-harm should receive more urgent intervention as determined by the provider practice.
- The screening should occur during a qualified encounter or up to 14 days prior to the date of the qualifying encounter.
- The measure assesses the most recent depression screening completed either during the eligible encounter or within the 14 days prior to that encounter. Therefore, a clinician would not be able to complete another screening at the time of the encounter to count towards a follow-up, because that would serve as the most recent screening. In order to satisfy the follow-up requirement for a patient screening positively, the eligible clinician would need to provide one of the aforementioned follow-up actions, which does not include use of a standardized depression screening tool.

Follow-Up Plan:

- The follow-up plan must be related to a positive depression screening; for example: “Patient referred for psychiatric evaluation due to positive depression screening.”

Examples of a follow-up plan include, but are not limited to:

- Referral to a practitioner or program for further evaluation for depression, for example, referral to a psychiatrist, psychologist, social worker, mental health counselor, or other mental health service such as family or group therapy, support group, depression management program, or other service for treatment of depression.
Other interventions designed to treat depression such as behavioral health evaluation, psychotherapy, pharmacological interventions, or additional treatment options.

Should a patient screen positive for depression, a clinician should opt to complete a suicide risk assessment when appropriate and based on individual patient characteristics. However, for the purposes of this measure, a suicide risk assessment or additional screening using a standardized tool will not qualify as a follow-up plan.

This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center (https://ecqi.healthit.gov/qdm) for more information on the QDM.

<table>
<thead>
<tr>
<th>Transmission format</th>
<th>TBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial patient population</td>
<td>All patients aged 12 years and older at the beginning of the measurement period with at least one eligible encounter during the measurement period.</td>
</tr>
<tr>
<td>Denominator</td>
<td>Equals initial population.</td>
</tr>
<tr>
<td>Denominator exclusions</td>
<td>Patients who have been diagnosed with depression or with bipolar disorder.</td>
</tr>
<tr>
<td>Numerator</td>
<td>Patients screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age appropriate standardized tool AND, if positive, a follow-up plan is documented on the date of the eligible encounter.</td>
</tr>
<tr>
<td>Numerator exclusions</td>
<td>NA</td>
</tr>
</tbody>
</table>
| Denominator exceptions | Patient reason(s):  
  - Patient refuses to participate, or  
Medical reason(s):  
  - Documentation of medical reason for not screening patient for depression (e.g., cognitive, functional, or motivational limitations that may impact accuracy of results; patient is in an urgent or emergent situation where time is of the essence and to delay treatment would jeopardize the patient's health status). |
| Supplemental data elements | For every patient evaluated by this measure, also identify payer, race, ethnicity and sex. |
Patient Experience Domain

For AMP MY 2020 and MY 2021
Overview

MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021

• None.

Description

This section includes the AMP guidelines and specifications for POs that participate in the Patient Experience domain for MY 2020 & MY 2021. AMP uses the Patient Assessment Survey (PAS) to assess PO performance. Health plans do not submit data for the Patient Experience domain; POs voluntarily participate in the survey.

The Patient Assessment Survey (PAS) program is a multi-stakeholder collaborative activity to produce patient care experience ratings of medical groups in California. It is the nation’s largest system for evaluating and publishing physician group ratings based on the patient’s experience.

Survey instrument

The PAS survey contains a set of patient experience measures on access to care, provider communication, office staff interactions, coordination of care and overall ratings of care. The survey is based on the industry-standard CG-CAHPS® instrument with some customization for topics of interest locally.

Participation

For MY 2020 & MY 2021, PAS offers two group-level survey options for POs serving patients in California: 1) a Commercial survey (HMO and POS patients), and 2) a Medi-Cal survey. POs with over 1,000 enrollees are invited to participate. Registration information will be emailed in October 2020.

During the registration process, POs will be given information on various survey options and the associated fees. POs are required to provide up-to-date contact information and data on member enrollment, geographic locations served and other PO characteristics, and must agree to the terms outlined in the PAS Participation Agreement.

POs will have the option to download and sign off on the terms outlined in the Business Associate Agreement with the survey vendor for the project, the Center for the Study of Services (CSS).

In addition to participating in the PAS Group Survey, POs may have added supplemental doctor level survey options. These are not required or used for AMP.

3CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).
PO Requirements

In addition to formal registration, POs must adhere to the following requirements.

- Meet deadlines that will be specified during the registration process.
  - Failure to meet deadlines will result in forfeiture of the PO’s participation in the PAS project and no points earned in the Patient Experience domain of the applicable AMP programs.

- Sign up for the PAS at the same reporting level at which the PO will be reported for AMP. All domains must be reported at the same level.
  - The survey vendor may not separate results for groups who have not registered sub-units.

- At the time of registration, sign off on the PAS Participation Agreement.

- At the time of registration, submit (or confirm) the PO logo and executive (i.e., medical director) signature, which will be printed on the survey cover letter and instrument.

- Provide accurate information on the PO’s coding practices and provider specialties, as requested in an online survey to be hosted by the survey vendor.

- Submit data files on all eligible patients, patient visits and providers, from which the patient sample will be drawn.
  - POs will be given a set of data specifications that define the layout of the files and the information required within each field. All data submissions must meet the data quality criteria identified by PAS.

- Pay participation fees associated with the survey options elected by the PO within 30 days of invoice receipt.
  - Fees will be listed on the registration site.

Performance Areas

The following key performance areas are recommended for payment in AMP:

- Access to Care Composite.
- Provider Communication Composite.
- Care Coordination Composite.
- Office Staff Composite.
- Overall Ratings of Care Composite.
Measurement Year 2020 PAS Patient Experience Questions

Refer to the table below for a list of composites collected and recommended for payment for AMP in MY 2020 and in the MY 2020 measure set. Questions regarding the survey instrument can be directed to Emily London at elondon@pbgh.org.

<table>
<thead>
<tr>
<th>Performance Area</th>
<th>Primary Care and Specialist Version</th>
<th>Question #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Access Composite</strong></td>
<td>Timely appt. for care needed right away</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Timely appt. for check-up or routine care</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Same day response to office hours contact</td>
<td>10</td>
</tr>
<tr>
<td><strong>Provider Communication Composite</strong></td>
<td>Doctor explanations easy to understand</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Doctor listens carefully</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Doctor shows respect</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Doctor spends enough time</td>
<td>18</td>
</tr>
<tr>
<td><strong>Care Coordination Composite</strong></td>
<td>Doctor knows important medical history</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Office followed up on test results</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Discussed all Rx medicines</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Doctor informed about other care</td>
<td>27</td>
</tr>
<tr>
<td><strong>Office Staff Composite</strong></td>
<td>Clerks and receptionists helpful</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Clerks and receptionists courteous and respectful</td>
<td>29</td>
</tr>
<tr>
<td><strong>Overall Ratings of Care Composite</strong></td>
<td>Overall rating of doctor</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Overall rating of care</td>
<td>30</td>
</tr>
</tbody>
</table>

Specifications: Patient Population Surveyed

Only adults are surveyed for multispecialty POs. There are two options for assessing pediatric performance:

1. Conduct a second group-level survey process for pediatric patients, which would be sent to the parent of the patient sample.
2. Select the doctor-level survey of pediatricians when completing the registration process.

For more information on assessing pediatric performance, contact Emily London by email at elondon@pbgh.org.

Sampling

To be included in any sample, each group must meet all the data criteria listed in the PAS data specifications. Groups were notified if they failed specific criteria and were provided with assistance to either address the issue or determine whether the group was capable of meeting the requirement. Groups may be exempted from meeting specific data criteria and may be accepted for the project with an explicit waiver from the PAS Project Manager.
Fielding Surveys

The standard survey protocol consists of three emails (where email addresses are available) to complete the survey via website; two mailed surveys, with a cover letter option to complete the survey via the survey website, using a unique web ID; and up to four attempts by Computer Assisted Telephone Interview (CATI), where phone numbers are available. The cover letter is printed with the logo of the patient's PO and is signed by the PO's medical director or other executive signatory.

The emails occur over at least one week in early December. The first mailing occurs in mid-January 2020; the second occurs in mid-February and is sent only to patients who did not respond to the first mailing. Patients who do not respond to the second mailing are contacted by phone in mid-March. As patients respond to the survey, they are removed from further contact attempts.

Mail, web and phone interviews are available in English and Spanish for all patients, and all mailed cover letters include a message in Spanish inviting patients to request a Spanish version of the survey via a toll-free number.

POs are also given the option to field the survey in English and an alternative language (Spanish, Chinese, Vietnamese or Korean). Patients receiving the alternative language survey receive a cover letter in English, with a translation in the alternative language printed on the back of the letter, and a copy of the survey instrument in the alternative language.

Any communications to patients in advance of the survey are prohibited in order to maintain a consistent survey methodology for all participating medical groups. Examples of communication include, but are not limited to, letters or postcards that inform patients of the possible receipt of the PAS. For groups with historically low response rates, additional intervention is included in the survey process to increase response rates, such as oversampling and reminders.

Response File Preparation

When survey fielding is complete, the survey vendor cleans the data (e.g., removes duplicate interviews, merges response data with the original sample data, conducts consistency checks between question items). Response data files from mail, web and telephone interview sources are cleaned for out-of-range responses for each question. All responses are kept where the patient confirms a visit with the physician in the past 6 months. Respondents to the PCP survey must also confirm that the doctor named on the survey is their PCP.

Analysis of Survey Data

If any POs do not have a sufficient number of survey responses to meet the reliability threshold for AMP reporting (overall ratings and composites), CSS will combine MY 2018 and 2019 responses together into a two-year rollup.

Each PO’s results are adjusted for patient case-mix to control for differences across POs. In MY 2020, the case-mix adjustment model will control for the following:

- Age.
- Gender.
- Education level.
- Race/ethnicity—primary language of respondent.
- Single-item physical health status.
- Single item mental health status.
- Specialty type of physician that patient rated (44 categories).
- Survey response mode (mail/internet, phone).
- Language in which survey was completed.
POs receive the following reports of their results, pending fulfillment of participation fees.

- **Summary AMP Report** (May 2021): question and composite level scores.
- **Full Report** (June 2021): PDF group detailed results including benchmarks, trending, PCP/Specialist scores, and a comparison of provider groups’ question and composite level scores within geographic region; Excel dataset contains de-identified patient-level records for Provider Group’s patients only; records include physician identifier.

Survey results are made publicly available for consumers through the California Department of Managed Health Care’s Office of the Patient Advocate consumer website (www.opa.ca.gov/report_card).

**Key Dates for PAS**

<table>
<thead>
<tr>
<th>Activity or Milestone</th>
<th>Time Frame or Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAS Registration Information emailed to POs.</td>
<td>September, 2020</td>
</tr>
<tr>
<td>PAS Registration Site Live.</td>
<td>October, 2020</td>
</tr>
<tr>
<td>Legal agreements completed (Participation Agreement, BAA).</td>
<td>October, 2020</td>
</tr>
<tr>
<td>Deadline to register for RY 2020 PAS.</td>
<td>October, 2020</td>
</tr>
<tr>
<td>Optional Data Format Checking prior to data submission</td>
<td>October – November, 2020</td>
</tr>
<tr>
<td>Submit Data for Survey Sampling.</td>
<td>November, 2020</td>
</tr>
<tr>
<td>Data corrections due.</td>
<td>November, 2020</td>
</tr>
<tr>
<td>Doctor Survey participants approve provider list.</td>
<td>November, 2020</td>
</tr>
<tr>
<td>Survey fielding period.</td>
<td>December, 2020–April, 2021</td>
</tr>
<tr>
<td>Participation fees due to PAS.</td>
<td>May, 2021</td>
</tr>
<tr>
<td>Group survey results sent to groups.</td>
<td>June, 2021</td>
</tr>
<tr>
<td>Doctor survey results sent to groups.</td>
<td>June, 2021</td>
</tr>
</tbody>
</table>

**For More Information**

Contact Emily London by email at elondon@pbgh.org.
Appropriate Resource Use Domain Technical Specifications

For AMP MY 2020 and MY 2021
Overview

In recognition of the growing issue of healthcare affordability, the AMP Governance Committee (formerly the P4P Executive and Steering Committees) charged IHA with developing standardized resource use measures to be implemented as part of the AMP program. Resource use measures were already being used for incentive payments by individual plans and physician groups. Incorporating them into AMP aligns measurement across plans for consistent identification of unwarranted variation in care delivery and provides an opportunity to address these areas to ensure appropriate use of limited health care dollars in delivering quality care.

Measures By Priority Area

- **All-Cause Readmissions (PCR).**
- **Emergency Department Visits.**
  - Ambulatory Care (AMB).
  - Emergency Department Utilization (EDU).
- **Frequency of Selected Procedures (FSP).**
- **Generic Prescribing (GRX).**
- **Inpatient Utilization.**
  - Acute Hospital Utilization (AHU).
  - Hospital Average Length of Stay (HALOS).
  - Inpatient Utilization—General Hospital/Acute Care (IPU).
- **Outpatient Utilization.**
  - Outpatient Procedure Utilization—Percentage Done in Preferred Facility (OSU).

Measure Development and Testing

The Resource Use measures were selected by a multi-stakeholder group of AMP Committee and IHA board members, based on resource use measures currently in use and their potential to improve efficient delivery of appropriate, quality care. The detailed specifications for the non-HEDIS measures on the following pages were developed by a workgroup of participating POs and health plans, with technical support from Onpoint and NCQA.

These measures are calculated by Onpoint from claims, encounter, eligibility, pharmacy and appropriate use data submitted by participating health plans. POs and health plans do not self-report Resource Use measures.

Calculating Measure Results

Each measure is calculated in two ways.

1. **Results for each contracted health plan.** Rates are run on each health plan’s data for each contracted PO. Each plan applies its actual costs for the PO to the utilization results provided, and shares savings generated by a PO’s improvement over the previous year’s performance.

2. **Results aggregated across all contracted health plans.** A PO’s results for each measure is aggregated across all contracted plans. This lets POs understand how their utilization compares with that of other POs.
A confidence interval of 95 percent is provided for all measures, representing the range within which the true rate would appear 95 percent of the time.

**Enrollment in Plan and PO**

For the service to be counted for any measure, members must be enrolled in the plan and the PO on the date of service. For example, for *Outpatient Procedures Utilization—Percentage Done in Preferred Facility*, the procedure is attributed to the PO and plan where the member was enrolled on the date of the procedure. The service is not counted in the measure if an enrollment record does not identify a PO in which a member was enrolled on the date of service.

**Which Services Count?**

Report all services for which the organization actually paid or expects to pay. *Do not include* services or days denied for any reason. If a member is enrolled retroactively, count all services for which the organization has paid or expects to pay. Services should be included regardless of provider location (e.g. in-state or out-of-state) and a health plan’s status as primary or secondary coverage for the member.

**Risk Adjustment**

The selected risk-adjustment methodology is indicated in each measure’s specification. Risk adjustment was determined to be unnecessary for two measures:

- For *Outpatient Procedures Utilization*, a standard list of outpatient procedures is used, which CMS has determined can be done in an ambulatory outpatient setting, independent of member risk.
- For *Generic Prescribing*, specific therapeutic areas are measured, which makes the eligible population more homogenous.

**Observed-to-Expected Ratio**

A common characteristic of the measures that includes risk adjustment is the use of an "observed-to-expected" ratio (also known as an observed/expected [O/E] ratio). In all calculations, the observed rate (per the specifications) is divided by an expected rate, which considers the risk or illness burden of the PO’s population. POs with higher-risk (i.e., sicker) members are expected to have higher utilization and, therefore, have higher expected rates. Similarly, POs with lower risk scores are expected to have lower utilization and have lower expected rates. It is important to note that the calculation of the expected rate is based on utilization and risk patterns in the AMP population, not on national or other external benchmarks. Specifically, to calculate the expected rate, a statistical model is developed that summarizes the relationship between observed rates and relative risk scores across the AMP population and provides an expected rate for a given level of risk. Because the distribution of observed rates by relative risk score varies by measure, the specific statistical model used to fit the data depends on the measure.

The O/E ratio compares the PO’s observed rate to the expected rate and allows straightforward interpretation of how the PO’s performance compared with the performance of the AMP population:

- An O/E ratio of 1.0 means the PO’s rate was the same as expected, based on the risk of its population.
- An O/E ratio of 1.1 means the rate was 10 percent higher than expected.
- An O/E ratio of 0.9 means the rate was 10 percent lower than expected.
Guidelines for HEDIS Utilization Measures

The following guidelines are specific to the HEDIS utilization measures in the Resource Use Domain:

- **Ambulatory Care (AMB).**
- **Frequency of Selected Procedures (FSP)**.
- **Inpatient Utilization—General Hospital/Acute Care (IPU).**

*Risk adjustment for age and sex is applied to the measure reported rates.

**GUIDANCE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021**

- Added note to #6 in Specific Instructions for Utilization Tables to clarify shading in reporting tables.

**Specific Instructions for Utilization Tables**

1. **Members who switch product lines.** Unless otherwise specified, assign members to the product and product line in which they are enrolled on the date of service for the relevant service. If the service is an inpatient claim/encounter, use the member’s discharge date to assign the product line. Assign Medi-Cal Managed Care members to the Medicaid-eligibility category (e.g., Medicaid/Medicare, the disabled) based on the date of service or date of discharge (inpatient) for the relevant service.

2. **Services provided during the measurement year.** Report information on services that occurred during the measurement year in the Utilization tables (unless stated otherwise in the measure specification).

3. **Which services count?** Report all services the organization paid for or expects to pay for (i.e., claims incurred but not paid). *Do not include* services and days denied for any reason. If a member is enrolled retroactively, count all services for which the organization paid or expects to pay.

The organization may have:

- Covered the full amount.
- Paid only a portion of the amount (e.g., 80 percent).
- Paid nothing because the member covered the entire amount to meet a deductible.
- Paid nothing because the service was covered as part of a per member per month (PMPM) payment.
- Denied the service.

**Count the service if:**

- The organization paid the full amount or a portion of the amount (e.g., 80 percent).
- The member paid for the service as part of the benefit offering (e.g., to meet a deductible), or
- The service was covered under a PMPM payment.

**Do not count the service if:**

- The organization denied the service for any reason, unless the member paid for the service as part of the benefit offering (e.g., to meet a deductible), or
The claim for the service was rejected because it was missing information or was invalid for another reason.

When confirming that an ED visit or observation stay does not result in an inpatient stay, all inpatient stays must be considered, regardless of payment status (paid, suspended, pending, denied). For example, if an ED visit is paid but an inpatient stay is denied, the ED visit resulted in an inpatient stay and is not included in the Ambulatory Care measure when identifying ED visits.

4. **Medicaid eligibility reporting categories.** For the organization’s Medicaid HEDIS submission, report certain utilization data separately for each of the following eligibility categories:
   - Medicaid/Medicare Dual-Eligibles.
   - Disabled.
   - Low Income.
   - Total Medicaid.

Refer to *Enrollment by Product Line* for more information on defining Medicaid categories.

5. **Stratification by product line/eligibility category.** Members covered by different product lines tend to vary considerably by sociodemographic characteristics and enrollment and utilization patterns. For this reason, report measures separately for each product line (Medicaid, commercial, Medicare).

Measures will have up to six tables. Complete only the tables relevant to the organization (tables reflecting the product lines the organization serves). Tables that apply to each measure are designated as follows (where XXX is the abbreviation for a specific measure).

1. Table XXX-1a Total Medicaid.
2. Table XXX-1b Medicaid/Medicare Dual-Eligibles.
3. Table XXX-1c Medicaid—Disabled.
4. Table XXX-1d Medicaid—Other Low Income.
5. Table XXX-2 Commercial.
6. Table XXX-3 Medicare.

Medicaid members who have a restricted benefit package are not reported separately but are included in Table XXX-1a (Total Medicaid). Therefore, the sum of Table XXX-1b (Medicaid/ Medicare Dual-Eligibles), Table XXX-1c (Disabled) and Table XXX-1d (Other Low Income) does not equal Table XXX-1a (Total Medicaid). Information on the categorization of Medicaid members will be provided to the organization by the state. If the state does not provide these data, the organization may report “Total Medicaid” only.

Report Medicare/Medicaid members (including “dual eligibles”) in Table XXX-1a, Table XXX-1b and Table XXX-3 only if they are enrolled in the organization’s Medicare contract required to report HEDIS and in the organization’s Medicaid managed-care contract.

**Commercial members.** Report “direct pay” and “group” members as commercial members. Table XXX-2 reports the organization’s commercial members.

6. **Calculating member months.** A table for reporting member months by age category (and gender category, if required) is provided for most measures. Complete the tables for all
members with the relevant benefit during the measurement year using the following
guidelines and formulas.

**Member months** are a member’s “contribution” to the total yearly membership.

**Note:** Cells in the reporting tables are shaded according to how data are reported:

- **No shading:** Data are reported by the organization
- **Light gray shading:** Data are calculated by the organization’s data reporting system (i.e. Onpoint).
- **Solid black shading:** Data are not used or reported.

<table>
<thead>
<tr>
<th>Reported by the organization</th>
<th>Calculated by Onpoint</th>
<th>Data not used</th>
</tr>
</thead>
</table>

**Step 1** Determine member months using a specified day of each month (e.g., the 15th or the last
day of the month), to be determined according to the organization’s administrative
processes. The day selected must be consistent from member to member, month to
month and from year to year. For example, if the organization tallies membership on the
15th of the month and Ms. X is enrolled in the organization on January 15, Ms. X
contributes one member month in January.

*Retroactive enrollment.* The organization may include any months in which members were
enrolled retrospectively and for which the organization received a retroactive capitation
payment.

**Step 2** Use the member’s age on the specified day of each month to determine the age group to
which member months will be contributed. For example, if an organization tallies
membership on the 15th of each month and Ms. X turns 25 on April 3 and is enrolled for
the entire year, then she contributes three member months (January, February and March)
to the 20–24 age category and nine member months to the 25–29 age category.

7. **Calculating member years.** Member years will be produced after the organization enters
member months data. Medicaid data remain in member months format.

**Member years** serve as a proxy for annual membership and are calculated as:

\[
\text{X member months} / 12 \text{ months} = \text{Y member years}
\]

8. **Matching enrollment with utilization.** Run enrollment reports used for member month
calculations to determine utilization rates (such as days/1,000 members per year) within
30 days of the claims reports and for the same time period. Include retroactive additions
and terminations in the reports.

Organizations that report utilization services must also report benefit enrollment (e.g.,
pharmacy and mental health member months).

9. **Reporting outpatient services.** To report outpatient procedures and services, count the
total number of specified services the organization paid for, or expects to pay for, during
the measurement year. Use the formulas and guidelines below to complete the tables:

**Age of members** Report age as of the date of service.
Counting multiple services

If a member receives the same service or procedure at two different times (e.g., CABG procedures six months apart), count them as two procedures. Count services, not the frequency of procedure codes billed (e.g., if a surgeon and a hospital submit separate bills pertaining to the same surgical episode with the same date of service, count only one).

Organizations must develop their own systems to avoid double counting.

Visits/1,000 member months

(Total visits/member months) x 1,000.

Visits/1,000 member years

(Total visits/member months) x 1,000 x 12.

10. Reporting inpatient services—discharges. Identify inpatient utilization and report by discharge date, rather than by admission date, and include all discharges that occurred during the measurement year, using the guidelines and formulas outlined below.

Age of members

Unless otherwise specified, report member age as of the date of service. If the service is an inpatient claim/encounter, use age as of the date of discharge.

Counting multiple services

If a patient receives the same service or procedure at two different times (e.g., CABG procedures six months apart), count them as two procedures. Count services, not the frequency of procedure codes billed (e.g., if a surgeon and a hospital submit separate bills pertaining to the same surgical episode with the same date of service, count only one).

Organizations must develop their own systems to avoid double counting.

Counting transfers

Treat transfers between institutions as separate admissions. Base transfer reports within an institution on the type and level of services provided. Report separate admissions when the transfer is between acute and nonacute levels of service or between mental health/chemical dependency services and non-mental health/chemical dependency services.

Count only one admission when the transfer takes place within the same service category but to a different level of care; for example, from intensive care to a lesser level of care or from a lesser level of care to intensive care.

Mental health and chemical dependency transfers

Count as a separate admission a transfer within the same institution but to a different level of care (e.g., a transfer between inpatient and residential care). Each level must appropriately include discharges and length of stay (count inpatient days under inpatient; count residential days under residential).

Discharges

Total discharges associated with specified diagnosis codes. If the organization cannot report by discharge date, report data by admission date and indicate the reason.
<table>
<thead>
<tr>
<th><strong>Discharges/1,000 member months</strong></th>
<th>(Total discharges/member months) × 1,000.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discharges/1,000 member years</strong></td>
<td>(Total discharges/member months) × 1,000 × 12.</td>
</tr>
<tr>
<td><strong>Discharges/1,000 female member months, stratified</strong></td>
<td>Member months within the particular age and gender category specified in each row of the table. For example, [(total discharges for female members 20–34) ÷ (member months of female members 20–34)] × 1,000.</td>
</tr>
<tr>
<td><strong>Discharges/1,000 female member years, stratified</strong></td>
<td>Members within the particular age and gender category specified in each row of the table. For example, [(total discharges for female members 20–34 years) ÷ (member months of female members 20–34)] × 1,000 × 12.</td>
</tr>
</tbody>
</table>

11. **Reporting inpatient services—length of stay and days.** Use the formulas below to report length of stay (LOS), average length of stay (ALOS) and total days:

**LOS**

All approved days from admission to discharge. The last day of the stay is not counted unless the admission and discharge date are the same.

LOS = discharge date – admit date – denied days.

**Note:** When an inpatient revenue code (i.e., UB or equivalent code) is associated with a stay, the LOS must equal at least one day. If the discharge date and the admission date are the same, then the discharge date minus admission date equals one day, not zero days.

**ALOS**

Total days/total discharges.

**Total days incurred**

The sum of the length of stay for all discharges during a measurement year. The total does not include the last day of the stay (unless the last day of stay is also the admit day) or denied days.

Total days incurred includes days before January 1 of the measurement year for discharge dates occurring during the measurement year.

Total days incurred does not include days during the measurement year that are associated with discharge dates in the year after the measurement year.

Total days incurred = Sum of LOS for each discharge during the measurement year.

**Total days incurred/1,000 member years**

(Total days incurred/member months) × 1,000 × 12.
**Ambulatory Care (AMB)**

**Measure Updates September 2020 for AMP MY 2020 and 2021**
- None.

**Modifications From HEDIS**
- None.

**Description**

This measure summarizes utilization of ambulatory care in the following categories:
- Outpatient Visits including telehealth.
- ED Visits.

*Note: Onpoint will run this measure for MY 2020 and 2021. Health plans and POs are not expected to report it.*

**Calculations**

*Note: Members in hospice are excluded from this measure. Refer to General Guideline 15: Members in Hospice.*

**Product lines**

Report the following tables for the Medi-Cal Managed Care product line:
- Table AMB-1a Total Medicaid.
- Table AMB-1b Medicaid/Medicare Dual-Eligibles.
- Table AMB-1c Medicaid—Disabled.
- Table AMB-1d Medicaid—Other Low Income

**Member months**

For each table, report all member months for the measurement year. Refer to Specific Instructions for Utilization Tables for more information.

**Counting multiple services**

*For combinations of multiple ambulatory services* falling in different categories on the same day, report each service that meets the criteria in the appropriate category.

**Outpatient visits including telehealth**

Identify outpatient visits using any of the following.
- Outpatient visits *(Ambulatory Outpatient Visits Value Set)*.
- Telephone visits *(Telephone Visits Value Set)*.
- E-visits or virtual check-ins *(Online Assessments Value Set)*.
Count multiple codes with the same practitioner on the same date of service as a single visit. Count visits with different practitioners separately (count visits with different providers on the same date of service as different visits).

Report services without regard to practitioner type, training or licensing.

**ED visits** Count each visit to an ED once, regardless of the intensity or duration of the visit. Count multiple ED visits on the same date of service as one visit. Identify ED visits using either of the following:

- An ED visit (ED Value Set).
- A procedure code (ED Procedure Code Value Set) with an ED place of service code (ED POS Value Set).

Do not include ED visits that result in an inpatient stay (Inpatient Stay Value Set).

**Exclusions (required)**

The measure does not include mental health or chemical dependency services. Exclude visits for mental health or chemical dependency. Any of the following meet criteria:

- A principal diagnosis of mental health or chemical dependency (Mental and Behavioral Disorders Value Set).
- Psychiatry (Psychiatry Value Set).
- Electroconvulsive therapy (Electroconvulsive Therapy Value Set).

**Note**

- *This measure provides a reasonable proxy for professional ambulatory encounters. It is neither a strict accounting of all ambulatory resources nor an effort to be all-inclusive.*
- *Supplemental data may not be used for this measure.*
**Table AMB-1: Ambulatory Care**

<table>
<thead>
<tr>
<th>Age</th>
<th>Member Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1</td>
<td></td>
</tr>
<tr>
<td>1-9</td>
<td></td>
</tr>
<tr>
<td>10-19</td>
<td></td>
</tr>
<tr>
<td>20-44</td>
<td></td>
</tr>
<tr>
<td>45-64</td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age</th>
<th>OUTPATIENT VISITS</th>
<th>ED VISITS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Visits</td>
<td>Visits/1,000 Member Months</td>
</tr>
<tr>
<td>&lt;1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10-19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-64</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Frequency of Selected Procedures (FSP)**

**Measure Updates September 2020 for AMP MY 2020 and 2021**
- Added a note about reporting the three procedures not included in the FSP-1a and FSP-2 tables.
- Updated the “Count as one procedure...” definition in the Calculations section.
- Updated the ordering of the procedures to align with the HEDIS specification.
- Removed the Member Months table and Procedures/1,000 Member Months column in the FSP-1a and FSP-2 tables.

**Modifications From HEDIS**
- The AMP FSP measure specification includes adjustment for age and sex and adjusted rates of procedures per 1,000 member years.
- Removed the Member Months table and Procedures/1,000 Member Months column in the FSP-1a and FSP-2 tables, as they are not used in AMP reporting.

**Description**
This measure summarizes the utilization of frequently performed procedures that often show wide regional variation and have generated concern regarding potentially inappropriate utilization. This measure is for internal reporting only.

Methodologies for adjusting for age/sex differences will be developed and tested. Adjusted rates of procedures will be reported per 1,000 member years.

The FSP risk adjustment methodology involves calculating an expected rate of procedures based on a member's age and gender that can be compared against the observed rate of procedures. This expected rate is based on a locally estimated scatterplot smoothing (LOESS) regression that is calculated and applied by Onpoint. Once the observed to expected ratio is calculated, this is translated back to a risk-standardized rate by applying the observed average rate of procedures for all of the AMP population. Note that the risk adjustment for FSP does not incorporate diagnosis information.

*Note:* Onpoint will run this measure for MY 2020 and 2021. Health plans and POs are not expected to report it.

**Calculations**
*Note:* Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

**Product lines**
- Report the following tables for the Commercial HMO/POS and Medi-Cal Managed Care product line
  - Table FSP-1a Total Medicaid*.
  - Table FSP-2 Commercial.

*Note:* For the three procedures not included in the FSP-1a or FSP-2 tables (Total hip replacement, Total knee replacement and Carotid endarterectomy), include all eligible members.
*Report this table for Total Medi-Cal Managed Care only; reporting by eligibility category will result in small numbers.

<table>
<thead>
<tr>
<th>Ages</th>
<th>All ages.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous enrollment</td>
<td>None. Include all members who are enrolled in a PO and in the health plan for one day or more during the measurement year.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>NA.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>None.</td>
</tr>
<tr>
<td>Benefit</td>
<td>Medical.</td>
</tr>
<tr>
<td>Measurement period</td>
<td>Calendar year. The measurement period is January 1–December 31.</td>
</tr>
<tr>
<td>Member years</td>
<td>Determine the PO’s total member years of enrollment in a health plan as the sum of the number of days during the measurement year when each eligible member was enrolled in the plan and the PO. For each PO, calculate member years by dividing the total member days by 365.</td>
</tr>
<tr>
<td>Procedures</td>
<td>Report counts for the procedures as specified regardless of the site of care (e.g., inpatient or ambulatory setting). Report the number of procedures rather than the number of members who had the procedures. Do not double-count the same procedure.</td>
</tr>
</tbody>
</table>

**Count as one procedure...** To avoid double counting events, all events must be at least 14 days apart. For example, If the date of service for a CABG is February 1, then the service date for the next CABG must be on or after February 15.

If there are two events within 14 days, include only the first procedure. For example, if the date of service for a CABG is February 1, include the February 1 CABG and do not include CABGs that occur on or between February 2 and February 14.

*For procedures that occur during an inpatient stay, use the date of service when identifying that events are at least 14 days apart.*

**Tonsillectomy**
Tonsillectomy (Tonsillectomy Value Set). Report tonsillectomy (with or without adenoidectomy).

Do not report adenoidectomy performed alone.

**Bariatric weight loss surgery**
Bariatric weight loss surgery (Bariatric Weight Loss Surgery Value Set). Report the number of bariatric weight loss surgeries.

**Hysterectomy**
Report abdominal and vaginal hysterectomy separately.

- Abdominal Hysterectomy Value Set.
- Vaginal Hysterectomy Value Set.

**Cholecystectomy**
Report open and laparoscopic cholecystectomy separately.

- Open Cholecystectomy Value Set.
- Laparoscopic Cholecystectomy Value Set.
Back surgery

Back surgery (Back Surgery Value Set). Report all spinal fusion and disc surgery, including codes relating to laminectomy with and without disc removal.

PCI

Percutaneous coronary intervention (PCI Value Set). Report all PCIs performed separately. Do not report PCI or cardiac catheterization performed in conjunction with (on the same date of service as) a CABG in the PCI rate or the cardiac catheterization rate; report only the CABG.

Cardiac catheterization

Cardiac catheterization (Cardiac Catheterization Value Set). Report all cardiac catheterizations performed separately. Do not report a cardiac catheterization performed in conjunction with (on the same date of service as) an PCI in the cardiac catheterization rate; report only the PCI.

Do not report PCI or cardiac catheterization performed in conjunction with (on the same date of service as) a CABG in the PCI rate or the cardiac catheterization rate; report only the CABG.

CABG

Coronary artery bypass graft (CABG Value Set). Report each CABG only once for each date of service per patient, regardless of the number of arteries involved or the number or types of grafts involved.

Do not report PCI or cardiac catheterization performed in conjunction with (on the same date of service as) a CABG in the PCI rate or the cardiac catheterization rate; report only the CABG.

Prostatectomy

Prostatectomy (Prostatectomy Value Set). Report the number of prostatectomies.

Total hip replacement

Total hip replacement (Total Hip Replacement Value Set). Report the number of total hip replacements.

Total knee replacement

Total knee replacement (Total Knee Replacement Value Set). Report the number of total knee replacements.

Carotid endarterectomy

Carotid endarterectomy (Carotid Endarterectomy Value Set). Report the number of carotid endarterectomies.

Mastectomy

Report the number of mastectomies. Report bilateral mastectomy procedures as two procedures.

Identify unilateral mastectomies using any of the following:

- Unilateral Mastectomy Value Set.
- Unilateral Mastectomy Left Value Set.
- Unilateral Mastectomy Right Value Set.

Identify bilateral mastectomies using either of the following:

- Bilateral mastectomy (Bilateral Mastectomy Value Set).
- Unilateral mastectomy (Unilateral Mastectomy Value Set) with a bilateral modifier (Bilateral Modifier Value Set).
- Both of the following on the same date of service:
- Unilateral mastectomy (Unilateral Mastectomy Value Set) with a left-side modifier (Left Modifier Value Set) (same procedure).
- Unilateral mastectomy (Unilateral Mastectomy Value Set) with a right-side modifier (Right Modifier Value Set) (same procedure).

**Lumpectomy**  Lumpectomy (Lumpectomy Value Set). Report the number of lumpectomies.

**Note**

- Supplemental data may not be used for this measure.

**Table FSP-1a: Frequency of Selected Procedures**

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Age</th>
<th>Sex</th>
<th>Number of Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bariatric weight loss surgery</td>
<td>0-19</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20-44</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Tonsillectomy</td>
<td>0-9</td>
<td>Male and Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10-19</td>
<td>Male and Female</td>
<td></td>
</tr>
<tr>
<td>Hysterectomy, abdominal</td>
<td>15-44</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Hysterectomy, vaginal</td>
<td>15-44</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Cholecystectomy, open</td>
<td>30-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15-44</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td>Cholecystectomy, (laparoscopic)</td>
<td>30-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15-44</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Back surgery</td>
<td>20-44</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Mastectomy</td>
<td>15-44</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Lumpectomy</td>
<td>15-44</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Female</td>
<td></td>
</tr>
</tbody>
</table>
Table FSP-2: Frequency of Selected Procedures

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Age</th>
<th>Sex</th>
<th>Number of Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bariatric weight loss surgery</td>
<td>0-19</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20-44</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Tonsillectomy</td>
<td>0-9</td>
<td>Male and Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10-19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hysterectomy, abdominal</td>
<td>15-44</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hysterectomy, vaginal</td>
<td>15-44</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholecystectomy, open</td>
<td>30-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15-44</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholecystectomy, (laparoscopic)</td>
<td>30-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15-44</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedure</td>
<td>Age</td>
<td>Sex</td>
<td>Number of Procedures</td>
</tr>
<tr>
<td>--------------------</td>
<td>------</td>
<td>-------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Back surgery</td>
<td>20-44</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>PCI</td>
<td>45-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Cardiac catheterization</td>
<td>45-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>45-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Prostatectomy</td>
<td>45-64</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td>Mastectomy</td>
<td>15-44</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Lumpectomy</td>
<td>15-44</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45-64</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>65+</td>
<td>Female</td>
<td></td>
</tr>
</tbody>
</table>
Measure Updates September 2020 for AMP MY 2020 and 2021

- None.

Modifications From HEDIS

- None.

Description

This measure summarizes utilization of acute inpatient care and services in the following categories:

- Maternity.
- Surgery.
- Medicine.
- Total inpatient (the sum of Maternity, Surgery and Medicine).

Note: Onpoint will run this measure for MY 2020 and 2021. Health plans and POs are not expected to report it.

Calculations

Note: Members in hospice are excluded from this measure. Refer to General Guideline 15: Members in Hospice.

Product lines

Report the following tables for the Medi-Cal Managed Care product line:

- Table IPU-1a Total Medicaid.
- Table IPU-1b Medicaid/Medicare Dual-Eligibles.
- Table IPU-1c Medicaid—Disabled.
- Table IPU-1d Medicaid—Other Low Income.

Member months

For each table, report all member months for the measurement year. Refer to Specific Instructions for Utilization Tables for more information.

Maternity rates are reported per 1,000 males and per 1,000 female total member months for members 10–64 years in order to capture deliveries as a percentage of the total inpatient discharges.

Days

Count all days associated with the identified discharges. Report days for total inpatient, maternity, surgery and medicine.

ALOS

Refer to Specific Instructions for Utilization Tables for the formula. Calculate average length of stay for total inpatient, maternity, surgery and medicine.
Use the following steps to identify and categorize inpatient discharges.

**Step 1** Identify all acute inpatient discharges on or between January 1 and December 31 of the measurement year. To identify acute inpatient discharges:
1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
3. Identify the discharge date for the stay.

**Step 2** Exclude discharges with a principal diagnosis of mental health or chemical dependency (Mental and Behavioral Disorders Value Set) on the discharge claim.

Exclude newborn care rendered from birth to discharge home from delivery (only include care rendered during subsequent rehospitalizations after the delivery discharge). Identify newborn care by a principal diagnosis of live-born infant (Deliveries Infant Record Value Set). Organizations must develop methods to differentiate between the mother’s claim and the newborn’s claim, if needed.

**Step 3** Report total inpatient, using all discharges identified after completing steps 1 and 2.

**Step 4** Report maternity. A delivery is not required for inclusion in the Maternity category; any maternity-related stay is included. Include birthing center deliveries and count them as one day of stay.

Starting with all discharges identified in step 3, identify maternity using either of the following:
- A maternity-related principal diagnosis (Maternity Diagnosis Value Set).
- A maternity-related stay (Maternity Value Set).

**Step 5** Report surgery. From discharges remaining after removing maternity (identified in step 4) from total inpatient (identified in step 3), identify surgery (Surgery Value Set).

**Step 6** Report medicine. Categorize as medicine the discharges remaining after removing maternity (identified in step 4) and surgery (identified in step 5) from total inpatient (identified in step 3).

**Note**
- Supplemental data may not be used for this measure.
Table IPU-1: Inpatient Utilization—General Hospital/Acute Care

<table>
<thead>
<tr>
<th>Age</th>
<th>Member Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1</td>
<td></td>
</tr>
<tr>
<td>1-9</td>
<td></td>
</tr>
<tr>
<td>10-19</td>
<td></td>
</tr>
<tr>
<td>20-44</td>
<td></td>
</tr>
<tr>
<td>45-64</td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age</th>
<th>Discharges</th>
<th>Discharges/1,000 Member Months</th>
<th>Days</th>
<th>Days/1,000 Member Months</th>
<th>Average Length of Stay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Inpatient</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-44</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-64</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Maternity* |            |                                 |      |                          |                        |
| 10-19 |        |                                 |      |                          |                        |
| 20-44 |       |                                 |      |                          |                        |
| 45-64 |       |                                 |      |                          |                        |
| Unknown |        |                                 |      |                          |                        |
| Total |            |                                 |      |                          |                        |

| Surgery |            |                                 |      |                          |                        |
| <1  |            |                                 |      |                          |                        |
| 1-9 |            |                                 |      |                          |                        |
| 10-19 |        |                                 |      |                          |                        |
| 20-44 |       |                                 |      |                          |                        |
| 45-64 |       |                                 |      |                          |                        |
| 65-74 |       |                                 |      |                          |                        |
| 75-84 |       |                                 |      |                          |                        |
| 85+  |            |                                 |      |                          |                        |
| Unknown |        |                                 |      |                          |                        |
| Total |            |                                 |      |                          |                        |

*The Maternity category is calculated using member months for members 10–64 years.
<table>
<thead>
<tr>
<th>Age</th>
<th>Discharges</th>
<th>Discharges/1,000 Member Months</th>
<th>Days</th>
<th>Days/1,000 Member Months</th>
<th>Average Length of Stay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-44</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-64</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Generic Prescribing (GRX)

Measure Updates September 2020 for AMP MY 2020 and 2021

- None.

Modifications From HEDIS

- This is a non-HEDIS measure.

Description

The level of generic prescribing will be measured as a simple prescription rate for overall generic prescriptions:

<table>
<thead>
<tr>
<th>Generic Prescribing Rate</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>All drugs, excluding injectables</td>
</tr>
</tbody>
</table>

Plan-defined definitions of “brand” and “generic” will be used to calculate the measure, based on how a prescription was paid, and will accommodate plan-specific contracting arrangements that price brand-name drugs at generic rates.

Note: Onpoint will run this measure for MY 2020 and 2021. Health plans and POs are not expected to report it.

Eligible Population

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

- Product lines: Commercial HMO/POS and Medi-Cal Managed Care (report each product line separately).
- Ages: All ages.
- Continuous enrollment: None. Because the denominator of this measure is based on prescriptions, not on members, there is no continuous enrollment requirement.
- Benefit: Members must have pharmacy benefits coverage on the fill date of the prescription. The measure is based on all pharmacy claims received by participating health plans for members enrolled in the PO at any point in the measurement year. Pharmacy claims are attributed to a PO if the member was enrolled in the PO on the fill date on the pharmacy claim.
- Measurement period: Calendar year. The measurement period is January 1–December 31.
Measure Definition 1: Overall Generic Prescribing Rate

Overall Generic Prescribing Rate =  
\[
\frac{\text{Number of Prescriptions for All Generic Drugs}}{\text{Number of Prescriptions for All Drugs}}
\]

A prescription reflects a 30-day supply or less. To account for multi-month fills (i.e. days supplied exceeds 30 days) divide the days’ supply by 30 and round down to the nearest whole number. For example, a 100-day supply is equal to three prescriptions (100/30 = 3.33, rounded down to 3).

Denominator

**Step 1** Identify all *paid* pharmacy claims for members enrolled in the PO at any point during the measurement year.

**Step 2** Ensure that the member was enrolled in the PO on the fill date and had pharmacy benefits coverage.

**Step 3** Identify the NDC code for the drug filled on the prescription.

**Step 4** Identify and exclude claims for self-injectable drugs.

**Step 5** All other paid pharmacy claims are included in the denominator.

Numerator

**Step 1** *For all prescriptions in the denominator*, determine whether the prescription was filled with a generic version of the drug or with a brand drug priced as a generic for that therapeutic area. This is determined by a flag supplied by the health plan on the pharmacy claim, indicating whether the drug was a generic or a brand drug priced as a generic.

**Step 2** Count the prescription in the numerator if it was filled with a generic drug.
Outpatient Procedures Utilization—Percentage Done in Preferred Facility (OSU)

Measure Updates September 2020 for AMP MY 2020 and 2021

• None.

Modifications From HEDIS

• This is a non-HEDIS measure based on a former HEDIS Utilization measure.

Description

This measure summarizes utilization of preferred facilities for outpatient/ambulatory procedures. (Outpatient surgeries are included in the definition of “procedures.”) One metric will be reported for each PO:

• Percentage of outpatient procedures performed in a preferred facility (by plan).

No risk adjustment will be applied.

Note: Onpoint will run this measure for MY 2020 and 2021. Health plans and POs are not expected to report it.

Eligible Population

Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Product lines Commercial HMO/POS and Medi-Cal Managed Care (report each product line separately).

Ages All ages.

Continuous enrollment None.

Allowable gap NA because there is no continuous enrollment requirement.

Anchor date None.

Benefit Medical.

Measurement period Calendar year. The measurement period is January 1–December 31.

Total outpatient procedures Count the total number of ambulatory surgery/procedure encounters/claims. A claim with a code from any of the following value set combinations meet the criteria.

• Ambulatory Surgery Option A Value Set with Ambulatory Surgery UBTOB Value Set.
Report only outpatient procedures performed at a hospital outpatient facility or at a free-standing surgery center, which will be identified by Bill Type = 83x or 13x in the medical claims submission by health plans to Onpoint Health Data. Professional claims are not used to identify outpatient procedures.

Count multiple outpatient procedures on the same date of service as one ambulatory procedure.

Exclusions (required)

- Exclude claims and encounters that indicate the encounter was for mental health or chemical dependency. Any of the following meet criteria.
  - A principal diagnosis of mental health or chemical dependency (Mental and Behavioral Disorders Value Set).
  - Psychiatry (Psychiatry Value Set).
  - Electroconvulsive therapy (Electroconvulsive Therapy Value Set).
- ED visits are not included in the measure. Identify ED visits using either of the following:
  - An ED visit (ED Value Set).
  - An ED procedure code (ED Procedure Code Value Set) with an ED place of service code (ED POS Value Set).

Outpatient Procedures Calculation

Step 1 Identify the denominator.

1a Identify the total number of ambulatory surgery/procedure encounters/claims using the value set below.

- Ambulatory Surgery Option A Value Set with Ambulatory Surgery UBTOB Value Set.

1b Report only outpatient procedures performed at a hospital outpatient facility or at a free-standing surgery center. Ambulatory surgery/procedures performed at a hospital outpatient facility or at a free-standing surgery center are identified by Bill Type = 83x or 13x in the medical claims submission from health plans to Onpoint Health Data.

Step 2 Identify the numerator. Count the total number of ambulatory surgery/procedures performed at a preferred facility. A preferred facility is a contracted, free-standing ambulatory surgery center (ASC) (i.e. Bill Type = 83x and Contracted Outpatient Facility Flag =1 in medical claims submission).

Hospital outpatient facilities will be considered “non-preferred”.

Step 3 Calculate the observed rate for each PO.

Observed rate = number of ambulatory surgery/procedures performed at a preferred facility divided by the total number of ambulatory surgery/procedure encounters/claims performed at a hospital outpatient facility or at a free-standing surgery center.

Separate rates will be calculated for each health plan and aggregated across all contracted health plans.
Guidelines for HEDIS Risk Adjusted Utilization Measures

The following guidelines are specific to the HEDIS risk adjusted utilization measures in the Resource Use Domain:

- All-Cause Readmissions (PCR).
- Emergency Department Utilization (EDU).
- Acute Hospital Utilization (AHU).

**Note:** The HCC Risk Adjustment tables for Measurement Year 2020 are available for free order in the NCQA Store (http://store.ncqa.org/index.php/catalog/product/view/id/3761/s/hedis-my-2020-risk-adjustment-tables/).

Once ordered, the HCC Risk Adjustment tables for HEDIS MY 2020 will be made available in the My Downloads section of My NCQA (https://my.ncqa.org/Downloads) by November 1, 2020.

The HCC Risk Adjustment tables for Measurement Year 2021 are available for free order in the NCQA Store (http://store.ncqa.org/index.php/catalog/product/view/id/3762/s/hedis-my-2021-risk-adjustment-tables/).

Once ordered, the HCC Risk Adjustment tables for HEDIS MY 2021 will be made available in the My Downloads section of My NCQA (https://my.ncqa.org/Downloads) by March 31, 2021.

**GUIDANCE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021**

- Renamed the Utilization Risk Adjustment Determination section to Risk Adjustment Comorbidity Category Determination.
- Added telephone visits to Risk Adjustment Comorbidity Category Determination.
- Replaced references to “encounters” with “denominator units” in the Risk Adjustment Comorbidity Category Determination section.
- Replaced references to “Table CC-Comorbid” with “Table CC-Mapping” in the Risk Adjustment Comorbidity Category Determination section.
- Replaced references to “HCC column” with “Comorbid HCC columns” in step 5 in the Risk Adjustment Comorbidity Category Determination section.
- Updated the Example: Table HCC—Comb in step 5 in the Risk Adjustment Comorbidity Category Determination section.

**Guidelines**

1. **Which services count?** Include all services, whether or not the organization paid for them or expects to pay for them (include denied claims) when applying risk adjustment in the Risk Adjusted Utilization measures (PCR, AHU, EDU). *Do not include* denied services (only include paid services and services expected to be paid) when identifying all other events (e.g., the IHS in the PCR measure or observed events in the other risk adjusted utilization measures).

When confirming that an ED visit does not result in an inpatient stay, all inpatient stays must be considered, regardless of payment status (paid, suspended, pending, denied). For example, if an ED visit is paid but an inpatient stay is denied, the ED visit resulted in an inpatient stay and is not included in the EDU measure when identifying observed ED visits.

The organization may have:

- Covered the full amount.
• Paid only a portion of the amount (e.g., 80 percent).
• Paid nothing because the member covered the entire amount to meet a deductible.
• Paid nothing because the service was covered as part of a PMPM payment.
• Denied the service.

Count the service as paid or expected to be paid if:
• The organization paid the full amount or a portion of the amount (e.g., 80 percent).
• The member paid for the service as part of the benefit offering (e.g., to meet a deductible), or
• The service was covered under a PMPM payment.

Count the service as denied if:
• The organization denied the service for any reason, unless the member paid for the service as part of the benefit offering (e.g., to meet a deductible), or
• The claim for the service was rejected because it was missing information or was invalid for another reason.

2. Risk adjustment. Organizations may not use supplemental data sources when applying the risk adjustment methodology.

Organizations may not use Risk Assessment Protocols to supplement diagnoses for calculation of the risk adjustment scores for these measures. The measurement model was developed and tested using only claims-based diagnoses and diagnoses from additional data sources would affect the validity of the models as they are currently implemented in the specification.

3. Counting transfers. Unless otherwise specified in the measure, treat transfers between institutions as separate admissions. Base transfer reports within an institution on the type and level of services provided. Report separate admissions when the transfer is between acute and nonacute levels of service or between mental health/chemical dependency services and non-mental health/chemical dependency services.

Count only one admission when the transfer takes place within the same service category but to a different level of care; for example, from intensive care to a lesser level of care or from a lesser level of care to intensive care.

4. Mental health and chemical dependency transfers. Unless otherwise specified in the measure, count as a separate admission a transfer within the same institution but to a different level of care (e.g., a transfer between inpatient and residential care). Each level must appropriately include discharges and length of stay (count inpatient days under inpatient; count residential days under residential).

5. Observation stays without discharge date. For observation stays (Observation Stay Value Set) that do not have a recorded discharge date, set the discharge date to the last date of service on the claim.

6. Direct transfers. A direct transfer is when the discharge date from the initial stay precedes the admission date to a subsequent stay by one calendar day or less. For example:
• A discharge on June 1, followed by a subsequent admission on June 1, is a direct transfer.
• A discharge on June 1, followed by a subsequent admission on June 2, is a direct transfer.
• A discharge on June 1, followed by a subsequent admission on June 3, is not a direct transfer; these are two distinct stays.
• A discharge on June 1, followed by a subsequent admission on June 2 (with discharge on June 3), followed by a subsequent admission on June 4, is a direct transfer.
Direct transfers may occur from and between different facilities and/or different service levels. Refer to individual measure specification for details.

**Risk Adjustment Comorbidity Category Determination**

**Step 1** Identify all diagnoses for encounters during the classification period for each denominator unit of the measure (i.e. denominator event or member). Include the following when identifying encounters:
- Outpatient visits (Outpatient Value Set).
- Telephone visits (Telephone Visits Value Set).
- Observation visits (Observation Value Set).
- ED visits (ED Value Set).
- Inpatient events:
  - Nonacute inpatient encounters (Nonacute Inpatient Value Set).
  - Acute inpatient encounters (Acute Inpatient Value Set).
  - Acute and nonacute inpatient discharges (Inpatient Stay Value Set).

Use the date of service for outpatient, observation and ED visits. Use the discharge date for inpatient events.

For PCR, exclude the primary discharge diagnosis on the IHS.

**Step 2** Assign each diagnosis to a comorbid Clinical Condition (CC) category using Table CC—Mapping. If the code appears more than once in Table CC—Mapping, it is assigned to multiple CCs.

Exclude all diagnoses that cannot be assigned to a comorbid CC category. For members with no qualifying diagnoses from face-to-face encounters, skip to the Risk Adjustment Weighting section.

All digits must match exactly when mapping diagnosis codes to the comorbid CCs.

**Step 3** Determine HCCs for each comorbid CC identified. Refer to Table HCC—Rank.

For each denominator unit’s comorbid CC list, match the comorbid CC code to the comorbid CC code in the table, and assign:
- The ranking group.
- The rank.
- The HCC.

For comorbid CCs that do not match to Table HCC—Rank, use the comorbid CC as the HCC and assign a rank of 1.

*Note: One comorbid CC can map to multiple HCCs; each HCC can have one or more comorbid CCs.*

**Step 4** Assess each ranking group separately and select only the highest ranked HCC in each ranking group using the “Rank” column (1 is the highest rank possible).

Drop all other HCCs in each ranking group, and de-duplicate the HCC list if necessary.
Example  Assume an encounter with the following comorbid CCs: CC-85, CC-17 and CC-19 (assume no other CCs).

- CC-85 does not have a map to the ranking table and becomes HCC-85.
- HCC-17 and HCC-19 are part of Diabetes Ranking Group 1. Because CC-17 is ranked higher than CC-19 in Ranking Group Diabetes 1, the comorbidity is assigned as HCC-17 for Ranking Group 1.
- The final comorbidities for this denominator unit are HCC-17 and HCC-85.

Example: Table HCC—Rank

<table>
<thead>
<tr>
<th>Ranking Group</th>
<th>CC</th>
<th>Description</th>
<th>Rank</th>
<th>HCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>NA</td>
<td>CC-85</td>
<td>Congestive Heart Failure</td>
<td>NA</td>
<td>HCC-85</td>
</tr>
<tr>
<td>Diabetes 1</td>
<td>CC-17</td>
<td>Diabetes With Acute Complications</td>
<td>1</td>
<td>HCC-17</td>
</tr>
<tr>
<td></td>
<td>CC-18</td>
<td>Diabetes With Chronic Complications</td>
<td>2</td>
<td>HCC-18</td>
</tr>
<tr>
<td></td>
<td>CC-19</td>
<td>Diabetes Without Complication</td>
<td>3</td>
<td>HCC-19</td>
</tr>
</tbody>
</table>

Step 5  Identify combination HCCs listed in Table HCC—Comb.

Some combinations suggest a greater amount of risk when observed together. For example, when diabetes and CHF are present, an increased amount of risk is evident. Additional HCCs are selected to account for these relationships.

Compare each denominator unit’s list of unique HCCs to those in the Comorbid HCC columns in Table HCC—Comb and assign any additional HCC conditions.

If there are fully nested combinations, use only the more comprehensive pattern. For example, if the diabetes/CHF combination is nested in the diabetes/CHF/renal combination, count only the diabetes/CHF/renal combination.

If there are overlapping combinations, use both sets of combinations. Based on the combinations, a denominator unit can have none, one or more of these added HCCs.

Example  For a denominator unit with comorbidities HCC-17 and HCC-85 (assume no other HCCs), assign HCC-901 in addition to HCC-17 and HCC-85. This does not replace HCC-17 and HCC-85.

Example: Table HCC—Comb

<table>
<thead>
<tr>
<th>Comorbid HCC 1</th>
<th>Comorbid HCC 2</th>
<th>Comorbid HCC 3</th>
<th>HCC-Combination</th>
<th>HCC-Comb Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCC-17</td>
<td>HCC-85</td>
<td>NA</td>
<td>HCC-901</td>
<td>Combination: Diabetes and CHF</td>
</tr>
<tr>
<td>HCC-18</td>
<td>HCC-85</td>
<td>NA</td>
<td>HCC-901</td>
<td>Combination: Diabetes and CHF</td>
</tr>
<tr>
<td>HCC-19</td>
<td>HCC-85</td>
<td>NA</td>
<td>HCC-901</td>
<td>Combination: Diabetes and CHF</td>
</tr>
</tbody>
</table>
All-Cause Readmissions (PCR)

MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021

- Revised the measure description.
- Added a Note to the definition of “plan population” to clarify that it should be used as a denominator for the outlier rate.
- Removed “Risk Adjustment Tables” from the Definitions.
- Replaced references to “Table HCC-Surg” with references to the “Surgery Procedure Value Set” in the Risk Adjustment Determination section.
- Replaced references to “Table PCR-DischCC” with “Table CC_Mapping” in the Risk Adjustment Determination section.
- Removed references to specific risk weight tables in the Risk Adjustment Weighting section.
- Clarified rounding rules in step 8 of the Risk Adjustment Weighting section.
- Revised the data element tables to separate the Medicaid and commercial product lines from the Medicare product line.

MODIFICATIONS FROM HEDIS

- The 18–64 age band is not reported for Medicare Advantage.
- NCQA refers to this measure as “Plan All-Cause Readmissions.”
- Expected rates are normalized by Onpoint to reflect the performance of the population being measured (e.g., Commercial HMO/POS or Medicare Advantage).
- The Skilled Nursing Care and SES Stratification for the Medicare Advantage product line is not reported.

Description

All-Cause Readmissions is the same measure as the CMS Stars measure Plan All-Cause Readmissions.

For members 18 years of age and older, the number of acute inpatient and observation stays during the measurement year that were followed by an unplanned acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission.

POs and health plans are not expected to run this measure. For reporting purposes, expected rates are normalized to reflect the performance of the population being measured (e.g., Commercial HMO/POS or Medicare Advantage). Onpoint will calculate the expected rates and normalize reflect the performance of the population being measured.

Note: For Commercial HMO/POS, Commercial ACOs and Medi-Cal Managed Care, report only members 18–64 years of age. For Medicare Advantage, report only members 65 years of age and older.

Definitions

IHS

Index hospital stay. An acute inpatient or observation stay with a discharge on or between January 1 and December 1 of the measurement year, as identified in the denominator.
**MY 2020 and 2021 AMP Appropriate Resource Use Specifications: All-Cause Readmissions**

### Index Admission Date
The IHS admission date.

### Index Discharge Date
The IHS discharge date. The index discharge date must occur on or between January 1 and December 1 of the measurement year.

### Index Readmission Stay
An acute inpatient or observation stay for any diagnosis with an admission date within 30 days of a previous Index Discharge Date.

### Index Readmission Date
The admission date associated with the Index Readmission Stay.

### Planned hospital stay
A hospital stay is considered planned if it meets criteria as described in step 3 (required exclusions) of the numerator.

### Plan population
Members who meet all of the following criteria:
- 18 and older as of January 1 of the measurement year.
- Continuously enrolled for at least 395 days, with no more than one gap in enrollment of up to 45 days during the 395-day period, between January 1 of the year prior to the measurement year and December 1 of the measurement year.

Assign members to the product and product line at the start of this defined continuous enrollment period.

**Note:** The plan population is only used as a denominator for the Outlier Rate.

### Outlier
Medi-Cal Managed Care and Medicare Advantage members in the eligible population with four or more index hospital stays on or between January 1 and December 1 of the measurement year.

Commercial members in the eligible population with three or more index hospital stays between January 1 and December 1 of the measurement year.

Assign members who transition between product lines during the measurement year to the product they were enrolled in on January 1 of the measurement year. If the member is an outlier and has a gap on January 1 of the measurement year, the member is assigned to the product line based on their last enrollment segment prior to January 1.

### Nonoutlier
Members in the plan population who are not considered outliers.

### Classification Period
365 days prior to and including an Index Discharge Date.

### Eligible Population

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Refer to General Guideline 52: Reporting for small denominator limits.
Product line: Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).

Ages:
- For Commercial HMO/POS, ages 18–64 as of the Index Discharge Date.
- For Commercial ACO, ages 18–64 as of the Index Discharge Date.
- For Medicare, ages 65 and older as of the Index Discharge Date.
- For Medicaid, ages 18–64 as of the Index Discharge Date.

Continuous enrollment: 365 days prior to the Index Discharge Date through 30 days after the Index Discharge Date in the health plan and PO (parent level).

Allowable gap: No more than one gap in enrollment of up to 45 days during the 365 days prior to the Index Discharge Date and no gap during the 30 days following the Index Discharge date.

Anchor date: Index Discharge Date for the health plan and the PO (parent level, or, for eligible POs, subgroup level).

Benefit: Medical.

Event/diagnosis: An acute inpatient or observation stay discharge on or between January 1 and December 1 of the measurement year. The denominator for this measure is based on discharges, not members. Include all acute inpatient or observation stay discharges for nonoutlier members who had one or more discharges on or between January 1 and December 1 of the measurement year. Follow the steps below to identify acute inpatient and observation stays.

Administrative Specification

Denominator: The eligible population.

**Step 1** Identify all acute inpatient and observation stay discharges on or between January 1 and December 1 of the measurement year. To identify acute inpatient and observation stay discharges:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set) and observation stays (Observation Stay Value Set).
2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
3. Identify the discharge date for the stay.

Inpatient and observation stays where the discharge date from the first setting and the admission date to the second setting are two or more calendar days apart must be considered distinct stays.

The measure includes acute discharges from any type of facility (including behavioral healthcare facilities).

**Step 2** Direct transfers: For discharges with one or more direct transfers, use the last discharge.
Using the discharges identified in step 1, identify direct transfers between acute inpatient and observation or between observation and acute inpatient using the definition found in the Guidelines for Risk Adjusted Utilization Measures.

Exclude the hospital stay if the direct transfer's discharge date occurs after December 1 of the measurement year.

**Step 3** Exclude hospital stays where the Index Admission Date is the same as the Index Discharge Date.

**Step 4** Exclude hospital stays for the following reasons:
- The member died during the stay.
- Female members with a principal diagnosis of pregnancy (Pregnancy Value Set) on the discharge claim.
- A principal diagnosis of a condition originating in the perinatal period (Perinatal Conditions Value Set) on the discharge claim.

*Note:* For hospital stays where there was a direct transfer (identified in step 2), use the original stay and any direct transfer stays to identify exclusions in this step.

**Step 5** Calculate continuous enrollment.

**Step 6** Remove hospital stays for outlier members and report these members as outliers in Table PCR-1/2/3.

*Note:* Count discharges with one or more direct transfers (identified in step 2) as one discharge when identifying outlier members.

**Step 7** Assign each remaining acute inpatient or observation stay to an age and stratification category using the reporting instructions below.

**Risk Adjustment Determination**

For each IHS among nonoutlier members, use the following steps to identify risk adjustment categories based on presence of observation stay status at discharge, surgeries, discharge condition, comorbidity, age and gender.

**Observation Stay** Determine if the IHS at discharge was an observation stay (Observation Stay Value Set). For direct transfers, determine the hospitalization status using the last discharge.

**Surgeries** Determine if the member underwent surgery during the stay (Surgery Procedure Value Set) Consider an IHS to include a surgery if at least one procedure code is present from any provider between the admission and discharge dates.

**Discharge condition** Assign a discharge Clinical Condition (CC) category code or codes to the IHS based on its primary discharge diagnosis, using Table CC_Mapping. For direct transfers, use the primary discharge diagnosis from the last discharge.

Exclude diagnoses that cannot be mapped to Table CC_Mapping.

**Comorbidities** Refer to the Risk Adjustment Comorbidity Category Determination in the Guidelines for Risk Adjusted Utilization Measures.
Risk Adjustment Weighting

For each IHS among nonoutliers, use the following steps to identify risk adjustment weights based on observation stays status at discharges, surgeries, discharge condition, comorbidity, age and gender. Weights are specific to product line (Medicare Advantage 65+, commercial, Medi-Cal Managed Care). Refer to the reporting indicator column in the risk adjustment tables to ensure that weights are linked appropriately.

**Step 1** For each IHS discharge that is an observation stay, link the observation stay IHS weight.

**Step 2** For each IHS with a surgery, link the surgery weight.

**Step 3** For each IHS with a discharge CC Category, link the primary discharge weights.

**Step 4** For each IHS with a comorbidity HCC Category, link the comorbidity weights.

**Step 5** Link the age and gender weights for each IHS.

**Step 6** Sum all weights associated with the IHS (i.e., observation stay, presence of surgery, primary discharge diagnosis, comorbidities, age and gender) and use the formula below to calculate the Estimated Readmission Risk for each IHS:

\[
\text{Estimated Readmission Risk} = \frac{e^{\sum \text{Weights For IHS}}}{1 + e^{\sum \text{Weights For IHS}}} \quad \text{OR} \quad \frac{\exp(\text{sum of weights for IHS})}{1 + \exp(\text{sum of weights for IHS})}
\]

**Note:** “Exp” refers to the exponential or antilog function.

**Step 7** Calculate the Count of Expected Readmissions for each age and stratification category. The Count of Expected Readmissions is the sum of the Estimated Readmission Risk calculated in step 6 for each IHS in each age and stratification category.

\[
\text{Count of Expected Readmissions} = \sum \text{(Estimated Readmission Risk)}
\]

**Step 8** Use the formula below and the Estimated Readmission Risk calculated in step 6 to calculate the variance for each IHS.

\[
\text{Variance} = \text{Estimated Readmission Risk} \times (1 - \text{Estimated Readmission Risk})
\]

**Example:** If the Estimated Readmission Risk is 0.1518450741 for an IHS, then the variance for this IHS is 0.1518450741 \times 0.8481549259 = 0.1287881476.

**Note:** When calculating variance at the IHS level, do not round. Organizations must sum the variances for each stratification and age when populating the Variance cells in the reporting tables. When reporting, round the variance to 4 decimal places using the .5 rule.

**Numerator** At least one acute readmission for any diagnosis within 30 days of the Index Discharge Date.
Step 1 Identify all acute inpatient and observation stays with an admission date on or between January 3 and December 31 of the measurement year. To identify acute inpatient and observation admissions:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set) and observation stays (Observation Stay Value Set).
2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
3. Identify the admission date for the stay.

Step 2 Direct transfers: For discharges with one or more direct transfers, use the last discharge.

Using the discharges identified in step 1, identify direct transfers between acute inpatient and observation or between observation and acute inpatient using the definition found in the Guidelines for Risk Adjusted Utilization Measures.

Step 3 Exclude acute hospitalizations with any of the following criteria on the discharge claim:

- Female members with a principal diagnosis of pregnancy (Pregnancy Value Set).
- A principal diagnosis for a condition originating in the perinatal period (Perinatal Conditions Value Set).
- Planned admissions using any of the following:
  - A principal diagnosis of maintenance chemotherapy (Chemotherapy Encounter Value Set).
  - A principal diagnosis of rehabilitation (Rehabilitation Value Set).
  - An organ transplant (Kidney Transplant Value Set, Bone Marrow Transplant Value Set, Organ Transplant Other Than Kidney Value Set, Introduction of Autologous Pancreatic Cells Value Set).
  - A potentially planned procedure (Potentially Planned Procedures Value Set) without a principal acute diagnosis (Acute Condition Value Set).

Note: For hospital stays where there was a direct transfer (identified in step 2), use the original stay and any direct transfer stays to identify exclusions in this step.

Step 4 For each IHS identified in the denominator, determine if any of the acute inpatient and observation stays identified in the numerator have an admission date within 30 days after the Index Discharge Date.

Note: Count each acute hospitalization only once toward the numerator, for the last denominator event.

If a single numerator event meets criteria for multiple denominator events, only count the last denominator event. For example, consider the following events:

- Acute inpatient stay 1: May 1–10.
- Acute inpatient stay 2: May 15–25 (principal diagnosis of maintenance chemotherapy).

All three acute inpatient stays are included as denominator events. Stay 2 is excluded from the numerator because it is a planned hospitalization. Stay 3 is within 30 days of Stay 1 and Stay 2. Count Stay 3 as a numerator event only toward the last denominator event (Stay 2, May 15–25).
**Reporting: Number of Members in Plan Population**

**Step 1** Determine member age as of January 1 of the measurement year.

**Step 2** Report the count of members in the plan population for each age group and the overall total. Enter these values in reporting Tables PCR-1/2 and PCR-A-3.

**Reporting: Number of Outliers**

**Step 1** Determine member age as of January 1 of the measurement year.

**Step 2** Report the count of outlier members for each age group and the overall total. Enter these values in reporting Tables PCR-1/2 and PCR-A-3.

**Calculated: Outlier Rate**

The number of outlier members divided by the number of members in the plan population, displayed as a permillage (multiplied by 1,000), for each age group and the overall total.

**Reporting: Denominator**

Count the number of IHS among nonoutlier members for each age group and enter these values into the reporting table under Count of Index Stays.

**Reporting: Numerator**

Count the number of observed IHS among nonoutlier members with a readmission within 30 days of discharge for each age group and enter these values into the reporting tables under Count of Observed 30-Day Readmissions.

**Calculated: Observed Readmission Rate**

The Count of Observed 30-Day Readmissions divided by the Count of Index Stays.

**Reporting: Count of Expected 30-Day Readmissions**

**Step 1** Calculate the Count of Expected Readmissions among nonoutlier members for each age group and overall total.

**Step 2** Round to four decimal places using the .5 rule and enter the Count of Expected Readmissions into the reporting tables.

**Calculated: Expected Readmission Rate**

The Count of Expected 30-Day Readmissions divided by the Count of Index Stays.

**Calculated: O/E Ratio**

The Count of Observed 30-Day Readmissions divided by the Count of Expected 30-Day Readmissions.

**Note**

- Supplemental data may not be used for this measure.
### Table PCR-1/2: Plan Population and Outlier Rate (Medi-Cal Managed Care, Commercial, 18-64)

<table>
<thead>
<tr>
<th>Age</th>
<th>Members in Plan Population</th>
<th>Outlier Members</th>
<th>Outlier Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-64 Total</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table PCR-A-3: Plan Population and Outlier Rate (Medicare Advantage, 18+)

<table>
<thead>
<tr>
<th>Age</th>
<th>Members in Plan Population</th>
<th>Outlier Members</th>
<th>Outlier Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>65-74</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65+ Total</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table PCR-B-1/2: Plan All-Cause Readmissions Rates Among Nonoutlier Members by Age (Medi-Cal Managed Care, Commercial, 18–64)

<table>
<thead>
<tr>
<th>Age</th>
<th>Count of Index Stays</th>
<th>Count of Observed 30-Day Readmissions</th>
<th>Observed Readmission Rate</th>
<th>Count of Expected 30-Day Readmissions</th>
<th>Expected Readmission Rate</th>
<th>Variance</th>
<th>O/E Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-44</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-64 Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table PCR-C-3: Plan All-Cause Readmissions Rates Among Nonoutlier Members by Age (Medicare Advantage, 18+)

<table>
<thead>
<tr>
<th>Age</th>
<th>Count of Index Stays</th>
<th>Count of Observed 30-Day Readmissions</th>
<th>Observed Readmission Rate</th>
<th>Count of Expected 30-Day Readmissions</th>
<th>Expected Readmission Rate</th>
<th>Variance</th>
<th>O/E Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>65-74</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65+ Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Emergency Department Utilization (EDU)

**Measure Updates September 2020 for AMP MY 2020/2021**

- Added definitions for “outlier” and “non-outlier.”
- Revised step 1 in the calculation of observed events to exclude ED visits that result in an observation stay.
- Added step 3 in the calculation of observed events to remove discharges for outlier members.
- Removed references to specific risk weight tables in the Risk Adjustment Weighting section.
- Removed step 3 to identify the base risk weight from the calculation of PPV and PUCV; renumbered subsequent steps.
- Clarified that for categories with a single member the covariance should be set to zero in step 4 of the Expected Count of Visits calculation.
- Added instructions to report outliers separate from non-outliers.
- Revised the data elements tables and added reporting columns for outliers.

**Modifications From HEDIS**

- None.

**Description**

For members 18 years of age and older, the risk-adjusted ratio of observed to expected emergency department (ED) visits during the measurement year.

*Note: Onpoint will run this measure for MY 2020 and 2021. Health plans and POs are not expected to report it.*

**Definitions**

- **Outlier**
  - Commercial members 18 years of age and older with four or more ED visits during the measurement year.

- **Non-outlier**
  - Commercial members 18 years of age and older with three or less ED visits during the measurement year.

- **Classification period**
  - The year prior to the measurement year.

- **PPV**
  - Predicted probability of a visit. The predicted probability of a member having an emergency department visit in the measurement year.

- **PUCV**
  - Predicted unconditional count of visits. The unconditional count of emergency department visits for members during the measurement year.

**Eligible Population**

*Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.*
Refer to General Guideline 52: Reporting for small denominator limits.

**Product lines**  
Commercial HMO/POS and Commercial ACO.

**Ages**  
18 years and older as of December 31 of the measurement year.

**Continuous enrollment**  
The measurement year and the year prior to the measurement year.

**Allowable gap**  
No more than one gap in enrollment of up to 45 days during each year of continuous enrollment.

**Anchor date**  
December 31 of the measurement year.

**Benefit**  
Medical.

**Event/diagnosis**  
None.

### Calculation of Observed Events

**Step 1**  
Count each visit to an ED once, regardless of the intensity or duration of the visit. Count multiple ED visits on the same date of service as one visit. Identify all ED visits during the measurement year using either of the following:

- An ED Visit (**ED Value Set**).
- A procedure code (**ED Procedure Code Value Set**) with an ED place of service code (**ED POS Value Set**).

Do not include ED visits that result in an inpatient stay (**Inpatient Stay Value Set**) or an observation stay (**Observation Stay Value Set**).

**Step 2**  
Exclude encounters with any of the following:

- A principal diagnosis of mental health or chemical dependency (**Mental and Behavioral Disorders Value Set**).
- Psychiatry (**Psychiatry Value Set**).
- Electroconvulsive therapy (**Electroconvulsive Therapy Value Set**).

**Step 3**  
For the remaining ED visits, calculate the number of visits per member and remove visits for outlier members. Report these members as outliers in Table EDU-A-2/3.

**Step 4**  
Calculate the total using all ED visits identified after completing steps 1–3. Assign each remaining ED visit to an age and stratification category using the reporting instructions below.

### Risk Adjustment Determination

For each non-outlier member in the eligible population, use the steps in the **Risk Adjustment Comorbidity Category Determination** in the Guidelines for Risk Adjusted Utilization Measures to identify risk adjustment categories based on presence of comorbidities.
Risk Adjustment Weighting and Calculation of Expected Events

Calculation of risk-adjusted outcomes (counts of ED visits) uses predetermined risk weights generated by two separate regression models. Weights from each model are combined to predict how many visits each member might have during the measurement year.

For each non-outlier member in the eligible population, assign Predicted Probability of a Visit (PPV) risk weights.

**Step 1** For each member with a comorbidity HCC Category, link the PPV weights.

**Step 2** Link the age-gender PPV weights for each member.

**Step 3** Sum all PPV weights associated with the member (HCC, age and gender).

**Step 4** Calculate the predicted probability of each member having at least one visit based on the sum of the weights for each member using the formula below.

\[
PPV = \frac{e^{\sum PPV \text{ Weights For Each Member}}}{1 + e^{\sum PPV \text{ Weights For Each Member}}}
\]

Truncate intermediate calculations to 10 decimal places.

For each member in the eligible population, assign Predicted Unconditional Count of Visits (PUCV) risk weights.

**Step 1** For each member with a comorbidity HCC Category, link the PUCV weights. If a member does not have any comorbidities to which weights can be linked, assign a weight of 1.

**Step 2** Link the age-gender PUCV weights for each member.

**Step 3** Calculate the predicted unconditional count of visits in the measurement year, by multiplying all PUCV weights (HCC, age and gender). Use the following formula:

\[
PUCV = \text{Age/gender Weight} \times \text{HCC Weight}
\]

*Note: Multiply by each HCC associated with the member. For example, assume a member with HCC-2, HCC-10, HCC-47. The formula would be:*

\[
PUCV = \text{Age/gender Weight} \times \text{HCC-2} \times \text{HCC-10} \times \text{HCC-47}
\]

*Note: Truncate intermediate calculations to 10 decimal places.*

**Expected count of ED Visits** Report the final member-level expected count of ED visits for each category using the formula below. Round to four decimal places using the .5 rule and enter these values into the reporting table.

\[
\text{Expected Count of ED Visits} = \text{PPV} \times \text{PUCV}
\]

**Step 4** Use the formula below to calculate the covariance of the predicted outcomes for each category (i.e., gender and age group). For categories with a single member \((n=1)\), set the covariance to zero. Do not round the covariance before using it in step 6.
\[ COV_c = \frac{\sum_{m=1}^{n_c} (PPV_m - mean(PPV)_c) \times (PUCV_m - mean(PUCV)_c)}{n_c - 1} \]

Where:
- \( c \) denotes an individual category
- \( n_c \) is the number of members in the category indicated by \( c \)
- \( m \) is an individual member within the category indicated by \( c \)
- \( PPV_m \) is the unrounded PPV for the member denoted by \( m \)
- \( mean(PPV)_c \) is the unrounded mean PPV in the category indicated by \( c \)
- \( PUCV_m \) is the unrounded PUCV for the member denoted by \( m \)
- \( mean(PUCV)_c \) is the unrounded mean PUCV in the category indicated by \( c \)

**Step 5** Once the covariance between PPV and PUCV for a given category is calculated, it can be used as indicated in the formula below to calculate the variance for that category.

\[
\text{Variance}_c = \sum_{m=1}^{n_c} (PPV_m \times PUCV_m)^2 \\
\times \left( 1 + (1 - PPV_m)^2 + \frac{2 \times COV_c}{PPV_m \times PUCV_m} \right)
\]

Where:
- \( c \) denotes an individual category
- \( n_c \) is the number of members in the category indicated by \( c \)
- \( m \) is an individual member within the category indicated by \( c \)
- \( PPV_m \) is the unrounded PPV for the member denoted by \( m \)
- \( PUCV_m \) is the unrounded PUCV for the member denoted by \( m \)
- \( n_c \) is the number of members in the category indicated by \( c \)

Round the variance for reporting to 4 decimal places using the .5 rule.

**Calculated: Number of Members in the Eligible Population**

The number of members in the eligible population (including outliers) for each age and gender group and enter these values into the reporting table (Table EDU-A-2/3).

**Reporting: Number of Non-Outliers**

The number of non-outlier members for each age and gender group and the overall total. Enter these values in the reporting table (Table EDU-A-2/3).

**Reporting: Number of Outliers**

The number of outlier members for each age and gender group and the overall total. Enter these values in the reporting table (Table EDU-A-2/3).
**Calculated: Outlier Rate**

The number of outlier members divided by the number of members in the eligible population, displayed as permillage (multiplied by 1,000), for each age and gender group and the overall total.

**Reporting: Number of Observed Events Among Non-Outlier Members**

The number of observed ED visits within each age and gender group and total.

**Calculated: Observed Visits per 1,000 Non-Outlier Members**

The number of observed ED visits divided by the number of non-outlier members in the eligible population, multiplied by 1,000 within each age and gender group and total.

**Reporting: Number of Expected Events Among Non-Outlier Members**

The number of expected ED visits within each age and gender group and total.

**Calculated: Expected Visits per 1,000 Non-Outlier Members**

The number of expected ED visits divided by the number of non-outlier members in the eligible population, multiplied by 1,000 within each age and gender group and total.

**Reporting: Variance Among Non-Outlier Members**

The variance (from Risk Adjustment Weighting and Calculation of Expected Events, PUCV, step 6) within each age and gender group and total.

**Note**

- Supplemental data may not be used for this measure.
### Table EDU-A-2/3: Eligible Population and Outlier Rate

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>Members in the Eligible Population</th>
<th>Non-Outlier Members</th>
<th>Outlier Members</th>
<th>Outlier Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-44</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-64 Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65+ Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table EDU-B-2/3: Non-Outlier Member Number of ED visits by Age and Risk Adjustment

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>Observed ED Visits</th>
<th>Observed ED Visits/1,000 Members</th>
<th>Expected ED Visits</th>
<th>Expected ED Visits/1,000 Members</th>
<th>Variance</th>
<th>O/E Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-44</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-64</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65+</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Acute Hospital Utilization (AHU)

**Measure Updates September 2020 for AMP MY 2020 and 2021**
- Removed references to specific risk weight tables in the Risk Adjustment Weighting section.
- Clarified that for categories with a single member the covariance should be set to zero in step 4 of the Expected Count of Hospitalization calculation.

**Modifications From HEDIS**
- None.

**Description**
For members 18 years of age and older, the risk-adjusted ratio of observed-to-expected acute inpatient and observation stay discharges during the measurement year reported by Surgery, Medicine and Total.

**Note:** Onpoint will run this measure for MY 2020 and 2021. Health plans and POs are not expected to report it.

**Definitions**

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outlier</td>
<td>Commercial members with three or more inpatient or observation stay discharges during the measurement year.</td>
</tr>
<tr>
<td>Non-outlier</td>
<td>Commercial members with two or less inpatient or observation stay discharges during the measurement year.</td>
</tr>
<tr>
<td>Classification period</td>
<td>The year prior to the measurement year.</td>
</tr>
<tr>
<td>PPD</td>
<td>Predicted probability of discharge. The predicted probability of a member having any discharge in the measurement year.</td>
</tr>
<tr>
<td>PUCD</td>
<td>Predicted unconditional count of discharge. The predicted unconditional count of discharges for members during the measurement year.</td>
</tr>
</tbody>
</table>

**Eligible Population**

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

Refer to General Guideline 52: Reporting small numbers.

- **Product lines**: Commercial HMO/POS.
- **Ages**: 18 years and older as of December 31 of the measurement year.
- **Continuous enrollment**: The measurement year and the year prior to the measurement year.
- **Allowable gap**: No more than one gap in enrollment of up to 45 days during each year of continuous enrollment.
- **Anchor date**: December 31 of the measurement year.
Benefit: Medical.
Event/diagnosis: None

Calculation of Observed Events

Use the following steps to identify and categorize acute inpatient and observation stay discharges.

**Step 1** Identify all acute inpatient and observation discharges during the measurement year. To identify acute inpatient and observation discharges:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set) and observation stays (Observation Stay Value Set).
2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
3. Identify the discharge date for the stay.

**Step 2** Direct transfers: For discharges with one or more direct transfers, use the last discharge.

Using the discharges identified in step 1, identify direct transfers between acute inpatient and observation or between observation and acute inpatient using the definition found in the Guidelines for Risk Adjusted Utilization Measures.

**Step 3** For the remaining observation and inpatient discharges, exclude inpatient and observation discharges with:

- A principal diagnosis of mental health or chemical dependency (Mental and Behavioral Disorders Value Set).
- A principal diagnosis of live-born infant (Deliveries Infant Record Value Set).
- A maternity-related principal diagnosis (Maternity Diagnosis Value Set).
- A maternity-related stay (Maternity Value Set).
- Inpatient and observation stays with a discharge for death.

*Note:* For hospital stays where there was a direct transfer (identified in step 2), use the original stay and any direct transfer stays to identify exclusions in this step.

**Step 4** For the remaining observation and inpatient discharges, remove discharges for outlier members and report these members as outliers in Table AHU-A-2/3.

*Note:* Count discharges with one or more direct transfers (identified in step 2) as one discharge when identifying outlier members.

**Step 5** Calculate the total using all discharges identified after completing steps 1–4.

**Step 6** Calculate surgery. Identify the surgery discharges (Surgery Value Set) from the total discharges (step 5).

**Step 7** Calculate medicine. Categorize as Medicine the discharges remaining after removing surgery (step 6) from the total discharges (step 5).

Risk Adjustment Determination
For each non-outlier member in the eligible population, use the steps in the Risk Adjustment Comorbidity Category Determination section in the Guidelines for Risk Adjusted Utilization Measures to identify risk adjustment categories based on presence of comorbidities.

**Risk Adjustment Weighting and Calculation of Expected Events**

Calculation of risk-adjusted outcomes (counts of discharges) uses predetermined risk weights generated by two separate regression models. Weights from each model are combined to predict how many discharges each member might have during the measurement year, given age, gender and presence or absence of a comorbid condition.

For each non-outlier member in the eligible population, assign Predicted Probability of Discharge (PPD) risk weights. Calculate the PPD for each service utilization category: Surgery, Medicine, Total.

1. **Step 1** For each member with a comorbidity HCC category, link the PPD weights.
2. **Step 2** Link the age-gender PPD weights for each member.
3. **Step 3** Sum all PPD weights (HCC, age and gender) associated with the member for each category (Medicine, Surgery, Total).
4. **Step 4** Calculate the predicted probability of having at least one discharge in the measurement year based on the sum of the weights for each member, for each category (Surgery, Medicine, Total), using the formula below.

\[
PPD = \frac{e^{\sum \text{PPD Weights For Each Member}}}{1 + e^{\sum \text{PPD Weights For Each Member}}}
\]

Truncate intermediate calculations to 10 decimal places.

For each non-outlier member in the eligible population assign Predicted Unconditional Count of Discharge (PUCD) risk weights.

1. **Step 1** For each member with a comorbidity HCC Category, link the PUCD weights. If a member does not have any comorbidities to which a weight could be linked, assign a weight of 1.
2. **Step 2** Link the age-gender PUCD weights for each member.
3. **Step 3** Calculate the predicted unconditional count of discharges in the measurement year, by multiplying all PUCD weights (HCC, age and gender) associated with the member for each category (Surgery, Medicine, Total). Use the following formula:

\[
PUCD = \text{Age/Gender Weight} \times \text{HCC Weight}
\]

**Note:** Multiply by each HCC associated with the member. For example, assume a member with HCC-2, HCC-10, HCC-47. The formula would be:

\[
PUCD = \text{Age/Gender Weight} \times \text{HCC-2} \times \text{HCC-10} \times \text{HCC-47}
\]

Truncate intermediate calculations to 10 decimal places.

**Expected count of hospitalization**

Report the final member-level expected count of discharges for each category using the formula below. Round to four decimal places using the .5 rule and enter these values in the reporting table.

\[
\text{Expected Count of Discharges} = \text{PPD} \times \text{PUCD}
\]
**Step 4** Use the formula below to calculate the covariance of the predicted outcomes for each category (gender, age group and type of hospital stay). For categories with a single member \( n_c = 1 \), set the covariance to zero. Do not round the covariance before using it in step 5.

\[
COV_c = \frac{\sum_{m=1}^{n_c} (PPD_m - \text{mean}(PPD)_c) \times (PUCD_m - \text{mean}(PUCD)_c)}{n_c - 1}
\]

Where:
- \( c \) denotes an individual category
- \( n_c \) is the number of members in the category indicated by \( c \)
- \( m \) is an individual member within the category indicated by \( c \)
- \( PPD_m \) is the unrounded PPD for the member denoted by \( m \)
- \( \text{mean}(PPD)_c \) is the unrounded mean PPD in the category indicated by \( c \)
- \( PUCD_m \) is the unrounded PUCD for the member denoted by \( m \)
- \( \text{mean}(PUCD)_c \) is the unrounded mean PUCD in the category indicated by \( c \)

**Step 5** Once the covariance between PPD and PUCD for a given category is calculated, it can be used as indicated in the formula below to calculate the variance for that category.

\[
\text{Variance}_c = \sum_{m=1}^{n_c} (PPD_m \times PUCD_m)^2 \times \left( 1 + (1 - PPD_m)^2 + \left( \frac{2 \times COV_c}{PPD_m \times PUCD_m} \right) \right)
\]

Where:
- \( c \) denotes an individual category
- \( n_c \) is the number of members in the category indicated by \( c \)
- \( m \) is an individual member within the category indicated by \( c \)
- \( PPD_m \) is the unrounded PPD for the member denoted by \( m \)
- \( PUCD_m \) is the unrounded PUCD for the member denoted by \( m \)

Round the variance for reporting to 4 decimal places using the .5 rule.

**Calculated: Number of Members in the Eligible Population**

The number of members in the eligible population (including outliers) for each age and gender group and the overall total.

**Reporting: Number of Nonoutliers**

The number of nonoutlier members for each age and gender group and the overall total. Enter these values in the reporting table (Table AHU-A-2/3).

**Reporting: Number of Outliers**

The number of outlier members for each age and gender group and the overall total. Enter these values in the reporting table (Table AHU-A-2/3).

**Calculated: Outlier Rate**
The number of outlier members divided by the number of members in the eligible population, displayed as permillage (multiplied by 1,000), for each age and gender group and the overall total.

**Reporting: Number of Observed Events Among Nonoutlier Members**

The number of observed discharges within each age and gender group and the overall total for each category (Surgery, Medicine, Total).

**Calculated: Observed Discharges per 1,000 Nonoutlier Members**

The number of observed discharges divided by the number of non-outlier members in the eligible population, multiplied by 1,000 within each age and gender group and the overall total for each category (Surgery, Medicine, Total).

**Reporting: Number of Expected Events Among Nonoutlier Members**

The number of expected discharges within each age and gender group and the overall total for each category (Surgery, Medicine, Total).

**Calculated: Expected Discharges per 1,000 Nonoutlier Members**

The number of expected discharges divided by the number of nonoutlier members in the eligible population, multiplied by 1,000 within each age and gender group and the overall total for each category (Surgery, Medicine, Total).

**Reporting: Variance Among Nonoutlier Members**

The variance (from Risk Adjustment Weighting and Calculation of Expected Events, PUCD, step 5) within each age and gender group and the overall total for each category (Surgery, Medicine, Total).

**Note**

- Supplemental data may not be used for this measure.
### Table AHU-A-2/3: Eligible Population and Outlier Rate

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>Members in Eligible Population</th>
<th>Non-Outlier Members</th>
<th>Outlier Members</th>
<th>Outlier Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-44</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-64 Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65+ Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table AHU-B-2/3: Non-Outlier Member Acute Inpatient and Observation Stay Discharges by Age and Risk Adjustment: Surgery

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>Observed Discharges</th>
<th>Expected Discharges</th>
<th>Variance</th>
<th>O/E Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Observed Discharges/1,000 Members</td>
<td>Expected Discharges/1,000 Members</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-44</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-64 Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65+Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table AHU-C-2/3: Non-Outlier Member Acute Inpatient and Observation Stay Discharges by Age and Risk Adjustment: Medicine

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>Observed Discharges</th>
<th>Observed Discharges/1,000 Members</th>
<th>Expected Discharges</th>
<th>Expected Discharges/1,000 Members</th>
<th>Variance</th>
<th>O/E Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-44</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-64 Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65+  Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>Sex</td>
<td>Observed Discharges</td>
<td>Observed Discharges/1,000 Members</td>
<td>Expected Discharges</td>
<td>Expected Discharges/1,000 Members</td>
<td>Variance</td>
<td>O/E Ratio</td>
</tr>
<tr>
<td>------</td>
<td>--------</td>
<td>---------------------</td>
<td>----------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>18-44</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-64 Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65+ Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Hospital Average Length of Stay (HALOS)**

### Measure Updates September 2020 for AMP MY 2020 and 2021

- None.

### Modifications from HEDIS

- This is a non-HEDIS measure.

### Description

This measure calculates a risk-adjusted inpatient average length of stay (ALOS) for maternity and non-maternity admissions. The numerator for this measure is the number of inpatient days and the denominator is the number of inpatient discharges. The final reported metrics are:

- Risk-adjusted ALOS for maternity inpatient discharges
- Risk-adjusted ALOS for non-maternity inpatient discharges

Risk adjustment for ALOS will be calculated using Medicare Severity-Diagnosis Related Group (MS-DRG).

*Note:* Onpoint will run this measure for MY 2020 and 2021. Health plans and POs are not expected to report it.

### Eligible Population

*Note:* Members in hospice are excluded from the eligible population. Refer to General Guideline 15: Members in Hospice.

**Product lines**

Commercial HMO and POS, Commercial ACO and Medi-Cal Managed Care (report each product line separately).

**ALOS**

Refer to Specific Instructions for Utilization Tables in the Guidelines for HEDIS Utilization Measures on page 196 for the formula. Calculate average length of stay for maternity and non-maternity (e.g. surgery and medicine).

**Continuous enrollment**

None.

**Step 1**

Identify all acute inpatient discharges on or between January 1 and December 31 of the measurement year. To identify acute inpatient discharges:

1. Identify all acute and nonacute inpatient stays (**Inpatient Stay Value Set**).
2. Exclude nonacute inpatient stays (**Nonacute Inpatient Stay Value Set**).
3. Identify the discharge date for the stay.
**Step 2**  
*Direct transfers:* For discharges with one or more direct transfers, use the last discharge. Using the discharges identified in step 1, identify direct transfers between acute inpatient and observation or between observation and acute inpatient using the following guidelines for counting transfers.  
*Count Transfers:* Unless otherwise specified in the measure, treat transfers between institutions as separate admissions. Base transfer reports within an institution on the type and level of services provided. Report separate admissions when the transfer is between acute and nonacute levels of service or between mental health/chemical dependency services and non-mental health/chemical dependency services. Count only one admission when the transfer takes place within the same service category but to a different level of care; for example, from intensive care to a lesser level of care or from a lesser level of care to intensive care.

**Step 3**  
Exclude discharges with a principal diagnosis of mental health or chemical dependency (Mental and Behavioral Disorders Value Set) on the discharge claim.  
Exclude newborn care rendered from birth to discharge home from delivery (only include care rendered during subsequent rehospitalizations after the delivery discharge). Identify newborn care by a principal diagnosis of live-born infant (Deliveries Infant Record Value Set). Organizations must develop methods to differentiate between the mother’s claim and the newborn’s claim, if needed.

**Step 4**  
Report ALOS for maternity. A delivery is not required for inclusion in the *Maternity* category; any maternity-related stay is included. Include birthing center deliveries and count them as one day of stay.  
Starting with all discharges identified in step 3, identify maternity using either of the following:  
- A maternity-related principal diagnosis (*Maternity Diagnosis Value Set*).  
- A maternity-related stay (*Maternity Value Set*).

**Step 5**  
Report ALOS for non-maternity. Calculate based on all discharges remaining after removing maternity (identified in step 4) from total inpatient (identified in step 3).

**Note**  
- Supplemental data may not be used for this measure.

**Risk Adjustment Calculation**

**Step 1**  
*Calculate expected ALOS for each MS-DRG by product line.* Collect ALOS values for all discharges into MS-DRG-specific “bins”. The expected ALOS for each DRG is the arithmetic mean of all ALOS values attributed to that DRG-bin.

**Step 2**  
*Calculate population ALOS.* The population ALOS is defined as the arithmetic mean of ALOS scores across all discharges, within each DRG bin.

**Step 3**  
*Calculate the observed/expected ratio for ALOS.* Divide the Observed ALOS by the Expected ALOS; multiply the observed to expected ratio by the population ALOS.
Step 4  Calculate risk-adjusted ALOS.

Risk-adjusted ALOS = [Σ Observed ALOS/Σ Expected ALOS] * population ALOS.

The same process is followed for the maternity and non-maternity risk adjusted ALOS calculations. For the maternity ALOS adjustment, DRGs are limited to maternity DRGs during the DRG case-mix adjustment.
Total Cost of Care Domain
Technical Specifications

For AMP MY 2020 and MY 2021
**Total Cost of Care (TCOC)**

**MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2020 AND 2021**
- Added clarifying information on normalization of relative-risk scores in Step 3 of Risk-Adjustment Determination.
- Clarified reporting time frame in definition of Member months.

**MODIFICATIONS FROM HEDIS**
- This is a non-HEDIS NQF-endorsed measure developed by HealthPartners.

**MODIFICATIONS FROM HEALTHPARTNERS**
- AMP includes ages greater than 1 for this measure.
- AMP uses a $250,000 truncation level amount, whereas HealthPartners uses $125,000.
- AMP applies a geographic adjustment in addition to risk adjustment.
- AMP includes capitated costs in the measure.
- AMP includes exclusion criteria for select services and payments.

**Description**

The average geography- and risk-adjusted costs per member per month (PMPM) for the care provided to a PO's members. Reported indicators include:
- Observed costs PMPM
- Risk-adjusted costs PMPM
- Geography and risk-adjusted costs PMPM

The endorsed specifications are available [here](#) and have been reproduced below with permission from HealthPartners for use in AMP. This measure will only be generated by Onpoint from data submitted by health plans and will not be reported by physician organizations. Participating health plans provide to Onpoint member-level total payments, along with member eligibility, claims, and encounter detail, for each contracted PO. This measure is based on actual costs associated with care for members enrolled to a PO, including all covered professional, pharmacy, hospital and ancillary care, as well as administrative payments and adjustments. Health plans include both capitation payments and FFS payments, including member copayments, paid to the PO or other providers caring for members of the PO. It does not include costs associated with mental health/chemical dependency, chiropractic, acupuncture, vision or dental services. Per member annual costs above $250,000 are truncated.

The total paid amount is then risk adjusted, adjusted for geography, and divided by the sum of the member months attributed to the PO. Risk adjustment will be performed using the Johns Hopkins’ Adjusted Clinical Grouper (ACG). Geographic adjustment is performed using the geographic adjustment factors published by CMS and based on the hospital wage index.
### Eligible Population

<table>
<thead>
<tr>
<th><strong>Product line</strong></th>
<th>Commercial HMO/POS, Commercial ACO, Medicare Advantage, Medi-Cal Managed Care (report each product line separately).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ages</strong></td>
<td>&gt;1 to 64 years of age for Commercial HMO, Commercial ACO, and Medi-Cal Managed Care and &gt;64 years of age for Medicare Advantage. Determine the age based on the last day of the measurement period (i.e. December 31 of the measurement year).</td>
</tr>
<tr>
<td><strong>Continuous enrollment</strong></td>
<td>For Commercial HMO/POS, Medicare Advantage, and Medi-Cal Managed Care, include members with at least 9 months of enrollment in the health plan and the PO during the measurement period. For Commercial ACO, include members with at least 9 months of enrollment in the health plan and at least 1 attributed month to an ACO during the measurement period.</td>
</tr>
<tr>
<td><strong>Allowable gap</strong></td>
<td>NA.</td>
</tr>
<tr>
<td><strong>Anchor date</strong></td>
<td>None.</td>
</tr>
<tr>
<td><strong>Benefit</strong></td>
<td>Medical.</td>
</tr>
<tr>
<td><strong>Measurement period</strong></td>
<td>The measurement period is January 1–December 31 of the measurement year. Include services with a date of service between January 1 and December 31 of the measurement year, and a date of payment between January 1 of the measurement year, and March 31 of the reporting year.</td>
</tr>
<tr>
<td><strong>Member months</strong></td>
<td>Member Months is the basis for reporting this measure. Member months come from a member’s eligibility records (which are submitted by health plans to Onpoint in the Member Identifier file). Determine the number of months during the measurement year that the eligible member was enrolled in both the health plan and PO. For Commercial ACO reporting, member months is determined by the days enrolled with the health plan only. Sum the monthly medical membership and pharmacy membership counts to the member level. <strong>Note:</strong> A member cannot have more pharmacy member months than medical member months. Each member will have a medical member month total and a pharmacy member monthly total.</td>
</tr>
</tbody>
</table>

### Total Cost of Care Calculation

**Step 1** Identify the eligible population as defined above.

**Step 2** Obtain member-level observed cost. This is the payment supplied by the health plan for a member’s cost while enrolled with a specific PO. It includes all professional, facility (inpatient and outpatient), pharmacy (including drug rebates), and other payments for services provided to a member.

The following services and payments are excluded from the observed cost amount:

- Mental health.
- Chemical dependency.
- Dental.
- AMP quality incentive payments.
- Vision.
- Chiropractic.
- Acupuncture.
If any of these services are included in a PO’s capitation agreement, the plan uses its own actuarial method to exclude. The following payments made to a PO that are not directly related to the delivery of services to individuals are included and attributed to members on a prorated basis:

- Capital infusions.
- Capitation administrative fee.
- Capitation deductions and adjustments.
- Capitation floors and guarantees.
- Non-AMP incentive payments.
- Shared risk payments.
- Special case rates for particular populations.
- Stop loss provisions.
- Non-claim bulk adjustments, including drug rebates.
- Non-claim payments (other).

**Step 3** *Calculate observed costs PMPM.*

Total observed costs PMPM = (Total Medical Cost/Medical Member Months) + (Total Pharmacy Cost/Pharmacy Member Months)

Total observed costs above $250,000 per member are truncated.

**Step 4** *Report Total Cost of Care service category costs PMPM.* For each member, report the following subcategories of cost:

<table>
<thead>
<tr>
<th>Overall</th>
<th>TCOC Service Categories</th>
<th>Service Category Breakdown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost: Total Facility</td>
<td>IHA generates this measure which is the sum of Total Inpatient Facility plus Total Outpatient Facility plus Other Facility costs</td>
</tr>
<tr>
<td></td>
<td>Cost: Total Inpatient Facility</td>
<td>Maternity Related</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-Maternity Related</td>
</tr>
<tr>
<td></td>
<td>Cost: Total Outpatient Facility</td>
<td>Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ambulatory Surgery Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Emergency Department</td>
</tr>
<tr>
<td></td>
<td>Cost: Other Facility FFS</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Cost: Professional FFS</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Cost: Total Pharmacy FFS</td>
<td>Pharmacy Cost: Specialty</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmacy Cost: All Other</td>
</tr>
<tr>
<td></td>
<td>Cost: Total Capitation</td>
<td>Capitation Cost: Global</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Capitation Cost: Professional Services</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Capitation Cost: Facility Services</td>
</tr>
</tbody>
</table>
### Risk-Adjustment Determination

**Step 1** Calculate risk scores. For each member in the eligible population, a member-level relative risk score (RRS) will be calculated using the Johns Hopkins’ ACG concurrent inputs (based on the claims/encounters submitted by the health plan).

- Age
- Gender
- ICD-10 Dx codes
- Revenue code
- RVN CPT4, CPT4, & CPT/Revenue CPT4 Modifier
- Place of service

The RRS are then normalized for the AMP HMO/POS population (i.e., across all POs and plans) to a benchmark of 1.0, incorporating partial year enrollment, to generate a member-level RRS. Commercial ACO, Medicare Advantage and Medi-Cal Managed Care risk scores are not normalized.

**Step 2** Calculate the average population cost PMPM.

Average Population Cost PMPM = (sum of member level medical cost/sum of member medical months) + (sum of member level pharmacy cost/sum of member pharmacy months)

This average population cost PMPM will be used for both plan-specific and all-plan calculations.

**Step 3** Calculate the risk-adjusted total cost of care PMPM.

Risk-adjusted total cost of care PMPM = PO-level observed total PMPM/risk score

### Geographic Adjustment Determination

*Calculate the geography and risk-adjusted total cost of care PMPM*

Geography and risk-adjusted total cost of care PMPM = Risk adjusted total cost of care PMPM/geographic adjustment factor, where the geographic adjustment factor is based on the Centers for Medicare and Medicaid Services (CMS) Hospital Wage Index (HWI).

The CMS HWI is normalized by dividing it by the average PO HWI to create the geographic adjustment factor (GAF).
MY 2021 Testing Measures

For AMP MY 2021
Overview

There will be opportunity for public comment before testing measure specifications are finalized by the AMP Technical Measurement and Governance Committees in October 2020. Selected measures will be tested in MY 2021 and are expected to be added to the MY 2022 AMP measure set (barring problems identified during testing).

IHA is in the process of developing a scaled-up, centralized process for collecting, using and disseminating supplemental clinical data (including PHQ-9 scores) from provider organizations to appropriate contracted entities. Starting in MY 2021, IHA intends to have a new data collection process for POs to submit data to IHA in a standard format. IHA data partner, Onpoint Health Data (Onpoint) will link provider clinical data to health plan claims data in order to generate measure results using the Electronic Clinical Data System (ECDS) reporting standard for the AMP program. IHA intends to release a standard data file layout for POs in advance of the data collection period.

POs are encouraged to participate in the supplemental clinical data collection in order to get a first look at their performance and help assess the validity of the measure for use in the AMP program. The MY 2021 testing measures are listed below.

Note: AMP does not have any MY 2020 testing measures. Electronic Clinical Data Systems (ECDS) Guidelines have been added below as a reference for the MY 2021 testing measures.

**Clinical**

- **Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)** will be added as a MY 2021 testing measure for the Commercial ACO product line. Self-reporting POs are encouraged to submit supplemental clinical data to IHA vendor. This measure will be run by Onpoint.

- **Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)** will be added as a MY 2021 testing measure for the Commercial ACO product line. Self-reporting POs are encouraged to submit supplemental clinical data to IHA vendor. This measure will be run by Onpoint.

- **Depression Remission or Response for Adolescents and Adults (DRR-E)** will be added as a MY 2021 testing measure for the Commercial ACO product line. Self-reporting POs are encouraged to submit supplemental clinical data to IHA vendor. This measure will be run by Onpoint.

**Data Quality** None.

**Advancing Care Information** None.

**Patient Experience** None.

**Appropriate Resource Use** None.

**Cost** None.
Guidelines for Measures Reported Using Electronic Clinical Data Systems (ECDS)

GUIDANCE UPDATES SEPTEMBER 2020 FOR AMP MY 2021

- None.

Description

Quality measures in the Electronic Clinical Data Systems (ECDS) reporting domain inspire innovative use of electronic clinical data to document high-quality patient care that demonstrates commitment to evidence-based practice. Organizations that report using ECDS encourage exchange of the information needed to provide high-quality services, ensuring it reaches the right people when it is most useful.

The ECDS reporting standard represents a step forward in adapting the AMP program to accommodate the expansive information available in electronic clinical datasets used for quality improvement.

ECDS are the network of data containing a member’s personal health information and records of their experiences within the health care system. They may also support other care-related activities directly or indirectly, including evidence-based decision support, quality management and outcome reporting. Data in these systems are structured such that automated quality measurement queries can be consistently and reliably executed, providing results quickly and efficiently to the team responsible for the care of members.

Health plans and POs that establish an enterprise network of interoperable electronic data systems will foster a member-centered, team-based approach to improving health care quality and better communication across health care service providers.

To qualify for ECDS reporting, the data must use standard layouts, meet the measure technical specification requirements and be accessible by the care team upon request. For additional information on ECDS measures, see the Guidelines section below and NCQA’s ECDS website.

Guidelines

ECDS measures follow the General Guidelines for Data Collection and Reporting.

1. Initial Population

The initial population for any ECDS measure includes all members who satisfy criteria, including age and participation criteria.

2. Data Collection

POs will submit data (including PHQ-9 scores) to IHA in a standard data file format starting in MY 2021. Onpoint will then link this clinical data to health plan claims data in order to generate measure results.

3. Types of ECDS Data

Organizations may use several data sources to provide complete information about the quality of health services delivered to its members. Data systems that may be eligible for ECDS reporting include, but are
not limited to, member eligibility files, EHRs, PHRs, clinical registries, HIEs, administrative claims systems, electronic laboratory reports (ELR), electronic pharmacy systems, immunization information systems (IIS) and disease/case management registries.

The data within these systems come in a variety of formats. The format type determines how the source is audited.

**Structured data**

Health care data residing in discrete, static fields using internationally recognized vocabulary standards are accepted as structured clinical data for ECDS reporting if it can be electronically extracted by a digital measure specification from an integrated data warehouse in a consistent and reliable fashion.

**Semistructured data**

Semistructured health care data are acceptable for use in ECDS reporting, if each QDE conforms to a uniform semantic structure and prescribed hierarchy, as prescribed by the logical definitions and attributes contained within each digital measure specification.

**Member-reported data**

Member-reported data from the legal health record are acceptable as member responses to a standardized assessment, delivered in a structured form through a secure application programming interface (API). Web APIs are remote applications communicating over the internet which transfer data between a client’s software (e.g., member’s mobile device) and a server system (e.g., healthcare database).

Every member-reported QDE must contain adequate metadata specificity, as defined by each measure’s technical specifications (e.g., date, service type, medication type, assessment type, modality).

Data sources are categorized using the following criteria:

**EHR/PHR**

Electronic health record/personal health record. Transactional systems that store clinically relevant information collected directly from or managed by a patient. An EHR contains the medical and treatment histories of patients and a PHR includes both the standard clinical data collected within a provider’s office or other care setting, in addition to information curated directly within the PHR by the patient though an API.

This data category includes biometric information and clinical samples obtained directly from a patient as well as clinical findings generated as a result of samples collected from a patient (e.g., pathology, laboratory and pharmacy records generated from entities not directly connected to the patient’s EHR).

**HIE/clinical registry**

HIEs and clinical registries eligible for this reporting category include state HIEs, IIS, public health agency systems, regional HIEs (RHO), Patient-Centered Data Homes™ or other registries developed for research or to support quality improvement and patient safety initiatives.

Doctors, nurses, pharmacists, other health care providers and patients can use HIEs to access and share vital medical information, with the goal of creating a complete patient record.¹ HIEs used for ECDS reporting must use standard protocols to ensure security, privacy, data integrity, sender and receiver authentication and confirmation of delivery.

¹[https://www.healthit.gov/providers-professionals/health-information-exchange/what-hie](https://www.healthit.gov/providers-professionals/health-information-exchange/what-hie)
Clinical registries collect information about people with a specific disease or condition, or patients who may be willing to participate in research about a disease. Registries can be sponsored by a government agency, nonprofit organization, health care facility or private company, and decisions regarding use of the data in the registry are the responsibility of the registry's governing committee.  

<table>
<thead>
<tr>
<th>Case management system</th>
<th>A shared database of member information collected through a collaborative process of member assessment, care planning, care coordination or monitoring of a member's functional status and care experience. Case management systems eligible for this category of ECDS reporting include any system developed to support the organization’s case/disease management activities, including activities performed by delegates.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative</td>
<td>Includes data from administrative claims processing systems for all services incurred (paid, suspended, pending and denied) during the period defined by each measure's participation as well as member management files, member eligibility and enrollment files, electronic member rosters, internal audit files, and member call service databases.</td>
</tr>
</tbody>
</table>

[2https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries]
## Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)*

*Adapted with financial support from the Centers for Medicare & Medicaid Services (CMS).

### MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2021
- Added as a Commercial ACO testing measure for MY 2021.

### MODIFICATIONS FROM HEDIS
- None.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Description</strong></td>
<td>The percentage of members 12 years of age and older who were screened for clinical depression using a standardized instrument and, if screened positive, received follow-up care.</td>
</tr>
<tr>
<td><strong>Measurement period</strong></td>
<td>January 1–December 31 of the measurement year.</td>
</tr>
<tr>
<td><strong>Clinical recommendation statement</strong></td>
<td>The U.S. Preventive Services Task Force (USPSTF) recommends screening for depression among adolescents 12–18 years and the general adult population, including pregnant and postpartum women. The USPSTF also recommends that screening be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment and appropriate follow-up.</td>
</tr>
</tbody>
</table>

| Scoring | Proportion. |
| Type    | Process.    |
| Item count | Person.    |
| Stratification | 1. 12–17 years.  
2. 18–64 years.  
3. 65 years and older.  
4. Total. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk adjustment</td>
<td>None.</td>
</tr>
<tr>
<td>Improvement notation</td>
<td>A higher rate indicates better performance.</td>
</tr>
</tbody>
</table>

**Definitions**

| Participation (Continuous Enrollment) | The identifiers and descriptors for each organization’s coverage used to define members’ eligibility for measure reporting. Allocation for AMP reporting is based on eligibility during the Participation Period.  
For self-reporting POs: The Participation Period in the PO (parent level).  
For health plans: The Participation Period in the health plan and the PO (parent level). |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Participation Period</td>
<td>The Measurement Period.</td>
</tr>
<tr>
<td>Allowable Gap</td>
<td>No more than one gap in enrollment of up to 45 days during the measurement period.</td>
</tr>
<tr>
<td>Anchor Date</td>
<td>December 31 of the measurement year.</td>
</tr>
</tbody>
</table>

**Depression Screening Instrument**

A standard assessment instrument that has been normalized and validated for the appropriate patient population. Eligible screening instruments with thresholds for positive findings include:

<table>
<thead>
<tr>
<th>Instruments for Adolescents (12–17 years)</th>
<th>Positive Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Health Questionnaire (PHQ-9)®</td>
<td>Total Score ≥10</td>
</tr>
<tr>
<td>Patient Health Questionnaire Modified for Teens (PHQ-9M)®</td>
<td>Total Score ≥10</td>
</tr>
<tr>
<td>Patient Health Questionnaire-2 (PHQ-2)®</td>
<td>Total Score ≥3</td>
</tr>
<tr>
<td>Beck Depression Inventory-Fast Screen (BDI-FS)®</td>
<td>Total Score ≥8</td>
</tr>
</tbody>
</table>
### Instruments for Adults (18+ years)

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Positive Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)</td>
<td>Total Score ≥17</td>
</tr>
<tr>
<td>Edinburgh Postnatal Depression Scale (EPDS)</td>
<td>Total Score ≥10</td>
</tr>
<tr>
<td>PROMIS Depression</td>
<td>Total Score (T Score) ≥60</td>
</tr>
<tr>
<td><strong>Patient Health Questionnaire (PHQ-9)®</strong></td>
<td>Total Score ≥10</td>
</tr>
<tr>
<td><strong>Patient Health Questionnaire-2 (PHQ-2)®,2</strong></td>
<td>Total Score ≥3</td>
</tr>
<tr>
<td><strong>Beck Depression Inventory-Fast Screen (BDI-FS)®,1,2</strong></td>
<td>Total Score ≥8</td>
</tr>
<tr>
<td><strong>Beck Depression Inventory (BDI-II)</strong></td>
<td>Total Score ≥20</td>
</tr>
<tr>
<td><strong>Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)</strong></td>
<td>Total Score ≥17</td>
</tr>
<tr>
<td><strong>Duke Anxiety-Depression Scale (DADS)®,1</strong></td>
<td>Total Score ≥30</td>
</tr>
<tr>
<td><strong>Geriatric Depression Scale Short Form (GDS)²</strong></td>
<td>Total Score ≥5</td>
</tr>
<tr>
<td><strong>Geriatric Depression Scale Long Form (GDS)</strong></td>
<td>Total Score ≥10</td>
</tr>
<tr>
<td><strong>Edinburgh Postnatal Depression Scale (EPDS)</strong></td>
<td>Total Score ≥10</td>
</tr>
<tr>
<td><strong>My Mood Monitor (M-3)®</strong></td>
<td>Total Score ≥5</td>
</tr>
<tr>
<td><strong>PROMIS Depression</strong></td>
<td>Total Score (T Score) ≥60</td>
</tr>
<tr>
<td><strong>Clinically Useful Depression Outcome Scale (CUDOS)</strong></td>
<td>Total Score ≥31</td>
</tr>
</tbody>
</table>

1Proprietary; may be cost or licensing requirement associated with use.

2Brief screening instrument. All other instruments are full-length.

### Initial Population

Members 12 years of age and older at the start of the Measurement Period who also meet criteria for Participation.

### Exclusions

- Members with bipolar disorder in the year prior to the Measurement Period.
- Members with depression that starts during the year prior to the Measurement Period.
- Members in hospice or using hospice services during the Measurement Period.
| Denominator | Denominator 1  
The Initial Population, minus Exclusions.  
Denominator 2  
All members from Numerator 1 with a positive depression screen finding between January 1 and December 1 of the Measurement Period. |
| --- | --- |
| Rate—Depression Screening (Population Criteria 1) | Numerator 1  
Members with a documented result of a depression screening performed using an age-appropriate standardized instrument between January 1 and December 1 of the Measurement Period. |
| Rate—Follow-Up on Positive Screen (Population Criteria 2) | Numerator 2  
Members who received follow-up care on or up to 30 days after the date of the first positive screen.  
Any of the following on or 30 days after the first positive screen:  
  - An outpatient, telephone, e-visit or virtual check-in follow-up visit with a diagnosis of depression or other behavioral health condition.  
  - A depression case management encounter that documents assessment for symptoms of depression or a diagnosis of depression or other behavioral health condition.  
  - A behavioral health encounter, including assessment, therapy, collaborative care or medication management.  
  - A dispensed antidepressant medication.  
  **OR**  
  - Documentation of additional depression screening on a full-length instrument indicating either no depression or no symptoms that require follow-up (i.e., a negative screen) on the same day as a positive screen on a brief screening instrument.  
**Note:** For example, if there is a positive screen resulting from a PHQ-2 score, documentation of a negative finding from a PHQ-9 performed on the same day qualifies as evidence of follow-up.
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)*

*Adapted with financial support from the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Medicare & Medicaid Services (CMS) under the CHIPRA Pediatric Quality Measures Program Centers of Excellence grant number U18HS020503, and with permission from the measure developer, Minnesota Community Measurement.

MEASURE UPDATES SEPTEMBER 2020 FOR AMP MY 2021

- Added as a Commercial ACO testing measure for MY 2021.

MODIFICATIONS FROM HEDIS

- None.

| Description | The percentage of members 12 years of age and older with a diagnosis of major depression or dysthymia, who had an outpatient encounter with a PHQ-9 score present in their record in the same assessment period as the encounter. |
| Measurement period | January 1–December 31 of the measurement year. The Measurement Period is divided into three assessment periods with specific dates of service:  
  - Assessment Period 1: January 1–April 30.  
  - Assessment Period 2: May 1–August 31.  
  - Assessment Period 3: September 1–December 31. |
| Clinical recommendation statement | Standardized instruments are useful in identifying meaningful change in clinical outcomes over time. Guidelines for adults recommend that providers establish and maintain regular follow-up with patients diagnosed with depression and use a standardized tool to track symptoms (Trangle, 2016). For adolescents, guidelines recommend systematic and regular tracking of treatment goals and outcomes, including assessing depressive symptoms (Cheung, 2018). The PHQ-9 tool assesses the nine DSM, Fourth Edition, Text Revision (DSM-IV-TR) criteria symptoms and effects on functioning, and it has been shown to be highly accurate in discriminating between patients with persistent major depression, partial remission and full remission (Kroenke, 2001). |


<table>
<thead>
<tr>
<th>Characteristics</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scoring</strong></td>
<td>Proportion.</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process.</td>
</tr>
<tr>
<td><strong>Item count</strong></td>
<td>Person.</td>
</tr>
</tbody>
</table>
| **Stratification** | 1. 12–17 years.  
2. 18–44 years.  
3. 45–64 years.  
4. 65 years and older.  
5. Total. |
| **Risk adjustment** | None. |
| **Improvement notation** | A higher rate indicates better performance. |

<table>
<thead>
<tr>
<th>Definitions</th>
<th></th>
</tr>
</thead>
</table>
| **Participation (Continuous Enrollment)** | The identifiers and descriptors for each organization’s coverage used to define members’ eligibility for measure reporting. Allocation for AMP reporting is based on eligibility during the Participation Period.  
For self-reporting POs: The Participation Period in the PO (parent level).  
For health plans: The Participation Period in the health plan and the PO (parent level). |
| **Participation Period** | The Measurement Period. |
| **Allowable Gap** | No more than one gap in enrollment of up to 45 days during the measurement period. |
### Anchor Date

December 31 of the measurement year.

### Interactive Outpatient Encounter

A bidirectional communication that is face-to-face, phone based, an e-visit or virtual check-in, or via secure electronic messaging. This does not include communications for scheduling appointments.

### Initial Population

**Initial Population 1**

Members 12 years and older at the start of the Measurement Period who also meet the criteria for Participation, with at least one Interactive Outpatient Encounter that starts during Assessment Period 1 (January 1–April 30), with a diagnosis of major depression or dysthymia.

**Initial Population 2**

Members 12 years and older at the start of the Measurement Period who also meet the criteria for Participation, with at least one Interactive Outpatient Encounter that starts during Assessment Period 2 (May 1–August 31), with a diagnosis of major depression or dysthymia.

**Initial Population 3**

Members 12 years and older at the start of the Measurement Period who also meet the criteria for Participation, with at least one Interactive Outpatient Encounter that starts during Assessment Period 3 (September 1–December 31), with a diagnosis of major depression or dysthymia.

### Exclusions

Members with any of the following at any time during the Measurement Period:
- Bipolar disorder.
- Personality disorder.
- Psychotic disorder.
- Pervasive developmental disorder.
- In hospice or using hospice services.

### Denominator

**Denominator 1**

The Initial Population 1, minus Exclusions.

**Denominator 2**

The Initial Population 2, minus Exclusions.

**Denominator 3**

The Initial Population 3, minus Exclusions.

### Rate—Utilization of PHQ-9 Period 1 (Population Criteria 1)

**Numerator 1**

A PHQ-9 score in the member’s record during Assessment Period 1 (January 1–April 30).
| Rate— Utilization of PHQ-9 Period 2 (Population Criteria 2) | Numerator 2  
A PHQ-9 score in the member’s record during Assessment Period 2 (May 1–August 31). |
|-----------------------------------------------------------|----------------------------------------------------------------------------------|
| Rate— Utilization of PHQ-9 Period 3 (Population Criteria 3) | Numerator 3  
A PHQ-9 score in the member’s record during Assessment Period 3 (September 1–December 31). |
**Depression Remission or Response for Adolescents and Adults (DRR-E)**

*Adapted with financial support from the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Medicare & Medicaid Services (CMS) under the CHIPRA Pediatric Quality Measures Program Centers of Excellence grant number U18HS020503, and with permission from the measure developer, Minnesota Community Measurement.*

**Measure Updates September 2020 for AMP MY 2021**

- Added as a Commercial ACO testing measure for MY 2021.

**Modifications From HEDIS**

- None.

<table>
<thead>
<tr>
<th>Description</th>
<th>The percentage of members 12 years of age and older with a diagnosis of depression and an elevated PHQ-9 score, who had evidence of response or remission within 4–8 months of the elevated score.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• <em>Follow-Up PHQ-9.</em> The percentage of members who have a follow-up PHQ-9 score documented within 4–8 months after the initial elevated PHQ-9 score.</td>
</tr>
<tr>
<td></td>
<td>• <em>Depression Remission.</em> The percentage of members who achieved remission within 4–8 months after the initial elevated PHQ-9 score.</td>
</tr>
<tr>
<td></td>
<td>• <em>Depression Response.</em> The percentage of members who showed response within 4–8 months after the initial elevated PHQ-9 score.</td>
</tr>
<tr>
<td>Measurement period</td>
<td>January 1–December 31 of the measurement year.</td>
</tr>
<tr>
<td>Clinical recommendation statement</td>
<td>The Institute for Clinical Systems Improvement recommends that clinicians establish and maintain follow-up with adult patients who have depression. Appropriate, reliable follow-up is highly correlated with improved response and remission scores (Kessler, 2016). The American Academy of Pediatrics recommends that adolescents with depression should be assessed for treatment response and remission of symptoms using a depression assessment tool such as the PHQ-9 Modified for Teens (Cheung, 2018).</td>
</tr>
</tbody>
</table>
Table: Characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scoring</td>
<td>Proportion.</td>
</tr>
<tr>
<td>Type</td>
<td>Outcome.</td>
</tr>
<tr>
<td>Item count</td>
<td>Person.</td>
</tr>
</tbody>
</table>
| Stratification          | 1. 12–17 years.  
                          | 2. 18–44 years.  
                          | 3. 45–64 years.  
                          | 4. 65 years and older.  
                          | 5. Total.                                                                                                                                  |
| Risk adjustment         | None.                                                                                                                                    |
| Improvement notation    | A higher rate indicates better performance.                                                                                             |

Table: Definitions

<table>
<thead>
<tr>
<th>Definitions</th>
<th>Details</th>
</tr>
</thead>
</table>
| Participation (Continuous Enrollment)           | The identifiers and descriptors for each organization’s coverage used to define members’ eligibility for measure reporting. Allocation for AMP reporting is based on eligibility during the Participation Period.  
                          | For self-reporting POs: The Participation Period in the PO (parent level).  
<pre><code>                      | For health plans: The Participation Period in the health plan and the PO (parent level).                                                                 |
</code></pre>
<p>| Participation Period                            | May 1 of the year prior to the Measurement Period through December 31 of the Measurement Period.                                                                                           |
| Allowable Gap                                   | No more than one gap in enrollment of up to 45 days during the measurement period. No gaps in enrollment are allowed from May 1 of the year prior to the Measurement Period through December 31 of the year prior to the Measurement Period. |
| Anchor Date                                     | December 31 of the measurement year.                                                                                                  |</p>
<table>
<thead>
<tr>
<th><strong>Intake Period</strong></th>
<th>May 1 of the year prior to the Measurement Period through April 30 of the Measurement Period.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Depression Follow-Up Period</strong></td>
<td>The 120–240 day period after the IESD.</td>
</tr>
<tr>
<td><strong>IESD</strong></td>
<td>Index Episode Start Date. The earliest date during the Intake Period where a member has a diagnosis of major depression or dysthymia and a PHQ-9 total score &gt;9 documented.</td>
</tr>
<tr>
<td><strong>Initial Population</strong></td>
<td>Members 12 years and older as of the start of the Intake Period who meet all the following criteria:</td>
</tr>
<tr>
<td></td>
<td>• A diagnosis of major depression or dysthymia that starts before and overlaps or starts when the PHQ-9 total score &gt;9 is documented during the Intake Period.</td>
</tr>
<tr>
<td></td>
<td>• Participation.</td>
</tr>
<tr>
<td><strong>Exclusions</strong></td>
<td>Members with any of the following at any time during the Intake Period or during the Measurement Period.</td>
</tr>
<tr>
<td></td>
<td>• Bipolar disorder.</td>
</tr>
<tr>
<td></td>
<td>• Personality disorder.</td>
</tr>
<tr>
<td></td>
<td>• Psychotic disorder.</td>
</tr>
<tr>
<td></td>
<td>• Pervasive developmental disorder. <strong>OR</strong></td>
</tr>
<tr>
<td></td>
<td>• In hospice or using hospice services during the Measurement Period.</td>
</tr>
<tr>
<td><strong>Denominator</strong></td>
<td>The Initial Population, minus Exclusions.</td>
</tr>
<tr>
<td><strong>Rate—Depression Follow-Up (Population Criteria 1)</strong></td>
<td>Numerator 1 A PHQ-9 total score in the member’s record during the Depression Follow-Up Period.</td>
</tr>
</tbody>
</table>
| Rate—Depression Remission (Population Criteria 2) | Numerator 2  
Members who achieve remission of depression symptoms, as demonstrated by the most recent PHQ-9 score of <5 during the Depression Follow-Up Period. |
|--------------------------------------------------|--------------------------------------------------|
| Rate—Depression Response (Population Criteria 3) | Numerator 3  
Members who indicate a response to treatment for depression, as demonstrated by the most recent PHQ-9 total score being at least 50 percent lower than the PHQ-9 score associated with the IESD, documented during the Depression Follow-Up Period. |
Appendices
## APPENDIX 1
### Summary of Measures and Changes

### SUMMARY OF MY 2020 and 2021 AMP MEASURE SPECIFICATION CHANGES

<table>
<thead>
<tr>
<th>MY 2020/MY 2021 Measures</th>
<th>Date of Update/ Modification From HEDIS</th>
<th>Measure Specification Update</th>
</tr>
</thead>
</table>
| Controlling High Blood Pressure (CBP)            | September 2020                          | • Revised the time frame in the event/diagnosis criteria to look for two outpatient visits with a diagnosis of hypertension in the first six months of the measurement year and the year prior to the measurement year.  
  • Removed the restriction that only one of the two visits with a hypertension diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.  
  • Added palliative care as a required exclusion.  
  • Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.  
  • Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.  
  • In the Administrative Specification, added telephone visits, e-visits and virtual check-ins as appropriate settings for BP readings.  
  • The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File. |
| Statin Therapy for Patients with Cardiovascular Disease (SPC) | September 2020                          | • Updated rules for allowable gap for the Medi-Cal Managed Care product line.  
  • Removed the restriction that only one of the two visits with an IVD diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.  
  • Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.  
  • Added palliative care as a required exclusion.  
  • Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.  
  • The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File. |
### Appendix 1—Summary of Measures and Changes

<table>
<thead>
<tr>
<th>PROPORTION OF DAYS COVERED BY MEDICATIONS (PDC):</th>
<th>Date of Update/ Modification From HEDIS</th>
<th>Measure Specification Update</th>
</tr>
</thead>
</table>
| MY 2020/2021 Measures | September 2020 | - Updated language in Treatment period.  
  - Updated language in Continuous Enrollment criteria to include a 1-day allowable gap.  
  - Added definition for Prescription Claims.  
  - Added clarification to Step 3 of numerator calculation.  
  - Changed Medication Table names.  
  - Added niacinamide to insulin medications.  
  - This non-HEDIS measure developed by the Pharmacy Quality Alliance (PQA). |
| **Proportion of Days Covered by Medications (PDC):** | Modifications From HEDIS |  
  - Renin Angiotensin System (RAS) Antagonists  
  - Statins  
  - Diabetes All Class  
  - Updated language in Treatment period.  
  - Updated language in Continuous Enrollment criteria to include a 1-day allowable gap.  
  - Added definition for Prescription Claims.  
  - Added clarification to Step 3 of numerator calculation.  
  - Changed Medication Table names.  
  - Added niacinamide to insulin medications.  
  - This non-HEDIS measure developed by the Pharmacy Quality Alliance (PQA). |
| **Comprehensive Diabetes Care (CDC):** | September 2020 | - Updated rules for allowable gap for the Medi-Cal Managed Care product line.  
  - Removed the restriction that only one of the two visits with a diabetes diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.  
  - Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.  
  - Added palliative care as a required exclusion.  
  - Deleted the HbA1c Level 7.0-9.0 Value Set.  
  - Updated the Administrative Specification logic and value sets for the Eye Exam indicator.  
  - Added telephone visits, e-visits and virtual check-ins to the Administrative Specification as appropriate settings for BP readings.  
  - Added Nebivolol-valsartan to the “Antihypertensive combinations” description in the ACE inhibitor and ARB Medications List.  
  - Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.  
  - Added polycystic ovarian syndrome to the optional exclusions. |
| **Optimal Diabetes Care (HbA1c Control; BP Control; Medical Attention for Nephropathy; Eye Exam)** | Modifications From HEDIS | - Optimal Diabetes Care Combination Rate is a non-HEDIS measure that is an “all or none” combination rate composed of four indicators.  
  - AMP does not include the Medicare SES Stratifications for the Eye Exam indicator.  
  - The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File. |
## Appendix 1—Summary of Measures and Changes

### Statin Therapy for Patients with Diabetes (SPD)

<table>
<thead>
<tr>
<th>Measure Specification Update</th>
</tr>
</thead>
<tbody>
<tr>
<td>Updated rules for allowable gap for the Medi-Cal Managed Care product line.</td>
</tr>
<tr>
<td>Added polycystic ovarian syndrome to the optional exclusions.</td>
</tr>
<tr>
<td>Removed the restriction that only one of the two visits with a diabetes diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.</td>
</tr>
<tr>
<td>Removed the restriction that only one of the two visits with an IVD diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis, step 2 required exclusions.</td>
</tr>
<tr>
<td>Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.</td>
</tr>
<tr>
<td>Added palliative care as a required exclusion.</td>
</tr>
<tr>
<td>Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.</td>
</tr>
<tr>
<td>Added Pitavastatin 1 mg to the Pitavastatin Moderate Intensity Medications List and deleted the Pitavastatin Low Intensity Medications List.</td>
</tr>
</tbody>
</table>

### Statin Use in Persons with Diabetes (SUPD)

<table>
<thead>
<tr>
<th>Measure Specification Update</th>
</tr>
</thead>
<tbody>
<tr>
<td>Added FERTILITY: Fertility Medications to the Medication Table.</td>
</tr>
<tr>
<td>Changed Medication Table to Table SUPD-A: Diabetes Medications to DIABETES: Diabetes Medications and Table SUPD-B: Statin Medications to STATINS: Statin Medications.</td>
</tr>
<tr>
<td>Added insulin aspart and niacinamide (DIABETES) to statins medications.</td>
</tr>
<tr>
<td>Added requirement that IPSD occurs ( \geq 90 \text{ days prior to the end of the measurement year} ).</td>
</tr>
<tr>
<td>Added exclusions for Rhabdomyolysis or Myopathy, Pregnancy, Lactation, or Fertility, Liver Disease, Pre-Diabetes, and Polycystic Ovary Syndrome (PCOS).</td>
</tr>
</tbody>
</table>

### Modifications From HEDIS

<table>
<thead>
<tr>
<th>Statin Therapy for Patients with Diabetes (SPD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 2020</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
</tr>
<tr>
<td>The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Statin Use in Persons with Diabetes (SUPD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 2020</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
</tr>
<tr>
<td>This is a non-HEDIS measure developed by the Pharmacy Quality Alliance (PQA).</td>
</tr>
</tbody>
</table>
## Appendix 1—Summary of Measures and Changes

<table>
<thead>
<tr>
<th>MY 2020/2021 Measures</th>
<th>Date of Update/Modification From HEDIS</th>
<th>Measure Specification Update</th>
</tr>
</thead>
</table>
| Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART) | September 2020 | • Removed the restriction that only one of the two visits with a rheumatoid arthritis diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.  
• Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.  
• Added Upadacitinib to the “Janus kinase (JAK)” description in the DMARD Medications List.  
• Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.  
• Added Mycophenolic acid to the “Immunosuppressive agents” description in the DMARD Medications List.  

<table>
<thead>
<tr>
<th>Modifications From HEDIS</th>
<th>The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.</th>
</tr>
</thead>
</table>
| Osteoporosis Management in Women Who Had a Fracture (OMW) | September 2020 | • Updated the instructions for excluding visits that result in an inpatient stay (steps 1 and 2).  
• Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.  
• Added palliative care as a required exclusion.  
• Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.  
• Added Romosozumab to the “Other agents” description in the Osteoporosis Medications List.  

<table>
<thead>
<tr>
<th>Modifications From HEDIS</th>
<th>The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.</th>
</tr>
</thead>
</table>
| Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) | September 2020 | • None.  

<table>
<thead>
<tr>
<th>Modifications From HEDIS</th>
<th>The AMP WCC measure only includes the BMI percentile indicator.</th>
</tr>
</thead>
</table>
| Childhood Immunization Status (CIS) | September 2020 | • Updated rules for allowable gap for the Medi-Cal Managed Care product line.  
• Added a requirement that LAIV (influenza) vaccination must occur on the child’s second birthday.  

<table>
<thead>
<tr>
<th>Modifications From HEDIS</th>
<th>The AMP CIS measure only includes one combination rate (Combination 10).</th>
</tr>
</thead>
</table>
| Immunizations for Adolescents (IMA) | September 2020 | • Updated rules for allowable gap for the Medi-Cal Managed Care product line.  
• None. |

September 1, 2020
## Appendix 1—Summary of Measures and Changes

<table>
<thead>
<tr>
<th>MY 2020/2021 Measures</th>
<th>Date of Update/Modification From HEDIS</th>
<th>Measure Specification Update</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlamydia Screening in Women (CHL)</td>
<td>September 2020</td>
<td>• Added Dienogest-estradiol (multiphasic) and removed Estradiol-medroxyprogesterone and Ethinyl estradiol-folic acid-levonorgestrel from the “Contraceptives” description in the Contraceptive Medications List.</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
<td></td>
<td>• None.</td>
</tr>
<tr>
<td>Cervical Cancer Screening (CCS)</td>
<td>September 2020</td>
<td>• Added palliative care as a required exclusion.</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
<td></td>
<td>• The measure exclusion is required.</td>
</tr>
<tr>
<td>Cervical Cancer Overscreening (CCO)</td>
<td>September 2020</td>
<td>• Added palliative care as a required exclusion.</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
<td></td>
<td>• This is a non-HEDIS measure.</td>
</tr>
<tr>
<td>Breast Cancer Screening (BCS)</td>
<td>September 2020</td>
<td>• Added palliative care as a required exclusion.</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
<td></td>
<td>• Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.</td>
</tr>
<tr>
<td>Colorectal Cancer Screening (COL)</td>
<td>September 2020</td>
<td>• AMP does not include the Medicare SES Stratifications.</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
<td></td>
<td>• The exclusion for members living long-term in an institution is optional for POs that do not have access to the LTI flag in the Monthly Membership Detail Data File.</td>
</tr>
<tr>
<td>Prenatal and Postpartum Care (PPC)</td>
<td>September 2020</td>
<td>• Revised the definition of last enrollment segment.</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
<td></td>
<td>• Clarified that visits that occur prior to the enrollment start date (during the pregnancy) meet criteria.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added telephone visits (Telephone Visits Value Set) e-visits and virtual check-ins (Online Assessments Value Set) to the Timeliness of Prenatal Care rate (administrative specification) and clarified in the Notes that services provided via telephone, e-visit or virtual check-in are eligible for use in reporting both rates.</td>
</tr>
</tbody>
</table>
## Appendix 1—Summary of Measures and Changes

<table>
<thead>
<tr>
<th>MY 2020/2021 Measures</th>
<th>Date of Update/Modification From HEDIS</th>
<th>Measure Specification Update</th>
</tr>
</thead>
</table>
| Child and Adolescent Well-Care Visits (WCV)| September 2020                       | • This measure is a combination measure that replaces the former “Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life” and “Adolescent Well-Care Visits” HEDIS measures.  
• Added members age 7-11 years.  
• Added age stratifications.  
• Removed the telehealth exclusion.                                                                                                                                                                                                 |
| Modifications From HEDIS                   | None                                 |                                                                                                                                                                                                                                                                                                                                                             |
| Asthma Medication Ratio (AMR)              | September 2020                       | • Removed the restriction that only three of the four visits with an asthma diagnosis be an outpatient telehealth, telephone visit, e-visit, or virtual check-in when identifying the event/diagnosis.  
• Clarified in step 1 when the diagnosis must be on the discharge claim.  
• Added Dupilumab to the “Anti-interleukin-4” description in the Dupilumab Medications List.  
• Clarified NDC code mapping requirement in the Notes.                                                                                                                                                                                                                             |
| Modifications From HEDIS                   | None                                 |                                                                                                                                                                                                                                                                                                                                                             |
| Appropriate Testing for Pharyngitis (CWP)  | September 2020                       | • Updated the instructions for excluding visits that result in an inpatient stay.  
• Removed Sulfisoxazole from the “Sulfonamides” description in the CWP Antibiotic Medications List.  
• Deleted step 8; this step is unnecessary because these members are removed in step 5.                                                                                                                                                                                                |
| Modifications From HEDIS                   | None                                 |                                                                                                                                                                                                                                                                                                                                                             |
| Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB) | September 2020                       | • Updated the instructions for excluding visits that result in an inpatient stay.  
• Removed Ticarcillin-clavulanate from the “Beta-lactamase inhibitors” description, Erythromycin-sulfisoxazole from the “Miscellaneous antibiotics” description and Norfloxacin from the “Quinolones” description in the AAB Antibiotic Medications List. |
| Modifications From HEDIS                   | None                                 |                                                                                                                                                                                                                                                                                                                                                             |
### Appendix 1—Summary of Measures and Changes

<table>
<thead>
<tr>
<th>MY 2020/2021 Measures</th>
<th>Date of Update/Modification From HEDIS</th>
<th>Measure Specification Update</th>
</tr>
</thead>
</table>
| Use of Opioids at High Dosage (HDO) | September 2020 | - Clarified the instructions for calculating covered days for the denominator.  
- Clarified the instructions for treatment period.  
- Added palliative care as a required exclusion.  
- Added medications lists for acetaminophen benzhydrocodone, aspirin codeine and codeine phosphate.  
- Removed Acetaminophen Hydrocodone 7.5 mg Medications List from the Hydrocodone description in Table HDO-A: Opioid Medications. |
| Modifications from HEDIS | None. |
| Concurrent Use of Opioids and Benzodiazepines (COB) | September 2020 | None. |
| Modifications from HEDIS | This is a non-HEDIS measure developed by the Pharmacy Quality Alliance (PQA). |
| Encounter Rate by Service Type (ENRST) | September 2020 | - Added clarification that health plans should submit the denominator as total member months.  
- Added a calculation for ‘overall rate’. |
| Modifications From HEDIS | This is a non-HEDIS measure. |
- Added clarifying information to Visits definition.  
- Added clarifying information to Step 3 of Encounter Format Calculation: Procedure Modifier and Rendering Provider Identifier Per Service Line. |
| Modifications From HEDIS | This is a non-HEDIS measure. |
### Appendix 1—Summary of Measures and Changes

<table>
<thead>
<tr>
<th>MY 2020/2021 Measures</th>
<th>Date of Update/Modification From HEDIS</th>
<th>Measure Specification Update</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Encounter Timeliness (ENLAG)</strong></td>
<td>September 2020</td>
<td>• Added additional reported Categories of Lagtime for Zero to 180 days and Zero to 364 days.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added clarifying information in Average Lagtime by Service Date and Average Lagtime by Paid/Remittance Date.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added definitions for Service Line, Claims, Institutional Claims, Institutional Encounters, Professional Claims, Professional Encounters, Pharmacy Claims/Encounters.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clarified time frame for included service dates in Step 4 of Encounter Timeliness Lagtime Categories Calculation.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clarified time frame for included service dates in Steps 1 and 2 of Encounter Timeliness Average Lagtime Calculation.</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
<td></td>
<td>• This is a non-HEDIS measure.</td>
</tr>
<tr>
<td><strong>Controlling High Blood Pressure (e-Measure)</strong></td>
<td>September 2020</td>
<td>• Updated eCQM Version Number.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated copyright.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated the clinical recommendations statement to remove outdated references and update with the most recent clinical recommendations.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated references.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added text to identify the Quality Data Model (QDM) version used in the measure specification.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added text to indicate whether the measure is patient-based or episode-based.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated denominator exclusions to add the word ‘consecutive’ to clarify that the Long-Term Illness (LTI) exclusion should be for 90 consecutive days.</td>
</tr>
</tbody>
</table>
### Appendix 1—Summary of Measures and Changes

<table>
<thead>
<tr>
<th>MY 2020/2021 Measures</th>
<th>Date of Update/Modification From HEDIS</th>
<th>Measure Specification Update</th>
</tr>
</thead>
</table>
| Screening for Depression and Follow-Up Plan (e-Measure)   | September 2020                        | • Updated eCQM version number.  
• Updated the measure developer field.  
• Revised description to improve alignment with measure intent and initial population language.  
• Updated copyright.  
• Updated disclaimer.  
• Revised rationale to align with updated guidelines and evidence.  
• Removed clinical recommendation statement from an outdated guideline.  
• Removed reference to outdated guideline.  
• Updated references to align with American Psychological Association (APA) formatting.  
• Removed guidance related to additional evaluation or assessment for depression and suicide risk assessment as appropriate follow-up. Added guidance about the importance of escalating patient care or certain circumstances which are not captured in the measure.  
• Added guidance about the intent of the denominator exclusions.  
• Added guidance to clarify the measure’s use of the most recent depression screening.  
• Added text to identify the Quality Data Model (QDM) version used in the measure specification.  
• Added text to indicate whether the measure is patient-based or episode-based.  
• Removed guidance inconsistent with measure intent.  
• Revised existing guidance pertaining to using an age-appropriate depression screening tool.  
• Revised guidance related to examples of appropriate follow-up plans.  
• Revised guidance to consolidate and more accurately reflect the intent of using a standardized age-appropriate depression screening tool.  
• Revised denominator exclusions language based upon subject matter experts’ feedback to reflect that any patient with a current or historical diagnosis of bipolar disorder or depression should be excluded from the measure.  
• Revised denominator exception language to follow a similar format as other eCQMs. |
| Patient Experience                                        | September 2020                        | • None.                                                                                                                                                     |
| Ambulatory Care (AMB)                                     | September 2020                        | • None.                                                                                                                                                     |
| Modifications From HEDIS                                  | September 2020                        | • None.                                                                                                                                                     |
## Appendix 1—Summary of Measures and Changes

<table>
<thead>
<tr>
<th>MY 2020/2021 Measures</th>
<th>Date of Update/Modification From HEDIS</th>
<th>Measure Specification Update</th>
</tr>
</thead>
</table>
| Frequency of Selected Procedures (FSP)       | September 2020                         | • Added a note about reporting the three procedures not included in the FSP-1a and FSP-2 tables.  
• Updated the “Count as one procedure…” definition in the Calculations section.  
• Updated the ordering of the procedures to align with the HEDIS specification.  
• Removed the Member Months table and Procedures/1,000 Member Months column in the FSP-1a and FSP-2 tables. |
| Modifications From HEDIS                    |                                        | • The AMP FSP measure specification includes adjustment for age and sex and adjusted rates of procedures per 1,000 member years.  
• The AMP FSP measure added Ages, Continuous enrollment, Allowable gap, Anchor date, Benefit, Measurement period and Member years sections for measure reporting reference.  
• Removed the Member Months table and Procedures/1,000 Member Months column in the FSP-1a and FSP-2 tables, as they are not used in AMP reporting. |
| Inpatient Utilization—General Hospital/Acute Care (IPU) | September 2020                         | ■ None.                                                                                                                                                                                                                      |
| Modifications From HEDIS                    |                                        | ■ None.                                                                                                                                                                                                                      |
| Generic Prescribing (GRX)                   | September 2020                         | ■ None.                                                                                                                                                                                                                      |
| Modifications From HEDIS                    |                                        | ■ Non-HEDIS measure.                                                                                                                                                                                                            |
| Outpatient Procedures Utilization—Percentage Done in Preferred Facility (OSU) | September 2020                         | ■ None.                                                                                                                                                                                                                      |
| Modifications From HEDIS                    |                                        | ■ Non-HEDIS measure based on former HEDIS Utilization specifications.                                                                                                                                                          |
## Appendix 1—Summary of Measures and Changes

<table>
<thead>
<tr>
<th>MY 2020/2021 Measures</th>
<th>Date of Update/Modification From HEDIS</th>
<th>Measure Specification Update</th>
</tr>
</thead>
</table>
| All-Cause Readmissions (PCR) | September 2020 | - Revised the measure description.  
- Added a Note to the definition of “plan population” to clarify that it should be used as a denominator for the outlier rate.  
- Removed “Risk Adjustment Tables” from the Definitions.  
- Replaced references to “Table HCC-Surg” with references to the “Surgery Procedure Value Set” in the Risk Adjustment Determination section.  
- Replaced references to “Table PCR-DischCC” with “Table CC Mapping” in the Risk Adjustment Determination section.  
- Updated the Note in the Risk Adjustment Weighting section for IHS that are discharged or transferred to skilled nursing care.  
- Removed references to specific risk weight tables in the Risk Adjustment Weighting section.  
- Revised the data element tables to separate the Medicaid and commercial product lines from the Medicare product line.  
- The 18-64 age band is not reported for Medicare.  
- NCQA refers to this measure as “Plan All-Cause Readmissions.”  
- Expected rates are normalized by IHA data aggregator to reflect the performance of the population being measured (i.e., commercial HMO or Medicare Advantage).  
- The Skilled Nursing Care and SES Stratification for the Medicare Advantage product line is not reported. |
<table>
<thead>
<tr>
<th>MY 2020/2021 Measures</th>
<th>Date of Update/Modification From HEDIS</th>
<th>Measure Specification Update</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Hospital Utilization (AHU)</td>
<td>September 2020</td>
<td>• Added definitions for “outlier” and “non-outlier.” • Revised step 1 in the calculation of observed events to exclude ED visits that result in an observation stay. • Added step 3 in the calculation of observed events to remove discharges for outlier members. • Removed reference to specific risk weight tables in the Risk Adjustment Weighting section. • Specified separate PPV and PUCV risk adjustment weight tables for the Medicare population age 18-64 and the Medicare population age 65 and older. • Removed step 3 to identify the base risk weight from the calculation of PPV and PUCV; renumbered subsequent steps. • Clarified that for categories with a single member the covariance should be set to zero in step 4 of the Expected Count of Visits calculation. • Added instructions to report outliers separate from non-outliers.</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Hospital Average Length of Stay (HALOS)</td>
<td>September 2020</td>
<td>• None.</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modifications From HealthPartners</td>
<td></td>
<td>This is a non-HEDIS measure.</td>
</tr>
<tr>
<td>Modifications From HEDIS</td>
<td></td>
<td>Non-HEDIS measure developed by HealthPartners.</td>
</tr>
<tr>
<td>Total Cost of Care (TCOC)</td>
<td>September 2020</td>
<td>• Added clarifying information on normalization of relative-risk scores in Step 3 of Risk-Adjustment Determination. • Clarified reporting time frame in definition of Member months.</td>
</tr>
<tr>
<td>Modifications From HealthPartners</td>
<td></td>
<td>AMP includes ages greater than 1 for this measure. • AMP uses a $250,000 truncation level amount, whereas HealthPartners uses $125,000. • AMP applies a geographic adjustment in addition to risk adjustment. • AMP includes capitated costs in the measure. • AMP includes exclusion criteria for select services and payments.</td>
</tr>
</tbody>
</table>

Appendix 1—Summary of Measures and Changes
### SUMMARY OF MY 2021 AMP TESTING MEASURES

<table>
<thead>
<tr>
<th>Measures</th>
<th>Date of Modification</th>
<th>Measure Specification Update</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)</td>
<td>September 2020</td>
<td>• Added as a Commercial ACO testing measure for MY 2021.</td>
</tr>
<tr>
<td></td>
<td>Modifications From HEDIS</td>
<td>• None.</td>
</tr>
<tr>
<td>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)</td>
<td>September 2020</td>
<td>• Added as a Commercial ACO testing measure for MY 2021.</td>
</tr>
<tr>
<td></td>
<td>Modifications From HEDIS</td>
<td>• None.</td>
</tr>
<tr>
<td>Depression Remission or Response for Adolescents and Adults (DRR-E)</td>
<td>September 2020</td>
<td>• Added as a Commercial ACO testing measure for MY 2021.</td>
</tr>
<tr>
<td></td>
<td>Modifications From HEDIS</td>
<td>• None.</td>
</tr>
</tbody>
</table>

### SUMMARY TABLE OF MY 2020/2021 AMP MEASURE REMOVALS

<table>
<thead>
<tr>
<th>MY 2020/2021 Measures</th>
<th>Date of Modification</th>
<th>Measure Specification Update</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult BMI Assessment (ABA)</td>
<td>September 2020</td>
<td>• Retired in MY2020 because the measure is less relevant, given that automatic calculation of BMI in EHRs is now a common standard of practice and occurs at most outpatient visits. This measure does not assess counseling or follow-up for patients either “at risk” or diagnosed as overweight or obese, and documentation of BMI assessment alone sets a relatively low threshold for quality care to address the nation’s ongoing obesity epidemic.</td>
</tr>
</tbody>
</table>
APPENDIX 2
PRACTITIONER TYPES

Clinical pharmacist
A pharmacist with extensive education in the biomedical, pharmaceutical, socio-behavioral and clinical sciences. Clinical pharmacists are experts in the therapeutic use of medications and are a primary source of scientifically valid information and advice regarding the safe, appropriate and cost-effective use of medications.

Most clinical pharmacists have a Doctor of Pharmacy (PharmD) degree and many have completed one or more years of post-graduate training (e.g., a general and/or specialty pharmacy residency). In some states, clinical pharmacists have prescriptive authority.

Dental practitioner
A practitioner who holds a Doctor of Dental Surgery (DDS) or a Doctor of Dental Medicine (DMD) degree from an accredited school of dentistry and is licensed to practice dentistry by a state board of dental examiners.

Certified and licensed dental hygienists are considered dental practitioners.

Mental health provider
A provider who delivers mental health services and meets any of the following criteria:

- An MD or doctor of osteopathy (DO) who is certified as a psychiatrist or child psychiatrist by the American Medical Specialties Board of Psychiatry and Neurology or by the American Osteopathic Board of Neurology and Psychiatry; or, if not certified, who successfully completed an accredited program of graduate medical or osteopathic education in psychiatry or child psychiatry and is licensed to practice patient care psychiatry or child psychiatry, if required by the state of practice.

- An individual who is licensed as a psychologist in his/her state of practice, if required by the state of practice.

- An individual who is certified in clinical social work by the American Board of Examiners; who is listed on the National Association of Social Worker’s Clinical Register; or who has a master’s degree in social work and is licensed or certified to practice as a social worker, if required by the state of practice.

- A registered nurse (RN) who is certified by the American Nurses Credentialing Center (a subsidiary of the American Nurses Association) as a psychiatric nurse or mental health clinical nurse specialist, or who has a master’s degree in nursing with a specialization in psychiatric/mental health and two years of supervised clinical experience and is licensed to practice as a psychiatric or mental health nurse, if required by the state of practice.

- An individual (normally with a master’s or a doctoral degree in marital and family therapy and at least two years of supervised clinical experience) who is practicing as a marital and family therapist and is licensed or a certified counselor by the state of practice, or if licensure or certification is not required by the state of practice, who is eligible for clinical membership in the American Association for Marriage and Family Therapy.
Appendix 2 – Practitioner Types

• An individual (normally with a master’s or doctoral degree in counseling and at least two years of supervised clinical experience) who is practicing as a professional counselor and who is licensed or certified to do so by the state of practice, or if licensure or certification is not required by the state of practice, is a National Certified Counselor with a Specialty Certification in Clinical Mental Health Counseling from the National Board for Certified Counselors (NBCC).

• A physician assistant who is certified by the National Commission on Certification of Physician Assistants to practice psychiatry.

• A certified Community Mental Health Center (CMHC), or the comparable term (e.g. behavioral health organization, mental health agency, behavioral health agency) used within the state in which it is located, or a Certified Community Behavioral Health Clinic (CCBHC).
  – Only authorized CMHCs are considered mental health providers. To be authorized as a CMHC, an entity must meet one of the following criteria:
    ▪ The entity has been certified by CMS to meet the conditions of participation (CoPs) that community mental health centers (CMHCs) must meet in order to participate in the Medicare program, as defined in the Code of Federal Regulations Title 42. CMS defines a CMHC as an entity that meets applicable licensing or certification requirements for CMHCs in the State in which it is located and provides the set of services specified in section 1913(c)(1) of the Public Health Service Act (PHS Act).
    ▪ The entity has been licensed, operated, authorized, or otherwise recognized as a CMHC by a state or county in which it is located.
  – Only authorized CCBHCs are considered mental health providers. To be authorized as a CCBHC, an entity must meet one of the following criteria:
    ▪ Has been certified by a State Medicaid agency as meeting criteria established by the Secretary for participation in the Medicaid CCBHC demonstration program pursuant to Protecting Access to Medicare Act § 223(a) (42 U.S.C. § 1396a note); or as meeting criteria within the State’s Medicaid Plan to be considered a CCBHC.
    ▪ Has been recognized by the Substance Abuse and Mental Health Services Administration, through the award of grant funds or otherwise, as a CCBHC that meets the certification criteria of a CCBHC.

OB/GYN and other prenatal care practitioner includes:
• Physicians certified as obstetricians or gynecologists by the American Medical Specialties Board of Obstetrics or Gynecology or the American Osteopathic Association; or, if not certified, who successfully completed an accredited program of graduate medical or osteopathic education in obstetrics and gynecology.
• Certified nurse midwives, nurse practitioners or physician assistants who deliver prenatal care services in a specialty setting (under the direction of an OB/GYN certified or accredited provider).

Ongoing care provider

The practitioner who assumes responsibility for the member’s care.

PCP

Primary care practitioner. A physician or nonphysician (e.g., nurse practitioner, physician assistant, certified nurse midwives) who offers primary care medical services.

Includes:
• General or family practice physicians.
• Geriatricians.
• General internal medicine physicians.
• General pediatricians.
• Obstetricians/gynecologists (OB/GYN).

Licensed practical nurses and registered nurses are not considered PCPs.

Only certified Federally Qualified Health Centers (FQHC) are considered PCPs. This must be reviewed and approved by an auditor.

• To be certified as an FQHC, an entity must meet any one of the following criteria:
  – Is receiving a grant under Section 330 of the Public Health Service (PHS) Act (42 United States Code Section 254a) or is receiving funding from such a grant and meets other requirements.
  – Is not receiving a grant under Section 330 of the PHS Act but is determined by the Secretary of the Department of Health and Human Services (HHS) to meet the requirements for receiving such a grant (qualifies as a “FQHC look-alike”) based on the recommendation of the Health Resources and Services Administration.
  – Was treated by the Secretary of HHS for purposes of Medicare Part B as a comprehensive Federally-funded health center as of January 1, 1990.
Appendix 2 – Practitioner Types

- Is operating as an outpatient health program or facility of a tribe or tribal organization under the Indian Self Determination Act or as an urban Indian organization receiving funds under Title V of the Indian Health Care Improvement Act as of October 1991.

- For certification as an FQHC, the entity must meet all of the following criteria (in addition to one of the criteria above):
  - Provide comprehensive services and have an ongoing quality assurance program.
  - Meet other health and safety requirements.
  - Not be concurrently approved as a Rural Health Clinic (RHC).
    - Only certified RHC are considered PCPs. This must be reviewed and approved by an auditor.
    - To be certified as a RHC, the entity must meet CMS requirements to qualify for payment via an all-inclusive rate (AIR) for medically-necessary primary health services and qualified preventive health services furnished by an RHC practitioner.

Prescribing practitioner

A practitioner with prescribing privileges, including nurse practitioners, physician assistants and other non-MDs who have the authority to prescribe medications.